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ABSTRACT
Schizophrenia is the most severe of all the psychoses, affecting approximately
1% of the world's population. Although the aetiology of the disorder is likely to be
multifactorial, evidence accumulated from numerous family, twin and adoption
studies has firmly established a significant genetic component. The identification
of the relevant genes by classical linkage analysis has been plagued by
problems such as genetic heterogeneity and polygenic inheritance, and as such
no decisive and replicable gene/disorder associations have yet been detected.
The densely spaced markers now available throughout much of the human
genome have facilitated whole genome positional cloning efforts. However the
presence of a cytogenetic rearrangement associated with the disorder provides
an extremely valuable research tool. A balanced t(1; 11) translocation has been
described which co-segregates with a broad range of related psychiatric
conditions, including schizophrenia, in a large Scottish family. Generation and
mapping of markers in the region of this translocation led to the construction of a
3Mb yeast artificial chromosome (YAC) contig across the chromosome 11
breakpoint. This thesis begins with the isolation of YAC end clones by
'splinkerette PCR', an improved alternative to vectorette PCR, which facilitated
the contig construction. A search for foetal brain-expressed genes from this YAC
was then undertaken, using two complementary methods based on cDNA
selection, ('hybrid fishing' and 'end ligation' coincident sequence cloning). A
thorough analysis of the product library and confirmatory hybridisation to the
YAC and cDNA led to the identification of an additional member of the a-tubulin
gene family, and several novel gene fragments, comprising at least two genes.
Extensive sequence and expression analysis of the a-tubulin gene suggest that
it is a processed pseudogene, although its potential as a candidate gene for
psychiatric illness in this family cannot be discounted. The novel gene fragments
have been mapped relative to each other and to rare cutter restriction sites in
cloned genomic DNA, allowing one group of four fragments to be tentatively
assigned to a single CpG island-associated gene. These can now be tested as
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Schizophrenia is one of the most severe of all mental illnesses. It is not a
'split mind' as is commonly believed, but rather a disorder characterised by
mental anguish or insanity, sometimes so debilitating that the sufferer
permanently loses all touch with reality. It affects one in every hundred
people world-wide, and its sufferers fill nearly a quarter of the hospital beds
in Britain (Wallace, 1987). One third of the prison population in the UK
suffers from the disorder. Mental illness accounts for 14% of certified
sickness absence, 14% of the National Health Service (NHS) Inpatient costs
and 23% of the NHS pharmaceutical costs (Medical Research Council Field
Review on Biological Psychiatry, 1993). More than one third of the urban
homeless in the UK have had contact with psychiatric services.
Despite many decades of research into schizophrenia, little is established
concerning the cause. Modern treatments do little more than ameliorate the
most bizarre symptoms, leaving many schizophrenics unable to cope in the
community and in a downward spiral of social isolation. There is convincing
evidence however that schizophrenia is, at least partly, a genetic disease.
So, as the pace of human genome research gathers speed, and knowledge
of molecular mechanisms increases, there is now a real possibility of gaining
an understanding of the underlying causes of the disorder.
1.2 Diagnosis of Schizophrenia
Although schizophrenia is probably an innate part of human existence, it was
not described until the beginning of the nineteenth century, by Pinel in 1798
and Haslam in 1809 (Wyatt, 1988). Kraepelin is credited with the first
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diagnostic description of the disease, 'dementia praecox' as he termed it, as
having a chronic course with progressive deterioration. Somewhat later,
Bleuler coined the modern day terminology when he described 'the group of
schizophrenias' (Wyatt, 1988).
Since these first descriptions of schizophrenia, there has been considerable
debate over how it should be correctly diagnosed. Schizophrenia is a
heterogeneous disorder both in clinical presentation and outcome, and as
such is sometimes difficult to classify. There have been many attempts to
devise reliable diagnostic systems, such as the American Diagnostic and
Statistical Manual (DSM), the Research Diagnostic Criteria (RDC) and the
International Classification of Diseases (ICD). Standardisation of diagnosis
by these structured interview schedules is most certainly beneficial.
Diagnoses of schizophrenia usually concur between the different diagnostic
systems, although they do differ in their treatment of fringe phenotypes.
1.3 Epidemiology of Schizophrenia
Schizophrenia has a rate in the general population of approximately 1%
(Wyatt, 1988). What is remarkable about a disorder so heterogeneous is that
this prevalence rate is virtually constant in all geographical regions it has
been tested, although there are a few isolated pockets of high incidence, for
instance Northern Sweden, Ireland and Finland (Wyatt, 1988). The fact that
the rate remains constant across widely varying cultures in developed and
developing nations is strongly suggestive that the underlying causes of
schizophrenia are fundamental and intrinsic to man, and the disorder is not
merely a result of cultural factors.
Of fifteen studies reviewed, ten have suggested that schizophrenia is a
disorder of falling incidence (Harrison and Mason, 1993). On closer
inspection however, it appears that these findings may be artefactual. The
2
apparent drop in incidence can probably be attributed to earlier intervention
by general practitioners and therefore more prompt treatment, fewer false
positives as a result of rigorous diagnostic practice and changes in the
accepted diagnostic criteria themselves, with the inclusion of only those who
have been ill for some time (Harrison and Mason, 1993).
1.4 Pathology of Schizophrenia
1.4.1 Symptoms
The most prevalent symptom in schizophrenia is lack of insight, which has
been found to occur more frequently in schizophrenia than in the other
psychoses (Cuesta and Peralta, 1994). The other symptoms of
schizophrenia fall loosely into positive and negative categories. Positive
symptoms include delusions, visual and auditory hallucinations (voices inside
the head arguing, keeping up a running commentary or broadcasting one's
thoughts), incoherent speech, positive thought disorder and inappropriate
affect (Michels and Marzuk, 1993). Negative symptoms are characterised by
social isolation, withdrawal, blunted affect, attentional impairment, loosening
of associations, poverty of speech and lack of initiative, interests and energy
(Rao and Moller, 1994).
To Bleuler, the four primary symptoms of the deficit state of schizophrenia
were thought association problems, ambivalence, affective abnormalities and
autistic thinking (Gallant et at, 1990). The more prominent symptoms of
delusions and hallucinations were secondary symptoms. This still seems
largely appropriate today, since the Schneiderian First Rank symptoms
(FRS) such as delusions and hallucinations, upon which early diagnostic
systems were based, have proved not to be pathognomic for schizophrenia
(Gallant et al, 1990). Andreasen and Olsen (1982) found that the frequencies
of purely positive symptoms, purely negative symptoms or a mixture of both
were approximately equal - each constituting a third of cases. However long
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term follow-up studies (Marneros et a/, 1992) have found that few
schizophrenics (18%) will have more than one episode of purely positive
symptoms, and only 6% would experience exclusively negative symptoms.
The vast majority would experience both during the course of their illness.
In the revised third version of the DSM (DSM IIIR), consideration is also
given to the length of illness - the disorder must have been present for at
least six months without a return to the premorbid level of psychosocial
adjustment for schizophrenia to be diagnosed (Gallant et at, 1990). A brief
episode of illness is diagnosed as schizophreniform disorder. The DSM IIIR
also stipulates that there must be an absence of manic or depressive
symptoms sufficient to qualify the individual for affective disorder (Gallant et
a/, 1990). The distinction between schizophrenia and affective disorder is
highly contentious and will be discussed in section 1.4.3)
1.4.2 Subdivision of 'the group of schizophrenias'
The DSM IIIR recognises five principal subtypes of schizophrenia (Gallant et
al, 1990).
The catatonic subtype is characterised by marked psychomotor disturbance
such as stupor, negativism, rigidity, purposeless movement and posturing.
The disorganised (or hebephrenic) subtype is recognised by incoherence,
flat or inappropriate affect, loosening of associations, grimaces and
mannerisms. There may be delusions and hallucinations but they are usually
fragmentary and disorganised. The paranoid subtype includes at least one
delusion and frequent auditory hallucinations related to one theme.
Associated with these are excessive anxiety, anger, argumentativeness and
sometimes violence. The undifferentiated subtype encompasses those
disorders which appear to fit none or several of the other subtypes. Finally, a
diagnosis of residual schizophrenia is given when there has been at least
one active episode, but there is now no prominent psychosis. Residual
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symptoms include emotional blunting, social withdrawal and eccentric
behaviour.
Several studies have attempted to ascertain whether these subtypes are
genetically distinct. Subtype is almost always consistent between two
affected MZ twins (McGuffin et al, 1987), which does suggest subtype
specificity in the inheritance of schizophrenia, if the finding is not due to
ascertainment biases.
An alternative subdivision of schizophrenia (Crow, 1980a) is the Type I/ Type
II split. Type I schizophrenia is characterised by mostly positive symptoms,
good response to neuroleptic drugs, normal CT scans and a
hyperdopaminergic aetiology. Type II schizophrenia however has mainly
negative symptoms, is associated with brain atrophy and cognitive
impairment and the aetiology is not dopaminergic.
A more radical proposal is to split schizophrenia into 'familial' and 'sporadic'
subtypes, that is genetic versus non-genetic (Murray et al, 1985). The belief
is that the genetic form is caused by an aberrant gene involved in brain
development, and the sporadic form is caused by obstetric complications (in
males) or auto-immunity (in females).
1.4.3 The schizophrenia spectrum
Psychiatric diagnoses other than schizophrenia are found to aggregate in the
relatives of schizophrenics, and as a result many studies have attempted to
define the extent of the schizophrenia 'spectrum'. The results are conflicting,
which can largely be attributed to methodological discrepancies. A general
consensus is that rates of schizoaffective disorder, schizotypal and paranoid
personality disorders and atypical psychosis are all increased in the relatives
of schizophrenics (Kendler et al, 1985). As such they can be tentatively
ascribed to the same genetic mechanism and included in the spectrum.
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Anxiety disorder, unipolar depression and alcoholism do not have a greater
incidence in the families of schizophrenics and therefore are not included
(Kendler et al, 1985).
The link with Bipolar Affective Disorder (Manic Depression)
There is an ongoing debate as to whether schizophrenia and affective
disorder are entirely distinct disorders or instead represent the two extremes
of a continuum of psychotic illness. Kraepelin believed that they were two
separate disorders; schizophrenia implying progressive deterioration and
affective disorder following a remitting course. The most recent,
methodologically superior family studies, in support, conclude that rates of
bipolar affective disorder are not increased in the relatives of schizophrenics.
Similarly there is no excess of schizophrenia in the relatives of affectively ill
probands (Baron and Gruen, 1991). However published case studies have
described monozygotic twins, one with schizophrenia and one with bipolar
disorder (Lohr and Bracha, 1992), and also a case of identical triplets where
two were diagnosed with schizophrenia and one bipolar disorder (McGuffin
et al, 1982). This could of course be a result of the unfortunate genetic
presence of both illnesses in the family, but it seems more likely that the two
diagnoses are a result of different manifestations of the same genetic defect.
Schizoaffective disorder, the co-existence of the symptoms of both
schizophrenia and affective symptoms in one individual, is diagnosed as a
discrete entity, but this implies nothing about its aetiology. Just as the other
schizophrenia spectrum disorders aggregate in relatives of both
schizophrenics and individuals with bipolar disorder, schizoaffective disorder
may too be an alternative manifestation of either disorder. Alternatively,
schizoaffective disorder may have an entirely different aetiology. Finally, the
presence of both sets of symptoms in schizoaffective disorder, and its
outcome intermediate between the two, has led many to believe that
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schizoaffective disorder is a median diagnosis on a continuum from
schizophrenia to affective disorder (Lapensee, 1992).
1.4.4 Age of onset
Schizophrenia is a disorder of late adolescence and adulthood. The usual
age of onset is 18-25 years for men and 26-45 years for women (Wyatt,
1988). The disorganised subtype has the earliest onset, and paranoid
schizophrenia the latest, with an average gap of thirteen years between them
(Beratis et al, 1994). Between siblings, the age of onset is correlated rather
than the time of onset, which is support for a genetic rather than
environmental aetiology (deLisi, 1992).
1.4.5 Course and outcome
After onset, the course of schizophrenia is highly variable. Some patients will
suffer one episode of psychosis and then return to near normal function,
whereas others will experience an unremitting deterioration. In general
however, schizophrenia is an episodic disease, with an average of more than
five admissions to a psychiatric hospital (Johnstone, 1993). Unlike
dementias, there is no evidence for progressive cognitive decline other than
that linked to normal ageing (Hyde et al, 1994). A World Health Organisation
(WHO) comparison of the course of schizophrenia across the world reveals
that 10-28% will remain chronically psychotic, 10-64% will be free of
symptoms at the time of follow-up, while 5-71% will exhibit 'good' social
adjustment (Eaton, 1991). The wide variation in the last two figures is partly
due to differing interpretation of terminology, but it is known that there is a
better average prognosis for schizophrenics in developing countries. This is
probably due to a requirement for fewer coping skills in order to function well
in the community. Ten percent of schizophrenic patients commit suicide,
although two thirds will attempt it.
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The outcome figures quoted above are improved considerably since
Kraepelin described dementia praecox, and there exists a general
impression that the disorder is becoming more benign (Harrison and Mason,
1993). In the early nineteenth century, 19.5% of schizophrenics were
classified as catatonic subtype, whereas in the 1970's it was only 5-10%. In
Kraepelin's time, 59% of catatonics and 75% of hebephrenics reached a
terminal state of profound dementia, with only 4.1% making a complete
recovery (Wyatt, 1988). It is unclear whether the greatly improved prognosis
today reflects a genuine progression to a milder form or is merely a result of
changed diagnostic systems and improved treatment regimes. A substantial
portion must be accredited to improved medications, but improvements in
treatment are also due to greater emphasis on psychosocial awareness,
such as teaching skills for symptom management, living and coping in the
community. There is a greater emphasis too on family involvement - with
education programmes, support and practical help (Torrey and Drake, 1994).
Estimates of good outcome are however confounded by the criteria used to
define them and changes in diagnostic practice. Care must be exercised
when interpreting outcome data across time. For instance the percentage of
schizophrenics with a good outcome now is only the same as it was in the
1950's, despite modern therapeutic techniques (Hegarty, 1994). This is
largely due to the adoption of the DSM IIIR for diagnosis, in which the
inclusion criteria for schizophrenia specify a long course of illness.
1.4.6 Relapse and Expressed Emotion
Relapse rates reported for schizophrenia vary considerably, from 33% up to
80% after two years (Davies, 1994). In addition to the effectiveness of the
maintenance medication, relapse rates are heavily dependent on the family
circumstances. Family attitudes to the ex-patient are measured in terms of
'expressed emotion' (EE), which is assessed by a semi-structured interview
of the family, rating factors such as hostility, warmth and emotional
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overinvolvement (Bebbington and Kuipers, 1994). An high EE family member
will have a tendency to generate or escalate conflict, and will be less
effective at coping. They are generally of the view that the disorder is within
the patient's control. A person of low EE will tend to avoid hostility and
believes that there is nothing the patient can do to control his symptoms.
There is a conclusive body of evidence to suggest that a patient in contact
with at least one family member of high EE (especially if that family member
is particularly significant, such as a parent or spouse) has a vastly increased
chance of relapse. Reciprocally, contact with a low EE family member can
even have a protective effect against relapse (Bebbington and Kuipers,
1994).
1.4.7 Sex Differences
Although the prevalence of schizophrenia is approximately equal for both
men and women, considerable variation is seen in the onset and course of
the disorder. Males exhibit an earlier and sharper peak for age of onset (18-
25 years) compared with females (26-45 years) (Wyatt, 1988). This has been
proven not to be a result of excessive 'help seeking1 behaviour in men or
differences in social role expectations between the sexes (Castle and
Murray, 1991). Males usually have more typical symptomatology, with more
negative features and a tendency to withdrawal and passivity. They are also
more likely to show poor pre-morbid social functioning and have lower pre¬
morbid IQ scores. In females the symptoms are usually characterised by a
stronger affective component, and the course of the disorder is usually less
severe than in males. Females respond better to neuroleptic medication, and
have fewer and shorter stays in a psychiatric hospital (Castle and Murray,
1991).
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Explanations proposed for these sex differences are increased role stress in
males, protective roles in females or hormonal differences (a triggering effect
of androgens and/or a protective affect of oestrogens). Epidemiological
studies have shown a second major peak of incidence for women, between
ages 40 and 45, which may be due to the pre-menopausal drop in oestrogen
levels. Also some studies have demonstrated changes in the
psychopathology of schizophrenics at different stages of the menstrual cycle,
with an exacerbation of symptoms seen when oestrogen levels are low
(Riecher-Rossler et al, 1994). Administration of oestrogens can ameliorate
psychosis, and in animals, chronic oestrogen treatment reduces the
sensitivity of the D2 receptor in the brain (Riecher-Rossler et al, 1994).
There is a slower pace of cerebral development in males, which makes them
statistically more prone to neurodevelopmental disorders in general.
Obstetric complications such as periventricular haemorrhage and asphyxia
are more likely during the birth of males (Castle and Murray, 1991). Obstetric
complications are known to cause increased ventricular size and are
correlated with an earlier age of onset of schizophrenia.
1.4.8 Reproductive fitness
It is generally accepted that schizophrenics have a reduced reproductive
fitness, of approximately 70% compared with unaffected individuals (Wyatt,
1988). This may be a biological phenomenon or just a secondary effect,
since the symptoms of the disorder may lessen the chances of marriage and
cause breakdown in existing family relationships. How then have the
deleterious mutations not been diluted out by natural selection? Assuming
that the new mutation rate of schizophrenogenic genes is not sufficient to
ensure their maintenance, some mechanism for their selective retention is
implied.
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From a genetic point of view, the simplest explanation is that many genes
are involved in the disease process. If this were due to aetiological
heterogeneity, then the normal new mutation rate may account for the
observed frequency of schizophrenia, by acting at many different loci yet
causing the same phenotype (Carter and Watts, 1971). If, on the other hand,
the involvement of many genes was due to a polygenic mode of inheritance,
the decrease in population frequency of an individual mutant allele would be
slower than if the disorder were caused by a single gene, since a
combination of mutant alleles is required before the deleterious phenotype is
present. The gene(s) may not be fully penetrant, and there may be no loss of
reproductive fitness in those with late onset (Ridley and Baker, 1990).
Historically, most reproduction would have taken place before even the
average age of onset of the phenotype, thus decreased reproductive fitness
may be a recent phenomenon, the effects of which are not yet apparent.
In addition, schizophrenogenic gene mutations may confer a biological or
sociological advantage on those carrying them. It is possible historically that
those experiencing delusions and hallucinations were revered as 'visionaries'
or 'mystics' and as such had a favourable place in society (Erlenmeyer-
Kimling and Paradowski, 1966). This would hardly seem applicable today,
yet the effect may not yet have been 'diluted out' by natural selection. The
advantage may alternatively be conferred onto unaffected mutation carriers,
the relatives of schizophrenics. This 'heterozygote advantage' may be in the
form of resistance to infectious disease (for instance influenza, see section
1.6.5), such as is seen for heterozygosity for sickle cell anaemia conferring
some resistance to malaria. One study found schizophrenics' relatives to
have an incidence of viral infections of only 40% that expected, but no
decrease in bacterial infections (Carter and Watts, 1971). It has also been
proposed that the relatives of schizophrenics are unusually creative or
intelligent people, however it is unclear whether this would confer a
reproductive advantage on them. Erlenmeyer-Kimling (1968) proposed that
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relatives of schizophrenics possess a genetically determined protection
against the stresses and strains of social interaction. Another study
(Erlenmeyer-Kimling and Paradowski, 1966) found an increase in
reproductivity in the sisters of schizophrenics - 140% that of the normal
population.
1.4.9 Premorbid functioning
The best predictor of prognosis after onset of schizophrenia is the level of
premorbid functioning, as indicated by social ability and factors such as
marital and occupational status. Poor social competence is correlated with a
poor prognosis, and is also linked to an earlier age of onset (Eaton, 1991).
Therefore it is of great significance to study pre-morbid adjustment in
schizophrenics, with a view to increased accuracy of identification of those at
risk.
The age of onset of schizophrenia is usually for convenience taken to be the
time of first hospitalisation, which usually correlates with the first onset of
positive symptoms (deLisi, 1992). However there is normally an insidious
onset of negative symptoms before this, and subtle signs of abnormality are
usually present since childhood. Two large prospective studies of British birth
cohorts have attempted to correlate particular childhood behaviours with a
greater risk for developing schizophrenia. Jones et al (1994) found that pre-
schizophrenics reached milestones of motor development (especially
walking) later, and had more speech problems. They had low educational
test scores at ages 8, 11 and 15 and exhibited a solitary play preference at
ages 4 and 6. In early adolescence, pre-schizophrenics rated themselves as
less socially confident, and teachers rated them as more anxious in social
situations. There was also a preponderance of twitches, grimaces and
severe nail biting in pre-schizophrenics.
Similar results were found in a study by Done et al (1994). At age seven,
they found a significantly greater degree of social maladjustment in pre-
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schizophrenics, which was particularly significant in boys. These boys were
rated as 'over-reactive', that is more anxious for acceptance and more
deviant than their classmates, and displaying hostility and inconsequential
behaviour. Social maladjustment in pre-schizophrenic girls however was not
generally not noticeable until age 11. Signs of 'under-reactive' behaviour
were then noted, such as timidity, withdrawal, lethargy, apathy and
depression, suspiciousness and unwillingness to work.
A study of neonates born to schizophrenic mothers (therefore at high risk for
the later development of schizophrenia) revealed an increase in abnormal
neurological signs compared with controls (Blennow and McNeil, 1991).
These neonates exhibited unusual wakefulness and displayed deviations in
sensitivity to stimulation and tests of reflexes, complex responses and
excitability/depression.
By assessment on the Waldrop Physical Anomalies scale, schizophrenics
have been found to have an increased frequency of minor physical
abnormalities (MPAs) (Lohr and Flynn, 1993). Such abnormalities include
low set ears, a high steepled palate, a curved fifth finger and partial
syndactyly between the two middle toes. Presence of MPAs in
schizophrenics has been correlated with poor premorbid adjustment and
early age of onset (Lohr and Flynn, 1993). The presence of such minor
physical anomalies is normally indicative of developmental disturbance, and
is therefore consistent with the neurodevelopmental hypothesis of
schizophrenia (see section 1.7.2).
The occurrence of hand morphology discrepancies is of particular relevance
to schizophrenia, since the ectodermal cells which will form the hand skin
migrate in the fourth or fifth month of gestation, the same time as the bulk of
neuronal migration to the cortex (Bracha, 1991). While under obvious genetic
programming, this implies that hand morphology abnormalities can exist as
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'fossilised' evidence for a prenatal insult such as ischaemia or toxicity. In a
study of 24 pairs of monozygotic twins, it was consistently found that the
schizophrenic co-twin exhibited more hand morphology abnormalities than
the unaffected twin (Bracha, 1991). There was also a trend towards more
dysmorphology of the right hand, which suggests a developmental brain
lesion in the left hemisphere. This is consistent with some other observations
of neuropathological changes in schizophrenics (see section 1.4.11).
1.4.10 Markers of predisposition
Since there is considerable evidence that schizophrenia occurs as a result of
a neurodevelopmental lesion, it is theoretically possible to detect those at
risk for the disorder well before the onset of the diagnostic symptoms. Since
the precise neurodevelopmental anomaly is not yet known, work has focused
on identifying genetically transmitted markers which are correlated with and
specific to schizophrenia. Six criteria have been proposed for a good
candidate marker (Holzman, 1992). It would have a low base rate in the
population, would be stable over time and relatively specific to the diagnostic
entity. It should also aggregate in the relatives of affected but not unaffected
individuals, be genetically transmitted and identify those at risk for
developing schizophrenia. Several traits have been identified which are good
candidates for biological markers of schizophrenia. These are smooth pursuit
eye tracking, event related potentials and continuous performance test
ability.
Smooth pursuit eye tracking: When visually tracking a sinusoidally moving
object, the eye will normally move smoothly, with occasional compensatory
saccades when the eye moves too fast or too slowly. It has been found that
an abnormality of eye tracking is associated with schizophrenia, such that
'catch-up' saccades are required more frequently and the smooth pursuit is
interrupted by more random saccadic intrusions (Levy et al, 1994). Eye
tracking dysfunction is found in 5-9% of normal individuals, 21% of non-
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psychotic psychiatric patients and 53-86% of schizophrenics. A great number
of studies have replicated these findings (reviewed in Levy et al, 1994).
Eye tracking dysfunction seems to be relatively specific to schizophrenia,
and is not an effect caused by drug treatment. Importantly, the same deficit
can often be seen aggregating in the non-psychotic biological relatives of
schizophrenics, which suggests that it is genetically transmitted. Holzman
(1974) found eye tracking dysfunction in 45% of clinically well first degree
relatives of schizophrenics, as compared with 10.5% of relatives of non-
schizophrenics and 8.3% of normal individuals. In addition, the concordance
for eye tracking dysfunction between twins has been found to be twice as
high in monozygotic pairs than dizygotic pairs, as would be expected for a
genetic trait. The above findings fulfil all the criteria for a good marker except
the last, which states that the marker should be able to identify those at risk.
Eye tracking dysfunction is incapable of this because not all schizophrenics
display the marker (14-50% of schizophrenics exhibit normal eye tracking),
and not all the individuals with the deficit develop schizophrenia.
These observations led Matthysse (1986) to propose a 'latent trait' model for
schizophrenia. They assumed that schizophrenia and eye tracking
dysfunction are independent phenotypic expressions of a latent trait,
transmitted by a single gene. This does not rule out the possibility that other
genes affect the expressivity of the latent trait, and as such is not
incompatible with the observed non-Mendelian segregation of schizophrenia
in families. Experiments testing mathematical models of the structure and
parameters of the latent trait hypothesis have been tested, have generally
yielded results which closely fit those predicted (Levy et al, 1994).
Event related potentials (ERPs): ERPs are a measure of brain electrical
activity related to sensory, motor and cognitive responses to specific stimuli.
The P300, which reflects the cognitive work done by the subject after a
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stimulus, has been found to be of a decreased amplitude in some
schizophrenics (Holzman, 1992). There is probably also a small but
significant delay in P300 latency, though this has not been proven by all
studies undertaken. Well siblings of schizophrenics have also been found to
show changes in the P300 component of the ERP.
Another component of the ERP is the P50 wave, which occurs as a response
to repeated auditory stimuli. In most individuals, the magnitude of the P50
response diminishes considerably with repetition of the stimulus, due to
habituation (Holzman, 1992). In schizophrenics however, the diminution of
the P50 is much smaller. Adler et al (1982) found that in normals, the
magnitude of the P50 after a second stimulus was only 13.9% of that after
the first. In unmedicated, acutely psychotic schizophrenics however, the ratio
was 90%. This effect has also been shown to occur in unaffected family
members of schizophrenics and is therefore genetically transmitted.
Continuous performance test: There are many tests of continuous attention;
in general they involve a series of stimuli presented to the subject briefly, and
in quick succession. The subject must respond each time a target stimulus
appears. In such tests, it has been found that 40% of schizophrenics showed
a deficit in performance, with an increased frequency of errors of omission
(not responding to the target stimulus) and commission (responding to a
non-target stimulus) (Holzman, 1992). The effect was present both during
acutely psychotic episodes and in remission, and was also found in
unmedicated schizophrenics. It has also been detected in unaffected siblings
and offspring of schizophrenics, and those diagnosed with schizophrenia




The techniques of computed tomography (CT) and magnetic resonance
imaging (MRI) can be used for brain imaging studies on living subjects. CT
uses x-rays to differentiate between bone, brain tissue and cerebrospinal
fluid (CSF). MRI has now largely superseded CT due to its greater resolution
and no requirement for exposure to large doses of ionising radiation (Potts et
at, 1993).
The first report of structural changes in the brains of schizophrenics was a
CT study (Johnstone et al, 1976) showing that the ventricular spaces of
schizophrenics were larger than those of controls. Since then there have
been a great number of CT and MRI studies, from which the consistent
findings are ventricular enlargement and cortical atrophy (Bachneff, 1991).
There is also a localised volume reduction, with the temporal lobe, especially
the hippocampus and the parahippocampal gyrus, being primarily affected
(Roberts and Bruton, 1990). The pathology is usually of equal severity in
both male and female patients and also between the left and right
hemispheres although several studies have reported a greater degree of
abnormality in the left hemisphere (Waddington, 1993). In addition, disturbed
cytoarchitecture of the pyramidal cells of the hippocampus has been
reported, and post mortem studies of schizophrenics have revealed a
decrease in brain weight (average 6%) and brain length (average 4%)
relative to controls (Roberts and Bruton,1993).
The nature of the structural pathology seen in the brains of schizophrenics is
unfortunately not completely specific to the disorder. Structural brain
changes are not seen in all schizophrenics. In one study of ventricular size
50% of the patient sample overlapped with the normal range (Cannon and
Marco, 1994). However, specificity to pathology can be seen in twin studies,
where the schizophrenic co-twin is always found to have larger ventricles
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than the well co-twin (Reveley et at, 1992). These well co-twins do often
have enlarged ventricles when compared with unrelated controls however.
Increased ventricular size is also seen in other pathologies, such as
Alzheimer's disease and Parkinson's disease. Hence it cannot be used alone
as a diagnostic marker for schizophrenia.
There is also little evidence for subgroupings of schizophrenia being related
to particular structural pathologies. An association between ventricular
enlargement and negative symptoms has been proposed, but the evidence
for this is inconclusive (seven positive out of twenty studies reviewed)
(Cannon, 1991). It was also suggested that only sporadic cases of
schizophrenia would show brain pathology, but evidence contrary to this
argument has been supplied by family studies.
Functional changes
Functional studies of the brain have mainly relied on the technique of
positron emission tomography (PET), which uses radioactive ligands to
measure metabolic or neurochemical activity. The resolution of PET is
sufficient to be able to study small structures, but use of the technique is
severely limited by exposure of the subject to non-trivial amounts of ionising
radiation. Non-radioactive techniques such as magnetoencephalography
(MEG) and magnetic resonance spectroscopy (MRS) are safer but are not so
widely used.
With the exception of the many PET studies on neurotransmitter levels and
receptor densities (see section 1.7.1), the major findings of functional studies
in schizophrenics are of hypofrontality (Cleghorn et at, 1991). Hypofrontality
is a reduction in the hyperfrontal pattern which is seen in well individuals, as
measured by the increase in blood flow and glucose utilisation when subjects
are asked to perform tasks requiring use of the frontal cortex (e.g. the
Wisconsin card sorting task). Hyperfrontality is known to be reduced only
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slightly by the use of neuroleptic drugs.
1.4.12 Neurochemistry
The clinical manifestation of schizophrenia gives reason to suppose that
there may be abnormalities in neurotransmission, either as a causative factor
or at least as a reliable marker of the disorder. Consequently there is a
plethora of experimental data both supporting or refuting the idea that
neurotransmitters are involved in the disease. Unfortunately many of the
earlier studies were plagued by methodological problems and errors and as
such a clear picture is yet to emerge. Standardised experimental procedures
in combination with the improved structural and functional brain imaging
techniques now available should clarify the situation. The involvement of
neurotransmitters in schizophrenia has been reviewed in section 1.7.1.
1.5 Treatment of Schizophrenia
Treatment for schizophrenia in the early part of this century and earlier was
for the most part ineffective and often highly dangerous. Injection of
adrenaline, fever induction and vasectomy proved of little therapeutic use
(Hegarty 1994), whereas alternatives such as psychosurgery and sleep
therapy carried tremendous risks (Frankenburg, 1994). In the 1920's Henry
Cotton 'removed organs in a frantic desire to improve his cure rate, and
probably only alleviated psychosis by terminating his patients' lives!'
(Frankenburg, 1994).
The first effective treatments were not seen until the introduction of insulin
coma, chemoconvulsive therapy and electroconvulsive therapy (ECT) in the
1930's. The first antipsychotic drug, reserpine, was derived from the roots of
the plant Rauwolfia serpentina, known in central Asia for centuries as
'insanity herb' (Frankenburg, 1994). At the same time in the 1950's,
chlorpromazine, developed as a surgical anaesthetic, was found to have
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antipsychotic properties (Frankenburg, 1994). Reserpine and chlorpromazine
became the prototype antipsychotic drugs, upon which many others have
been modelled. These drugs are known as 'typical' neuroleptics.
These drugs are however far from perfect. They show an incomplete clinical
efficiency, especially for the treatment of the negative symptoms, and can
produce a disturbing array of extrapyramidal side effects (Livingston, 1994).
The side effects of chlorpromazine for instance are undue sedation,
autonomic symptoms, weight gain and movement disorders including drug-
induced Parkinsonism and even tardive dyskinesia in 25% of chronically
treated patients (Livingston, 1994). Indeed, the term 'neuroleptic', by which
these drugs are now known, implies induction of extrapyramidal side effects
in addition to antipsychotic properties.
The last decade has seen the development of 'atypical' neuroleptics - so
called because they have antipsychotic properties but do not induce
extrapyramidal side effects. The prototype atypical neuroleptic clozapine was
withdrawn in the 1970's after it caused fatal cases of agranulocytosis, but
was reintroduced in the 1980's and is now one of the most effective
antipsychotics. It exhibits an enhanced efficiency in the alleviation of positive
but especially negative symptoms compared to typical neuroleptics and has
the lowest risk for inducing tardive dyskinesia (Pickar, 1995). Clozapine is
also effective in up to 70% of previously treatment resistant cases.
1.5.1 Mechanism of action
Typical neuroleptics cause a blockade of neurotransmitter receptors,
particularly the dopamine receptor D2. The specificity for D2 varies between
different drugs, between the extremes of haloperidol (which blocks D2 and
has little effect on any other receptors) and fluoxetine (which blocks
serotonin reuptake only) (Gershon and Rieder, 1992). The atypical
neuroleptics also block dopamine receptors, but do so specifically in the
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mesolimbic dopamine system rather than the nigrostriatal system. This has
led to the proposal that dopamine receptor blockade in the former is
responsible for antipsychotic action, whereas blockade in the latter causes
extrapyramidal side effects (Pickar, 1995). Clozapine is a weak D2 receptor
blocker compared with conventional agents, and instead exhibits a higher
efficiency for the D1 and especially the D4 receptors. It also has a high
affinity for a broad range of serotonin receptors (especially 5HT6 and 5HT7),
and has activity at adrenergic (a1 and oc2), histaminergic (H1) and
muscarinic receptors (Pickar, 1995).
The importance of considering the interactions between the different
neurotransmitter systems, rather than focusing on dopamine, is becoming
clear. The development of the latest antipsychotic drug risperidone was in
response to the observation that addition of serotonin agonists such as
ritanserin to the regimen of patients receiving haloperidol improved the
treatment of negative symptoms, ameliorated depression and anxiety in
schizophrenics and reduced movement disorder (Livingston, 1994).
Risperidone is a highly potent antagonist of the serotonin receptor 5HT2, and
is also active at D2 and a1 and a2 adrenergic receptors (Livingston, 1994).
1.5.2 Strategy for administration
The choice of drug used is determined by many factors such as the
clinician's preference, side effects, the patient's medical history and the
family history of response and tolerance, the availability of routes for drug
administration and often financial considerations (Shen, 1994). Most patients
are maintained on medication after discharge from hospital, which has been
found to be 75% effective in relapse prevention compared with 20% relapse
in individuals who received a placebo (Shen, 1994). The effectiveness of
medication is obviously dependent on good compliance, which is often
difficult to achieve due to lack of insight and side effects. The decreased side
effects of atypical neuroleptics has improved compliance, although these
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drugs must be administered orally as opposed to intramuscular injection
(Hale, 1993).
1.6 Aetiology of schizophrenia
1.6.1 Evidence for a genetic component
Family studies
There have been many studies investigating the presence of schizophrenia
and other psychiatric disorders in the relatives of schizophrenic probands. All
except two (Pope et al, 1982 and Abrams and Taylor, 1983, which can be
severely criticised on methodological grounds) agree that rates of
schizophrenia are greatly increased in the relatives of schizophrenic
probands. Consistent with a genetic effect, the risk increases the closer the
relative, and hence the higher proportion of genes shared. Aggregated rates
of schizophrenia in relatives gathered from forty European studies conducted
between 1920 and 1987 suggest that siblings of schizophrenics have an age
corrected risk of 9% of developing the disease, parents have a risk of 6%,
offspring 13% and secondary relatives 2% (Prescott and Gottesman, 1993).
Spouses have a risk of 2%, a figure which is greater than the general
population risk of 1%, perhaps due to assortative mating. There is also
elevated risk for schizophrenia spectrum disorders in families, and when
these are taken into account a psychiatric morbidity may be found in
approximately 35% of the relatives of schizophrenics compared with only
10% of controls.
These figures provide evidence that schizophrenia is not caused by a single
gene with complete penetrance, since for such monogenic disorders the
familial risk is directly proportional to the genetic similarity (50% in first
degree relatives, 25% in second degree relatives etcetera).
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Twin Studies
Studies of concordance for psychiatric disorder within pairs of monozygotic
versus dizygotic twins are a useful way to show genetic influence, yet due to
the relatively rare incidence of both twinning and schizophrenia, it is not easy
to generate large numbers for credible studies. Most twin studies have
therefore been conducted in Scandinavia where complete Psychiatric and
Twin registers facilitate the systematic ascertainment of probands for a
region or entire country (Fischer et al, 1969).
Widely varying concordance rates for schizophrenia between twins have
been reported (Fischer et al, 1969), yet the salient point is that the
concordance between monozygotic (MZ) twins is always at least twice as
high as concordance between dizygotic (DZ) twins. This is consistent with a
genetic model for schizophrenia, since MZ twins are genetically identical, yet
DZ twins share only half their genes. In a review of eleven twin studies,
Gottesman and Shields (1982) found an average concordance rate of 57.7%
for monozygotic twins compared with only 12.8% for dizygotic twins.
Of concern to advocates of a 'purely genetic1 aetiology is that concordance
between monozygotic twins does not reach 100%. However risk of
schizophrenia in the offspring of both twins from a discordant MZ pair is
found to be the same, approximately 17% (Fischer, 1971). For discordant DZ
twins the risk to the offspring of the schizophrenic twin is also 17%, yet the
risk to the offspring of the normal twin is only 2%, not significantly different
from the population as a whole (Fischer, 1971). This suggests that the
normal twin of a discordant MZ pair does possess all the factors necessary
for the development of schizophrenia, since they can be passed on to the
next generation, but for some reason the phenotype is not expressed. This
has been attributed to either incomplete penetrance of the genes involved,
the necessity of a precipitating environmental factor, or both.
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A more stringent test of a genetic aetiology of schizophrenia comes from
studies of MZ twins reared apart, where one is known to have schizophrenia.
This has an advantage over conventional twin studies since the effect of
shared rearing environment (with the exception of the prenatal environment)
is removed. Acquiring these subjects is obviously extremely difficult and to
date there have been only sixteen pairs studied (Shields and Slater, 1967).
Of these ten were concordant and six discordant for schizophrenia. This
results in a concordance rate of 62.5%, which is similar to rates for twins
reared together and suggests little or no effect of shared environment.
Adoption Studies
Adoption studies have an advantage over family and twin studies because it
is possible to control for the effects of environment. There are two
fundamental ways to approach them - either the 'adoptees study method' in
which rates of the disorder are assessed in adoptees born to schizophrenic
mothers, or the 'adoptees' relatives study method' whereby diagnosis of
schizophrenia in the biological parents of schizophrenic adoptees is
assessed (Tienari, 1994).
Whichever method is used, the results always indicate a genetic aetiology for
schizophrenia. By the adoptees study method, Heston (1966) found that five
out of forty-seven (16.6%) adoptees born to schizophrenic mothers
developed the disorder themselves, compared with none of the fifty controls.
However half of the group of index adoptees exhibited major psychosocial
disorder. Similarly Rosenthal et al (1971) found a rate of 31.6% of
schizophrenia spectrum disorders in the index cases compared with 17.8%
in controls. In this study the mothers had not developed schizophrenia before
the adoption took place, to ensure that the foster parents had no idea that
the adoptee had an unusually high risk of becoming schizophrenic. Using the
adoptees' relatives method, Kety et al (1975) produced similar results - 8.7%
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of the biological parents of schizophrenic adoptees had psychiatric morbidity,
compared with only 1.9% of the controls.
The latter study included an important subsample: the paternal half siblings
of the adopted individuals. Paternal half siblings are related through a
common father, and therefore they do not share the same prenatal, perinatal
and post natal environment. They do however share 25% of their genes.
Kety found that the risk of schizophrenia was greater in the biological
paternal half siblings of the schizophrenic adoptees than in the paternal half
siblings of control adoptees. Kety et al (1978) believed that this data was "the
most compelling evidence we have that genetic factors operate significantly
in the transmission of schizophrenia."
1.6.2 Genetic Models
Despite convincing evidence that genetic factors are involved in the aetiology
of schizophrenia, the genetic mechanism(s) is proving remarkably elusive.
Part of the problem is that the mode of inheritance is unknown, since
schizophrenia does not exhibit classical Mendelian transmission in families.
The simplest genetic model is the single major locus (SML) model (Prescott
and Gottesman, 1993). The basic observation that large multiply affected
families are very unusual seems to preclude the existence of a highly
penetrant dominant allele, although modifications such as reduced
penetrance, imprinting, anticipation, variable age of onset and phenocopies
can be incorporated. A small number of isolated pockets have been reported
in which schizophrenia seems to be transmitted by a single dominant allele
(for instance Iceland and Northern Sweden), but in general single gene
effects would seem to make only a modest contribution to schizophrenia risk.
An oligogenic or polygenic model seems more favourable in this instance.
The multifactorial polygenic model (MFP) assumes a large number of genes
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of small and equal effect (Prescott and Gottesman, 1993). The mixed model
(Morton and McLean, 1974), which is currently favoured, incorporates a
polygenic background with or without a major locus and with or without
environmental effects.
1.6.3 Imprinting and Anticipation
There is currently much debate as to the possible role of genomic imprinting
and anticipation in schizophrenia, as potential ways to reconcile the apparent
complex mode of transmission with the existence of genes of major effect.
As yet, no evidence has been found to suggest that genomic imprinting may
play a role in psychiatric illness (Asherson et al, 1994).
The term 'anticipation' was first used by Mott in 1910, meaning an increase
in severity of illness across successive generations. Mott clearly recognised
the existence of the phenomenon in psychiatric illness, when he referred to
the 'the law of anticipation of the insane' (Asherson et al, 1994). There have
been several modern studies also seeking to prove that schizophrenia
becomes more severe in successive generations. Bassett and Honer (1994)
studied three generations of siblines selected for autosomal dominant like
inheritance. They demonstrated that patients in younger generations were
more frequently hospitalised, had an earlier age of onset and increased
severity of the disorder. It is possible that ascertainment biases alone are
responsible for this finding. There may be preferential ascertainment of
parents with late onset due to reduced fertility in those with early onset.
There may be preferential ascertainment of younger generation patients with
an early onset, since not all would have passed the risk period for developing
the disorder. Certainly not all studies have demonstrated the presence of
anticipation - Asherson et al (1994) concluded that anticipation was not
occurring in their sample of multiplex families and O'Neil et al (1993)
postulated that the effect was merely 'regression to the mean', meaning an
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early onset in the offspring of parents with a late onset and vice versa.
A molecular mechanism of anticipation has recently been identified as an
expansion of unstable trinucleotide repeat DNA sequences, in several
neurodegenerative disorders including Huntington's disease, myotonic
dystrophy, Fragile X syndrome, spino-cerebellar ataxia, and spinal and
bulbar muscular atrophy (Petronis and Kennedy, 1995). Much interest has
been generated in a search for unstable trinucleotide repeat sequences in
schizophrenia. Recently, two studies have been published which
demonstrate a positive association between triplet repeat expansions and
schizophrenia. The first (O' Donovan et at, 1995) used the repeat expansion
detection method (RED) to demonstrate a significantly increased repeat
length in a sample of schizophrenics and bipolar patients relative to controls.
The association was particularly significant for females. No correlation was
found between repeat length and age of onset, severity or the presence of
particular symptoms. The second report (Morris et at, 1995) also used RED
to demonstrate longer repeat lengths in schizophrenics than normals, an
association that was again highly significant for females. In this study
however an association was seen between a large repeat expansion and an
early age of onset.
An expansion of trinucleotide repeat sequences could form the basis for an
explanation of discordance in monozygotic twins, if a particular threshold
number of repeats is required for expression of the phenotype. Uneven
expansion of the repeats between the co-twins in the somatic cells during
development could result in only one twin of the two reaching the critical
threshold value. The unaffected twin would have a number of repeats just
below the threshold; further expansion in his or her offspring could explain
the higher than expected prevalence in the offspring of unaffected twins. If
the number of repeats correlates with severity of the disorder, then the
disorder would tend to follow a milder course in the affected twin of a
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discordant pair than in those of a concordant pair, since the discordant pair
would, on average, have a fewer number of repeats than the concordant
pair. Most data are consistent with this (Petronis and Kennedy, 1995).
1.6.4 Somatic Genetics
Genetics may play a role in the aetiology of schizophrenia without inherited
factors. Schizophrenogenic mutations taking place in critical somatic cells
during development may provide a genetic explanation for a disease which
outwardly may seem of sporadic and therefore environmental origin. In
addition to simple mutation, unstable DNA sequences and epigenetic factors
such as inactivation may be involved.
1.6.5 Evidence for an environmental component
Although the evidence for a genetic component in schizophrenia is
overwhelming, it is by no means suggestive that genetic influences are
necessary and sufficient to cause schizophrenia in all cases. The
discordance for schizophrenia seen in some pairs of monozygotic twins, the
non-Mendelian transmission of genetic factors and the lack of success in
identifying causative genetic loci all point towards there being an
environmental component in the aetiology of schizophrenia. Indeed many
cases of schizophrenia occur in the absence of a known family history of the
disorder and as such appear caused primarily by environmental factors.
Weiner (1985) has estimated that only 10% of schizophrenics have a family
history of schizophrenia (although 25% have a family history of schizoid
personality disorder). Few researchers would argue however, that
schizophrenia is caused by the environment alone, instead preferring a
multifactorial aetiology combining genetic predisposition and precipitating
environmental events (the diathesis-stress model).
Winter Birth
There is a proven excess of schizophrenic births during the Winter months,
which is not merely attributable to analytical methods (e.g. the age-incidence
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effect). There are three alternative explanations for this effect (Pulver et al,
1992). 1) There is some seasonally varying factor which affects intra-uterine
life and increases the risk for the development of schizophrenia in genetically
predisposed individuals. This may be infectious disease, a low protein diet or
pregnancy and birth complications. 2) Individuals genetically at risk for
schizophrenia have some biological advantage which protects them from
allergies or infections which are more prevalent during the Winter months
and may otherwise have caused mortality. 3) Seasonal patterns of
conception among the parents of schizophrenics. There is no evidence for
the latter.
Studies of the season of birth of schizophrenics from the Southern
hemisphere will prove useful. Since Winter occurs in the middle of the year in
the Southern hemisphere, the results would not be confounded by an age-
incidence effect. Preliminary results (Welham et al, 1995a and b) suggest
that an excess of pre-schizophrenic births in the Winter and early Spring
months may occur in the Southern hemisphere.
Social Class
There have been many studies investigating the social class of
schizophrenics, from which the general conclusion is that schizophrenia
occurs most frequently among the lowest social classes. This finding may be
viewed in two different ways, according to either the 'social causation1 (low
social class causes schizophrenia) or the 'social selection' (presence of
schizophrenia causes drift towards the lower classes) hypotheses (Kohn,
1976).
There are environmental factors sometimes associated with the lower
classes which may causes schizophrenia, such as greater environmental
and occupational hazards, increased prevalence of infectious agents, poor
maternal and obstetric care and limited resources to deal with stress in
addition to cognitive and personality factors. Perhaps the difficult conditions
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of life and a self-perception of helplessness which can be imposed by low
social class lead to a failure to cope with stress and precipitation of a
schizophrenic episode in those genetically predisposed (Kohn, 1976). The
socially debilitating nature of the disorder however does also implicate drift
towards the lower classes. The familial nature of schizophrenia is such that
drift of schizophrenic parents or grandparents towards the lower classes
would also contribute to this effect.
City Residence
It is interesting to note that the frequently proposed emergence of
schizophrenia as a disease entity was in the late 19th century, at a time
when the first large scale urbanisation of the population was also taking
place. Since then, many studies have found prevalence of schizophrenia to
be correlated with urban residence. This may be interpreted as either cause
or effect. Adverse environmental factors may aggregate in cities (for instance
pollution, infectious agents) yet on the other hand schizophrenics may drift
towards the inner city, where there is more likely to be cheap, single person
accommodation, casual labour and a lack of a close-knit social structure from
which a schizophrenic individual may feel excluded (Freeman, 1994).
Another alternative is the 'social residue' hypothesis, which implies a
selective loss of mentally healthy individuals from socially and
environmentally undesirable areas such as the inner city, leaving an excess
of the psychiatrically disturbed and socially incompetent (Freeman, 1994).
Stress
It is found that independent life events (that is, those not related to an
individual's personality or behaviour) tend to cluster before the onset or a
relapse of schizophrenia. However stress is usually interpreted to be only a
determinant of the time of a schizophrenic episode and not causative in
those not genetically predisposed to the disorder (Leff, 1992).
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Diet
Although less thoroughly documented, some associations between
schizophrenia and grain in the diet have been proposed, in the presence of
genetic vulnerability. A positive correlation has been proposed between the
incidence of schizophrenia and the consumption of grains (Hemmings,
1990). Case studies provide additional evidence, such as two patients whose
psychoses lessened when they were put on a grain free diet, only to relapse
again when gluten was added (Hemmings, 1990).
Trace elements may be involved in the aetiology of schizophrenia. There are
clinical similarities between schizophrenia and 'manganic madness' caused
by manganese poisoning (Donaldson, 1987); Dawson (1970) has proposed
that the high lithium concentration in the drinking water of some parts of
Texas may be responsible for the low levels of psychiatric admissions there;
Foster (1988) generated a correlation coefficient of 0.58 between
schizophrenia and areas of the United States in which there was a low
selenium level in the diet.
An increase in pre-schizophrenic births following pre-natal exposure to the
Dutch hunger Winter of 1944-45 has been reported. The nutritional
deficiency imposed during this famine is probably the cause, although other
factors such as toxicity from consumption of unusual foodstuffs (such as tulip
bulbs!) may be taken into account (Susser et al, 1995). Prenatal nutritional
deficiency can alter the functioning of neurotransmitter systems and can
affect the morphology and electrophysiological properties of the
hippocampus (Butler et al, 1994).
Prenatal exposure to alcohol may increase susceptibility to the development
of schizophrenia (Lohr and Bracha, 1989). A peak in beer sales in the late
Summer has been linked with the excess of pre-schizophrenic Winter births,
and the relatively high rate of alcoholism in Ireland may be responsible for
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the high incidence of schizophrenia there. Foetal alcohol syndrome (FAS)
has some clinical similarities to schizophrenia, and Alcohol Hallucinosis,
which develops 15-20 years after exposure to alcohol is virtually
indistinguishable from schizophrenia (Lohr and Bracha, 1989). Prenatal
exposure to alcohol in rats has been shown to cause alterations in the
organisation and volume of the hippocampus and also more general
neuronal loss.
Viral Infection
It has been proposed that schizophrenia is a genetic 'morphism', with both
favourable and unfavourable effects. It is the balance between the
disadvantageous schizophrenic symptoms (and decreased reproductive
fitness) and other, advantageous, properties conferred by the morphic gene
which is responsible for the gene's maintenance at a relatively high
population frequency (Huxley et al, 1964). The advantages conferred by this
morphic gene may include an increased resistance to surgical shock, burns,
arthritis and substances such as histamine and insulin. Thirty years ago, Eliot
Slater put forward the proposal that the reason schizophrenia was not
progressively eliminated from the population was due to an increased
resistance to infection (Wright et al, 1993). Carter and Watts (1971)
examined the frequency of commonplace infections in the first degree
relatives of schizophrenics. Their results showed that the relatives of
schizophrenics were just as likely as the controls to have suffered a bacterial
infection, but they were significantly less likely to have been recorded as
having a viral infection.
Since then there have been many studies investigating the proposed
association between prenatal exposure to influenza virus and subsequent
increased risk of developing schizophrenia. Many have focused on
assessing the rate of development of schizophrenia in individuals who were
in utero during the 'flu pandemic of 1957. Studies from Finland (Mednick et
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al, 1988), England and Wales (O'Callaghan et al, 1991), Japan (Kunugi et al,
1992), Ireland (Waddington, 1992) and Australia (McGrath, 1994) have all
reported a significant increase in the rate of schizophrenia. A study from
Scotland (Kendell and Kemp, 1989) gave equivocal results, although upon
reanalysis of the data it did appear to demonstrate a positive association.
Moreover the effect has been shown to be specific to those exposed during
the second trimester of gestation, between the 5th and 7th months, and in
some cases was only statistically significant for female schizophrenics.
Not all studies however have confirmed the association. Studies from the
USA (Torrey et al, 1991), the Netherlands (Selten and Slaets, 1994) and
England (Crow and Done, 1992) have reported no increase in schizophrenic
births following exposure to influenza virus in utero. In the pandemic studies
there is no proof that the mothers of later schizophrenics were actually
infected. Crow and Done (1992) found no association between 'flu and
schizophrenia when mothers' reports of 'flu symptoms were taken into
account. The method of data collection in this study is however not wholly
reliable (midwife interview of mother and study of case notes) and it must
also be borne in mind that up to 30% of people could have been infected
subclinically.
1.6.6 Environmental and/or genetic factors
Obstetric Complications
An excess of pregnancy, obstetric and peri-natal complications has been
found among schizophrenics, particularly males (Cantor-Graae et al, 1994).
Obstetric complications have also been equivocally linked with Winter birth,
and a negative family history of schizophrenia (Cantor-Graae et al, 1994).
Consistent with the neurodevelopmental hypothesis of schizophrenia it is
presumed that these difficulties cause damage to the foetal brain, for
instance by anoxia or haemorrhage. It is known that birth complications can
result in enlarged cerebral ventricles.
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Birth weight
Predisposition to later schizophrenia has been found to be associated with
low birth weight. In monozygotic twins discordant for schizophrenia it is
usually the affected co-twin who was lighter at birth (Rifkin et al, 1994). In the
general population, low birth weight is associated with reading difficulties,
language disorders and lower IQ, it is therefore possible that the low birth
weight occurs secondary to some form of neurodevelopmental pathology
(Rifkin et al, 1994). In the presence of other genetic and perhaps
environmental factors, this may be manifested as schizophrenia.
Head circumference
Some studies have found an association of schizophrenia with a small head
circumference at birth (Kunugi et al, 1995 and McNeil et al, 1993). Others
however have found no association (Kunugi et al, 1994).
Ethnicity
A British study of schizophrenics' racial background found that Afro-
Caribbeans had higher rates of admission to psychiatric hospitals than did
Caucasians, and more were diagnosed with schizophrenia (King et al, 1994).
In general, Afro-Caribbeans were found to have a twelve fold increase in risk
for developing schizophrenia relative to Caucasians and generally earlier
ages of onset (King et al, 1994). This may be due to biological factors, such
as differences in HLA antigens, but may also have a social component such
as the effect of emigration and experience of racism.
1.7 Hypotheses on the aetiology of schizophrenia
1.7.1 An abnormality in neurotransmission
Dopamine
The origins of the dopamine hypothesis of schizophrenia were based on two
primary observations. The first is that dopamine agonists such as
amphetamines can produce a psychosis similar to schizophrenia in normal
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individuals, and conversely drugs that potentiate dopamine activity generally
worsen the symptoms of schizophrenia. Secondly, the primary action of
neuroleptic drugs was found to be a blockade of dopamine receptors (Davis
et at, 1991). Taken together, a hyperdopaminergic hypothesis for
schizophrenia was proposed.
The evidence used to formulate the hyperdopaminergic theory came from
studies investigating the concentration of dopamine and its primary
metabolite homovanillic acid (HVA) in plasma and cerebrospinal fluid (CSF),
and the density of dopamine receptors in the brain. Studies investigating the
concentration of HVA in the CSF have yielded conflicting results, which can
probably be attributed to methodological problems and intra-individual
variation (Davis et at, 1991). Post mortem studies of dopamine and HVA
concentration in schizophrenic brains consistently show differences from
controls (usually an increase) (Davis et at, 1991), yet variability is seen in the
anatomical site exhibiting the difference. These specificities may be a
genuine finding, yet they may also be merely a product of varying analytical
and statistical methods, a medication effect or a consequence of
schizophrenia.
There are five types of postsynaptic dopamine receptor, termed D1-D5. The
D1 receptor (Sunahara et at, 1990), is found primarily in the cortex, and is
known to be positively coupled with adenylate cyclase, leading to an
increase in cAMP. The D2 receptor on the other hand (Grandy et at, 1989) is
found in striatal and limbic areas and leads to a decrease in cAMP. D2 has
two subtypes, D2a and D2b, which cannot as yet be differentiated
pharmacologically or physiologically. The D3 receptor (Sokoloff et at, 1990)
is similar to the D2 but its expression is restricted to the limbic areas. The D4
receptor (Van Tol et at, 1991) has a particularly high affinity for clozapine. D5
(Sunahara et at, 1991) is similar to D1 but with a higher affinity for dopamine.
35
Post mortem studies of brain D2 receptor concentration have fairly
consistently shown an increase in D2 receptor density in schizophrenics
(Owen and Simpson, 1994). This finding has been seen in drug-treated
patients but also in drug-naive patients, which suggests that it is not merely
an effect of neuroleptic medication. Recently Seeman et al (1994a) have
found a 6-fold increase in levels of D4 in schizophrenic brains relative to
controls.
There are a number of problems with the simple hyperdopaminergic theory,
particularly the conflicting results with respect to plasma and CSF HVA
concentration and the incomplete action of neuroleptics. An attractive extension
to the dopamine hypothesis has been proposed (Davis et al, 1991), which takes
into account observations essentially ignored by the original theory. These are
that damage to the frontal lobe in animals leads to a deficit state similar to the
negative symptoms seen in schizophrenia, and also that hypofrontality has been
clearly demonstrated in schizophrenics. This hypofrontality appears to be
associated with the dopamine system, since administration of amphetamines to
schizophrenics causes an increase in prefrontal blood flow and a concomitant
improvement in performance on the Wisconsin card sorting task. In addition,
schizophrenia has clinical similarities with Parkinson's disease, which is known
to involve a loss of dopaminergic neurons.
The model (Davis et al, 1991) proposes that schizophrenia is associated with
/?ypodopaminergic function in the frontal lobes, which can lead to
hyperclopaminergia in the mesolimbic system. The former would explain the
presence of negative symptoms, (untreatable by neuroleptics which decrease
dopamine function) and could also explain the lower plasma and CSF PIVA
levels sometimes seen in schizophrenics. The latter would be characterised by
the positive symptoms. If correct, this theory has implications for treatment
strategies, since it is possible that premorbid amelioration of the cortical
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hypodopaminergia with D1 or D5 agonists (since these receptor subtypes are
most prevalent in the cortex) may prevent the later onset of psychosis.
Serotonin
Evidence for involvement of serotonin (5HT) is derived through similar channels
as that for dopamine, namely that serotonin agonists (such as the
hallucinogenic drug lysergic acid diethylamide, LSD) can precipitate a psychotic
episode in a normal individual, and that serotonin antagonists are effective in
the treatment of schizophrenia (Owen and Simpson, 1994). Many neuroleptic
drugs have a high affinity for serotonin receptors in addition to dopamine
receptors, and those that do are often particularly effective in treating the
negative symptoms (for instance setoperone and ritanserin). It is possible that
abnormalities in the serotonin system play a role in Type II schizophrenia, that
characterised by negative symptoms (Bleich et al, 1988).
Studies on the serotonin system have mirrored those undertaken for dopamine.
Plasma and CSF levels of the primary metabolite 5-hydroxyindoleacetic acid
(5HIAA) have yielded inconsistent results, as have post mortem investigations
of serotonin receptor density (Bleich et al, 1988). However, cortical atrophy and
ventricular enlargement are irrefutably associated with a decrease in 5HIAA
(Bleich et al, 1994), and some studies reveal an increase in 5HT in platelets
from schizophrenics. This may be a consequence of a decrease in levels of
monoamine oxidase B (MAO-B) which is the principal degradative enzyme for
catecholamines (Mallet et al, 1994).
Studies on the concentrations of serotonin receptors (of which fifteen have been
cloned) are in their infancy, but there is a suggestion of deceased levels of
5HT2A and increased levels of 5HT1a in schizophrenic brains (Roth, 1994).
Glutamate
Glutamate is the primary excitatory neurotransmitter in the brain, with a
ubiquitous distribution (Owen and Simpson, 1994). Evidence for its involvement
37
in schizophrenia comes from the observation that phencyclidine (PCP), a potent
glutamate antagonist, can cause a schizophrenia-like psychosis. In many ways
this psychosis is a better model for schizophrenia than are those induced by
dopamine or serotonin agonists, since this is characterised by both positive and
negative symptoms (Owen and Simpson, 1994).
Glutamate receptors are divided into two types, NMDA (N-methyl D-aspartate)
and non-NMDA. The former has six subtypes and the latter may be split into
(R,S)-a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-preferring
or kainate preferring (Szpirer et al, 1994). Experiments have revealed a
decrease in non-NMDA receptors (Kerwin and Harrison, 1995) and an increase
in NMDA receptors (Beckwith et al, 1995) in schizophrenics, also an
upregulation of NMDA receptor mRNA in the hippocampus and a decrease in
CSF glutamate concentration. This indicates a general hypofunction in the
glutamate system in schizophrenia, which is consistent with the
neurodevelopmental hypothesis (section 1.7.2), since excitatory amino acids are
important trophic factors in the development of the hippocampus.
There are two alternative explanations for the mechanism by which glutamate
may cause disrupted development. Firstly, glutamate is involved in mediating
excitotoxity. Administration of glutamate causes opening of sodium channels
and subsequent excitation, but also leads to an influx of water which causes
toxicity and necrosis (Brown, 1992). Glutamate can also lead to apoptosis by
causing an influx of calcium and subsequent increase in superoxide. The
second theory relies on the fact that glutamate influences the organisation and
stability of microtubules, via phosphorylative modification of microtubule
associated proteins (MAPs). It has been hypothesised (Kerwin, 1993) that
excessive release of glutamate during development may lead to disruption of
microtubule assembly and a subsequent developmental anomaly in the
temporal lobe, causing schizophrenia.
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y-amino butyric acid (GABA)
GABA is a major inhibitory neurotransmitter. For decades, convulsive therapy
with metrazol (a GABA antagonist) has been used to treat schizophrenia, and
many antipsychotic drugs act to reverse GABA's inhibitory effect (Squires and
Saederup, 1991). This suggests a role for an excess of GABA in the aetiology of
the disorder. Some studies however have reported a decrease in glutamic acid
decarboxylase (the enzyme which converts glutamate into GABA) in
schizophrenics (Owen and Simpson, 1994), which suggests the opposite.
Acetylcholine (ACh)
Nicotinic acetylcholine receptors are implicated in the aetiology of schizophrenia
due to the association of smoking behaviour with schizophrenics (deLeon et al,
1995) and also because administration of nicotine to schizophrenics has been
found to transiently normalise the deficit in auditory sensory gating (Leonard et
al, 1995). A very high percentage of schizophrenic patients smoke (Lohr and
Flynn, 1992); the nicotine may reduce negative symptoms, reduce
extrapyramidal side effects and reduce the level of neuroleptic drugs in the
blood, hence smokers require higher doses. The a7-nicotinic acid receptor has
been cloned and found to be decreased in the hippocampus of schizophrenics
(Leonard et al, 1995).
Noradrenaline
It has been proposed that the lack of goal-directed behaviour seen in
schizophrenia could be the result of a deficit in noradrenergic function, and the
authors subsequently reported a drop in dopamine (^-hydroxylase (the enzyme
catalysing the last step in the synthesis of noradrenaline) activity in
schizophrenics (Owen and Simpson, 1994). However this has not been
replicated and it is possible that the finding was a result of drug treatment.
Cholecvstokinin (CCK)
There has been found to be a decrease in CCK mRNA in the temporal cortex
and frontal lobes of schizophrenics relative to controls (Humphries et al, 1995).
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Some post mortem studies have found a decrease in CCK receptors, yet others
have not (Owen and Simpson, 1994).
Opioids
The opioid (3-endorphin has been reported to cause a muscular rigidity similar to
that seen in the catatonia of schizophrenia, but studies of plasma and CSF
levels give conflicting results. Injection of the opioid receptor antagonist
naloxone is reported to cause a decrease in hallucinations (Owen and Simpson,
1994).
Prostaglandins-
The prostaglandins, especially prostaglandin E, are known to modulate
monoamine transmission. The activity of prostaglandin E may be decreased in
schizophrenics, thus resulting in increased dopamine and noradrenaline
transmission (Neylan and vanKammen, 1990). Abnormalities in the essential
fatty acids (EFAs) which are precursors for prostaglandins, form the basis of the
membrane hypothesis of schizophrenia (Horrobin and Huang, 1993).
Interactions between neurotransmitter systems
It is becoming clear that dysfunction in a single neurotransmitter system is
inadequate to explain the aetiology of a disease as symptomatically complex
as schizophrenia. It is also realised that the different neurotransmitters do
not act alone, but rather the systems interact to give one integrated
response. As such, the normal state is one of elasticity, where transient
changes in one system can be constantly compensated for or amplified by
another. It has been proposed that the pathology seen in psychiatric
disorders is a result of diminished plasticity in the neurotransmitter systems.
1.7.2 A neurodevelopmental anomaly
There has been considerable debate on the origin of the neuropathology
seen in schizophrenia. Kraepelin believed the disorder had the
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characteristics of a neurodegenerative process and the results of early CT
studies were used to substantiate this idea. However the absence of
correlation between length of illness and degree of degeneration did not fit
the hypothesis, neither did the visualisation of structural brain changes in
newly diagnosed patients. This instead suggested that the pathology was of
neurodevelopmental origin (Roberts and Bruton, 1990).
In favour of this is the noted absence of gliosis accompanying the
neuropathology. Gliosis occurs as a result of neuronal damage and is
characterised by a proliferation of glial cells with a concomitant rise in
associated glial proteins such as glial fibrillary acidic protein (GFAP), and
enzymes such as monoamine oxidase B (MAO-B) (Roberts and Bruton,
1990). A destructive lesion early in development (less than 6 months) would
leave no trace of gliosis, yet the type of pathology seen is indicative of the
last trimester of gestation and as such this is unlikely.
Other evidence for the neurodevelopmental hypothesis can be seen by the
fact that pre-morbid changes are seen in preschizophrenics (section 1.4.9),
in social behaviour and also on neurological and dermatoglyphic measures.
The excess of obstetric and perinatal complications seen in schizophrenics
may be as a result or be the causative factor of a neurodevelopmental
anomaly.
Crow (1980b) put forward a hypothesis that schizophrenia occurs as a result
of a mutation in a 'cerebral dominance' gene, or that which is responsible for
determining the asymmetry in size of the temporal lobes in the brains of
humans. Temporal lobe asymmetry is a relatively late evolutionary
phenomenon, believed to be linked to the development of language skills in
humans. This may be linked to handed-ness, which is believed to be
determined by a single dominant gene, termed the 'cerebral dominance
gene' or 'right shift factor'. Crow (1980b) proposed that the location of this
41
gene was within the pseudoautosomal region of the sex chromosomes (see
Section 1.10.1). Evidence for this theory is that the neuropathology seen in
schizophrenics is often more apparent on the left side of the brain. Also that
when psychotic symptoms accompany temporal lobe epilepsy, they are
schizophrenia-like if the focus is on the left hand side (Crow, 1980b). Finally
in a post mortem study (Crow et al, 1989), neuropathology was seen on both
sides of the brain in Alzheimer's patients, yet only on the left side in
schizophrenic patients.
The maternal viral hypothesis
In agreement with the neurodevelopmental theory of schizophrenia, it is
proposed that influenza may cause schizophrenia via an effect on the foetus.
This effect may be mediated by an auto-immune mechanism. The
complement of HLA alleles possessed by the mother determines her immune
response to influenza infection, and in certain cases it is proposed that
maternal antibodies produced against the virus will cross the immature foetal
blood-brain barrier and cross react with brain proteins. They perhaps
interfere with neuronal migration, which is known to occur during the second
trimester.
Evidence for the hypothesis can be seen when one considers other genetic
and environmental aspects known to be associated with schizophrenia.
There have been many suggestions of an association between
schizophrenia and the immune response. Schizophrenics are reported to
have elevated levels of immunoglobulins and a-interferon, and alterations in
cellular immunity (Wright et al, 1993). Linkage studies have proposed,
among others, a positive association between paranoid schizophrenia and
HLA-A9 (McGuffin and Stuart, 1986).
Some viruses, for instance influenza, Eppstein Barr virus and
cytomegalovirus, have capsular neuraminidases which can alter the sialic
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acid moieties on neural cell adhesion molecules (NCAMs) which regulate the
migration of neurons during embryogenesis (Wright et at, 1993). It is known
that in some cases antibodies directed against particular brain components
can be induced by viral infection (by for instance Group A streptococci or
Neisseria meningitides), and in the rabbit, anti-influenza antibodies are
produced which can cross react with mammalian and human hippocampal,
cortical and cerebellar tissue (Wright et at, 1993). Ironically, those mothers
with the optimal immune response may be those most likely to produce auto¬
immunity in the foetus yet themselves would be least likely to display overt
symptoms of influenza infection (Knight et at, 1987). Interestingly,
autoimmune diseases are more frequently seen in females, so it is
noteworthy that the influenza association with schizophrenia is possibly only
valid for females. It appears that other viral infections apart from influenza
are not involved in the pathogenesis of schizophrenia. O'Callaghan et al
(1994) studied the effect of infection by 16 different viruses, and none was
shown to be associated with an increase in incidence of schizophrenia.
A number of environmental observations on the disorder are also consistent
with the maternal viral hypothesis. There is an excess of schizophrenic births
during the winter and spring, coinciding with the time of most viral infections.
In addition, schizophrenia is more prevalent in urban areas, where viral
infection would spread most effectively. The association of obstetric
complications with schizophrenia is interesting as this represents another
time when the foetal blood brain barrier may be compromised (Wright et al,
1993). Males are known to be more prone to birth difficulties and perinatal
complications, so it has been suggested that this aetiology explains the
sporadic cases of schizophrenia in males, whereas virally-mediated
autoimmunity is responsible in females.
Other prenatal disturbances such as the effect of certain dietary deficiencies
or toxicity have been implicated in the aetiology of schizophrenia. Recently
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an association between prenatal Vitamin A excess or deficiency and
schizophrenia has been proposed (Goodman, 1995). This is due to the
observations that 1) the genes involved in metabolism and regulation of
Vitamin A and the retinoids lie in chromosomal contiguity with several
schizophrenia candidate genes, 2) that the former genes are known or
postulated to be involved in the regulation of the latter, and 3) that retinoid
dysregulation can cause pathologies and cranio-facial dysmorphisms similar
to those seen in schizophrenia.
1.7.3 The membrane hypothesis
Levels of certain essential fatty acids (EFAs) have been found to be reduced
in the membranes of red blood cells of schizophrenics, which have a
composition very similar to cells in the brain. The membrane hypothesis
proposes the existence of a defective acyl transferase (which inserts a type
of EFA into the phospholipid membrane) or an over active phospholipase A
(which removes EFAs from the membrane) (Horrobin et at, 1994). Consistent
with the latter are the facts that levels of phospholipase A have been found
to be elevated in some schizophrenics (Gattaz, 1990) and neuroleptic drugs
are known to inhibit phospholipase A. In addition, the activity of three
erythrocyte membrane ATP-ases (Na-K, Ca and Ca-Mg) has been found to
be reduced in schizophrenia and depression, which is linked to increased
activity of phospholipases (Rybakowski and Lehmann, 1994). The
membrane hypothesis can account for a number of epidemiological and
pathological features of the disorder (Horrobin et al, 1994).
1.7.4 Schizophrenia as cerebral diabetes
The effects of smoking and exposure to heterocyclic amines affect
components of the pathways of glucose metabolism, leading to a deficiency
in uptake of glucose into the cells and a state akin to diabetes. Smoking
behaviour is highly prevalent among schizophrenics; heterocyclic amines,
which cause neurotoxic damage, are more commonly found in the inner city
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where schizophrenia is also more commonly found. Nicotine and heterocyclic
amines have opposing effects on dopamine transmission, which could
perhaps resolve the discrepancy of findings suggesting either hyper- or
hypo-dopaminergia in schizophrenia (Holden et al, 1994).
As regards a diabetic state, the incidence of diabetes is more than 50% in
the first degree relatives of psychiatric patients which suggests some familial
loading between the two disorders, also insulin coma therapy was one of the
first effective treatments for schizophrenia. Thirdly, hypoglycaemia can cause
an overactivation of NMDA receptors (Holden et al, 1994), although it is
hypofunction of the glutamate system which is generally proposed.
1.8 Positional Cloning
Positional cloning, or 'reverse genetics' as it used to be known, is a method
for locating genes by a sequential narrowing of the genomic region in which
it may lie (Collins, 1992), made possible by the advent of recombinant DNA
technology. In the last twenty years it has superseded the classical methods
of 'functional cloning', in which the disease gene was approached from
knowledge of the biochemical defect and protein involved.
1.8.1 Linkage Analysis
The first step in this process of positional cloning normally involves genetic
linkage analysis. This is a general term encompassing methods used to
assess the proximity of a particular marker to the disease locus by analysis
of the frequency of recombination between the two. A marker very close to a
disease gene locus will recombine with the disease locus very infrequently,
whereas an unlinked marker will recombine with the disease gene locus at a
rate indistinguishable from that of markers across the rest of the genome.
The number of informative meioses limits the sensitivity of recombination
analysis. One recombination between two markers in 100 meioses
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corresponds to a genetic distance of 1cM between the markers, which in
man translates to an average physical distance of approximately 1Mb,
though this varies throughout the genome due to local recombination 'hot
spots' and 'cold spots'.
1.8.2 Global mapping of the human genome
The isolation of markers is a critical step in positional cloning; genetic
markers to enable more accurate linkage analysis and physical markers to
facilitate finer scale mapping once the approximate location of the disease
gene has been deduced.
In order to be useful in genetic linkage analysis, markers must contain
several different forms or alleles, that is, they must be polymorphic. Around a
disease gene locus, one allele from a tightly linked locus will tend to
segregate with the disease phenotype in a population, such that the disease
phenotype may be associated with a specific haplotype. This is termed
linkage disequilibrium, and implies that the disease mutation has arisen on a
specific chromosome and that there has been insufficient time since the
appearance of the mutation for random reassortment of closely linked
markers. The more polymorphic the marker, the more useful it is, since it will
be informative in a higher proportion of cases. The value of a marker is thus
estimated by its polymorphism information content (PIC) value.
The first polymorphisms to be useful in linkage studies were restriction
fragment length polymorphisms (RFLPs). RFLPs occur where a polymorphic
base pair results in the production or absence of a restriction enzyme site,
which may be detected by Southern blotting. The first comprehensive RFLP
maps of the entire human genome became available in 1987, with an
average of 10-15cM between the markers but many unmapped gaps.
46
A problem with RFLPs is that most have only two alleles and as such the
majority are uninformative in most families. Minisatellites (or Variable
Number of Tandem Repeats, VNTRs) are more useful since they have more
alleles. The differences between VNTR alleles lie in their length, which can
be detected by digestion at a flanking restriction enzyme site and then
Southern blotting. The initial reports were of the existence of approximately
100 VNTRs, and few more have been reported since then. Unfortunately
VNTRs do not have an even distribution throughout the genome, but rather
tend to be clustered towards the telomeres in human DNA (Hearne et al,
1992).
Since 1989, microsatellites have become the genetic markers of choice.
Microsatellites, or simple sequence repeats (SSRs) consist of di-, tri-, tetra-
and even penta-nucleotide repeat sequences of varying length, which are
short enough to be detected by PCR using flanking sequence primers (Litt
and Luty, 1989 and Weber et al, 1989). Microsatellites are randomly
distributed in the genomes of all eukaryotic organisms examined, except
yeast, at a frequency of approximately one every 30-40kb. This high
frequency, and the fact that they can be detected and scored by a simple
PCR reaction make them extremely useful for mapping purposes.
The implementation of PCR as a standard laboratory technique has
revolutionised physical as well as genetic mapping of the human genome.
PCR can be a quick and specific way to detect the presence of a marker
sequence, and it is highly amenable to automation. Indeed most physical
markers now available are short (200-500bp), specific, PCR-amplifiable
sequences of DNA, termed 'Sequence Tagged Sites' (STSs). The concept of
an STS map of the human genome was proposed six years ago (Olson et al,
1989) as a 'common language' for physical mapping. It was then envisaged
that in 5 years, an 10Okb-resolution STS map of the entire human genome
could be in place. Although this was a little optimistic, the principle of STS
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mapping was adopted worldwide. The first five year goal of the Human
Genome Mapping Project (HGMP), as defined in 1990, included the
production of high resolution genetic maps, with average spacing of 2cM,
and physical maps consisting of yeast artificial chromosome (YAC) contigs
with STS's spaced every 300kb (Jordan, 1992).
The pooling and standardisation of results and resources has greatly
facilitated worldwide collaboration on the HGMP. Enormous numbers of
markers are generated by large scale semi-automated projects, such as
Genethon in France, and because they are named according to a standard
protocol and information about them is publicly available through databases,
the efforts of all mapping laboratories can be directed towards a unified goal.
The success of standardisation has been reflected by the publication of
linkage and physical maps of the entire human genome.
The first comprehensive linkage maps of the human genome were published
in 1992 (NIH/CEPH collaborative mapping group, 1992). This map contained
1416 loci, consisting of RFLPs, protein polymorphisms, single base change
polymorphisms and microsatellites. These markers had been typed onto a
set of reference pedigrees made available by the Centre d'Etude du
Polymorphisme Humain (CEPH), which maintains a regularly updated
genotype database. An estimated 92% of the autosomal length of the human
genome was spanned by the map.
Although these maps contributed considerably to the mapping of a number
of simple monogenic genetic traits, the markers were not evenly distributed
throughout the genome, and the density of markers was insufficient to be
useful in the mapping of complex disorders or for refining linkage intervals to
distances suitable for gene identification. Incorporation of more microsatellite
markers was instrumental in the construction of more detailed subsequent
maps (Weissenbach et al, 1992). The most recent linkage map of the human
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genome (Gyapay et at, 1994) includes 2066 'CA' microsatellite markers,
typed by linkage analysis on eight large CEPH families. The average
distance between markers is now only 2.9cM, with 56% of the map covered
by markers at 1cM resolution and only one gap of over 20cM remaining.
1.8.3 Fine mapping of regions of interest
Once the region of interest has been identified by marker analysis or a
cytogenetic abnormality, it is often necessary to isolate more, densely
spaced markers from that region, such that it may be thoroughly analysed.
To aid the positioning of new markers, a large scale restriction map of the
region is useful. This can be achieved with pulse field gel electrophoresis
(PFGE) (Schwartz and Cantor, 1984), which is capable of resolving
fragments of more than a twelve megabases (Orbach et at, 1988), although it
is disadvantaged by its time-consuming and technically difficult nature.
Alternatively, fluorescent in situ hybridisation (FISH) could be used.
Hybridisation of FISH probes onto metaphase chromosomes requires
markers to be separated by more than ten megabases to achieve resolution,
whereas hybridisation onto the less compact interphase chromatin can
resolve markers separated by approximately 100kb. New techniques using
stretched chromatin have increased resolving power still further, to almost
5kb.
Somatic cell hybrids can be a useful tool both for the generation of new
markers and for the mapping of existing ones. They are made from a fusion
of human and rodent cells, after which the rodent cells segregate the human
chromosomes, resulting in a much reduced human content (Weiss and
Green, 1967). The content can be further reduced by either exposing the cell
to ionising radiation and then fusing it with a recipient cell line (radiation
hybrids) (Goss and Harris, 1975), or chromosome mediated gene transfer
(CMGT) (McBride and Ozer, 1973) in which a precipitate of donor fragments
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and CaP04 is applied to recipient cells. The stable hybrids thus produced
contain a small fraction of the human genome, which is useful for
intermediate-scale mapping of markers. For instance a complete radiation
hybrid map of 506 STS markers across chromosome 11 has been
assembled (James et al, 1994).
A somatic cell hybrid which segregates a small specific part of the human
genome can also be a useful tool for the isolation of markers from that
region. Alu-PCR (Nelson et al, 1989) uses primers derived from the
consensus of the Alu repeat to amplify inter-Alu fragments. Alu elements are
specific to human DNA, thus Alu-PCR will generate markers from the human
sequences in a somatic cell hybrid. Alu-PCR products can be used in bulk as
a FISH probe, or individual products can be used as a probe or sequenced
to create STS's.
The techniques of coincidence cloning (Devon et al, 1996) can give a higher
degree of specificity in marker isolation. A hybrid which contains only the
region of interest is rarely found; it is much simpler to define the region of
interest as that portion of the human genome shared by two hybrids. One
way to extract such sequences is to isolate the coincident sequences
between a pool of Alu-PCR products from each hybrid by a selective cloning
method (Aslanidis and deJong, 1991). The more stringent method of end
ligation coincidence sequence cloning (EL-CSC) (see section 1.8.5 for a
more detailed explanation) has been used to isolate single copy markers
coincident between somatic cell hybrids and a pool of microdissection clones
(Brookes et al, 1994).
On a larger scale, coincidence cloning using FISH technology can be used in
the isolation of markers from a region shared between two chromosomes.
The technique of 'coincidence painting' (Bailey et al, 1993) was designed for
use between a derivative chromosome from a translocation cell line and flow
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sorted normal chromosomes. The derivative chromosome is simplified,
labelled and used as a FISH probe onto a metaphase spread of the normal
chromosomes. After removing non-specifically bound probe by washing, the
region of coincidence can be visualised, and the product eluted off and
amplified. A similar method, in which the product is microdissected from the
slide, is termed 'Prep-ISH' (Hozier et al, 1994) (see section 1.8.5).
Microdissection and microcloning of a region of interest can be used to
generate markers. Microdissection of banded chromosomes (Senger, 1990)
can yield abundant, short, region-specific probes. The microdissection
technique used in this project was adapted from Weith (1994) which uses
unstained chromosomes viewed under phase contrast microscopy. This
yields clones of much greater size than the former technique. The validity of
microdissection and microcloning to obtain markers can be seen in this
project by the frequency of clones in close proximity to the translocation
breakpoint.
Recent improvements in DNA sequencing technology have made the
random sequencing of clones and subsequent generation of STSs a feasible
way to obtain densely spaced markers. The concept of 'Genomic Sequence
Sampling' (Smith et al, 1994) involves STS's across the whole genome,
separated by a short PCR-able distance. The first step is the construction of
highly redundant cosmid contigs across genomic regions, which would be
subjected to fingerprint analysis to orient and order them, and then the ends
of each cosmid would be sequenced to create a large set of ordered STS's.
PCR between two adjacent STS's could give direct access to any part of the
genome, and greatly facilitating fine mapping and sequencing to detect
genes. The feasibility of genomic sequence sampling has been modelled in a
simple eukaryotic organism (Smith et al, 1994).
Before the sequencing of the whole human genome begins in earnest, the
priority of the HGMP is the establishment of sufficiently dense marker maps
that any desired region of the genome can be accessed by PCR easily and
quickly. An estimated 3% of the human genome only is believed to code for
protein, and thus whole genome sequencing efforts were previously more
usefully directed at simpler organisms with less redundancy in their
genomes. In 1992 a project began to sequence the complete genome of the
nematode Caenorhabditis Elegans, which is approximately 100Mb long
(Sulston et al, 1992). Genes in C.Elegans are generally much smaller and
have fewer and shorter introns than their mammalian counterparts, and the
gene density is high. In addition, almost the entire genome was already
available in ordered and cloned YAC and cosmid form. A follow up two years
later reported the completion of sequencing for 2.2Mb of chromosome III
(Wilson et al, 1994).
1.8.4 Contig Assembly
Once a set of closely spaced markers is available for a region, a contig of
cloned recombinant DNA can be constructed. Many types of vector are now
available, which vary in the amount of recombinant DNA which can be
propagated in them and in their ease of use. The largest capacity cloning
vectors commonly used are yeast artificial chromosomes (YACs) (Burke et
al, 1987). More than one megabase of DNA can be cloned into YACs,
making them the usual vector of choice for preliminary large scale cloning of
a region. YACs are grown in the yeast Saccharomyces cerevisiae and so are
easy to propagate, and their large size makes genetic manipulation
straightforward. There are however several problems associated with YACs.
They are difficult to isolate in a pure form due to contamination with yeast
chromosomes, and have a low cloning efficiency. Deletions within the
recombinant DNA are a fairly common occurrence, as is chimaerism
resulting from co-cloning events, or recombination between copies of the
YAC within the yeast cell. For these reasons, greater reliance is now being
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placed on PACs (P1 artificial chromosomes) (loannou et al, 1994) and BACs
(Bacterial artificial chromosomes) (Shizuya et al, 1992). Approximately 100kb
of human DNA can be cloned into PAC vectors, which also contain the ability
to select for recombinants over non-recombinants, are stable in culture and
virtually never produce chimaeric clones. BACs can incorporate up to 300kb
of recombinant DNA and have all the advantages of propagation in bacterial
cells (high cloning efficiency, stable in culture and easy isolation of pure
DNA).
Contigs of YACs can be assembled by marker analysis and the ordering of
sequence tagged sites (STSs), also fluorescent in-situ hybridisation (FISH)
and the isolation and mapping of YAC end clones. Gaps in the contig can be
filled in by cosmids, which can incorporate about 40kb of sequence (Collins
and Hohn, 1978). The size of cosmids also makes them a useful tool for finer
scale mapping. It may be necessary to subclone further if a map of still finer
scale is required. Use can then be made of bacteriophage X vectors (up to
15kb of sequence) and bacterial plasmid vectors. Cloning into the single
stranded vector M13 is useful prior to sequence analysis; this approach is
currently used in the large-scale 'factory-style' sequencing initiatives, such as
the generation of ESTs (see section 1.8.5) and the sequencing of the human
genome.
YACs are currently the vector of choice for the large scale cloning of the
human genome and ultimately the production of contigs spanning every
chromosome. Due to the relative difficulty of cloning human DNA into YAC
vectors, much reliance has been placed on a small number of well-
documented reference libraries, for example from ICI (Anand et al, 1990),
the ICRF (Larin et al, 1991) and CEPH (Dausset et al, 1992). This has aided
the process of standardisation and facilitated collaboration between groups.
Much of the human genome YAC contig is already in place, although some
regions are far more thoroughly mapped than others. For instance a contig of
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overlapping cosmid clones spanning the entire long arm of chromosome 21
was described three years ago (Chumakov et al, 1992).
1.8.5 Methods for finding genes
Of the approximately 60, 000 to 100,000 genes in the human genome, only
approximately 175 have been mapped, cloned and associated with a
phenotype. This is not due to limitations in mapping procedures - there is
now a linkage map of the whole human genome with markers spaced on
average 2.9cM apart (Gyapay et al, 1994). Additionally many regions have
been cloned into YACs and cosmids and contigs assembled. The rate
limiting step in positional cloning is usually the identification of coding
sequences from within regions of genomic DNA.
There are several features of genes which can be exploited in order to
facilitate their detection. Firstly use can also be made of preferential cross-
species conservation of gene sequences. Secondly there are recognisable
sequence motifs associated with genes, for instance CpG islands, splice
consensus sites and the open reading frames themselves. Thirdly features of
gene expression can aid gene detection, namely the presence of mRNA and
the ability to make cDNA.
Zoo Blots Gene sequences have been more highly conserved throughout
evolution than inter-genic DNA, and as such there is a high probability that a
sequence present in several species will be part of a gene. Use of 'zoo blots'
has exploited this, and has been instrumental in the detection of a number of
genes, most notably the gene for Duchenne muscular dystrophy (Monaco et
al, 1986). A severe limitation of zoo blots however is that the probe used
must be of a small size. Whole YACs are too large to use as probes, since
they give an unacceptably high background. Whole cosmid inserts, a tenth of
the size of YACs, have been successfully applied to zoo blots, but in general
probes of only a few kilobases or less are more desirable.
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CpG Islands CpG islands are regions of the genome particularly rich in the
frequency of CpG dinucleotides. The frequency of CpG across a whole
vertebrate genome is only approximately 20-25% of that expected (Bird,
1987). This is largely due to methylation of 60-90% of cytosines, which may
be then deaminated to thymines. This mismatch is probably not recognised
by the DNA repair machinery. It has been found however that regions exist
at the 5' end of most genes, which have more than 10 times the density of
unmethylated C+G's than the genome as a whole (Bird, 1987). These
regions are termed CpG islands, or HTF (Hpa II tiny fragment) islands. They
are between 500bp and more than 2kb long, and often span the 5'-most
exons of the gene. It has been estimated that all housekeeping genes and
40% of tissue specific genes are associated with CpG islands (Larsen,
1992).
The presence of CpG islands as gene 'markers' can usefully aid gene
detection. CpG islands can be detected by the presence of rarely cutting
restriction enzyme sites. These enzymes have recognition sequences
composed entirely or largely of C and G nucleotides, and will only cut
unmethylated sequences. Thus the majority of the recognition sequences will
occur within CpG islands. For instance the enzyme Not I has an average of
0.12 cutting sites per island, but 89% of these sites occur in an island.
Similarly the enzymes Sac II, BssH II and Eag I have on average 1.2 sites
per island, and 74% of their sites will be in an island (Lindsay and Bird,
1987). Diagnostically it can be assumed that a short region containing two or
more sites for rare cutter restriction enzymes is highly likely to be a CpG
island.
Rare cutter restriction enzyme digestion of genomic regions can quickly
identify candidate regions for further analysis. Hanson et at (1991) used this
principle to identify and clone clusters of rare cutter restriction sites from the
HLA region of chromosome 6p. Others have developed PCR-based
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strategies to isolate the genomic regions flanking CpG islands. One method,
termed 'Island Rescue PCR', involves the digestion of DNA with rare cutting
enzymes, then ligation of vectorettes onto the cut cohesive ends. PCR is
then performed between the rare cutter site (vectorette primer) and an Alu
repeat sequence (Alu consensus primer). The PCR products can then be
used as probes on Northern blots or to isolate cDNA clones. Patel et al
(1991) originally described this method as applied to somatic cell hybrids.
Valdes et al (1994) then applied it successfully to YACs. This method
obviously depends on the presence of an Alu repeat element at a suitable
distance from the CpG islands and in the correct orientation.
Most recently, Cross et al (1994) have described a method to purify CpG
islands from a whole genome using an affinity column which binds
methylated DNA. The column consists of the rat methyl binding protein,
MeCP2, attached to a physical support. The DNA is digested with the
restriction enzyme Mse I, whose recognition site (TTAA) is rarely found
within CpG islands. Next, fragments containing clusters of methylated CpG's
are 'stripped' from the genome, by several rounds of purification on the
column. The CpG island regions are then methylated by the action of the
bacterial methyltransferase enzyme, which enables them to be selectively
retained by the column. The CpG islands can be eluted by the addition of
high-salt buffer.
Exon Trapping and Amplification The vast majority of genes in eukaryotic
DNA are composed of an intron-exon structure, the introns being spliced out
of the transcribed hnRNA to make a mature mRNA. The presence of splicing
indicates definitively the presence of a gene. The two methods of exon
trapping and exon amplification have been developed to detect genomic
DNA sequences containing splice sites. Exon trapping (Duyk et al, 1990)
involves shotgun cloning of DNA fragments into a retroviral shuttle vector
which contains a splice donor site. The vector is then transfected into
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mammalian cells. Pairing between vector splice donor and any genomic
splice acceptor sites will result in the production of a novel mature RNA,
which can be amplified by RT-PCR. This rather laborious method has now
been largely superseded by exon amplification (Buckler et al, 1991), a
slightly simpler version, which requires the presence of both a splice donor
and a splice acceptor site in the genomic DNA. Exon amplification is
currently viewed as one of the most efficient ways to detect genes, and has
been successfully applied in the cloning of the Neurofibromatosis type 2
gene (Trofatter et al, 1993) and the Huntington's disease gene (The
Huntington's disease collaborative research group, 1993) among others.
However it is limited by the small amount of DNA which can be inserted into
the (usually plasmid) vector, and not all sequences can be equally
propagated. In addition, exon amplification cannot detect genes without
introns, and exons with cryptic splice sites,. It is also technically demanding
due to a requirement for multiple transfections of animal cells.
Other methods to find genes also use the presence of splice sites. Liu et al
(1989) have designed degenerate hexanucleotide primers to splice donor
sites to prime cDNA synthesis from hnRNA in somatic cell hybrids. The
cDNA library thus constructed was then screened with total human genomic
DNA to identify those clones containing a human repeat. The method used
hnRNA rather than mature RNA since most human repetitive elements are
located in introns rather than exons. An alternative approach (Melmer and
Buchwald, 1992) is to use oligonucleotides corresponding to the splice site
consensus sequences as probes for hybridisation directly onto cosmid
libraries. Degenerate oligonucleotides of both 5' and 3' splice sites were
used, so to increase the proportion of intron-exon boundaries detected.
Sequencing The direct sequencing of large genomic regions and subsequent
detection of coding sequences by computer is rapidly becoming a feasible
approach, as automated sequencing and computer algorithms to detect
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genes improve. Direct sequencing seems likely to supersede many others
gene finding methods in the next few years, although to date it has been
largely applied to model systems. The program GRAIL is estimated to be
able to detect more than 90% of exons present in a given sequence, with
approximately 20% false positives.
The conventional approach involves subcloning of a region into M13,
constructing a highly redundant contig, sequencing the individual clones, and
performing more primer-directed sequencing to fill in the gaps before the
computer algorithms can be applied. The contig assembly in these projects is
a laborious task and it may not be necessary - Claverie (1994) has predicted
that a 2-fold coverage of a region by random fragment sequencing before
assembly of a contig gives a 90% probability of detecting the exons with
GRAIL.
Hybridisation to Northern blots and cDNA libraries Expression dependent
methods of gene finding vary considerably in their complexity and
usefulness. The simplest is hybridisation of probes onto Northern blots or
cDNA libraries. An obvious limitation is that the gene must be expressed,
and at a sufficiently high level in the tissue from which the RNA or cDNA has
been made. These methods are also generally not appropriate for large
probes, meaning that coverage of a large genomic region has to be by
sequential hybridisation of smaller fragments. Cosmid inserts have
successfully detected transcripts on Northern blots; these represent a
practical upper size limit on most occasions. The use of whole YACs as
probes onto cDNA libraries has been applied with some success. Pre-
annealing of the highly reiterative component of human genomic DNA to the
denatured YAC is used to block high copy repeat sequences which will lead
to false positives. Elvin (1990) used a 180kb YAC as a probe to detect a
cDNA derived from the aldose reductase gene. The false positive rate was
high, only 10% of the positive clones were also positive with an aldose
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reductase cDNA probe; the aldose reductase cDNA sequence did however
represent only -1% of the probe.
Subtractive cDNA hybridisation Many subtractive cDNA hybridisation
techniques exist. Jones et aI (1991) have developed a method to isolate
sequences transcribed in one hybrid cell line but not another. The second
cell line contains the same complement of human DNA as the first except the
region of interest. Small fragments of oligo-dT primed cDNA made from the
first cell line are hybridised to biotinylated poly(A)+ RNA from the second.
Any cDNA from a region contained in both cell lines will form a duplex and
can be removed by binding of the biotin residue to a streptavidin matrix. After
a second round of subtraction the remaining cDNAs can be used to screen a
cDNA library.
Coincidence Cloning
cDNA selection by PCR The various methodologies which fall under the
heading of 'coincidence cloning' involve the selection, in a clonable form, of a
duplex formed between two DNA sources. In the context of gene finding, one
of these DNA sources would be cDNA and the other a genomic region, such
that the products isolated would be transcribed sequences mapping to that
particular genomic region. The subset of techniques known as 'cDNA
selection' involve hybridisation of a whole cDNA library onto immobilised
genomic DNA (YACs or cosmids). One of the two resources must be pre-
blocked for high-copy repeats. In the first instance, the immobilisation of the
YACs was on a nylon filter, and the non-specifically bound cDNA species
could be washed off before elution and PCR amplification of the product. In
one study (Lovett et at, 1991), the DNA sources were an amplifiable foetal
kidney cDNA library (pre-blocked for high copy repeats) and a 550kb YAC.
The only fundamental methodological difference in the second study
(Parimoo et at, 1991) was that the immobilised genomic DNA, not the cDNA,
was quenched of available high copy repeats.
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The efficiency of coincidence cloning experiments can be expressed in terms
of an 'enrichment factor', which is the frequency of a particular DNA
sequence in the product relative to its frequency in the starting material. In
these experiments the enrichment factor was -1000-fold, which is insufficient
to recover rarer transcripts. The focus of cDNA selection experiments
therefore changed to solution rather than filter hybridisation, which produced
higher enrichment factors and in which the duplex-forming reaction was more
easily controlled. The denatured genomic DNA is attached to streptavidin-
coated magnetic beads by way of a biotin moiety added during amplification.
The pre-blocked, amplified, denatured cDNA is added before (Korn, 1992) or
after (Morgan, 1992) the genomic DNA fragments have been immobilised.
cDNAs forming stable duplexes with sequences present in the genomic DNA
will be retained during the washing steps and may then be eluted, amplified
and cloned. Further rounds of selection can be applied to increase the
enrichment still further.
End Ligation Coincident Sequence Cloning (EL-CSC) EL-CSC is an
extension of standard cDNA selection techniques, which can result in even
higher enrichment factors (Brookes, 1994 and Brookes et al, 1994). This is
due to the incorporation of an extra step before elution of the product cDNA,
the high stringency ligation of 'capture' oligonucleotides to the ends of the
cDNA while it is present in a duplex with the genomic DNA. The capture
oligonucleotides are complementary to linkers present at the ends of the
genomic DNA, and thus the ligation reaction can only take place if the ends
of the cDNA and genomic DNA are perfectly matched both in length and
end-sequence. Using EL-CSC six genes were isolated from pairing a human
foetal brain cDNA library with 260kb of pooled cosmids (Brookes at al, 1994).
Enrichment factors of greater than 106 fold can be achieved with EL-CSC,
which is at least 10-fold greater than those achievable with most cDNA
selection protocols. The spectrum of products generated by the two methods
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is however slightly different, so they should be viewed as complements
rather than alternatives.
Physical cDNA selection One of the great assets of coincidence cloning
technology relative to other gene finding methods is its ability to cope with a
wide variety of input genomic DNAs, both cloned and uncloned. It can even
be extended as far as the use of whole chromosomes, for instance in the
technique termed 'Preparative In-Situ Hybridisation' (Prep-ISH; Hozier et al,
1994). An amplified cDNA library is used as a fluorescent in-situ hybridisation
(FISH) probe onto an array of chromosomes fixed on a slide. After removal
of non-specifically bound fragments by washing, the region of coincidence
can be recovered by microdissection and microcloning. Since the human
genome can be resolved into up to 1000 recognisable chromosome bands,
an average cDNA library of 10,000 transcripts could in theory be reduced in
complexity to only 10 transcripts mapped to a particular region.
One of the main problems of coincidence cloning is the recovery of
artefactual products. High copy repeat elements can be adequately removed
by pre-blocking, but this does not remove lower copy repeats such as MERs
(Lovett, 1994). cDNA fishing may also legitimately recover other members of
a gene family or pseudogenes. More complex input DNAs compromise its
efficiency, and for this reason fewer artefactual products are recovered when
cosmids rather than YACs are used as the genomic input DNA (Lovett,
1994). YACs are problematic to isolate in a pure form, and there will
inevitably be contamination with yeast sequences to a certain extent. Parts
of the yeast genome show sufficient conservation with human DNA that they
may be genuinely recovered by coincidence; this is particularly important in
the case of ribosomal RNA (rRNA) sequences which are abundant in the
yeast genome. Pre-blocking with an excess of denatured rRNA can however
effectively remove the problem (Lovett, 1994).
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The quality of the cDNA resource is also of prime importance. It is generally
found that oligo-dT primed cDNA gives better results than a cDNA library
since the latter are often plagued with artefacts, and cross-homology can
occur between the vector sequences of the two input DNAs. The tissue of
origin must be carefully chosen to maximise the number of genes expressed
there. The advantage of EL-CSC is that it can theoretically recover genes
expressed at a very low level. Since coincidence cloning is heavily
dependent on PCR, the drawbacks of this technique must be recognised.
Amplification of the starting materials will result in a biased representation,
since the amplification favours shorter fragments and certain sequences.
Errors in sequence will also be introduced by the polymerase, though this
can be limited by including an enzyme with proof reading activity.
Whole genome efforts
Methods for detecting genes based on their chromosomal location ('top
down') are now complemented by an alternative ('bottom up') strategy based
upon direct sequencing of cDNAs. The latter has been developed in the last
few years, has been undertaken on a huge scale, and it is likely to be more
instrumental in the establishment of a primary gene map of the human
genome than the conventional positional cloning approach.
This 'bottom up' strategy is a massive programme to derive STS's for all
human cDNAs, termed Expressed Sequence Tags (EST's) (Adams et at,
1991). ESTs are derived from the sequence of the 3' end of random cDNA
clones from brain cDNA libraries. The 3' ends include the untranslated region
(UTR); this was chosen because 1) 3' UTRs rarely contain introns (so the
EST is of the same size in genomic DNA and cDNA), 2) the identification of a
poly(A) tail and polyadenylation signal is useful for verifying true human
mRNAs and 3) the 3' UTR sequence is often more gene specific than the
coding sequence and can therefore be used to distinguish between
members of a conserved gene family (Berry et al, 1995).
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The cDNA clones can be sequenced rapidly using automated procedures in
'factory-style' laboratories and as a result, EST sequences are currently
being added into the 'dbEST' database (Boguski et at, 1993) at the
phenomenal rate of approximately 1500 per day (Boguski and Schuler,
1995). It is estimated that more than 50% of all human genes are now
represented by at least one EST.
The rate limiting step in the establishment of a human gene map via ESTs is
the mapping of their chromosomal location. Until very recently, the large-
scale mapping of EST was merely to assign them to a particular
chromosome by PCR amplification in a set of somatic cell hybrids each
containing a single human chromosome (Polymeropoulos et at, 1992) or by
genetically mapping polymorphic cDNAs using the CEPH reference
pedigrees and database (Polymeropoulos et at, 1993). Now however use is
being made of the increasingly extensive YAC contigs and panels of
radiation hybrids - one group has reported the region-specific localisation of
318 EST-derived cDNAs, representing 308 human genes (Berry et at, 1995).
It is unfortunate that as more knowledge of the aetiology of human genetic
diseases becomes available, then the disease-causing genes themselves
become precious commodities. Controversial issues regarding the patenting
of genes have arisen, as several large-scale cDNA sequencing institutions
teamed with drug companies seize the opportunity of a lucrative future.
Fortunately the hitherto collaborative nature of the worldwide genome project
has not been in vain, since other institutions are now producing an equally
large EST database with unrestricted access for other researchers.
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1.9 Positional Cloning methodology used in complex
disorders
1.9.1 Linkage Analysis
Parametric linkage analysis on large multiply affected families has the power
to detect a locus contributing a modest susceptibility to a complex disorder.
The results are expressed as a logarithm of odds (lod) score, at a certain
distance (expressed as a recombination fraction, 0) from the disease locus. It
is accepted that a lod score of 3 or greater demonstrates significant linkage
at a particular locus (Risch, 1992); this implies an odds ratio of 1000:1 that
the two loci are linked.
The affected sib-pair and affected pedigree member methods
These are non-parametric linkage methods. Non-parametric methods are
more robust than parametric methods since they require no assumptions
about the mode of inheritance, and thus also avoid the necessity for testing
multiple models. Non-parametric methods lack some of the power of the
parametric methods, yet can out-perform parametric analysis if an incorrect
model is applied to the latter (Terwilliger and Ott, 1994).
Sib-pair analysis relies on the assumption that two siblings will share, on
average, 50% of their alleles. However two affected siblings will be expected
to share alleles tightly linked to the disease locus at a frequency greater than
50%. This can be detected in a sib-pair analysis with a sufficiently great
sample size. The affected-pedigree member method examines the frequency
of allele sharing between two affected members of a family, with the
assumption that alleles either at or very close to a disease locus will be
shared more frequently than would be expected by chance. Although it is
easier to obtain larger sample sizes than for sib-pair analysis, it is strongly




In an association study, the frequency of particular alleles at a polymorphic
locus in a sample of unrelated individuals is compared with the frequency of
this allele in controls (Hodge, 1994). An allele which occurs more frequently
with the disease phenotype than would be expected by chance can be
assumed to have a genetic locus close to a gene involved in the disease.
Association studies are not as powerful as parametric linkage studies, but
their advantage is that pedigree data are not required. This is particularly
useful in late-onset conditions where members of previous generations are
likely to be deceased.
Mutational Analysis of candidate genes
A particular form of association study is to search for mutations in a
candidate gene, which can then be tested for association with the disorder.
The association study is of particular importance so as to test whether the
mutation detected is in fact only a naturally occurring polymorphism of no
pathogenic significance. For instance, Nothen et al (1994) reported a null
mutation in the first exon of the D4 gene, leading to a truncated protein.
However it was found that this null allele occurred in about 2% of the normal
population, with a similar frequency in schizophrenics and controls.
1.9.3 Testing candidate genes
Once a gene has been found which demonstrates an association with the
disorder, studies must be undertaken to assess the nature of the gene in
relation to the disorder. Evidence accrued from several avenues will
contribute to the status of the candidate gene.
Firstly, a search can be undertaken for mutations in the gene in affected
individuals. Gross deletions and large chromosome abnormalities can be
detected by Southern blotting and/or cytogenetics. Other methods are
required for the detection of smaller deletions and point mutations. Several of
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these rely on altered electrophoretic mobility, for instance single strand
conformation polymorphism (SSCP) analysis or denaturing gradient gel
electrophoresis (DGGE). Others depend on cleavage at a mismatch, for
instance RNase A cleavage, use of the E.Coli mutS protein which binds to
mismatched DNA or the hydroxylamine osmium tetroxide (HOT) technique.
Alternatively the mutation/polymorphism can be detected by direct
sequencing in patients versus controls.
The standing of a candidate gene can also be tested by logical analysis of its
expression pattern and function. Hybridisation onto Northern blots and RT-
PCR analysis can reveal in which tissues the gene is expressed. RNA in situ
is time consuming but can give more suggestion of the function of the gene
by its specific spatial and temporal expression pattern. If the gene is novel
then sequence analysis and database searching can reveal clues as to its
function, via homologies with other known genes. If there are no homologies,
the protein sequence of the gene should be analysed for sequence motifs
indicative of transmembrane regions, DNA binding regions etcetera.
In a heterogeneous condition such as schizophrenia, a gene mutated in one
family must be tested in other affected families. If it appears to be normal in
these others, then tests should be carried out on biochemically and
evolutionary related genes. One approach which may be particularly useful
for complex disorders is to exploit the cross-species conservation of genes,
by studying animal models. Once predisposing genes have been identified
and mapped in an animal, use can be made of knowledge of syntenic
regions between the animal and the human genomes to attempt to identify
the human counterparts. Although the genes which predispose to disease in
an animal may not be exactly the same as those underlying human disease,
there are often similarities in terms of number and interactions of genes and
the specific physiological process involved. Elucidation of the genes involved
in an animal model is simpler than in humans due to the availability of inbred
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strains in which the genetic background is known, and directed matings. An
understanding of the genetic basis for the complex disorder in non-obese
diabetic (NOD) mice has been achieved (Ghosh et al, 1993).
The mouse mutant reeler has recently been identified as being caused by a
single gene defect (D'Arcangelo et al, 1995). Reeler is an autosomal mouse
mutation causing impaired motor co-ordination, tremors and ataxia. Neurons
fail to reach their correct locations in the developing brain. The mutation has
been found to be in a gene, dubbed 'reelin', which resembles extracellular
matrix proteins involved in cell adhesion. The study of animal model
phenotypes such as this may provide clues as to the underlying genetic
basis of comparable phenotypes in humans.
For a more thorough investigation of the function of a novel gene, transgenic
mice could be made by inserting a mutated version of the gene (for dominant
genes) or by knocking out both copies of the normal gene (for recessive
genes). Any phenotype thus produced in the mouse could be analysed and
correlated with phenotype seen in man. Rat transgenic animals are useful for
the study of dominant negative phenotypes. Animal studies of this type have
begun using the prime candidate genes in schizophrenia, neurotransmitter
receptor genes. Injection into the brain of an antisense oligonucleotide
directed against the D2 receptor can block D2 receptor activity by causing a
steric hindrance or creating a substrate for RNase H. It was found that D2
activity was effectively blocked across the whole striatum (as measured by
the drop in binding of radio-labelled spiperone) and caused a decrease in
spontaneous locomotor activity in the rat (I.J. Creese, presented at the
'International Congress on Schizophrenia Research', Virginia, USA, 1995).
Sasaoka and Tonegawa (1995) have produced transgenic mice which either
overexpress the D4 gene or are knock-outs for the NMDA receptor R2B. The
aim will be to cross the two mice to study the effect of defects in both the
dopamine and glutamate systems. The work is still in the early stages, but
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some hyperactivity and exaggerated startle response has been noted in the
D4+ mice.
1.10 Previous Attempts to Find Genes Associated with
Psychiatric Disorders
There are currently three fundamental approaches to finding genomic
regions associated with psychiatric disorders (Bassett, 1991). The first is to
focus on certain regions of the genome, those for which there is some a
priori evidence for involvement with the disorder. This may include regions
previously implicated in linkage studies, chromosomal regions where
particular cytogenetic abnormalities are linked with psychiatric illness, or
information derived from case studies in which schizophrenia is seen to
segregate with another genetic disease whose locus is known. The second
approach is to carry out linkage and segregation analysis across the whole
genome, to find 'hot-spots' for regions likely to be linked with the disorder.
Recently formed collaborative consortia between research groups world¬
wide, and the ever-increasing density of markers available for analysis have
made this feasible. The third and final method is to study candidate genes,
drawing upon knowledge from hypothetical aetiologies. Linkage and
association analysis can be performed using polymorphisms detected within
the genes, or a more direct search for mutations can be carried out. This
approach proved extremely useful in Alzheimer's disease when mutations
were found in the gene for the amyloid precursor protein (APP) (Goate et at,
1991).
1.10.1 Linkage in candidate regions
Chromosome 5q
The much heralded first positive linkage of a genomic locus with
schizophrenia was announced in 1988 (Sherrington et al, 1988). The report
of a partial trisomy of 5q in a schizophrenic boy and his schizophrenic
maternal uncle (Bassett et al, 1988), generated interest in performing linkage
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studies with markers from the region of the trisomy. Sherrington et al
reported a maximum multipoint LOD score of 6.49 at markers with two RFLP
markers in the region (5q11-13). These data came from analysis of 39 cases
of schizophrenia from 2 British and 7 Icelandic families, with a broad
phenotypic definition, dominant mode of transmission and 86% penetrance.
This result has however never been replicated. In the same issue of Nature
as the original paper was a report excluding linkage at 5q11-13 in a large
Swedish kindred (Kennedy et al, 1988). Since then many other linkage
studies have been carried out, all with the same negative conclusions (for
example Detera-Wadleigh et al, 1989, St.Clair et al, 1989, Aschauer et al,
1990, Crowe et al, 1991, McGuffin et al, 1990 and Macciardi et al, 1992).
The original report of linkage might therefore have been due to chance or to
inappropriate methodology or statistics. Alternatively it is possible that the
families studied segregated a rare form of the disorder. The latter is plausible
for the Icelandic families, since they were geographically isolated, but seems
unlikely due to the inclusion in the positive findings of the two British families.
One patient has been reported in which there is a co-occurrence of
schizophrenia and Treacher Collins syndrome, which is a disorder of cranio¬
facial development. Two siblings of the patient also had a psychiatric
diagnosis. Treacher Collins syndrome has been mapped to 5q31-34. A
cytogenetic survey of the patient was performed to detect any gross
chromosomal deletions of the Treacher Collins region plus the putative
schizophrenia locus, but no abnormalities were detected (Nimgaonkar et al,
1993a).
Chromosome 11 q
There have been three reports of chromosome translocations involving
chromosome 11 q associated with psychiatric illness. The first, a balanced
translocation between chromosomes 1 and 11 (St.Clair et al, 1990) forms the
basis for this thesis and therefore is described in detail later (section 1.12.2).
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A second translocation t(11 ;9)(q22.3;p22) was found to co-segregate with
affective disorder in at least 5 members of an extended pedigree (Smith et
al, 1989). The chromosome 11 breakpoint was estimated to be within 210kb
of the dopamine D2 receptor. Thirdly, a balanced translocation between
11 q25 and 6q14.2 was reported to co-segregate with psychotic illness in a
three generation family (Holland and Gosden, 1990).
Linkage analysis with other markers on chromosome 11 has however not
yielded any significant lod scores. D11S35 gave a lod of 1.49 in a Japanese
study (Nanko et al, 1992) and 1.8 (conservatively corrected score) in another
study of 23 multiply affected schizophrenics (Gill et al, 1993).
The sex chromosomes
Evidence for the involvement of the sex chromosome in schizophrenia has
arisen from an apparent excess of sex chromosome abnormalities seen in
schizophrenics. Sex chromosome aneuploidies such as Turner's syndrome
(XO), Klinefelter's syndrome (XXY), triple X, XYY and mosaicism for X
chromosome aneuploidies have all been observed among female
schizophrenics (Barr et al, 1994a) However a strict X linked mode of
inheritance can be excluded due to the presence of male to male
transmission in some families. Parametric linkage analysis and affected sib-
pair analysis across the entire X and Y chromosomes yielded a positive but
statistically insignificant maximum lod score of 1.83 at the marker DXS7 (De
Lisi, 1994). Crow et al, (1993) have reported an excess of shared alleles at
the androgen receptor gene locus between male sib pairs. This locus is a
candidate gene for schizophrenia due to the observed sex differences in the
age of onset and course of the disorder.
The pseudoautosomal region of the X and Y chromosomes has been
particularly implicated. This is a region at the tip of the X and Y
chromosomes which contains regions of sequence similarity between the
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two, and undergoes a single obligatory recombination during meiosis. As a
result, the genes at the telomere segregate independently of sex, and there
is an increasing gradient of sex linkage until the boundary of the
pseudoautosomal region is reached (Ishida et al, 1993). An involvement of
the pseudoautosomal region in schizophrenia was first implicated when it
was noted that there tended to be a higher concordance for schizophrenia in
same-sex siblings than in opposite-sex pairs. This can be explained under a
model of paternal transmission of a pseudoautosomal allele, which would be
passed on the X chromosome to daughters or the Y chromosome to sons.
The model also implies that the excess of concordance should be in those
families where the disorder is paternally derived. Some studies have
confirmed the excess of same-sex pairs (Gorwood et al, 1992 and Asherson
et al, 1992), whereas others have refuted it (Ishida et al, 1993).
Despite this observation and many parametric and non-parametric linkage
and association studies, there have been no consistent reports of linkage to
markers in the pseudoautosomal region. Collinge et al (1989) reported a
positive linkage result with the marker DXYS14, but others have failed to
replicate this in other families (d'Amato et al, 1992 and Parfitt et al, 1991).
Asherson et al (1992) found an excess of shared alleles at DXYS14 in
schizophrenics but excluded this marker by linkage. An analysis of the entire
pseudoautosomal region in a Swedish kindred produced no significant
linkage (Barr et al, 1994a), although Crow et al (1994) reported a lod score
of 2.44 at the gene MIC2, which is located within the pseudoautosomal
region.
The human lymphocyte antigen (HLA) region, 6p21.3
The HLA region was a candidate for linkage analysis since many
immunological abnormalities have been associated with schizophrenia.
Changes in T cell dependent reactions have been noted, along with an
increase in numbers of CD3+ and CD4+ cells. Association studies have been
71
performed with many HLA antigens. In a sample of 100 Belgian
schizophrenics a significant negative association was found between
schizophrenia and the DPB1*0101 allele (relative risk of 0.27) and a positive
association was revealed with CD4*A4 (relative risk 1.79) (Zamani et at,
1994). A slightly decreased chance of paranoid schizophrenia has been
found in those expressing the HLA-A1 allele, but an increased chance with
HLA-A9, A28, B18, B27 and Cw24. Risk of hebephrenic schizophrenia is
slightly associated with the A1 and B15 alleles. (Douglass et at, 1993)
Chromosome 2
The report of a balanced translocation t(2; 18)(q21 ;q23) segregating with
schizophrenia in a family (Genest et a/, 1976) prompted a linkage study
using markers located at 2q21. No evidence for linkage was found, and
50cM around 2q21 could be excluded (Aschauer et at, 1993).
Chromosome 9
A G-banding survey of schizophrenics versus controls (Nanko et at, 1993a),
revealed an increased frequency of a pericentric inversion of chromosome 9
relative to controls (Serra et at, 1990). This was in concordance with an
increased prevalence of the same chromosome anomaly found in male
patients with paranoid psychosis (Axelsson and Wahlstrom, 1984). However
a linkage study on three multiply affected families using markers from the
region of the inversion (D9S55, D9S15 and D9S202) resulted in no
significant lod scores (Nanko et at, 1994a).
1.10.2 Whole genome scans
A whole genome scan of patients from 39 systematically ascertained
multiplex families (Pulver et at, 1994a) revealed a maximum lod score of 1.54
at chromosome 22q12-q13.1, a region which contained several candidate
genes. This slight positive finding was then followed up by a collaboration of
4 groups using families from Ireland, USA, France, England, Wales and
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Japan (Pulver et al, Diehl et at, Gill et al and Laurent et al, 1994b). This
follow up study found no evidence for linkage in this region of chromosome
22q.
Other chromosome 22 studies have revealed no consistent results - a) The
marker D22S55 (22q) gave a slightly positive lod score in a whole genome
scan with 329 polymorphic loci, which remained positive when the affected
pedigree member method was employed (Coon et al, 1994a). b) A linkage
study of 9 families with 10 chromosome 22 markers gave a maximum lod
score of 2.09 at D22S276. Non-parametric tests also gave suggestive but
not conclusive evidence for linkage with this marker (Coon et al, 1994b). c)
Polymeropoulos (1994) scanned 105 families with 10 chromosome 22
markers and found no evidence for linkage, d) Linkage analysis with markers
D22S274 and D22S283 (22q12-13) on twenty three UK and Icelandic
families yielded no significant lod scores (Kalsi et al, 1995).
Linkage analysis with an autosomal dominant mode of inheritance, using 180
polymorphic markers in a Swedish kindred resulted in no positive findings,
but 330cM of the genome were able to be excluded from involvement in this
family (Barr et al, 1994b).
The only significant lod score which has been produced by a whole genome
scan thus far is that of Wang et al (1995). Linkage analysis of markers
covering 10% of the genome was performed on 186 Irish families, which
resulted in a maximum lod score of 3.2 at D6S260 which maps to 6p23. Use
of the affected pedigree member method also gave significant results at this
locus. The positive results did not include the HLA region.
73
1.10.3 Analysis of candidate genes
Dopamine Receptors
The genomic loci of the five dopamine receptors are prime candidates for
linkage to schizophrenia due to the proposed abnormalities in the functioning
of the dopamine system in the disorder. D3 and D4 are of particular
significance; the former due to its restricted limbic expression pattern and the
latter due to its high affinity for clozapine, the most effective antipsychotic
drug. The cloning and molecular analysis of the receptor genes yielded
polymorphisms which could be used for linkage analysis. For instance the D2
gene contains a polymorphic base pair which results in an alternative amino
acid (serine or cysteine) at position 311 (Itokawa et al, 1993). D3 contains a
Bal I RFLP (Lannfelt et al, 1992), and D4 has a variable number of copies of
a 48bp tandem repeat in the putative third cytoplasmic loop (Van Tol et al,
1992). More than twenty alleles of D4 may exist as a result of this repeat,
which may be of significance in schizophrenia since different alleles exhibit
different binding affinities for clozapine and spiperone.
Despite many attempts, no consistent linkages or associations have been
reported at any dopamine receptor locus. (D1_: Campion et al, 1994. D2:
Campion et al, 1994, Nanko et al, 1994c. D3: Yang et al, 1993, Nanko et al,
1993b, Nimgaonkar et al, 1993b, Nanko et al, 1994b, Shaikh et al, 1993
(bipolar affective disorder). D4: Sommer et al, 1993, Nothen et al, 1994, Barr
et al, 1993, Shaikh et al, 1994, Macciardi et al, 1994, Seeman et al, 1994b,
Lim et al, 1994 (bipolar affective disorder)). One finding, replicated once, was
an excess of homozygosity for D3 alleles in schizophrenics (Crocq et al,
1992). This was replicated to a lesser extent by Mant et al (1994), although
other many other studies have found no such association (Nothen et al,
1993).
In addition to linkage studies, the status of the dopamine receptor genes as
candidates for schizophrenia has been examined by sequence analysis.
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Sarkar et al (1991) sequenced 7 regions of functional significance (including
the coding sequence and splice junctions) of the D2 gene in 14
schizophrenics and 4 normal controls. No associations were found.
Linkage has been carried out for markers at the dopamine transporter gene,
mapped to 11 p15.3, whose activity is the termination of dopamine function
by reuptake into the pre-synaptic terminal. No positive lod score was found
(Persico et al, 1995).
Other neurotransmitter receptors
Coon et al (1994c) examined the coding region of the GABAa(31 subunit gene
for sequence variants. SSCP analysis revealed a C to G change which
would result in glutamate rather than histidine at position 396, a highly
conserved portion of the gene. This variant was found in 2 out of 3 affected
siblings in one family, but not in a further 155 unrelated schizophrenics; it
was also found in 1.1% of controls.
Hallmayer et al (1992) performed linkage analysis with markers spanning
19cM around the 5HT2 gene on chromosome 13. Linkage at this locus was
excluded in a Swedish kindred.
Amyloid Precursor Protein (APP)
Mutations in the gene APP has recently been discovered in early-onset
Alzheimer's disease patients. Since 30-40% of Alzheimer's patients display
psychotic symptoms, APP is also a candidate gene for schizophrenia. In
1992 Jones et al reported a single case in which a patient with schizophrenia
had a point mutation in the APP gene, a C to T transversion that would result
in a valine rather than alanine at position 713. This variant was however not
found in a further 100 schizophrenics or 100 non-demented controls (Jones
et al, 1992), 39 Japanese schizophrenics (Fukuda et al, 1993), or 86
schizophrenics (Coon et al, 1993a) and as such is most likely to be a rare
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non-pathogenic variant.
Linkage analysis was carried out on 24 multiply affected families with a
marker at the APP locus, and SSCP mutation analysis on one member from
each family. Neither approach resulted in a positive result (Asherson et al,
1993). Linkage analysis also gave negative results with markers spaced at
20cM intervals along chromosome 21 q.
No association analyses have yet been reported with other genes involved in
Alzheimer's disease (for instance ApoE4 and S182) although their status as
candidate genes in schizophrenia has been mentioned (Goodman, 1994).
Tyrosinase
There have been several reports of families in which schizophrenia is
associated with tyrosinase negative oculocutaneous albinism (OCA). Baron
(1976) described a 22-member family of Yemenite-Jewish origin, among
which 5 individuals were diagnosed with OCA and schizophreniform
psychosis. Another report described a link between OCA and schizophrenia
in 2 out of 3 siblings of an Irish family (Clarke and Buckley, 1989). It is
possible that this association reflects the chromosomal location of a gene
predisposing to schizophrenia, that is near tyrosinase on chromosome 11 q.
Alternatively a metabolic abnormality or the disordered neuroanatomy
associated with albinism may predispose to schizophrenia.
Porphobilinogen Deaminase (PBGD)
The gene PBGD is involved in acute intermittent porphyria, which makes it a
candidate gene for schizophrenia since individuals suffering from porphyria
sometimes display signs of mental disturbance reminiscent of schizophrenia.
An association study (Sanders et al, 1991) using a dichotomous PBGD
RFLP revealed a relative risk for schizophrenia of more than 2 in individuals
possessing the A2 allele, and an earlier age of onset in A2 homozygotes.
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Later Owen et al (1992) attempted to replicate this study but found no
positive associations.
Genes involved in Usher's syndrome
A sibship of 8 has been reported in which there were 3 cases of Usher's
syndrome and 6 cases of mental retardation (Sharp et al, 1994). In addition,
many other members of the family have psychiatric disorders. The primary
symptom of Usher's syndrome is deafness, so it is of interest that
schizophrenia is associated with abnormalities in auditory information
processing. A gene for Usher's syndrome TypelB has recently been
discovered to be myosin Type VII, mapping to chromosome 11 q (Weil et al,
1995).
Phenylalanine hydroxylase (PAH)
Lack of PAH is responsible for phenylketonuria (PKU). The gene is a
candidate gene in schizophrenia for the following reasons: a) Patients with
PKU and their first degree relatives often display behavioural abnormalities
including psychosis, b) In the absence of PAH, increased plasma and urine
levels of phenylethylamine (PEA) are observed. The same has been
observed in schizophrenics, c) PEA potentiates dopamine and
norepinephrine in the same way as amphetamines (reviewed in O'Reilly and
Davis, 1993).
An association study between mutations of PAH and schizophrenia however
proved negative (Sobell et al, 1993).
Dystrophin
A Brazilian family has been described in which schizophrenia cosegregates
with Becker muscular dystrophy (Zatz et al, 1991). Southern blot analysis
however revealed no detectable large exonic deletions (Lindor et al, 1994).
In addition, 2 out of a series of 35 patients with Becker muscular dystrophy
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were diagnosed also with schizophrenia (Beggs et al, 1991).
Huntingtin
The symptoms of schizophrenia are seen in 5-10% of Huntington's disease
patients. One schizophrenic (non-HD) individual has been reported whose
number of trinucleotide repeats falls outside the normal range and within that
for Huntington's disease (St.Clair, 1994). In another study the schizophrenic
probands all had repeat lengths at the HD locus within the normal range
(Rubinsztein et al, 1994).
1.10.4 Linkage studies in bipolar affective disorder
Attempts to locate genes implicated in bipolar affective disorder has mirrored
the efforts in schizophrenia. A significant linkage was first detected in an Old
Order Amish population, at the Harvey ras and insulin loci on 11 p15
(Egeland et al, 1987). This result was however not replicated in Icelandic
(Hodgkinson et al, 1987) or North American Irish families (Detera-Wadleigh
et al, 1987), and later the finding was withdrawn by the original authors.
Completion of typings, further linkage analysis upon extensions of the
pedigree and onset of the illness in two family members negated the result
(Kelsoe et al, 1989).
Despite exclusion of linkage to 11 p15, a positive association was reported
for the tyrosine hydroxylase (TH) gene in a French population (Leboyer et al,
1990). Interestingly enough, TH maps to 11 p15. TH is a good candidate
gene in psychiatric illness since it is a rate limiting enzyme in catecholamine
synthesis. This finding has however not been replicated (Lim et al, 1993).
The other major locus implicated in bipolar affective disorder is Xq28,
containing the loci for deutan colour blindness and glucose-6-phosphate
dehydrogenase (G6PD). There have been repeated reports of linkage to
these two classical markers, one study generating a lod score of nearly 8 for
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a highly penetrant dominant gene (Baron et at, 1977). More recently, linkage
has been reported at the blood clotting Factor IX locus (Mendlewicz et at,
1987). However, this gene lies on Xq27, a sufficiently great distance from the
other positive loci that it cannot be seen as a replication of the earlier
findings.
Whole genome scans have also been attempted for bipolar disorder. In one
study (Coon et at, 1993b), eight multiplex families were examined for linkage
with 328 markers across the genome. Four markers gave a lod score of
more than 1 (D5S39, D5S43, D5S62 and D11S85), but only D5S62
remained positive upon analysis by the affected pedigree member method.
This marker maps to distal 5q, in a region containing several
neurotransmitter receptors (D1, adrenergic receptors a1 and (32, GABA
receptor a1 and a glutamate receptor) which are good candidate genes in
schizophrenia (Coon et at, 1993).
1.11 Problems with Linkage Studies in Complex Disorders
It can be seen from the wealth of negative or at least unconvincing results
from linkage and association studies to date, that there has been no single
locus identified unequivocally to be involved in the aetiology of schizophrenia
or other psychoses.
For single locus genetic traits, conventional linkage studies are extremely
adept at detecting genuine linkage between the disease locus and a marker.
To date, positive linkage scores have been generated in more than 400
cases. For the following reasons however, basic linkage analysis is not so
effective for complex traits such as schizophrenia.
1) Linkage analysis requires assumption of a single gene model, whereas a
polygenic system with modifications from the environment is more likely
(Baron et at, 1990). A variety of linkage studies must be carried out under
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different models of inheritance, for instance dominant, recessive or mixed,
which may not intuitively fit the pattern of segregation seen in the family.
2) Gene frequency and penetrance must be specified. Again, a range must
be used. Although misspecification of genetic parameters will usually not
prevent the detection of linkage, it will result in an erroneous recombination
frequency between the marker and the disease locus (Cloninger, 1994).
3) Diagnostic boundaries are critical and must be specified in advance.
Nothing is known concerning the aetiological homogeneity of the
schizophrenia spectrum disorders and so it is unclear which disorders should
be grouped together for linkage analysis (Baron et al, 1990). False positive
inclusions will increase the estimated genetic distance between the marker
and the disease until it becomes so great that a genuine linkage is not
detected. General guidelines for inclusion have been formulated from the
results from family studies (Levinson and Mowry, 1991). Probands must
have a diagnosis of strict schizophrenia, with a course of at least two years.
Relatives are included as affected if they have been diagnosed with
schizoaffective disorder (but not if more than two relatives have
schizoaffective disorder), schizotypal and paranoid personality disorder,
schizophreniform illness, atypical psychosis and delusional disorder.
Families are not excluded if they contain a case of bipolar affective disorder
or depressive psychosis or if the inheritance of schizophrenia appears to be
bi-lineal (Levinson and Mowry, 1991).
In some cases the power to detect linkage in families can be increased by
including those affected by the neurocognitive traits previously discussed as
'markers' for schizophrenia (section 1.4.10) (Keefe et al, 1991). These may
include eye-tracking dysfunction, attentional deficit and abnormalities in the
P300 and P50. In future studies, some use may be made of the
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neuroanatomical changes seen in some schizophrenics, and the decrease in
cortical glucose utilisation.
Normally a range of linkage analyses are required using broad to narrow
definitions of the schizophrenia spectrum.
4) The aetiology of schizophrenia may be heterogeneous (Baron et al, 1990).
The enormous variety in symptoms and course of illness plus the many
proposed aetiological explanations does indeed suggest that heterogeneity
may exist. In addition, phenocopies of the disorder may be caused by
substance abuse and organic brain disorders such as temporal lobe
epilepsy, Huntingdon's disease and porphyria. Approximately 25-30% of
carefully diagnosed schizophrenics show evidence of organic impairment
with CT scans (Faraone and Tsuang, 1985).
5) Assortative mating occurs more frequently between psychiatric patients
and as such may cause aetiologically distinct forms of the disorder to
segregate in one family (Rieder and Gershon, 1978).
6) The number of affected individuals required to detect linkage is great. An
estimated 200 sib-pairs are needed in order to achieve 80% power to detect
linkage with a LOD of 3 at 0=0.1 with a fully informative marker (Kruglyak
and Lander, 1995). One large, multiply affected pedigree alone may contain
sufficient power to detect linkage, but the family may be segregating a rare
form of the disease, and the linkage is critically dependent on the diagnosis
of key family members (Cloninger, 1994). Large, multiply affected families
are also hard to find due to incomplete penetrance, decreased reproductive
fitness and high geographical mobility. Families containing more than one
schizophrenic member are often unstable and become disrupted (St.Clair et
al, 1994). Reliance may then be placed on sketchy and sometimes unreliable
case notes and information from relatives concerning the diagnosis of absent
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or deceased family members. Small families may have fewer complicating
factors such as assortative mating and phenocopies, but larger numbers are
required.
1.12 Current Strategies To Find Genes Involved In
Psychiatric Disorders
It has become evident from the plethora of negative linkage results that
classical methods for detecting linkage in single gene disorders may well be
inappropriate for use in complex disorders such as schizophrenia. There are
two fundamental ways to overcome this problem. Firstly the methodology
used for linkage studies of unrelated individuals can be improved. Second is
the identification of simple systems in which the disorder can be clearly
demonstrated to be linked with a physical marker. The best example of the
latter has been the identification of a large single family in which mental
illness segregates with an unambiguous cytogenetic abnormality, a balanced
translocation between chromosomes 1 and 11.
1.12.1 Methodology of linkage studies
There must be large samples of pedigrees, systematically ascertained with
standardised procedures to aid collaboration and replication (Cloninger,
1994). A range of standardised inclusion criteria should be implemented, and
the models decided upon prior to analysis (Baron et at, 1990). When
possible, attempts should be made to separate subtypes of schizophrenia
into aetiologically distinct varieties (for instance subgroupings according to
age of onset and mode of inheritance produced positive linkage for
Alzheimer's disease) (Cloninger, 1994).
Use must be made of the more sophisticated linkage methods now available,
which can deal with a range of affectedness rather than a simple dichotomy
of affected versus non-affected. Complex methods of segregation analysis
can now test for single locus and polygenic components, while taking into
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account reduced penetrance, variable age of onset and phenocopies. As has
been learned from linkage analysis for Insulin-dependent Diabetes Mellitus
(IDDM), it may be necessary to combine segregation and linkage
approaches in order to detect a genuine association (Julier et at, 1991).
Replication by independent researchers is critical. Standardised procedures
will facilitate replication. Confirmation of linkage in the light of more markers,
updated diagnoses and extension of the pedigrees will increase the validity
of any linkages detected.
1.12.2 A family in which mental illness is strongly associated with a
balanced translocation, t(1;11)(q42.2;q21).
A large Scottish pedigree has been reported (St.Clair et at, 1990), in which a
balanced translocation between chromosomes 1q and 11 q has been found
to segregate with psychiatric illness. The proband was first ascertained in
1968 during a cytogenetic survey of boys admitted to Scottish borstals.
Information regarding other members of the family was accrued through the
MRC Human Genetics Registry which contains information and annual
clinical follow-up data on 282 pedigrees with familial autosomal
abnormalities. Seventy-seven family members were then included in a
detailed analysis, of whom 58 were still living. Diagnoses of all those with
major mental illness were evaluated by a psychiatrist blind to karyotype
status, and 30 of the 58 living family members were interviewed and rated
according to the structured criteria of the SADS-L. Information regarding the
other 28 living family members was ascertained by study of case notes and
discussion with general practitioners and relatives.
It was found that 23 members of the family met Research Diagnostic Criteria
for mental and or behavioural disorders. There were 3 cases of
schizophrenia, 2 of schizoaffective disorder, 6 of recurrent unipolar major
depression, 3 of generalised anxiety disorder, 1 of minor depressive disorder
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and 3 of alcoholism. Among these, 2 had committed suicide and 3 attempted
suicide. A further 5 members of the family had or were receiving treatment
for adolescent psychiatric disorders (including severe conduct disorder,
chronic generalised anxiety, learning difficulties and educational disturbance,
bizarre behaviour and mixed adolescent conduct and emotional disorders.
Karyotyping of the 77 family members revealed that 34 carried the t(1; 11)
rearrangement. 16 of these 34 (49%) had a psychiatric diagnosis. In
contrast, only 5 of the 43 (12%) members without the translocation had a
psychiatric diagnosis, and none of these were major mental illness (1 was
generalised anxiety, 1 minor depressive disorder and 3 alcoholism). It is
interesting to note that the only psychiatric diagnoses present in family
members not carrying the translocation are ones not normally included in the
schizophrenia spectrum of presumed aetiological homogeneity.
Lod scores against chance linkage of the translocation with the mental
illness were calculated. A range of gene frequencies and penetrances were
implemented. Under a narrow model including solely schizophrenia and
schizoaffective disorder the lod score was 2.19, but it rose to 3.33 with the
inclusion of major depressive disorder. Using a broad definition of affected
status, incorporating the above diagnoses plus adolescent conduct and
emotional disorder, the maximum lod score of 4.34 was achieved. When
generalised anxiety, minor depression and alcoholism were included in the
affected phenotype, the lod scores fell to below significance.
This provides strong evidence that there is a dominant locus predisposing to
major mental illness in this family near one or both of the translocation
breakpoints. There has been prior reason to assume the existence of a
predisposition locus on chromosome 11 q. Firstly there are two other 11 q
translocation breakpoints associated with psychiatric illness. There are also
several candidate genes located on 11 q, such as the dopamine D2 receptor
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gene and a neural cell adhesion molecule (NCAM) gene (St.Clair et at,
1994). Associations have been reported between psychiatric illness and
albinism and also porphyria; the genes responsible for these illnesses
(tyrosinase and PBGD respectively) are located on 11 q. Finally Usher's
syndrome has been mapped to near the breakpoint and a family has been
described in which schizophrenia co-segregates with Usher's syndrome
(St.Clair et al, 1994).
1.13 Experimental Background to the Project
Since there were many reasons to suggest that a locus predisposing to
schizophrenia lies on chromosome 11 q, it was decided that this side of the
translocation breakpoint should be cloned as a priority. Lymphoblastoid cell
lines were set up from translocation carriers and non-carriers in the family.
Genetic linkage analysis was carried out with available polymorphic markers
in the region, using markers from both chromosomes 1 and 11. On
chromosome 11 no recombinations were found with tyrosinase (TYR) and
the anonymous markers D11S388, and FISH analysis revealed that they
were the closest known markers flanking the breakpoint (Fletcher et al,
1993). The distance between TYR and D11S388 has been estimated at
7.2cM (NIH/CEPH collaborative mapping group, 1992), a distance too great
to begin positional cloning without the aid of more markers. To this end, the
translocation-derived chromosomes were segregated into separate mouse-
human somatic cell hybrids (MIS7 and MIS39) using cell surface marker
selection strategies (Fletcher et al, 1993). Analysis of markers on these
hybrids confirmed the finding that TYR was the closest known marker above
the breakpoint, and D11S388 the closest below. Further mapping resources
were generated by X-irradiation of the chromosome 11-only hybrid J1, to
create stable chromosome fragment cell lines. The human DNA content of
these four WJX hybrids was assessed by PCR marker analysis and FISH
with Cot 1 human DNA (Fletcher et al, 1993).
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To generate markers in the interval between TYR and D11S388, the
technique of microdissection and microcloning was used. This technique
exploits the fact that the chromosomal abnormality can be visualised under
phase-contrast microscopy; the derived chromosome 1 contained a
discontinuity on the long arm of 1q. Two microdissection experiments were
undertaken (Muir et al, 1995). In the first, 160 fragments derived from the
translocation breakpoint region were microdissected, digested with EcoR1
and cloned into lambda vectors. This led to over 400 recombinant clones
with an average insert size of 0.3kb. The second experiment yielded over
600 clones with a larger insert size, average 1.5kb. PCR amplification of
these clones with vector primers gave a total library length of more than 1Mb
(ignoring redundancy). The clones from both libraries were screened with a
(GT)25 dinucleotide repeat probe, and five positives were found in the second
library (Muir et al, 1995).
A set of 86 repeat-free microclones from the second library were then used
as hybridisation probes onto a Southern blot containing the WJX
chromosome 11 fragment hybrids and MIS7.4 (the hybrid containing the
derived chromosome 1). Forty-nine of these were assigned to chromosome
11 and 37 to chromosome 1, approximately half each, which confirms the
validity of the microdissection approach. A pool of all the microdissection
clones from each library was labelled as a FISH probe and 'painted' back
onto metaphase spreads from a translocation patient in the family. Signal
was obtained on the normal chromosome 1 (band 1q42.2) and 11 (band
11 q21) plus the derived chromosome 11 as expected (Muir et al, 1995).
The 49 clones from the second experiment mapping to chromosome 11 were
assigned to regions according to results of mapping them to the somatic cell
hybrid panel. Clones mapped to all the regions defined, with the exceptions
of the regions defined by NCAM and DRD2 (Evans et al, 1995). They also
defined 2 new intervals on chromosome 11. Eleven of the microdissection
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clones however map to the region immediately distal to the breakpoint, as
defined by the marker D11S873, a recently defined marker that lies
centromeric to D11S388 (Litt et al, 1993). The distance between TYR and
D11S873 can be estimated by subtraction to be ~5.6cM (NIH/CEPH
Collaborative Mapping Group, 1992), and hence the eleven novel
microdissection clone markers within this region should provide a sufficiently
dense framework to construct a YAC contig across the region.
Five repeat free microclones from the eleven (MD220, MD283, MD176,
MD122 and MD471) were used to screen gridded libraries of YAC
recombinants (Evans et al, 1995). Two libraries were screened, the ICI YAC
library (Anand et al, 1990) (courtesy of the UK HGMP Resource Centre) and
the ICRF Reference library (Larin et al, 1991) (courtesy of Dr. Hans
Lehrach). Twenty three independent YACs were isolated in this way. These
were screened for positivity with the eleven microclones and thus a simple
first generation contig could be assembled, with just a single gap This
however contained no information about the orientation of the contig or the
extent of overlap between YACs (Evans et al, 1995).
1.14 Aims of this Thesis
1) To isolate end clones from the YACs efficiently, developing and using
splinkerette PCR (an alternative to vectorette PCR). This to include a
demonstration of the superior function of splinkerettes compared with
vectorettes.
2) To map the end clones isolated back onto the YACs, thus assessing the
extent of overlap between the YACs and enable the construction of a
detailed contig of the region.
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3) To map some of the YACs in the contig by pulse field gel electrophoresis
to aid in the production of a large scale restriction map of the region and a
search for CpG islands.
4) To undertake a search for genes in the region nearest the breakpoint,
using hybrid-fishing coincident sequence cloning (HF-CSC).
5) To analyse the results of the HF-CSC experiment in comparison with a
parallel end-ligation coincident sequence cloning (EL-CSC) experiment.
6) To map the products isolated onto the genomic region of interest.
7) To prove the genie nature of products identified and to begin to assess




All chemical were supplied by BDH unless otherwise stated.
All solutions and methods were taken from or adapted with minor
modifications from Sambrook et al (1989) unless otherwise stated.
2.1 Bacterial Cell Culture and Plasmid DNA Preparation
2.1.1 Media and solutions
All media were sterilised by autoclaving.
Terrific broth
In 900ml water dissolve 12g tryptone (Difco), 24g yeast extract (Difco), 4g
glycerol. Autoclave then add 100ml autoclaved phosphate solution (0.1 M
KH2P04 & 0.72M K2HP04).
L-aaar
In 1 litre water dissolve 10g tryptone, 5g yeast extract, 10g NaCI, 2.46g
MgS04, 15g agar (Oxoid Ltd).
Ampicillin (Sigma)
Make stock at 50mg/ml in dH20, filter sterilise. Store at -20°C.
Use at final concentration 50jig/ml.
Tetracycline (Siamaf
Make stock at 5mg/ml in 100% ethanol. Store at -20°C.
Use at final concentration 50|.ig/ml.
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X-Gal (Sigma)
Make stock at 20mg/ml in DMF (Sigma). Store protected from light at -20°C.
Use at final concentration of 40pg/ml.
IPTG (Sigma)
Make stock at 100mM. Store protected from light at -20°C.
Use at final concentration of 0.5mM.
Hogness Solution
3.6mM K2HP04, 1.3mM KH2P04, 2mM Na3Ci.2H20, 1mM MgSO4.7H20, 4.4%
glycerol.
Make stock at 10x concentration. Filter sterilise.
GTE
50mM glucose, 10mM EDTA, 25mM Tris.HCI (pH 8)
Use autoclaved Tris and EDTA. Sterile filter the glucose.
2.1.2 Growing bacterial cells on agar plates
The desired volume (up to ~200|il) of bacterial cells is pipetted onto the
surface of the L-agar, and is then spread by a sterile bent glass rod until the
liquid has thoroughly soaked into the agar. (If more cells than are contained
in 200pl are required, the cells may be concentrated by 1 min centrifugation
in a microfuge followed by resuspension of the pellet in a smaller volume.)
The plates are then inverted and incubated for 12-16 hours at 37°C. Cells
were viable from plates stored at 4°C for several weeks.
2.1.3 Frozen stocks of bacterial colonies
The selected colony was restreaked on a fresh L-agar plus ampicillin plate,
then a single colony from the new plate was used to inoculate 5ml of Terrific
broth plus ampicillin. After incubation at 37°C for approximately 16 hrs, a
1/10 volume of 10x Hogness solution was added to 1mI of the culture in a
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standard 1.5ml eppendorf tube (Treff). This was then frozen and stored at
-70°C.
To reactivate cells from frozen stocks, a plastic loop was passed across the
surface of the frozen culture and sufficient cells would be picked up to
spread on an L-agar plate and grow at 37°C.
2.1.4 Use of colony picker
A colony picking robot (Hybaid) was used according to the manufacturer's
instructions to spot the CSC product library colonies onto filters and in the
preparation of their frozen stocks.
2.1.5 Preparation of plasmid DNA (small scale)
The method used was a modification of the alkaline lysis method of Jones
and Schofield (1990).
The desired colony on an agar plate was used to inoculate 6ml of Terrific
broth plus ampicillin and was grown at 37°C overnight with continuous
shaking at 250rpm. The culture was then centrifuged for 1min in a standard
1.5ml eppendorf tube, adding 1,5ml of the culture at a time and retaining the
pellet. The pellet was then resuspended in 200|il GTE (50mM glucose,
10mM EDTA, 25mM Tris.HCI (pH 8) and left on ice for 5mins. Next, 500jil of
freshly prepared 0.2M NaOH/1% SDS was added, mixed thoroughly by
vortexing and left on ice for 5mins. This step is to lyse the bacterial cell wall
and denature the DNA. To neutralise, 250pl of 3M KAc (pH 4.8) was then
added, mixed thoroughly as before and left on ice for 10 mins.
The tube was then centrifuged twice for 10 mins at RT at 11,000rpm and in
each case the supernatant was retained. This is to remove the cellular
debris. RNase A (Sigma) was then added at a final concentration of 20pg/ml
and left at 37°C for 10mins. The supernatant was then extracted twice with
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200jul chloroform (Fisons), mixing the layers thoroughly by vortexing and
then separating them by centrifugation for 1min.
The DNA was then precipitated by adding an equivalent volume of 100%
isopropanol (Fisons) and immediately centrifuging for 10 mins at RT. The
supernatant was discarded and the pellet then washed briefly in 500pl 70%
ethanol and dried under vacuum.
2.1. 6 Precipitation with polyethylene glycol (PEG)
The DNA prepared for ABI sequencing was subjected to a further
precipitation. The pellet was resuspended in 33.6pl dFI20, then 6.4|il NaCI
and 40|il autoclaved 13% PEG8000 were added. After thorough mixing, the
tube was incubated for 20 mins on ice and then the DNA was precipitated by
centrifugation for 15 mins at 4°C. The supernatant was then removed and
the pellet dried under vacuum. The pellet was then resuspended in 20gJ of
dH20. To check the concentration of plasmid DNA recovered, 1pl of the 20pl
was run on a 0.8% agarose gel, and the intensity of the bands compared
with standards.
2.1.7 Preparation of plasmid DNA (large scale)
The selected bacterial colony was grown overnight at 37°C, with shaking at
250rpm, in 4ml Terrific broth plus ampicillin, then this 4ml was used to
inoculate a 400ml for a further overnight culture. The culture was then
centrifuged in 50ml volumes at 4000rpm for 20mins at 4°C. The pellet was
then resuspended in 16ml GTE and left for 5mins on ice. Next, 32ml of
freshly prepared 0.2M NaOH/1% SDS was added, mixed thoroughly by
vortexing and left for 5mins on ice, before adding 16ml 3M KAc (pH 4.8),
again mixing and leaving for 10 mins on ice.
The tubes were then centrifuged at 4000rpm for 20 mins at 4°C and the
supernatant retained. This supernatant was then filtered gently through 4
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layers of gauze into fresh centrifuge bottles. 36ml of isopropanol was then
added and the bottles spun immediately at 4000rpm for 10 mins at 4°C. The
supernatant was discarded and the pellet was washed with 20ml of 70%
ethanol and centrifuged at 4000rpm for 10 mins at 4°C. The supernatant was
once again discarded and the bottles drained. The pellet was resuspended in
2.5ml TE (pH 8) and transferred to a Universal tube.
Next, 3.55g CsCI and 200pl of EtBr (5mg/ml stock) (Boehringer Mannheim)
were added and the solution transferred to a 'quickseal' tube (Beckmann). A
balance tube was made up if necessary with TE, CsCI and EtBr. The tube
was then spun for 20hrs at 80,000rpm at 20°C in a fixed angle rotor. The
plasmid band was then carefully extracted through the side of the tube with a
needle and syringe and placed in a 15ml tube. The plasmid DNA was then
extracted three times with a 0.25x volume of CsCI-saturated isopropanol.
Water was then added to increase the volume approximately twice, and then
the DNA was ethanol precipitated. The resulting pellet was resuspended in
1ml water and the concentration of plasmid DNA checked by running 1pl on
a 0.8% agarose gel and comparing the band intensities with standards.
2.2 Cloning of DNA Molecules into Plasmid Vectors
2.2.1 Strain of bacteria used
The competent cells were made from E.coli, strain XL1-Blue (Stratagene).
The genotype of XL1-Blue cells is: recA1 endA1 gyrA96 thi-1 hsdR17 supE4
relA1 lac [F' proAB laclq ZAM15 Tn10 (Tetr)]
2.2.2 Preparation of competent cells
Using a sterile loop, XL1-B!ue bacterial cells from a frozen stock were
streaked out onto a fresh L-agar plate and grown at 37°C overnight with
continuous shaking at 250rpm. One of the resulting colonies was then used
to inoculate 10mls of Terrific broth plus tetracycline, which was left at 37°C in
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a shaking incubator overnight. This whole culture was then used to inoculate
11 of Terrific broth, and this was grown shaking at 37°C. The absorbance at
600nm of the culture was continually checked on a spectrophotometer.
The cells were harvested when the Abs600 was between 0.5 and 1.0, which is
still in the log phase of growth. The flask containing the culture was then
chilled on ice for 15-30 mins then the contents were centrifuged in ice cold
50ml Falcon tubes for 15 mins at 4000rpm at 4°C. The supernatant was
discarded and the pellets resuspended in a total of 11 of sterile water before
centrifugation as before. The pellets were resuspended in a total of 500ml
sterile water and re-centrifuged. Pellets were then resuspended in 20ml of
10% glycerol and centrifuged again. The final resuspension was in 2-3ml of
10% glycerol. This cell suspension was then aliquoted into 40pl volumes in
1.5ml eppendorf tubes and snap frozen on dry ice plus methanol (Fisons).
The aliquots were stored at -70°C.
2.2.3 Test transformation of competent cells
In order to quantify the competence of the cells prepared as above, they
were subjected to a test transformation (see section 2.2.4) using 1ng of pBS
vector alone as the transforming DNA. Cells transformed with pBS will
contain an ampicillin resistance gene and can therefore be selected for on L-
agar plus ampicillin plates. The competence of the cells is measured in cfu's
per pg of transformed DNA. Values of 107 to 5x108 cfu's/pg pBS were
routinely achieved.
2.2.4 Plasmid vector
The plasmid vector used was pBluescribe (pBS; Stratagene) which is a
2746bp plasmid derived from pUC19 (Yanisch-Perron et al, 1985). It
contains an ampicillin resistance gene and a multiple cloning site flanked by
T3 and T7 promoters.
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All the DNA molecules cloned possessed cohesive termini, which were
compatible with a restriction enzyme site in the multiple cloning site of pBS.
The digested insert molecules were therefore directly ligated into pBS
linearised with the appropriate enzyme. However the 5'-phosphate groups
from the vector were firstly removed by phosphatase treatment, so as to
prevent recircularisation of the plasmid during ligation. The circular plasmid
containing an insert of DNA was then used to transform competent cells.
2.2.5 Electro-transformation of competent cells
An aliquot of competent cells was thawed on ice, and then the transforming
DNA (usually 1pl of the ligation reaction) was added, mixed with the cells and
left on ice for 1min. This was then transferred to an ice-cold cuvette
(Flowgen) and subjected to a pulse of 2.5kV in a BioRad Gene Pulser. The
cells were swiftly mixed with 1ml of Terrific broth, transferred to an eppendorf
tube and left at 37°C for 1 hr to enable the cells to begin to express the
ampicillin resistance gene conferred by the transformed plasmid. Aliquots of
several different volumes were then spread onto L-agar plus ampicillin plates
and incubated overnight at 37°C.
2.2.6 Selection for colonies that contain recombinant plasmids
Selection was by a simple process of blue/white selection. The polylinker of
the vector pBS interrupts the {3-galactosidase producing gene, lac Z.
However the disruption is in-frame and results in a harmless insertion of a
few amino acids into the (3-galactosidase gene. Expression of this gene
within bacterial cells can result in the production of a blue colour if the
medium on which the cells are grown contains the chromogenic substance
X-Gal and the derepressor of the Lac operon, IPTG. If however the polylinker
site in the plasmid is interrupted by an insert of foreign DNA, a functional (3-
galactosidase enzyme cannot be transcribed and hence the resultant
colonies are white.
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2.3 Yeast Cell Culture and DNA Extraction
2.3.1 Media and solutions
All media were sterilised by autoclaving
AHC broth and agar
AHC is a rich selective medium which lacks uracil and tryptophan. It was
used for selective growth of YAC recombinants prior to the isolation of YAC
DNA and the production of plugs.
In 1 litre water dissolve 1.7g yeast nitrogen base (without amino acids and
NH4S04) (Difco), 5g NH4S04and 10g casein hydrolysate (low salt). Adjust pH
to 5.8. 17-20g of Bacto agar (Difco) were added to each litre of broth to make
AHC agar. Autoclave. Add 50ml filter sterilised 40% glucose and 10ml of
2mg/ml adenine sulphate.
YPD broth and agar
YPD medium was used for growing yeast cultures.
In 1 litre water dissolve 20g bactopeptone (Difco), 5g yeast extract (Difco)
and 5g NaCI. Add 1.5% agar for YPD agar. Autoclave. Add 40% sterile
glucose.
SCE
In 500ml water dissolve 1M sorbitol, 0.1M Na3Ci, 60mM EDTA, pH7.
Solution 1
6ml 50mM EDTA, 2ml SCE, 10Opil (3-mercaptoethanol (Sigma), 4mg
zymolyase (ICN Biomedicals).
Solution 2
50ml 0.5M EDTA, 250pl 2M Tris.HCI, pH 7.5, 3.75ml (Tmercaptoethanol.
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Solution 3
200ml 0.5M EDTA, 1ml 2M Tris.HCI pH7.5, 2g N-laurylsarcosinate.
Immediately before use add 1mg/ml proteinase K (Boehringer Mannheim).
2.3.2 Preparation of yeast DNA
A 5ml yeast cell culture was grown overnight in AHC and was centrifuged for
4 mins at 3000rpm (in a Sorvall T6000). The pellet was resuspended in 0.5ml
1M sorbitol, 0.1 M EDTA solution, pH7.5 and transferred to a microfuge tube.
20pl of 2.5mg/ml zymolyase was added to break down the cell wall, and the
tube incubated at 37°C for 2 hours. The tube was then centrifuged for 1 min
at 11,000rpm, the supernatant discarded and the pellet resuspended in
0.5ml of 50mM Tris.HCI pH7.4, 20mM EDTA.
10Opil of 10% SDS was added, and mixed in carefully but thoroughly, before
incubation at 65°C for 30 mins. The proteins were then precipitated by
adding 200pl 5M KAc, pH5.4. The tube was then left on ice for 1 hr, then
centrifuged at 100,000rpm for 5 mins. The supernatant was transferred to a
fresh tube and to it was added 1 volume of isopropanol. This was mixed and
left at RT for 5 mins, before centrifuging at 11,000 rpm for at least 10 sees.
The supernatant was then removed with a pastette, and the pellet left to air
dry. The pellet was then resuspended in 0.3ml TE, pH 7.4. RNA was
removed by digesting with 1.5jjJ 10mg/ml pancreatic RNase (Sigma) at 37°C
for 30 mins. The DNA was then precipitated by adding 15|il 5M NaCI and
900jllI 100% ethanol, and then pelleted by centrifugation. The supernatant
was then removed, the pellet was washed in 500jil of cold 70% ethanol and
dried. The pellet was then resuspended in 200pl TE, pH7.4.
2.3.3 Preparation of yeast DNA plugs for PFGE
This method allows for the extraction of intact yeast chromosomes, including
yeast artificial chromosomes (YACs), from cells. It was adapted from Maule
(1994).
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A 12ml culture was grown from a single colony. The culture was grown in
selecting AHC medium at 30°C for 24 hours or until the cells reached
approximately 108 cells/ml. The culture was then subjected to centrifugation
at 3,000 rpm for 10 mins. The supernatant was discarded and the cell pellet
washed twice in 15ml 50mM EDTA, pH7.5. After washing, the cell pellet was
resuspended in 0.6ml Solution 1, and was mixed, but not vortexed.
Immediately, 0.75ml 1% LMP agarose (Gibco, BRL) at 50°C in 0.125M
EDTA, pH7.5 was added. After mixing thoroughly, 100|il aliquots of the
solution were quickly dispensed into plug moulds and left to cool at 4°C.
Once set, the plugs were ejected into a Falcon tube containing 10ml Solution
2 and were incubated at 37°C for 6 hours or overnight. The Solution 2 was
then replaced with 10ml Solution 3 and the tube left at 50°C overnight. This
step was repeated with fresh Solution 3. The Solution 3 was replaced with
0.5M EDTA and the plugs stored at 4°C.
2.4 Purification and Concentration of DNA
2.4.1 Phenol/chloroform/ether extraction
To remove proteins from DNA samples, the DNA can be extracted with
organic solutions. Two methods were used:
a) DNA was extracted twice with a phenol/water/chloroform mixture (Applied
Biosystems). This involved adding 1/10 volume of the organic mixture,
vortexing vigorously and then centrifugation at 11,000rpm for 2 mins. The
upper, aqueous layer was then carefully removed, avoiding precipitated
protein at the interface between the two layers. The DNA was then
recovered by ethanol precipitation.
b) DNA was extracted first with a 1/10 volume mixture of chloroform (Fisons)
and isoamylalcohol (Sigma) in a 24:1 ratio. A second extraction was then
performed with an equal volume of water-saturated ether (Fisons). After
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separation of the aqueous layer from the ether, the tube was left open to the
air for 10 mins to allow evaporation of any residual ether, and then DNA was
ethanol precipitated.
2.4.2 Ethanol precipitation
To concentrate DNA and remove salts, a 1/10 volume of 2M NaAc, pH 5.5
was added to the DNA solution, followed by 2-21/2 volumes of 100% ethanol
at -20°C. The contents of the tube were mixed and then chilled at -70°C for
1hour to overnight. The tube was then centrifuged at 11,000rpm for 15 mins
at 4°C. The supernatant was poured off, and the pellet dried under vacuum.
The pellet was then resuspended in the desired volume of dH20.
2.4.3 Drop dialysis
DNA solutions were drop dialysed to remove salts. A 0.025|im drop dialysis
filter (Millipore) was placed on the surface of a pool of sterile water in a Petri
dish. After 5 mins, the DNA solution (maximum 20|il) was placed as a drop
onto the surface of the filter and left for 30 mins, during which the
concentration of salts in the sample equilibrates with the water. The drop




1M Tris.HCI, pH8.0; 20mM EDTA; 1M boric acid, pH8.3.
20x TAE
0.8M Tris.HCI, pH 8.0; 20mM EDTA; 0.4M acetic acid.
10x DNA Loading Buffer
20% Ficoll (Pharmacia), 100mM EDTA, orange G (Sigma).
99
6% Denaturing Polvacrylamide
Pre-prepared acrylamide/ bis acrylamide (19:1) sequencing solution (Severn
Biotech Ltd.) was used, containing 6% w/v acrylamide, 7M urea and 1x TBE.
33mls of this solution was used to pour each gel. 33pl of TEMED (Sigma)
and 0.2ml of freshly made 10% ammonium persulphate were added to the
acrylamide before pouring the gel.
10x MOPS
0.2M MOPS, 0.05M NaAc, 0.01 M EDTA, pH to 7.0, autoclave.
2.5.2 Size markers used in Gel Electrophoresis
250ng of the appropriate size marker was used per gel. Size markers used
were:
a) X DNA digested with Hind III (Boehringer Mannheim)
b) 0X174 digested with Hae III (Boehringer Mannheim)
c) 1kb ladder (Gibco BRL)
Saccharomyces cerevisiae strains YP148 (Jones et al, 1989) and AB792
(Link and Olson, 1991) were used as size markers for PFGE.
Table 2.1 lists the sizes of the bands in XHind III, 0X Hae III and the 1kb
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2.5.3 Agarose gel electrophoresis
DNA molecules were separated according to their size on horizontal agarose
medium EEO (Sigma) gels. The percentage of agarose used to make the
gel depended on the size range of the DNA molecules to be resolved.
Digested genomic DNA or plasmid DNA was commonly run on 0.8% agarose
gels, whereas smaller fragments, such as most PCR products, were run on
1-2% agarose gels. All agarose gels were made with and run in 1x TAE. To
stain the DNA, ethidium bromide was added to all agarose gels and the
running buffer at a concentration of 250pg/ml of buffer. 1/10 of the sample
volume of 10x loading buffer was added to the DNA prior to loading the
sample on the gel. Either mini gels (30ml agarose) or midi gels (120ml
agarose) were used depending on requirements; gels were run at 25-80V
depending on resolution and run-time required.
DNA fragments were visualised on a mid range UV transilluminator and
photographed using a video copy processor (Mitsubishi).
2.5.4 Purification of DNA from agarose
DNA fragments were run in low melting point agarose (Ultrapure LMP
agarose, Gibco BRL) in 1x TAE. Gels were viewed on a mid range UV
transilluminator and the required fragment was excised using a sterile scalpel
blade as quickly as possible to minimise nicking of the DNA. Care was taken
to ensure that a minimum of agarose was excised with the required DNA
band.
Isolation of DNA from gel slices was by agarase treatment. The gel slice was
diluted with water to decrease the percentage agarose to 0.8%, then 1/25
volume of 25x agarase buffer (Boehringer Mannheim) was added. Large gel
slices were split into aliquots of ~ 10Opil each. The gel slices were then melted
at 70°C for 10 mins, during which they were mixed and spun down several
times. The slices was left to cool to 37°C, then 1 pi (0.5-1 unit) agarase
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(Boehringer Mannheim) per 10Opil was added. The reaction was left to
proceed for 2hrs at 37°C, then the DNA was ethanol precipitated at -70°C
from 1hrto overnight.
2.5.5 Polyacrylamide gel electrophoresis
Denaturing polyacrylamide/urea gels were used to resolve DNA sequencing
ladders. The following electrophoresis procedure was used for non-
automated sequencing of PCR products.
Glass plates were prepared by washing thoroughly in detergent and distilled
water, followed by 100% ethanol. The front plate was coated with
dimethyldichlorosilane and left to dry. The back plate was treated with 30pl y-
methacryloxypropyl- dimethoxysilane (Sigma) and 30pil glacial acetic acid
(Fisons) in 10ml 100% ethanol and left to dry. The plates were then rinsed
briefly in 100% ethanol (back plate) or distilled water (front plate) and dried.
Spacers were placed along the sides of the back plate, the front plate was
placed on top, then the sides and bottom of the plates were sealed together
with tape. Freshly prepared polyacrylamide was then poured between them.
An inverted sharks-tooth comb was inserted to form a flat top to the gel, and
clamps were applied to the plates' edges. The gel was allowed to set for at
least an hour at room temperature.
Prior to running the gel, the tape was removed from the bottom of the plates.
A metal plate was clamped to the front of the gel to ensure even heat
distribution. The comb was removed and the surface of the gel flushed with
1x TBE to remove excess urea. The comb was then re-inserted and the gel
loaded with up to 10pil sample. The gels were run in 1x TBE on a vertical
slab gel apparatus (Scotlab) at 30W for 2 hours, or until the dye in the
loading buffer had reached the bottom of the gel.
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After electrophoresis, tape at the sides of the plates was removed and the
front plate was lifted off, leaving the gel stuck to the back plate. The gel was
fixed by washing in 15% methanol, 5% glacial acetic acid for 20 mins. It was
then dried in an 80°C oven. The gel was then exposed to x-ray film.
2.5.6 Pulsed field gel electrophoresis
Agarose plugs were washed once in TE and equilibrated to the running
buffer (0.5x TBE) over three hours. A 1% agarose (MP agarose, Boehringer
Mannheim) gel was made up in 0.5x TBE and the plugs inserted into the
wells. The wells were sealed with 1% LMP agarose and the gel run in pre-
cooled sterile 0.5x TBE at 12°C. Gels were run using the Chef-DR II pulse
field tank and control module (Biorad); run times and conditions were varied
depending on the size resolution required.
After electrophoresis, DNA was stained by gently agitating the gel in running
buffer containing 250pg/ml ethidium bromide for 20 minutes. The DNA was
then visualised and photographed as in section 2.4.3.
2.5.7 Electrophoresis of RNA
RNA molecules were separated by electrophoresis on agarose gels
containing 10% 10x MOPS and 17% formaldehyde. 1.2% medium EEO
(Sigma) agarose was dissolved in 1x MOPS, left to cool to 50°C, then the
formaldehyde was added and the gel poured immediately. The gels were left
to set, and then loaded, in a fume hood.
The RNA sample to be loaded onto the gel (5|ig) was made up to the
required volume containing 50% formamide, 10% 10x MOPS and 16%
formaldehyde. Prior to loading the sample was heated to 65°C for 20 mins,
cooled on ice for 5 mins, and then 1x loading buffer was added. Gels were
run at 30V overnight.
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After electrophoresis, the RNA was stained by gently agitating the gel in
dH20 containing 250jig/ml ethidium bromide for 10 mins. The background
staining was then removed by similarly agitating the gel in dH20 for as long
as necessary. The RNA was then visualised and photographed as for DNA.
2.6 Transfer of DNA and RNA to membranes
2.6.1 Southern transfer
DNA was transferred from gels to nylon membranes by capillary blotting.
This method was adapted from Southern (1975).
Gels were photographed next to a ruler to allow for future sizing of DNA
fragments.
To aid the transfer of large yeast chromosomes and YACs, pulsed field gels
were additionally UV-irradiated on a mid range transilluminator for 3 mins, or
gently agitated in 0.25M HCI at RT for 20 mins.
The DNA was denatured by gently shaking the gel in denaturing solution
(0.5M NaOH, 1.5M NaCI) for 45 minutes. The gel was then neutralised by
gently shaking in neutralising solution (1M Tris.HCI, 2M NaCI, pH 5.5) for 45
minutes and then rinsed. A large strip of 3MM filter paper (Whatman) was
soaked in 20 X SSC (3M NaCI, 0.3M Na3C6H507.2H2O, pH7.0) and placed on
a board. The ends of the paper were placed in a reservoir of 20x SSC,
forming a wick. The gel was placed inverted on top of the wet filter paper,
then a correctly sized piece of nylon membrane (Hybond-N, Amersham), was
placed directly onto the gel. Two pieces of 3MM blotting paper, pre-soaked in
2x SSC, were placed on top of the membrane. Air bubbles were removed
carefully. Any exposed wick was screened off with Saran wrap (Dow
Chemical Company), then a weighted stack of paper towels was placed on
top.
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Pulsed field gels were blotted for two days, with a change of paper towels
midway. Other gels were blotted for either 5 hours or overnight. After
blotting, the membranes were left to air dry, and then DNA was bound to the
filter by exposing it to 1200|aJoules of UV irradiation in a Stratalinker
(Stratagene). Alternatively the membranes were baked at 80°C for 1hour.
Nylon membranes were stored in Saran wrap or between two sheets of 3MM
paper at RT.
2.6.2 Transfer of RNA to nylon filters (Northern blotting)
RNA was transferred from agarose gels to Hybond-N nylon membrane in the
same way as for DNA except that the denaturation and neutralising steps
were omitted, and 10x SSC replaced 20x SSC as the solution beneath the
wick.
2.6.3 Transfer of bacterial colonies to filters and replication of filters
Nitrocellulose (Schleicher and Schuell) or nylon (Hybond-N, Amersham)
circular filters were labelled with an asymmetric pattern of dots and laid
carefully on the surface of the agar plate, so as to avoid air bubbles. The
filter was left on the surface for approximately 10 sees while the pattern of
orientation dots from the filter was copied onto the bottom of the Petri dish.
The filter was then peeled off, being careful not to smear the colonies, and
left face up. To make a replica, another, unmarked, filter was then gently laid
on top of the first filter and pressure was applied evenly across the surface to
transfer the colonies. The pattern of dots was copied onto the back of the
replica filter before separating the two. The colonies on the agar plates were
left at 37°C for several hours to 'recover'.
2.6.4 Fixation of the bacterial colonies to filters by lysis
One sheet of 3MM paper was soaked in each of the following solutions:
a) 10% SDS
b) denature - 1.5M NaCI, 0.5M NaOH
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c) neutraliser - 1,5M NaCI, 0.5M Tris.HCI (pH 7.5)
d) 2x SSC
The excess was then poured off and the sheets of 3MM placed in trays. The
filters were placed face up on the sheets of 3MM and left for 1 min in SDS,
then 3 mins in denature, 3 mins in neutraliser and 30 sees in SSC. The filters
were left to air dry and were then baked at 80°C in a vacuum for 20 mins
(nitrocellulose) or UV irradiated as in section 2.6.1 (nylon).
2.7 Radiolabelling of DNA
2.7.1 Preparation of DNA for probes
DNA to be used as a probe was either in solution or contained within a gel
slice. 25-50ng was labelled for a single hybridisation. Gel slices to be used
as hybridisation probes were treated as follows. After electrophoresis of DNA
in an LMP gel the required fragment was excised and diluted with 1-3 times
(depending on concentration) its volume of water. The slice was melted at
70°C and vortexed, before storage at -20°C. Before use in a labelling
reaction, the slice was remelted at 70°C.
For oligonucleotide probes, 25-50ng of the precipitated oligonucleotide was
used.
2.7.2 Random Priming of DNA probes
This method is adapted from Feinberg and Vogelstein (1983 and 1984).
A labelling reaction with [a-32P]-dCTP involves random priming from
hexanucleotides and then polymerisation along the DNA strand catalysed by
the Klenow fragment of E.Coli polymerase 1. A radiolabeled base is
incorporated at every C nucleotide.
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The DNA strands were firstly denatured by heating to 100°C for 10 mins.
DNA in solution was then kept on ice to prevent reannealing of the strands,
DNA in a gel slice was cooled to 37°C. The labelling reaction was carried out
using either a Random Prime kit (Boehringer Mannheim) or a Hi-Prime kit
(Boehringer Mannheim). For the random prime kit, 11 pil total of DNA plus
water was mixed with 3pl 10piCi/pil [a-32P]-dCTP (Amersham), 1pl (2 units)
Klenow enzyme, 1jil each of dATP, dTTP and dGTP and 2|il reaction buffer.
For the Hi-Prime kit, 13jil of DNA plus water was mixed with 3|il lOpCi/pl [a-
32P]-dCTP and 4pJ Hi-Prime (which contains the enzyme, nucleotides and
buffer). The reactions were then incubated at 37°C for 1 hour (Random
Prime or Hi-prime with a gel slice) or 10 mins (Hi-Prime with DNA in
solution).
The percentage incorporation of the radiolabeled nucleotide was checked by
TCA precipitation of ~0.5|il of the reaction mix on a GF/B circular filter
(Whatman). If the incorporation was 50% or above, the unincorporated
nucleotides were removed by running the probe through a Sephadex G-50
Nick column (Pharmacia Biotech). The storage buffer was removed and then
the column was washed by running through ~600|il TE. The probe was then
added to the top of the column, followed by 380pl TE. The probe was then
eluted with a further 400pil TE, and collected in a tube containing 500p.g
sonicated salmon sperm DNA (Sigma). The probe was denatured by heating
to 100°C for 10 mins, and was kept on ice until adding it to the
prehybridisation solution in the bottle.
Hybridisation due to high copy number repetitive elements in the probe could
be minimised by 'stripping' the probe. The probe was denatured at 100°C for
10 mins in the presence of 500pg sonicated salmon sperm DNA and 250gg
sonicated human DNA. It was then left to reanneal for V2 hour at 68°C before
addition to the hybridisation bottle.
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2.7.3 End-labelling of DNA oligonucleotides
This labelling reaction involves the transfer of the radiolabeled terminal
phosphate group of [y-32P]ATP to the terminal 5'-OH group of the
oligonucleotide.
25-50ng oligonucleotide DNA was mixed with 3pl (30pCi) [y-32P]ATP
(Amersham) and 1pl (10 units) PNK (Boehringer Mannheim), in a totai of
20pJ 1x PNK buffer (5mm Tris.HCI, pH 8, 1mM MgCI2, 0.5mM DTT). The
reaction was incubated at 37°C for 40 mins, then the probe was added to the




5x SSC, 10% dextran sulphate, 0.1% sodium pyrophosphate, 0.1% SDS and
5x Denhardt's solution. 5x Denhardt's solution contains 0.1% ficoll, 0.1%
PVP and 0.1% BSA (Sigma). Filter before use.
Oligonucleotide hybridisation solution
5x SSC, 0.05% BSA, 0.05% ficoll, 0.1% SDS, 0.05% PVP, 0.1% sodium
pyrophosphate. Filter before use.
2.8.2 Prehybridisation of filters
Under a solution of 2x SSC, the filter was placed between two slightly larger
sheets of gauze. For hybridisation to multiple filters with a single probe, up to
3 layers of filters could be placed in the same bottle, with layers of gauze
separating them. Air bubbles trapped between the filter and the gauze were
removed. The filter and gauzes were then rolled up together, transferred to a
glass hybridisation bottle (Hybaid) and unrolled onto the surface of the bottle.
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Denatured sonicated salmon sperm DNA was added to the prehybridisation
solution at a concentration of lOOpg/ml. 12ml of prehybridisation solution
was added to a small bottle and 18ml to a large bottle, and the bottle rotated
in an hybridisation oven (Hybaid) at 68°C for a minimum of 1 hour before
adding the probe.
For oligonucleotide probes, prehybridisation (and hybridisation) was
performed at a temperature ~10°C lower than the Tm of the oligonucleotide,
commonly 48°C.
2.8.3 Hybridisation conditions
For random-primed probes, hybridisation was carried out at 68°C overnight.
For oligonucleotide probes, the hybridisation was overnight at a temperature
10°C lower than the Tm of the oligonucleotide (commonly 48°C).
2.8.4 Washing conditions
Following hybridisation, the filters were removed from the bottle and
separated from the layers of gauze. In a plastic tray, the filters were washed
with 3 changes of ~500ml washing solution (0.1-4x SSC, 0.1% SDS) using
gentle agitation. The temperature of the wash and the concentration of SSC
depended on the washing stringency required. For random-primed probes, a
high stringency wash (3x 20 mins in 0.1x SSC, 0.1% SDS at 68°C) was
commonly used. For oligonucleotide probes, the washing steps were far less
stringent (3x 5 mins in 4x SSC, 0.1% SDS at RT).
The filters were then wrapped in Saran wrap (Dow Chemical Company),
avoiding creases.
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2.8.5 Detection of hybridisation signal
Autoradiography The filters were placed in a light-tight cassette with a signal
enhancing screen. They were then exposed to X-OMAT x-ray film (Kodak)
for a length of time dependent on the amount of radiolabeled probe left
bound to the filter (several minutes to several days). Filters hybridised to 32P-
labelled probes were exposed at -70°C, those labelled with 35S were exposed
at RT. Stratagene Glogos II luminescent markers were used for alignment.
The film was developed on an automatic x-ray film processor RGII (Fuji).
Phosphorimaging Alternatively, the filters were exposed to a phosphor
screen (Molecular Dynamics) for hours to several days. The screen was then
scanned on a Phosphorlmager (Molecular Dynamics), where a laser beam
converts the radioactive signal into a digital image, with variations in the pixel
value proportional to the amount of radioactive signal present. The grey-
scale image was adjusted as desired and was then printed on a laser printer.
2.8.6 Removal of radioactive probe from filters
Filters may be used several times with different hybridisation probes, so it
was sometimes necessary to remove radioactive probes from filters. This
was done in one of two ways. Firstly, the filters could be washed in 0.4M
NaOFI at 50°C for 30 mins, to denature the probe DNA strand from the
surface of the filter. The neutral pH was then restored by a 30 min wash in
0.1x SSC, 0.1% SDS, 0.2M Tris.HCI, pH 7.5, also at 50°C. Alternatively the
filters could be subjected to one very stringent wash, in 0.1% SDS (i.e. Ox
SSC) at 100°C for 5 mins.
The filters were then exposed to x-ray film overnight to check that all the
probe had been removed.
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2.9 Enzymatic Manipulation of DNA
2.9.1 Restriction enzyme digestion of genomic DNA
Digestions of DNA with restriction endonucleases were carried out in the
appropriate buffer at the recommended temperature. Restriction enzymes
were supplied by Boehringer Mannheim, NEB and Gibco BRL. 1 pig of DNA
was digested in 5-1 Opl containing 1/20 volume 0.1 M spermidine (Sigma),
using 1-2 units of enzyme for V/z hours. Human genomic DNA was digested
overnight. If two different enzymes were used, both of which required the
same buffer, the digests were carried out simultaneously. Otherwise, after
digestion with one enzyme, the sample was drop dialysed for 30 mins. The
appropriate buffer was then added and the second digestion carried out.
When necessary, reactions were terminated by heating to 68°C or 80°C for
15 minutes, according to the heat sensitivity of the enzyme (NEB Catalogue,
1992). Restriction digests which were to be run on gels were terminated by
the addition of 1/10th of their volume of "stop mix" (100mM EDTA, pH8.0;
20% Ficoll and Orange G).
2.9.2 Restriction digestion of agarose plugs
This protocol was adapted from Maule, 1994.
Plugs were soaked in a large excess of sterile TE at room temperature for 10
mins. A 20mg/ml solution of PMSF was prepared, at 55°C, in propan-2-ol.
Plugs were then transferred to a solution of TE containing 40pg/ml PMSF
(Sigma). PMSF is a potent inhibitor of Proteinase K and was used to
inactivate residual Proteinase K that may be present in the plugs as a result
of their preparation. The plugs were incubated in this solution for 30mins at
50°C with one change of solution after 30 minutes. The plugs were then
soaked in 30 plug volumes of 1x restriction enzyme buffer for 2 hours at
room temperature, with frequent inverting.
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For restriction enzyme digestion, each plug was placed in an eppendorf tube
and put on ice. Plugs were digested in 100|il volume which contained 1x
restriction buffer, 0.1% Triton X100 (Sigma), 200jig/ml BSA and 20 units of
restriction enzyme. Any air bubbles were removed to ensure good contact of
the plug with the enzyme solution. Digestion was carried out overnight at the
appropriate temperature. Following digestion, the tube was cooled on ice for
15 minutes, and the liquid removed with a fine tipped pastette. The plugs
were then rinsed in 1ml ice-cold TE. The TE was removed, then 200pil 'plug
stop mix' (9.4ml dH20, 0.4ml EDTA, pH 8, 0.25ml TAE and Orange G) was
added and the tubes were left on ice for 20 mins.
2.9.3 Dephosphorylation of 5' termini
Calf intestinal phosphatase (CIP) was used to dephosphorylate the 5' ends
of the vector molecules before cloning. This prevents recircularisation of
vector molecules during the ligation step.
7pg DNA was dephosphorylated with 0.1 unit CIP (Boehringer Mannheim) in
50jllI 1x CIP buffer (10mM Tris.HCI, pH 8.3, 1mM ZnCI2, 1mM MgCI2) at 37°C
for 30 mins. The reaction was stopped by the addition of 1 pil of 0.5M EDTA.
The dephoshorylated DNA was then chloroform/isoamyl alcohol then ether
extracted and ethanol precipitated. The pellet was resuspended in 10pil TE.
2.9.4 Phosphorylation of 5' termini
Addition of a phosphate group to a DNA strand ('kinasing') is by transfer of
the terminal phosphate of yATP. It is necessary to kinase oligonucleotides
before they can be ligated to restriction enzyme digested DNA.
4pg oligonucleotide DNA was mixed with 1pl (10 units) polynucleotide kinase
(PNK; Boehringer Mannheim) and 0.5-1 mM ATP (Boehringer Mannheim) in
1/10 volume 10x PNK buffer (50mM Tris.HCI, pH 7.5, 10mM MgCI2, 5mM
DTT) in a total volume of 50pl. The reaction was incubated at 37°C for 30
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mins. The sample was then chloroform/isoamylalcohol then ether extracted
and ethanol precipitated. A recovery of 25% was assumed.
2.9.5 Ligation of cohesive termini
On ice, the insert DNA and the vector DNA were mixed, typically in a ratio of
5:1 vector to insert. 10-100ng of vector DNA was normally used. The
reaction was carried out in 1 0-50jliI using 0.1 unit of bacteriophage T4 DNA
ligase (Boehringer Mannheim), in 1x ligase buffer (66mM Tris.HCI, pH 7.5,
5mM MgCI2, 1mM DTT, 1mM ATP). The ligation mixture was then incubated
at 16°C overnight, or at RT for 41/2 hours (the latter for vectorette and
splinkerette ligations). The enzyme was then inactivated by heating to 65°C
for 15 mins.
For a trial ligation, 100ng of bacteriophage 7 digested with Hind III was
religated under the same conditions. The extent of ligation could be
visualised by running the religated product on a 0.8% agarose gel.
2.10 Oligonucleotides
2.10.1 Oligonucleotide Synthesis
Oligonucleotides were synthesised (by Agnes Gallagher) as ammonium
stocks on an Applied Biosystems 381A oligonucleotide synthesiser.
Oligonucleotides for use as FISH probes or for magnetic bead capture were
synthesised incorporating a 5' biotin moiety.
Oligonucleotides were precipitated from ammonium stocks by ethanol
precipitation of 350p! of the stock. The precipitated DNA was resuspended in
500pl water and the concentration assessed by measuring the Abs260. An
absorbance of 1 corresponds to a concentration of 25pg/ml for single
stranded DNA.
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2.10.2 Oligonucleotide primer Design
The vectorette primers were obtained from ICI. Splinkerette sequences and
primers were designed to be comparable with those of the vectorette
(personal communication). The sequences of two published primers were
used, that is the primers '291' and '292', for the amplification of recombinant
DNA inserts in the plasmid pBS ('forward' and 'reverse' primers from
Stratagene catalogue, see table 2.2 for sequences).
Other primers were designed using the programme Oligo4 (Hybaid). Primers
were between 19 and 46 nucleotides in length depending on the DNA source
on which they would be used. They were chosen to be stable
oligonucleotides with a Tm between 55°C and 70°C. A maximum hairpin
structure or potential dimerism of 3 nucleotides (preferably less) was
permissible, but only a 2 nucleotide internal match if it involved the 3' end. If
possible the A+T : C+G ratio was near 50%.
In two instances, it was necessary to synthesise slightly degenerate primers
due to unresolved sequence ambiguities.
2.10.3 Duplexing oligonucleotides
In certain cases it was necessary to form a duplex between two
complementary (or partially complementary) oligonucleotides. The two
oligonucleotides (150|ig/ml each) were mixed together in 10jllI 1x TM (10mM
Tris.HCI, pH 7.5, 5mM MgCI2) and the tubes were placed in a small volume
of water at 90°C. The water was then left to cool to below 30°C over a period
of 15-30 mins.
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2.11 Amplification of DNA by the Polymerase Chain Reaction
(PCR)
PCR is a technique used for the amplification of a specific DNA sequence
(Saiki et at, 1988; Mullis and Faloona, 1987). The specificity is provided by
oligonucleotide primers complementary to the 5' ends of the two strands of
the sequence to be amplified. These primers anneal to the template DNA
strand and direct amplification by a thermostable polymerase. The PCR
reaction is a series of cycles, each consisting of three steps. The first is a
short high temperature step (92-94°C) to denature the template. This is
followed by a reduction in temperature to allow the primers to anneal to the
template (~50-65°C depending on the primers used), then finally the
temperature is increased to 72°C (or 68°C for long PCR) to permit extension
from the primers by the polymerase. Multiple cycles of these three steps
result in exponential amplification of the desired sequence.
2.11.1 PCR conditions
Commonly 100ng of template genomic DNA was amplified in 50|il in 0.5ml
microcentrifuge tubes (Robbins Scientific), with 0.2|il (1 unit) Amplitaq
(Perkin Elmer Cetus) in 1x reaction buffer (10mM Tris.HCI, pH 8.3, 50mM
KCI, 1.5mM MgCI2, 0.01% (w/v) gelatin) and 0.1% Triton X-100 (Sigma). The
reaction employed 300ng of each primer and 200|iM each dNTP (Advanced
Biotechnologies). The reaction was overlaid with 40|il mineral oil (Sigma).
PCR programmes were run on an Hybaid Omnigene machine or Perkin
Elmer Cetus DNA thermal cycler. The basic programme was 30 cycles of 3
different steps:
a) Denaturation: A short step at 93-94°C. Usually 30 sees in the first cycle
and 15 sees thereafter.
b) Annealing: The annealing temperature is critical in determining the
success of the PCR reaction, and is dependent on the structure of the
116
primer. Primer Tm's were determined using the 'Melt2' programme (J.G.
Wetmur, personal communication); an annealing temperature of ~5°C lower
than the Tm was used. Annealing steps were 30 sees or 1 min long,
c) Extension: Carried out at 72°C. The extension time is also critical in
determining the success of the PCR, since longer products need longer
extension times (approximately 1 min per kb of sequence). Ten cycles of
three different extension times was generally used, the length progressively
increasing until the time estimated for effective elongation was reached.
After the reaction, 5-1 Opl of the PCR reaction was visualised by
electrophoresis on 0.8-2% agarose gels.
Steps to increase specificity
'Hot Start' PCR (Chou et al, 1992) was commonly used. The PCR reaction
was set up as 2 separate mixes, one containing the DNA and primers, the
other containing the enzyme, buffer and nucleotides. The mixes were heated
to 90°C for several minutes, before combining them. Addition of the enzyme
to the DNA at a temperature at which the DNA is denatured helps to prevent
mispriming before the initial denaturing temperature is reached.
Touch Down' PCR (Don et al, 1991) implies a decreasing annealing
temperature per cycle until the final annealing temperature is reached. This
means that during the first few critical cycles, only highly specific primer-
template interactions can occur, which selects for amplification of the correct
product during the rest of the reaction. An annealing temperature 10°C
above the calculated value was used in the first cycle, which decreased by
2°C each cycle until the final annealing temperature was reached.
Long PCR
For amplification between the seven novel gene products resulting from the
CSC experiment, an 'Expand' (Boehringer Mannheim) or 'Takara' (Takara
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Shuzo Co.) long PCR kit was used. These kits incorporate two thermostable
DNA polymerases, Taq polymerase for high processivity, plus a second
polymerase which possesses a 3'-5' exonuclease (proofreading) activity. The
kits were used according to the manufacturer's instructions, apart from slight
changes to the suggested programme and the procedure for setting up the
reactions. Details are given in section 6.5.3.
2.11.2 PCR amplification of plasmid inserts
This method was adapted from Taylor (1991).
A toothpick stab of a bacterial colony was transferred to a tube containing
50jil of water. This tube was then heated to 96°C for 4 mins. 1jil of this was
then used as the template for a PCR reaction. Primers used were Universal
primers designed to the polylinker sequence of pBS, 291 and 292 (see table
2.2).
The PCR reaction mix was exactly as in section 2.11.1.
The PCR programme used was:
Denaturing: 93°C for 30 sees in first cycle and 15 sees thereafter.
Annealing: 52°C for 1 min.
Extension: 72°C, 10 cycles of 1 min, 10 cycles of 2 mins, 10 cycles of 3
mins.
2.12 Sequencing of DNA
2.12.1 Cycle sequencing of plasmid inserts
Sequencing of plasmid clones was done on an ABI automated sequencing
machine (Applied Biosystems). Thermal cycling of sequencing reactions
increases signal intensity and decreases sensitivity to reaction conditions.
Dye terminator chemistry was used, that is dideoxy-nucleotides terminated
the sequencing reaction at each base to generate the ladder of fragments.
118
Each of the four dideoxy-nucleotides is labelled with a different dye, such
that the attached computer can recognise the peak of dye corresponding to a
particular base at each position.
Plasmid DNA for sequencing was prepared by alkaline lysis followed by PEG
precipitation according to the protocols in sections 2.1.5 and 2.1.6. The
sequencing reactions were performed using a Taq DyeDeoxy Terminator
Cycle Sequencing kit (Applied Biosystems) according to the manufacturer's
instructions. Ideally, approximately 200ng plasmid DNA was used in the
reaction, although results were produced with as little as ~20ng. 18ng of
either primer 291 or 292 was used per reaction, depending on the orientation
of the sequence required.
The cycle sequencing reaction was performed on a Perkin Elmer Cetus DNA
thermal cycler. The programme was as follows: Place tubes in rack
preheated to 96°C. Perform 25 cycles of 96°C for 30 sees, 50°C for 15 sees
and 60°C for 4 mins. Rapid thermal ramp to 4°C and hold.
As much as possible of the mineral oil was removed with a pipette, then 90(il
water was added. The DNA was then extracted twice with an equal volume
of a phenol/water/chloroform mixture (Applied Biosystems) and then ethanol
precipitated, using Applied Biosytems NaAc and 3 volumes of cold 100%
ethanol. The tubes were then placed on ice for 15 mins, before centrifugation
for 15-20 mins at 11,000rpm. The supernatant was then removed, and the
pellet dried for 1 min at 85°C in a thermal cycler. Immediately before loading
onto a sequencing gel, each pellet was resuspended in 4pl stop mix (1pl of
50mM EDTA, pH 8, 30mg/ml Blue Dextran to 5|il deionised formamide).
The samples were loaded onto a 6% acrylamide gel (prepared by Agnes
Gallagher), which was run in 1x TBE at 2500V, 45mA for 12 hours. The
sequence data was gathered by the computer and displayed as a visual
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output of differently coloured peaks, or DNA sequence which was directly
amenable to computer analysis.
2.12.2 Sequencing of PCR products
This method has been modified from Winship, 1989.
In order to directly sequence PCR products, the required product must be
purified from a gel in order to separate it from primer dimers and any
spurious products. A substantial amount of DNA is required in the reaction
itself, so in some cases the product of several PCR reactions was pooled
and concentrated into a smaller volume by ethanol precipitation. The
resulting product was then gel purified by running it on a 1% (typically) LMP
agarose gel and excising the required band. The DNA was recovered from
the gel slice by agarase treatment and ethanol precipitation. The precipitate
was resuspended in 10-40pl and the DNA concentration checked by running
1 pi on a gel next to a known amount of size marker. Approximately 200ng
DNA was used per sequencing reaction.
The sequencing reactions were carried out using a Sequenase Version 2.0
kit (Amersham). Firstly, the DNA was mixed with 300ng sequencing primer,
1.25|il DMSO and 2.5pl 5x Sequenase reaction buffer and made up to a total
volume of 12.5pl with water. The mix was then denatured by heating it to
96°C for 3 mins on a thermal cycler. The tube was then immediately plunged
into liquid nitrogen or dry ice to snap freeze DNA mix and prevent the
strands from reannealing.
A labelling mix was made up from the kit containing 1.75pl enzyme dilution
buffer, 1gl DTT, 0.4pl dITP labelling mix and 0.25pl Sequenase enzyme per
reaction. To this was added 1.6pl dH20 and 0.5pl of 10pCi/pl [a-abS]-dATP
(Amersham) per reaction, and the tube kept on ice. One tube of DNA mix
was thawed quickly by rubbing between the fingertips, then 5.5gl of the
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labelling mix was immediately added and mixed by pipetting. 3.5|il of this
was then immediately applied to the side of 4 eppendorf tubes, each one
containing 2.5ptl of one of the 4 termination mixes containing 10% DMSO
(G,A,T and C). The 4 tubes were then briefly spun to combine the labelling
and termination mixtures simultaneously. The time from thawing the DNA to
mixing with the termination mix was approximately 45 sees.
The termination tubes were transferred to a 37°C water bath and incubated
for 5 mins. The reaction was then stopped by the addition of 4pl kit stop mix
(95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene
cyanol FF). Reactions were stored at -20°C until loading on a gel. Prior to
loading they were heated to 80°C for 2 mins to denature the DNA.
2.12.3 Analysis of sequence data
The sequences obtained were edited and manipulated using GCG (Genetics
Computer Group) programmes available through the HGMP Computing
service (Devereux et al, 1984). Database searches were performed using the
GCG Blast (Altschul et al, 1990) and Fasta (Pearson and Lipman, 1988)
programmes.
2.13 'Catch Linkering' of YAC and cDNA
Catch linkering is a method for amplifying DNA, for instance a whole YAC,
into a simplified resource. It is an alternative to Alu-PCR (Nelson et al, 1989),
yet is not dependent on the presence of any specific sequence elements
other than frequent restriction enzyme sites. DNA is digested with Sau3AI,
and then a short double stranded 'catch linker' is ligated onto each cohesive
end. The intervening DNA can then be amplified by PCR using primers
designed to the catch linkers. Catch linkered material can be labelled and
used as a probe for FISH (Shibasaki et al, 1995), or (as in this case) as a
substrate for Coincident Sequence Cloning.
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2.13.1 Preparation and digestion of DNA
YAC DNA was isolated from a pulsed field gel as a 1% LMP agarose slice,
using minimal ethidium bromide staining and UV irradiation. The DNA was
then purified from the gel slice by agarase treatment, and ethanol
precipitated for 1 hr.
The resulting pellet was resuspended in 5|il 1x restriction enzyme buffer A
(Boehringer Mannheim) and digested with Sau3AI at 37°C for 1 hr. The
enzyme was heat killed by heating at 70°C for 15 mins. The sample was
then placed on ice.
2.13.2 Preparation of catch linkers
Catch linker oligonucleotides were 477 / 479 for YAC DNA and 727 / 731 for
cDNA (table 2.2).
Oligonucleotide 477 was synthesised with and without biotin at the 5' end.
Oligonucleotides 479 and 731 were phosphorylated at the 5' end to enable
them to be ligated to the restriction enzyme digested YAC DNA. 1pg of each
oligonucleotide was duplexed in 10pil TM to form the double stranded linker.
2.13.3 Ligation of catch linkers
100ng linker DNA was then ligated onto ~20ng digested YAC (quantity
judged from the initial pulsed field gel) or cDNA, in 20pJ volume at 16°C
overnight. The sample was then briefly spun and placed on ice.
2.13.4 PCR amplification
1|il of the ligated material was then amplified by PCR, using 600ng
oligonucleotide 477 or 727 as the primer. Biotinylated 479 was used if
labelled product was desired (see table 2.2).
The PCR programme used was:
Denaturation: 93°C for 15 sees
Annealing: 54°C for 30 sees
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Extension: 72°C for 1 min (cycles 1 -10), 2 mins (11 -20) and 4 mins (21-35).
10gl of the PCR product was examined on a 1.5% agarose gel. The
remainder was ethanol precipitated and resuspended as appropriate to
future use.
2.13.5 Detection of biotin labelling efficiency
The extent to which the catch-linker PCR product was labelled with biotin
could be detected by binding the biotin residues to streptavidin conjugated
with the enzyme alkaline phosphatase. Action of the enzyme on a substrate
(nitroblue tetrazolium, NBT), together with another compound (5-bromo-4-
chloro-3-indolylphosphate, BCIP) causes formation of a coloured product.
1pl of a series of dilutions of the PCR product (1/10 to 1/1000) was spotted
onto a nitrocellulose filter, and the filter baked at 80°C for 20 mins. The filter
was then re-hydrated in Buffer 1 (0.1 M Tris.HCI, pH 7.5, 0.15M NaCI) for 1
min, then incubated in Buffer 2 (3% BSA in Buffer 1) for 1 hour at 65°C in a
sealed hybridisation bag. Immediately prior to use, a dilution of alkaline
phosphatase-streptavidin (AP-SA, Vector Laboratories) conjugate was made
by adding 20|llI of the 1mg/ml AP-SA solution to 20ml Buffer 1 in a
polypropylene tube. The filter was then incubated in the AP-SA solution for
10 mins at RT with gentle agitation. The solution was removed and the filter
washed twice with 40-80ml Buffer 1 for 15 mins at RT with gentle agitation.
An alkaline phosphatase substrate kit (Vector Laboratories), containing the
NBT and BCIP, was then used according to the manufacturer's instructions
to cause the formation of the coloured product. The filter was incubated with
the dye solution in a sealed hybridisation bag for 30-270 mins in the dark.
When suitable staining had developed, the reaction was stopped by washing
the filter in 20mM Tris. HCI, pH 7.5, 0.5mM EDTA .
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2.14 Coincident Sequence Cloning
Coincident Sequence Cloning (CSC) is a method for isolating the sequences
shared between two DNA resources (see section 1.8.5). This is achieved by
denaturing the two DNA sources, mixing them ('integration') and then
recovering the duplexes which are formed between the two resources (inter-
resource duplexes, IRDs). In this context, the two resources used were the
YAC D0485 and foetal brain cDNA, so that the product should be transcribed
sequences from the YAC.
At all times during the preparation of the Source DNAs, their integration and
cloning, great care was taken so that the samples would not become
contaminated. All materials used were dedicated solely to CSC, fresh
solutions were made up and autoclaved, and all labware was washed with
water and then ethanol.
2.14.1 Preparation of YAC DNA
The YAC D4085 was catch linkered (section 2.13) using biotinylated 477 as
the PCR primer, by Tony Brookes.
Before use in the CSC experiments it was necessary to purify the catch
linkered product from a gel, to remove primer dimers. It is preferable to do
this without staining the DNA with ethidium bromide or exposing it to UV
irradiation.
The catch linker PCR product was ethanol precipitated and resuspended in
10(il dH20. 9pl of the sample was then run on a 1.5% LMP agarose gel in a
minigel apparatus, without ethidium bromide staining. The remaining 1pl
was run in a parallel, test track next to a pX Hae III marker track. When the
loading dye had reached the bottom of the gel, this test and marker tracks
was sliced away from the gel and stained with ethidium bromide. The DNA in
these tracks was then viewed on a UV transilluminator. The top and bottom
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positions of the catch linker product with respect to the marker were noted,
and the gel was nicked where it should be cut to remove the primer dimers.
This test track was then aligned alongside the rest of the gel, and the gel
sliced across at the position of the nick.
In order to concentrate the product DNA into a smaller volume of gel, the
orientation of the gel was reversed and the product run back up towards the
wells. Loading dye placed in a hole at the bottom of the gel before turning it
round was used to judge when the run was complete. A second <})X Hae III
marker track was sliced off and stained, and nicks made at the positions
corresponding to the top and bottom of the catch linker product smear. This
track was then aligned with the track containing the product, and the product
was excised from the gel, guided by the nicks in the marker track.
The DNA was purified from the gel slice by agarase treatment and then was
ethanol precipitated overnight. The resulting pellet was resuspended in 5pl
dH20. The concentration was estimated by running 0.5|il on a 1% agarose
gel. The remaining 4.5pl (~800ng) was used in the HF-CSC experiment.
2.14.2 Preparation of cDNA
10pg cDNA was catch linkered (section 2.13) using 727 as the PCR primer,
by Tony Brookes. For the EL-CSC experiment, the linkers were then
removed by complete digestion with Sau3AI.
2.14.3 Preparation of 'blocking' DNA
Human Cot1 DNA and ribosomal DNA were used to preanneal to the
denatured Source I and II DNAs, to prevent inter-resource hybridisation due
to high copy repeat elements and ribosomal sequences.
Ribosomal Blocking DNA 50pg yeast DNA, plus 20jng each of the two
ribosomal DNA plasmid clones pA and pB (obtained from Dr I. Gonzalis,
125
Hahnemann University, Philadelphia, USA) were mixed in 2ml dH20 and then
sonicated twice for 30 sees to reduce the fragment length to approximately
500bp to 1kb. The 2ml was aliquoted into eppendorf tubes and ethanol
precipitated. The precipitate was resuspended in 45pl dH20, and the
concentration checked by running 1 pi of a 1/10 dilution on a 1.2% agarose
gel.
Cot1 DNA Two 10pg aliquots of Cot1 human genomic DNA were ethanol
precipitated and vacuum dried.
4pg of the ribosomal blocking DNA in 3pl was used to resuspend each pellet
of Cot 1 DNA.
2.14.4 Integration of the YAC and cDNA
800ng YAC DNA and 10pg cDNA were made up separately to 5.4pl in water.
To each was added 10pg Cot 1 DNA and 4pg ribosomal blocking DNA in 3pl
volume and 1.8pl 1M NaOH and the tubes placed at 37°C for 5 mins to
ensure the denaturation is complete. The tubes were then warmed to 50°C
and 9.8gl FNET/HCI (6pl formamide, 2pl NET (400mM Tris. HCI, pH7.8, 2.5M
NaCI, 50mmM EDTA), 1.8|il 1M HCI) at 50°C was added to each to
neutralise the alkali. The neutral pH of each was confirmed by spotting 0.5pl
of each onto Indicator paper. The tubes were then incubated at 45°C for pre-
annealing with the blocking DNA. The cDNA was incubated for 4hours, and
the YAC DNA for 30 mins. After this, the two DNA mixes were combined and
left submerged at 45°C overnight to permit the formation of the IRDs.
The integration and subsequent steps were also performed using controls of
'cDNA only' and 'no DNA'.
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2.14.5 Selection of the Inter Resource Duplexes (IRDs) (HF-CSC)
IRD selection was by means of attachment of the biotin residues on the YAC
DNA linkers to streptavidin coated magnetic beads. cDNA:cDNA duplexes
and non-specific IRDs were removed by washing steps, whilst retaining the
DNA attached to the beads. The strands present in a duplex with the
biotinylated YAC DNA were then eluted by a high temperature wash. The
cDNA present in this eluate (i.e. that which had been present in an IRD) was
then PCR amplified using primers designed to the cDNA-specific linkers.
25pl M280 streptavidin coated magnetic beads (Dynal) were washed in
phosphate buffered saline/BSA according to the manufacturer's instructions
and then incubated for 15 mins at RT in 10Opil TEN-S/P (0.1% SDS,
0.5mg/ml PVP in TEN buffer (TEN buffer: 10mM Tris.HCI, pH7.4, 1mM
EDTA, 100mM NaCI)). This buffer was then replaced with 10Opil TEN-S/P
containing 10pg sonicated salmon sperm DNA and incubated for a further 15
mins. This buffer was then removed and the beads resuspended in 25jllI
TEN-S/P.
The duplexed DNA was made to 0.1% SDS, 0.5mg/ml PVP and then this
solution was used to replace the bead solution. The DNA/bead mixture was
incubated for 30 mins at RT with occasional mixing.
Washes were performed with 6 changes of 150pJ TEN at RT, then 8 changes
of 1 50jllI 0.1x SSC at 68°C. The product was eluted by heating the beads to
90°C for 4 mins in 10pl dH20 before immobilisation of the beads and recovery
of the buffer/eluate DNA. The eluate was then passed through a further
magnetic separation to remove all traces of beads.
2.14.6 Selection of the IRDs (EL-CSC)
The protocol follows that of HF-CSC until the duplexed DNA has been
incubated with the beads.
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Washes were performed with six changes of 150|il TEN at RT and then four
changes of 150|il 0.1x SSC at 68°C. The beads were then resuspended in
20pl TEN and heated to 60°C before adding, in 1 jllI, 250ng capture
oligonucleotide 732 and 250ng kinased capture oligonucleotide 735 (table
2.2). This was then left to cool over a period of 1 hour and washed in 4
changes of 10Opil TEN. A 5 minute ligation reaction was then performed at
45°C in 20|il volume, using 10 units of Taq DNA ligase (Cambio), and then
the reaction was stopped by adding 1pl 500mM EDTA. The sample was then
washed with 3 changes of 10Optl TEN at 45°C and 5 changes of 0.1 x SSC at
65°C.
2.14.7 PCR amplification of the product
1pl of the eluate and controls were amplified in duplicate with 600ng of the
cDNA linker primer 727 (HF-CSC) or 789 and 596 (EL-CSC) (table 2.2). The
programme used was:
Denaturation: 93°C for 30 sees in the 1st cycle and 15 sees thereafter.
Annealing: 54°C for 30 sees
Extension: 72°C for 11/2 mins (cycles 1-10), 21/2 mins (cycles 11-20), 4 mins
(cycles 21-29) then 8 mins (cycle 30)
Also 0.4pil of the beads (with YAC DNA attached) was amplified with 600ng
of the YAC linker primer 477 (HF-CSC) (table 2.2), using the first 20 cycles of
the PCR programme above.
The duplicate PCR reactions were pooled and then 8pl was visualised on a
2% agarose gel.
2.14.8 Cloning of the product DNA
A library was made from the product DNA by cloning the PCR product into
pBS vector.
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20|llI of the product DNA was chloroform/isoamyl alcohol then ether extracted
and ethanol precipitated. The pellet was resuspended in 5p.l. The DNA was
then heat shocked at 65°C for 5 mins and cooled to RT, to disentangle the
molecules. The concentration was checked by running 1 pi on a 2% agarose
gel, and then the remainder was digested with EcoRI in a total of 10pl. The
enzyme was heat killed at 70°C for 10 mins, and then the sample was
ethanol precipitated. The pellet was resuspended in 10jul and subjected to
heat shock as above.
20ng of the digested product DNA was ligated to 20ng pBS DNA (digested
with EcoRI and phosphatased by Tony Brookes), in a total of 20pl at 16°C
overnight. The ligation mix was then drop dialysed and 1 jllI was used for
electro-transfomation of competent cells.
2.15 Extraction of RNA and Preparation of cDNA
2.15.1 Extraction of RNA
The extraction of RNA from tissue samples was performed using RNazol B™
(Biogenesis Ltd.). RNazol B promotes the formation of complexes of RNA
with guanidinium and water molecules, and abolishes hydrophilic interactions
of DNA and proteins. During the extraction step, the RNA remains in the
aqueous phase, while DNA and proteins are removed from it.
Tissues from which the RNA was to be extracted were frozen as quickly as
possible and then stored at -70°C. To extract the RNA, 1ml RNazol B was
added to a small piece of the tissue (~1cm3) in a plastic bijou, and the tissue
was homogenised using an electric homogeniser. The homogeniser had
been pre-sterilised by soaking in dH20 containing 0.1% diethyl pyrocarbonate
(DEPC) and then baking at 80°C for at least 1 hour. In between
homogenising different tissue samples the homogeniser was rinsed first in
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Virkon, then in dH20 and finally in ethanol. After homogenising the sample
was kept on ice. The following steps were carried out in a fume hood.
The RNazol B solution was transferred to a screw-cap eppendorf tube
containing 10Opil chloroform. The tube was inverted repeatedly for 15 sees
and then placed on ice for 15 mins before centrifugation at 11,000 rpm for 15
mins at 4°C. The upper, aqueous phase was then transferred to a second
screw-cap tube, 1 volume of isopropanol was added, and the tube left on ice
for 15 mins. The tube was then centrifuged as before, and the supernatant
discarded. The pellet was washed twice in 75% ethanol, and the open top
covered with a small piece of Parafilm (American National Can Ltd.) which
had been pierced many times with a needle. The pellet was then vacuum
dried for not longer than 10 mins. The pellet was dissolved in 100pl of
DEPC-treated water by agitating it at 4°C overnight.
The concentration of the RNA was calculated by reading the absorbance of a
1 in 200 dilution in DEPC-treated water at 260nm and 280nm. The
concentration of the RNA (in mg/ml) was obtained by multiplying the Abs260 of
the diluted sample by 10. The ratio of the Abs260 to the Abs280 provides a
measure of the quality of the RNA. All values obtained were within the
expected range (1.6 to 2.0). RNA samples split into aliquots of 10pil and
stored at -70°C.
2.15.2 DNase treatment of RNA
For RNA samples to be used as a template for RT-PCR, it was necessary to
pre-treat the RNA with DNase. This ensures that any RT-PCR products are
genuinely derived from RNA template and not DNA. The efficiency of the
DNase treatment can be checked by including a minus reverse transcriptase
control during first strand cDNA synthesis (see section 2.15.3).
4pg RNA was treated with 10 units/pg DNase I (Boehringer Mannheim) and
10 units/pg RNase Inhibitor (Boehringer Mannheim) in a total of 40pJ 1x
130
Transcription buffer (Ambion) at 37°C for 30 mins. It was then extracted with
an equal volume of a 1:1 ratio of phenokchloroform, and precipitated with
1/10th volume of 5M ammonium acetate and 3 volumes 100% ethanol at
-70°C for 30 mins. The tube was then centrifuged for 15 mins at 11,000 rpm
at 4°C. The pellet was vacuum dried and resuspended in 8pl DEPC-treated
dH20. A recovery of 50% of the RNA was assumed.
2.15.3 First strand cDNA synthesis
The volume of 2(ig of DNase-treated RNA was adjusted to 8jllI, and then it
was heated to 65°C for 10 mins, and cooled on ice. To this 8pl was added
the components of the First strand cDNA synthesis kit (Pharmacia Biotech),
that is 5pl bulk strand reaction mix, 1 pil DTT and 1jil pd(N)6 primer. The bulk
strand reaction mix contains Moloney Murine Leukaemia Virus reverse
transcriptase which catalyses the polymerisation of dGTP, dCTP, dATP and
dTTP into a single cDNA strand. The reaction was left to proceed at 37°C for
1 hour, after which the cDNA was used directly in a PCR reaction (5pJ per
reaction).
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SPLINKERETTE PCR AND PHYSICAL MAPPING OF YACS
3.1 Introduction
3.1.1 PCR walking
PCR is widely used for the exponential amplification of sequences between
two known oligonucleotide primers. The requirement for primers at both ends
of the molecule to permit amplification is also the technique's major
drawback, since this implies that some knowledge of DNA sequence at both
ends of the desired product is necessary. In most instances this limitation
further implies a need for laborious cloning and sequencing steps before the
region can be amplified. Many methods have therefore been developed
which circumvent the need for sequence information at both ends of the
molecule, and enable the amplification of a product which extends outwards
from a region of known sequence. This is termed 'PCR walking'.
The majority of published methods enabling PCR walking are based upon
one of three themes. Those themes are i) randomly primed PCR, ii) inverse
PCR and iii) linker-adapter PCR.
Randomly primed PCR (Fig. 3.1) relies on interactions between imperfectly
base-paired primer and template to initiate priming. In order for a primer to
function, it does not need perfect match with the template along its whole
length. Indeed, under sufficiently low stringency conditions, successful
priming can result when the primer has only partial 3' end homology with the
template, with a perfect match of only two bases at the 3' end (Parker et at,
1991). PCR walking can thus be achieved employing a single sequence
specific primer and random 'walking' primers (Parker et at, 1991, Dominguez
and Lopez-Larrea, 1994). Nested PCR using a sequence specific primer
internal to the first, in combination with a walking primer, will increase the
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specificity of the reaction. An alternative is to use the sequence specific
primer alone, which at low annealing temperatures will initiate priming from
non-specific sites where there is some chance homology at the 3' end (Parks
et al, 1991). Thermal Assymetric Interlaced (TAIL) PCR (Liu and Whittier,
1995) overcomes some of the problems of background products
encountered in randomly primed PCR, by alternating high and low stringency
cycles. High stringency cycles allow priming from a long sequence specific
primer only. Low stringency cycles also permit priming from a short arbitrary
degenerate primer. The combination of the two, followed by two rounds of
nested PCR will decrease the amount of product primed solely by the
arbitrary primer.
The technique of Inverse PCR (Ochman et al, 1988) (Fig. 3.2) utilises two
primers from the region of known sequence, which face in opposite
directions. The DNA is digested with a restriction enzyme which has no site
between the primers, and then it is re-ligated under conditions which favour
the formation of monomeric circles. The two sequence specific primers may
then be used to amplify around the circle of DNA between them.
The various methods of Linker-adapter PCR (Fig. 3.3) are a popular choice
for PCR walking. Linker-adapter PCR involves amplification between a
sequence specific primer and a primer complementary to a downstream
synthetic linker sequence which has been ligated on to restriction enzyme
digested DNA. In 'oligo-cassette mediated PCR' (Rosenthal and Jones,
1990), linkers are ligated onto the ends of digested DNA, then sequence
specificity is provided by linear amplification from a biotinylated sequence
specific primer. This product may be isolated by attachment to streptavidin-
coated magnetic beads. There can then follow an exponential PCR reaction
on the isolated sequences between the same sequence specific primer and
the linker primer. A similar method, in which linkers are ligated to genomic
DNA after linear amplification from the sequence specific primers is termed
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Ligation Mediated PCR (Mueller and Wold, 1989). This procedure was
developed as a new method for in-vivo footprinting of DNA sequences.
Several linker-adapter PCR methods involve a specially designed linker,
such that extension from the linker primer cannot take place without prior
extension from the sequence specific primer. This is usually due to the
absence of a sequence complementary to the linker primer at the beginning
of the reaction. The sequence to which the linker primer can anneal must be
synthesised by extension from the sequence specific primer. In this way,
artefactual linker-linker products are not produced. In the simplest case, this
may involve a linker which has not been kinased at the 5' end of the bottom
strand, such that there is no covalent bond formed between the linker
sequence complementary to the primer and the genomic DNA (Kalman et al,
1990). Extension from the linker primer will therefore terminate at the end of
the linker until that strand has been generated by extension from the
sequence specific primer.
Linkers in which the primer portion of the linker is single stranded will prevent
extension from the linker primer (top strand) in the first cycle (Roux and
Dhanarajan, 1990). This however provides opportunity for extension from the
3' end of the bottom strand to generate a sequence complementary to the
primer (Upcroft and Healey, 1993). This may be prevented by the presence
of a mismatched tail (Roux and Dhanarajan, 1990) or an amine group
(Siebert et a!, 1995) on the bottom strand.
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Figure 3.1 Randomly Primed PCR (adapted from Parker et al, 1991)
The targeted and internal primers are complementary to a known sequence.
The walking primers are of arbitrary sequence. The walking primers will
hybridise to multiple sites on both DNA strands, but a targeted PCR product
will only be produced when a walking primer anneals at a suitable distance
from the targeted primer on the complementary strand. Nested PCR using







Figure 3.2 Inverse PCR (adapted from Ochman et al, 1988)
The core region (known sequence) is depicted as a thick straight line. The
filled and open boxes represent upstream and downstream flanking regions
respectively.
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Figure 3.3 Linker-Adapter PCR
Different methods employ different strategies to avoid amplification between
two linker primers (not shown), for instance mismatched linker strands (Roux
and Dhanajaran, 1990), an amine group on one linker strand (Siebert et al,
1995), unligated linkers (Kalman et al, 1990) or preselection of material
amplified by the sequence specific primer by binding to magnetic beads
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3.1.2 Vectorettes
The vectorette™ is an example of a specially designed linker (Arnold and
Hodgson, 1991 and Riley et al, 1990). It comprises a double stranded
sequence of ~50bp, with one cohesive end rendering it suitable for ligation to
restriction enzyme digested DNA (Fig. 3.4). The associated vectorette primer
and nested primer are of the same sequence as part of the top strand of the
linker. However, sequences complementary to these primers are not present
in the linker, since there is a 'bubble' of mismatched bases between the top
and bottom strands. The 3' end of the vectorette primer is situated within the
mismatched region. Extension from a sequence specific primer however will
copy the top strand into its complement, and hence form a priming site for
the vectorette primer. Exponential amplification may then ensue between the
sequence specific primer and the vectorette primer.
The design of the vectorette linker is such that it should prevent amplification
of molecules possessing vectorettes at both ends. The specificity of the
vectorette PCR reaction is however not absolute, especially for amplification
of longer PCR products (>2kb) from uncloned genomic DNA. Illegitimate
products resulting from non-specific annealing of either primer may be
minimised by the use of a sufficiently high annealing temperature. However,
background products may also result from a phenomenon we term 'end-
repair' priming, which is intrinsic to the design of vectorettes (Devon et al,
1995). End-repair priming is caused by the presence of the free cohesive
ends of unligated vectorettes and genomic DNA. The cohesive ends possess
a 5' overhang which may be filled in during the first extension step of the
PCR reaction. Following denaturation, these filled-in ends are able to anneal
to each other, and the 4bp overlap thus produced is sufficiently stable to be
able to initiate priming (Sommer and Tautz, 1989). This enables extension
from the genomic DNA across the vectorette, thus producing a sequence
complementary to the vectorette primer. It also enables extension from the
vectorette along the genomic DNA.
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3.1.3 Splinkerettes
The splinkerette, an alternative to the vectorette, was developed in response
to the prevalent end-repair priming in vectorette PCR. The splinkerette is a
specialised linker sequence, used exactly as the vectorette, but its design is
such that end-repair priming can not occur (Devon et al, 1995). Instead of a
mismatched region between the top and bottom strands, the splinkerette
incorporates a hairpin structure on the bottom strand (Fig 3.4). After the first
denaturation step of the PCR reaction, the free 3' end of the bottom strand
will flip back on itself to form the hairpin, and may then begin elongation
further along the bottom strand. The elongation will continue until the end of
the bottom strand is reached, thus forming a stable double stranded
structure which is not available for end-repair priming. The bottom strand of
the splinkerette is not kinased, and hence there is no covalent bond between
it and the genomic DNA. This prevents elongation from the hairpin along the
whole length of the genomic DNA to the splinkerette linker at the other end.
Figure 3.4 Schematic Diagram of the Vectorette and Splinkerette (from













3.2 A Comparison of Vectorettes and Splinkerettes
A practical comparison of the ability of vectorette and splinkerette PCR to
execute efficient PCR walking on total human genomic DNA was
undertaken. Model systems were chosen for target PCR products where
primers and/or sequence information was available, and the size of the
expected PCR product was known. Two target PCR products were chosen.
The first was a fragment from exon 13 of the cystic fibrosis transmembrane
regulator (CFTR) gene on chromosome 7. The distance between available
primers and the next Sau3AI site, to which the linker could be ligated, was
calculated from sequence information to be ~290bp. The second was a
product of from the first intron of Wilm's Tumour 1 (WT1) gene on
chromosome 11. The target product from the primers to the next BamHI site
(also compatible with the linkers) was estimated to be ~2.3kb from a
published restriction map of the gene (Tadokoro et al, 1992). For both
products, two primers were available in the same orientation to enable
nested PCR to be carried out, and an oligonucleotide (for CFTR) or a clone
(for WT1) was available to be used as a probe to verify the specific nature of
the PCR products.
To enable direct comparison, the splinkerette and vectorette were designed
to be compatible with the same external and nested primers. Total human
genomic DNA was digested with Sau3AI or BamHI. The splinkerette and
vectorette used possessed a 4bp GATC overhang, thus rendering them
suitable for ligation to Sau3AI, BamHI, Bgl II or Bel I digested DNA.
Splinkerettes or vectorettes were ligated on to the ends of the digested
genomic DNA molecules. For the 290bp product, ligation was with a 3:1
molar ratio linker:insert. For the 2.3kb product, the molar ratio used was 15:1
linker:insert, as recommended for the vectorette by ICI. Vectorette ligations
were performed for 41/2hrs at RT as recommended by ICI. Splinkerette
ligations were initially performed overnight at 4°C (used for the 290bp
product PCR), but it was found that a superior result was produced with a
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41/2hr ligation at RT, as for the vectorette. These ligation conditions were
therefore used for the 2.3kb target product.
3.2.1 The 290bp product
PCR amplification was performed on Sau3AI digested, linker ligated DNA,
using the external CFTR primer, 861, plus the vectorette/ splinkerette primer.
Nested PCR was then carried out using the internal CFTR primer, 860, plus
the nested vectorette/splinkerette primer (see table 2.2 for primer
sequences). The PCR programmes used were:
Primary PCR
Hot start for 5 mins at 90°C.
Denaturation: 93°C for 30 sees in first cycle and 15 sees thereafter.
Annealing: Touch down from 65-55°C for 1 min.
Extension: 72°C, 5 sees (cycles 1-10), 15 sees (11 -20), 45 sees (21-30).
Nested PCR
No hot start
Denaturation: 93°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: 55°C for 1 min.
Extension: 72°C, 5 sees (cycles 1-10), 15 sees (11-20), 45 sees (21-30).
After the primary PCR, the spectrum of products was very similar for the
vectorette and the splinkerette (Fig 3.5). Both produced a major band at
290bp plus other bands and a background smear. Upon reamplification with
the nested primers however, this was reduced to a single band of the
expected size for both linkers, with equal intensity between the vectorette
and the splinkerette (Fig 3.5). When the nested primer, 860, was used as an
oligonucleotide probe on to the primary PCR products, the major band
hybridised strongly with equal intensity for the vectorette and splinkerette
tracks (Fig 3.5).
145
M 1 2 3 4 5 6
Figure 3.5 Amplification of a 290bp product by splinkerette or vectorette PCR
The marker used is 250ng px Hae III
Tracks 1 and 2 show 8|il of the vectorette and splinkerette primary PCR
product respectively (generated using the external CFTR primer (861) plus
the vectorette/splinkerette primer), resolved on a 4% agarose gel.
Tracks 3 and 4 show the result of hybridisation of tracks 1 and 2 respectively
with the internal CFTR oligonucleotide (860).
Tracks 5 and 6 show 10ptl of the vectorette and splinkerette secondary PCR
product respectively (generated using the internal CFTR primer (860) plus
the nested vectorette/splinkerette primer), resolved on a 4% agarose gel.
It can be seen that vectorette PCR and splinkerette PCR perform equally
under these conditions.
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3.2.2 The 2.3kb product
Primary PCR amplification of linker ligated BamHI digested DNA was
performed using the external WT1 primer, 50, plus the vectorette/
splinkerette primer. Nested PCR was then carried out using the internal WT1
primer, 51, plus the nested vectorette/ splinkerette primer (see table 2.2 for
primer sequences). The PCR programmes used were:
Primary PCR
Hot start for 5 mins at 90°C.
Denaturation: 95°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: Touch down from 70-60°C for 30 sees.
Extension: 72°C, 2 mins (cycles 1 -10), 4 mins (11 -20) and 6 mins (21-30).
Nested PCR
Hot start
Denaturation: 95°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: Touch down from 71-61 °C for 30 sees
Extension: 72°C, 2 mins (cycles 1-10), 4 mins (11-20), 6 mins (21-30).
No product was visible after primary PCR for either the vectorette or the
splinkerette. However upon reamplification with the nested primers, a strong
band of 2.3kb upon a faint background smear was visible for the splinkerette,
whereas an intense smear only was produced by the vectorette (Fig. 3.6).
These products were hybridised with a 1.1 kb Xho I and Not I restriction
fragment from the clone WTexl (obtained from Andreas Schedl), which
contained part of the target PCR product. The 2.3kb band in the splinkerette
track hybridised strongly to the probe, verifying that it was the target PCR
product. A band of the right size was also seen in the vectorette track, but its
intensity was very low (Fig. 3.6).
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Figure 3.6 Amplification of a 2.3kb product by splinkerette or vectorette PCR
(taken from Devon et al, 1995)
The marker used is 250ng of the 1kb ladder.
Tracks 1 and 2 show 10|il of the vectorette and splinkerette secondary PCR
product respectively (generated using the internal WT1 primer (51) plus the
nested vectorette/splinkerette primer), resolved on a 1% agarose gel.
Tracks 3 and 4 show the result of hybridisation of tracks 1 and 2 respectively
with a 1.1 kb probe derived from within the target PCR product.
It can be seen that the decreased non-specific priming associated with
splinkerette PCR relative to vectorette PCR permits the generation of the
2.3kb product by splinkerette PCR only.
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3.2.3 Discussion
Splinkerette PCR and vectorette PCR both performed equally in the
amplification of a short, 290bp fragment from total human genomic DNA.
Both enabled the production of the correct fragment (as verified by
hybridisation) after one round of PCR, but other bands and a smear were
also produced. Only after a second round of nested PCR was the correct
band cleanly produced.
Splinkerette PCR was however significantly more effective than vectorette
PCR in the amplification of a 2.3kb fragment. After two rounds of PCR the
correct product was produced as a strong band by splinkerette PCR, but
vectorette PCR resulted in a non-specific smear obscuring the real product.
The difference in competence between splinkerette and vectorette PCR can
be attributed to the different structures of the linkers themselves. The hairpin
structure of the splinkerette implies that it cannot partake in end-repair
priming, which may be responsible for most of the background products seen
in vectorette PCR. The differences are not caused by variation in primer
efficiency, since the same primer and PCR conditions were used for the
splinkerette and vectorette. Ligation conditions and genomic DNA were also
identical for both.
The superior functioning of splinkerettes was seen only for the longer target
PCR product. For the shorter target product, the vectorette and splinkerette
performed equally. The reason for this may lie in the PCR bias towards the
amplification of shorter molecules. When the target product was short,
amplification of the specific product was favoured in the reaction. For a
longer target product however, competition from smaller non-specific
products is more significant. The low level of end-repair priming of
splinkerettes reduced the competition from smaller non-specific products,
allowing the genuine product to be made. Amplification of the target product
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by vectorette PCR was however significantly encumbered by competition
from small non-specific products.
3.3 Isolation of End Clones from YACs
3.3.1 Introduction
The isolation of the terminal sequences of recombinant DNA from YACs is
an important step in the construction of a YAC contig. Hybridisation or PCR
mapping of end-clone sequences onto other YACs provides a quick and
easy way to score for overlap between them and will also determine which
YACs extend the furthest at both ends of an emerging contig.
End clones can be isolated by subcloning of the YAC into cosmids or
plasmid libraries and then selected by hybridisation with the YAC vector
arms. The technique of 'junction trapping' (Patel et at, 1993) involves the
isolation of end clones by subcloning the YAC into plasmids and the
amplifying the end clones by performing PCR with the plasmid vector primer
and the YAC vector primer.
Techniques which necessitate a cloning step can be laborious and time
consuming, and for this reason PCR based techniques for the isolation of
end clones are more commonly used. All the PCR based techniques make
use of primers derived from the YAC vector arm to provide the end-
specificity. The other primer may be derived from the Alu consensus
sequence (Nelson et al, 1989), a linker such as a vectorette (Riley et al,
1990) or splinkerette (Devon et al, 1995), or even another primer from the
YAC vector for inverse PCR (Ochman et al, 1988, Arveiler and Porteous,
1991).
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3.3.2 Isolation of end clones from chromosome 11 YACs in the region
of the t(1 ;11) breakpoint
A total of 23 YACs had been isolated by screening the ICI YAC library
(Anand et al, 1990) and the ICRF Reference Library (Larin et al, 1991) with 5
repeat-free microdissection clones from the interval nearest the translocation
breakpoint. These had been screened for positivity with the 11 microclones
from this region, thus enabling the assembly of a first generation contig,
which contained a single gap (Fig. 3.7). This contig however contained no
information regarding overlap between individual YACs or the orientation of
the contig.
Figure 3.7 First generation YAC contig. YACs (grey bars) had been
screened by PCR for positivity with the microdissection clone markers
(dotted lines). The contig contains a single gap, between YACs D0485 and
8AB2.
Microdissection Clone Markers
122 176 412 471 543 104 437 220 283 282
8AB2, A04135
H0921, D0165, 38CE7, 5FD7, 34GE5, 34GF5
D11155
H07131, A0846, 15IE11, 11EA9
16GB9
C04151, 19EE2, 33EB11, 2AH11, 11BA9, 21BG4
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Splinkerette PCR was the method chosen for the isolation of end clones from
the ICI YACs. A PCR-based method was chosen due to its speed and
specificity. Splinkerette PCR had been proven to be at least as effective as
vectorette PCR in PCR walking from total human genomic DNA (section 3.2)
so it was assumed that it should also be competent in the isolation of YAC
end fragments, perhaps succeeding in the amplification of longer products
where vectorette PCR would have failed. (ICRF YAC end clones were
isolated by vectorette PCR by John Brown.)
Approximately 0.5(ig total yeast plus YAC DNA was double digested with
BamHI and Bgl II. These enzymes have cohesive ends compatible with
ligation to splinkerettes, and cut genomic DNA with a frequency suitable for
the isolation of long end clones (BamHI average size fragment = 5.4kb; Bgl II
average size fragment = 2.25kb (Drmanac et at, 1986)). Splinkerettes were
then ligated onto the digested ends in a 4:1 ratio linkerinsert. The ligated
DNA was then PCR amplified with the splinkerette primer or nested primer
and a primer derived from the YAC vector. YAC vector primers used were
227 or 373 ('left hand side'), and 225, 556 or 464 ('right hand side') (see
table 2.2). Primers 225, 227, 556 and 373 were taken from or modified from
Arveiler and Porteous, 1991. Primer 556 was used in some cases as the
'right hand side' primer, but it occasionally resulted in non-specific products
from the yeast genome, so a new primer, 464, was designed from the
pYAC4 sequence. A single round of PCR was generally sufficient to
generate a single end-clone product free from background smear.
A standard PCR programme was used in all cases. This was:
Hot start for 5 mins at 90°C.
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: Touch down from 68-58°C for 30 sees.
Extension: 72°C, 3 mins (cycles 1-10), 5 mins (cycles 11-20), 8 mins (cycles
21-30).
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A total of 24 end clones were isolated, from 38 attempted (Fig. 3.8a). The
average size of the fragments was 1,7kb. Table 3.1 lists all the ICI YAC end
clones isolated, with their sizes. The bands were excised from a gel and
used as hybridisation probes onto a panel of all the ICI YACs digested with
EcoRI (Fig. 3.8b). Included on the filter was a track of total human genomic
DNA and a track of total yeast genomic DNA, both digested with EcoRI.
Table 3.1 End Clones Isolated from ICI YACs
!
= isolated by Euan Slorach
*
= isolated by Sheila Christie
°°
= isolated by Kathy Evans
ND = not determined
YAC NAME LHS/RHS pYAC4 LENGTH OF HUMAN
FRAGMENT PRIMER END CLONE HIGH COPY
(kb) REPEAT
2AH11 L 227 1.0 -
5FD7 L 227 3.0 -
8AB2 lJ 227 2.1 +
R 556 1.2 -
11BA9 u 227 1.4 +
11EA9 [J 227 1.1 -
R 556 0.7 -
15IE11 R 225 2.1 ND
16GB9 L 227 0.6 +
R 464 3.0 -
19EE2 L 227 1.4 +
21BG4 L 227 1.4 +
33EB11 L 227 1.1 -
R 464 3.5 +
34GE5 L* 227 2.8 +
R* 464 1.2 -
34GF5 L* 227 2.8 +
R* 464 1.2 -
35IA2 L°° 227 4.0 +
36IF5 U 227 0.8 -
R 464 3.6 +
37GE11 r 227 0.6 -
37GE12 L°° 227 0.6 -
38CE7 R* 464 0.5 -
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Figure 3.8 End Clones isolated from the ICI YACs
A) Tracks 1 to 4 show end clones from the left hand end of YACs 33EB11, 2AH11,
21BG4 and 19EE2 respectively. 1Opl of the PCR product generated by splinkerette PCR
using pYAC4 primer 227 is resolved on a 1% agarose gel. The marker used is 250ng 4>x
Hae III. B) Hybridisation of left hand end clones from YACs 21BG4 (upper) and 2AH11
(lower) onto a panel containing EcoRI digests of the ICI YACs, total human genomic
DNA (H) and total yeast genomic DNA (Y). The end clone from YAC 21BG4 contains a
high copy human repeat and gives a signal on YACs 11EA9, 16GB9, 21BG4, 11BA9,
19EE2 and 15IE11 (left to right). The end clone from YAC 2AH11 is a single copy
sequence and gives a signal on YACs 16GB9, 21BG4, 11BA9, 19EE2, 2AH11 and




A single round of non-optimised splinkerette PCR cleanly generated an end
clone in 63% of cases. Where failures occurred, it was usually because the
PCR reaction resulted in multiple bands rather than a single one. The non¬
specific bands were derived from the yeast genome, since upon
hybridisation to a panel of total yeast plus YAC DNAs, a band was seen in
every track. The production of non-specific bands could have been reduced
by using pure YAC DNA as the template for PCR, by optimisation of the PCR
conditions and by implementation of a second round of PCR using nested
primers. In some cases, the distance between the pYAC4 primer and the
nearest BamHI or Bgl II site may have been too great for standard PCR.
Long PCR conditions could have been used, or the YAC DNA could have
been digested with enzymes other than BamHI and Bgl II. Bel I and Sau3AI
also create cohesive ends compatible with the existing splinkerette. The
average size of Sau3AI digested fragments is small (325bp; Drmanac et at,
1986) so use of this enzyme would create a high probability that end clones
could be isolated, but they would generally be too small to be useful after
removal of the YAC vector DNA.
The average size of the end clones isolated was 1,7kb, which is a useful size
for hybridisation probes. The pattern of signal seen upon hybridisation to a
panel of the YACs provided some evidence that the PCR product probe was
a real end clone, if it hybridised to the YAC from which it was derived, plus a
discrete set of the other YACs. The final proof that the products were
genuine end clones could have been derived by sequencing of the YAC
vector junction with the recombinant DNA insert. This however was deemed
not necessary for the end clones isolated, since only those in which a single
strong band was produced in the PCR reaction were used, and no
discrepancies were found when mapping them onto the panel of YACs.
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The track of human genomic DNA was used to assess the repetitive nature
of the probe. A single band of the same size as that on the YAC panel
indicated a single copy probe, whereas probes which gave a smear on
human genomic DNA were of a repetitive nature. High copy human repeats
(probably Alu sequences) were present in 43% of probes tested. The Alu
element is approximately 300bp long, one sixth of the average end clone
length. This implies that Alu repeats constitute at least 8% of the total length
of the genomic DNA in the end clones, which is close to the figure quoted for
the whole genome (5%) (Shen et al, 1991).
The results generated from hybridisation of the end clones enabled scoring
of overlap between YACs. It also provided data suggestive of chimaerism in
YACs 36IF5, 33EB11 and 38CE7. This chimaerism was further investigated
by FISH analysis of catch linkered YAC material (Shibasaki et al, 1995) (by
Yoshiro Shibasaki and Diane Lawson). End clone data also identified clonal
YACs, for which end clone PCR products were of the same size and gave
identical mapping results. Three sets of clonal YACs were discovered. These
were a group of three (19EE2, 11BA9 and 21BG4; 11BA9 only shown on
Fig. 3.9), and two groups of two (37GE11 and 37GE12, 34GE5 and 34GF5;
37GE11 and 34GE5 shown on Fig. 3.9).
Cumulated data from mapping of these ICI YAC end clones, together with
those isolated from the ICRF YACs, enable the final contig map to be drawn
(Fig. 3.9). The order of microdissection clones 176 and 122 on the first
generation contig map was reversed. In addition YAC 6DB11 was found not
to be positive for MD282, and the position of the latter was moved to that of
MD437. The gap in the contig which had been present before the addition of
end clone data had been removed by the hybridisation of the left hand end
clone from YAC A0846, and confirmed by the isolation of further YACs and
end clones (37GE11, 37GE12 and 35IA2) (by Kathy Evans). The extent of
overlap between YACs could not be judged by this preliminary end clone
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mapping, but it could be estimated by combining the end clone data with
results from pulsed field electrophoresis sizing of the YACs (by John Maule)
and scoring of microdissection clone markers. The total length of the contig
was approximately 3Mb.
Study of published linkage maps of the human genome (Gyapay et al, 1994)
suggested that some genetic markers should lie within the contig. The
position of the YAC contig on chromosome 11 was initially defined as
between the gene tyrosinase (TYR) and the microsatellite marker D11S388,
a distance estimated as 7.2cM. Genethon markers which lie in between
these two markers are D11S931, D11S1342, D11S1358, D11S1332 and
D11S873, all of which are microsatellites. The first three and the latter two
fall into two groups among which the recombination rate is zero, and there is
a genetic distance of 0.1 cM between the two groups. PCR mapping on YACs
from the contig enabled placement of these genetic markers on the contig
(see Fig. 3.9). D11S931, D11S1342, D11S1358 and D11S1332 were located
within YAC D0485, and D11S873 was within YAC A04135 (and others).
FISH analysis was performed (by Yoshiro Shibasaki and Diane Lawson)
using catch-linkered YAC material and D11S931/MD104 positive cosmids
isolated from ICRF chromosome 11 cosmid library (obtained from H.
Lehrach). This established the orientation of the contig (as in Fig. 3.9) and
also that YAC D0485 spanned the translocation breakpoint. The markers on
this YAC were all located below the translocation breakpoint except
D11S931, which lay an estimated 100kb above the breakpoint towards the
centromere. Finer mapping of YAC D0485 then began with the subcloning of
the YAC into cosmids, to establish more accurately the position of the
translocation breakpoint and enable further analysis of the mechanism of the
translocation. These further mapping efforts will be discussed briefly in
Chapter 7.
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3.4 Long Range Restriction Site Mapping of YACs by Pulsed
Field Gel Electrophoresis (PFGE)
Once the YAC contig had been constructed with end clone isolation and
mapping, it was necessary to build a long range restriction map of the region,
for finer mapping and to establish the position of genetic markers, and partly
to look for restriction enzymes sites characteristic of CpG islands. I was
responsible for the construction of the restriction map of two of the ICI YACs,
19EE2 and 8AB2, and was involved in the mapping of D0485 (see Chapters
5 and 6).
3.4.1 Restriction enzyme digestion and PFGE of YACs
Agarose plugs containing the YACs 19EE2 and 8AB2 (made by John Maule)
were digested singly with the enzymes Not I, BssH II, Sfi I, Sal I, Mlu I and
Eag I (the latter for 8AB2 only). The digest patterns were then resolved on a
0.5% pulsed field gel by running at 180V for 30 hrs with a pulse time of 50
sees. Markers used were 3B3, YP148 and concatemers of the phage X
genome, which give bands spaced every 48kb. The gel was Southern
blotted.
Enzymes which did not cut within the YAC resulted in a single YAC derived
band on the gel, which could be used to estimate the total size of the YAC.
19EE2 was estimated at 280kb and 8AB2 was 450kb. The total size of the
YAC derived bands in every track should add up to this figure. If the total
size of the YAC bands exceeded the total length of the YAC, then it was
likely that the digestion had been incomplete.
3.4.2 Identification of the fragments derived from the YAC ends
Probes derived from the YAC vector arms were used to identify those
fragments of human DNA at the ends of the YAC. The enzymes chosen for
digestion do not cut within the vector sequence, to ensure that the nearest
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enzyme sites were within the insert of human DNA, and that a single band
would result from hybridisation with the vector arm probes.
2|ig of pBR322 DNA was digested with the restriction enzymes BamHI and
Pvu II. The digested DNA was then run on a 0.8% LMP agarose gel.
Digestion with these two enzymes gave two bands, which were excised from
the gel to be used as probes. The upper band (~2.8kb) was the left arm
probe and the lower band (~1.7kb) was the right arm probe.
Sizes of the fragments hybridising to the left and right vector arms
respectively are shown in Table 3.2.
3.4.3 Identification of other YAC derived fragments
Hybridisation with human Cot1 DNA was used to identify all the bands
containing human DNA. Human Cot1 DNA is largely comprised of Alu
repetitive elements, which are human specific and thus do not hybridise to
yeast sequences. Alu elements are sufficiently frequent that it is highly likely
that all digestion bands of a size resolved by PFGE (i.e. >10kb) will hybridise
to human Cot1 DNA.
By subtraction it could be calculated which bands were present in the YAC
but not derived from either end. In both YACs, for all the enzymes used, this
resulted in a maximum of one extra band, which could therefore be placed
between the two end fragments. Table 3.2 shows the sizes of bands
hybridising to Cot1 DNA but not derived from either end of the YAC.
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Table 3.2 Sizes of bands (kb) produced by hybridisation to restriction
digested YACs 19EE2 and 8AB2.
Restriction
Enzyme
Left vector arm Right vector arm Additional bands
(Cot1 positive)
19EE2
Not I 280 280 -
BssH II 280 280 -
Sfi I 50 150 80
Sal I 130 150 -
Mlu I 190 90 -
8AB2
Not I 450 450 -
BssH II 160 160 130
Sfi I 220 230 -
Sal I 180 50 220
Mlu I 180 120 150
Eag I 120 250 80
3.4.4 Placement of microdissection clone markers on the map
YAC 19EE2 is positive for one microdissection clone, MD122. Using the
insert of this clone as a probe gave a pattern of hybridisation identical to that
produced with the right hand end probe. This allowed placement of MD122
within the smallest fragment defined by the right vector arm probe, that is
80kb between the end of the YAC and the nearest Sfi I site (Fig. 3.10).
YAC 8AB2 is positive for two microdissection clone markers, MD471 and
MD412. MD412 gave a pattern of hybridisation identical to the left vector arm
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probe, enabling positioning of this marker at a maximum distance of 120kb
from the left hand end of the YAC to the nearest Eag I site. MD471
hybridised to the internal fragment where applicable, and to the right end
fragment in other cases. This marker was therefore placed within a 70kb Sfi I
/ BssH //fragment (Fig. 3.10)
Figure 3.10 Long range restriction maps of ICI YACs 19EE2 and 8AB2.
Shaded areas represent digest bands positive for MD122 (19EE2) or MD471
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Pulsed field maps of some other YACs in the contig were constructed in a
similar manner. YACs D0485, A0846, D11155 and A04135 were mapped by
John Brown, YACs 36IF5 and 16GB9 by Kathy Evans and YAC 14IA11 by
John Maule (data not shown). Combining the results from these YACs with
those for 8AB2 and 19EE2 enabled a long range restriction map to be
produced across the whole YAC contig (data not shown). This map included
all the microdissection clone markers depicted in Fig. 3.9. The exact length
of the contig could not be determined due to the unknown degree of overlap
between YACs, but could be estimated as a minimum of 3Mb, as defined by
the minimal set of non-overlapping YACs D0485, D11155 and H0921.
The number of genes within the region could be estimated from the number
of Not I sites within the YAC contig, since 89% of Not I sites occur within a
CpG island (Lindsay and Bird, 1987). There were only three Not I sites within
the entire contig, all of which occurred at the proximal end of YAC D0485.
This suggests that the region contains few genes. However, only 12% of
islands contain a Not I site (Lindsay and Bird, 1987), and only 40% of tissue
specific genes are associated with a CpG island (Larsen et at, 1992), so this
presumption must be viewed with caution. The presumed distribution of
genes is consistent with the cytogenetic location of the contig, at the junction
between a G (gene poor) an R (gene rich) band.
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CHAPTER 4
A SEARCH FOR GENES IN THE BREAKPOINT REGION
BY COINCIDENT SEQUENCE CLONING
Once it had been established that YAC D0485 spanned the translocation
breakpoint it was important to begin to search for genes in this region, with a
view to explaining the significance of the translocation event in relation to
psychiatric illness. The choice of method for gene finding was coincident
sequence cloning. Both a hybrid fishing CSC (HF-CSC) and an end ligation
(EL-CSC) experiment were carried out. The hybrid fishing experiment and
product analysis was carried out entirely by myself. The end ligation
experiment was carried out by Tony Brookes, and then the product library
was analysed by Kathy Evans, myself, Tony Brookes and Susan Anderson.
This chapter is concerned with the hybrid fishing experiment only except
where otherwise stated.
The input DNAs in the CSC experiment were YAC D0485 (genomic
resource) and human foetal brain cDNA (cDNA resource) (obtained from
Derek Blake, Institute of Molecular Medicine, Oxford). Both the genomic and
the cDNA resources were catch linkered, so as to create a simplified
resource, amplified via linker sequences appropriate for use in CSC.
4.1 Amplification of the Product cDNA
The two input DNA sources were integrated as in section 2.14.4, then after
the washing steps the product cDNA was eluted. This product was amplified
with primer 727 which is complementary to the linker sequences present on
the ends of the cDNA molecules. The two control products, 'cDNA only' and
'no DNA' were also amplified with primer 727. The programme used was:
Denaturation: 93°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: 54°C for 30 sees.
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Extension: 72°C for 1 min 30 sees (cycles 1-10), 2 mins 30 sees (11-20), 4
mins (21-29) and 8 mins (cycle 30).
The PCR products were run on a 2% agarose gel (Fig.4.1). The product
cDNA track contained a smear of molecules larger than ~250bp, with one
major product band at ~500bp. This band was excised from the gel for future
use as a probe. In the 'cDNA only' track was a very faint smear. This
probably represents the small amount of cDNA which adhered non-
specifically to the beads and was not removed by the washing steps. The 'no
DNA' track was completely blank. This implies that no DNA which could be
amplified by primer 727 had been introduced to the experiment as a
contaminant. The negative control for the PCR reaction (no template DNA
included) was also blank.
4.2 Cloning of the Product cDNA
The linker used to amplify the cDNA incorporates an EcoRI site, which
greatly facilitated the cloning step since cohesive end cloning could be
employed. 20pl of the amplified product was digested with EcoRI and cloned
into pBS vector which had been digested with EcoRI and phosphatased.
20ng of the digested cDNA was ligated into 20ng of pBS vector in a total of
20|il. The transformation efficiency was approximately 3000 white colonies
per ng of product cDNA. The cells were plated at an optimum density, so that
individual colonies could be recognised and accurately picked. All the
colonies from several of these plates were lifted onto nitrocellulose filters, to
provide high density (-1500 colonies) filters for estimation of the frequency of
products. In addition 480 white colonies were picked at random and each
grown in a well of a microtitre plate. In this way, a representative portion of
the library was ordered onto five 12x8 grids, such that each colony could be
referred to by its plate number and grid reference. The library was
subsequently manipulated by a Hybaid colony picking robot, to make frozen





Figure 4.1 Amplified product cDNA from the HF-CSC experiment
The marker used is 250ng px Hae III (track 1).
Tracks 2 to 5 show 6gl PCR product resolved on a 2% agarose gel. Track 2
contains the product cDNA, linkered and amplified with primer 727. A major
product occurs at 500bp. Tracks 3 and 4 contain the CSC negative controls,
'cDNA only' and 'no DNA' respectively. Track 5 contains a 'no template' PCR
negative control.
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4.3 Analysis of the Product Library
4.3.1 Strategy for analysis of the library
A thorough analysis of the 480 clones comprising the gridded library was
undertaken, with an exhaustive analysis of the first 192 clones. The first step
was to identify by hybridisation clones containing high copy repeat elements
or ribosomal DNA, so that these could be excluded from further analysis.
Secondly, the major product was identified by using the PCR product band
as a probe onto the gridded filters. Thirdly, representative positive clones
were picked, and their insert amplified by PCR. Clones with a reasonably
sized insert (more than 100bp) were sequenced by single pass automated
cycle sequencing. The sequences at the end of the clones were checked to
ensure they contained the expected sequence derived from the iinker primer.
Sequences were edited to remove vector and primer sequences and were
then analysed by computer for sequence matches with already identified
products and sequences in the Genbank, EMBL and dbEST databases.
Probes were made from selected products by removing the vector
sequences by EcoRI digestion and then excising the insert band from an
LMP gel. All products identified were hybridised back onto the library to avoid
reselection of previously analysed products. The identity of representative
clones positive for a probe by hybridisation was verified by sequencing.
Clones whose identity had not been established by hybridisation were picked
at random, and those with an insert of reasonable size were sequenced.
4.3.2 Assessment of the frequency of high copy repeats and ribosomal
DNA sequences in the library
The high frequency of repetitive elements in both genomic DNA (Alu
elements comprise approximately 5% of the human genome; Shen et at,
1991) and cDNA (3-5% of cDNAs contain Alu elements; Crampton et al,
1981) means that genuine recovery of these repeats by coincidence can be
problematic. Clones which contain an Alu repeat are difficult to use as
hybridisation probes, since the signal resulting from the repeat will obscure
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that resulting from the non-Alu portion of the probe. Before integration, the
denatured genomic DNA and cDNA had been allowed to anneal to an
excess of Human Cot1 DNA, which is comprised almost entirely of high copy
repeat sequences, primarily Alu elements. It was hoped that this pre-
annealing step would 'quench' most of the Alu elements and prevent them
from occurring in the product DNA.
In order to estimate the frequency of clones containing Alu elements in the
product library, seven high density filters were screened with human Cot1
DNA. There were 44 positive clones, which gives a frequency of 0.4% clones
containing Alu elements. This frequency was sufficiently low that the
presence of high copy repeat elements would not hamper the analysis of the
product library. The five gridded filters were also screened with Cot1 DNA.
Six colonies out of the 480 gave strong positive signals. Two of these were
sequenced and they were found to be identical to each other, and to have
high homology with Alu-related repetitive elements present in known human
genes.
The presence of a high frequency of ribosomal DNA clones in the product
library was also a potential problem since there is a very high frequency of
ribosomal sequences in yeast DNA, which are sufficiently conserved with
their human counterparts that they may be recovered by coincidence.
Ribosomal DNA from two clones had been used to pre-anneal to the input
DNAs in order to block their involvement in IRD formation. The same clones
were labelled and used as a probe onto the product library, to assess the
efficiency of blocking. There were 52 positive clones on 6 high density
plates, which implies a frequency of 0.6%. This was deemed adequately low.
Only 2 clones from the grids gave a strong signal with the ribosomal DNA
probes. No further analysis was performed on these clones.
168
4.3.3 Identification of the major product
The one band resulting from the initial PCR reaction was likely to comprise a
product at high frequency in the library, and therefore was used as a probe
onto the gridded filters.
This probe hybridised to approximately 10% of the colonies (5% if only the
strong signals were included). Twenty clones which hybridised strongly were
picked, and the insert amplified by PCR. Five of these, which all had different
insert sizes, were chosen for sequencing. These were clones 1-6h, 2-2b, 2-
10b, 3-6c and 1-1 Od.
Out of these five clones, four (excepting 2-1 Ob) gave highly significant
database homology matches with parts of an a-tubulin gene. 2-2b (see figure
4.2) and 1-1 Od matched 5' portions of the gene, 1-6h matched the 3' end
(see figure 4.3), and 3-6c matched a more central section. The a-tubulin
clones 1-6h, 2-2b and 3-6c were used as probes onto the gridded library.
Almost all the clones which had been positive for the major PCR band probe
were positive for either 1-6h or 2-2b, confirming that the major product of the
HF-CSC was a-tubulin. There was no overlap in hybridisation pattern
between these two probes. There were no clones positive for 3-6c, except
itself.
The hybridisation of the PCR product probe to clone 2-1 Ob was strong and
unlikely to have been non-specific. The PCR band probe was therefore likely
to have contained 2-1 Ob sequences in addition to a-tubulin. The sequence of
this clone gave no significant matches in the databases. Three other
products were identified from the gridded library whose sequence matched
2-1 Ob. Further analysis on these clones will be described in section 4.6.
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Figure 4.2 Sequence match between the CSC clone 2-2b and
keratinocyte alpha tubulin gene ('ker').
2-2b TCGACTCTTAGCTTGTCGGGGACGGTAACCGGGACCCGGTGTCTGCTCCT 50
I II I I II I I I I I I I I I I II I I I II I I I I I I II I I
ker TGTCGGGGACGGTAACCGGGACCCGTGCTCTGCTCCT 50
2-2b GTCGCCTTCGCCTCCTG-ATCCCTAGCCACTATGCGTGAGTGCATCTCCA 100
I I I II I II I I I I I I I I I I I I I I I I I I I I I I I I II I I II I I I I I I I II I
ker GTCGCCTTCGCCTCCTGAATCCCTAGCCA-TATGCGTGAGTGCATCTCCA 100
2-2b TCCACGTTGGCCAGGCTGGTGTCCAGATTGGCAATGCCTGCTGGGAGCTC 150
I I I I I II I II I II II I I I I II I I I I I I II I I I I I I II I I I II I I I II I I I
ker TCCACGTTGGCCAGGCTGGTGTCCAGATTGGCAATGCCTGCTGGGAGCTC 150
2 -2 b TACTGCCTGGAACACGGCATCCAGCCCGATGGCCAGATGCCAAGTGACAA 2 0 0
I I I II I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I I II
ker TACTGCCTGGAACACGGCATCCAGCCCGATGGCCAGATGCCAAGTGACAA 200
2 -2 b GACCATTGGGGGAGGAGATGACTCCTTCAACACCTCCTTCAGTGAGACGG 2 50
I I I I I II I I I I I I I I I I I I II I I I I I I II I I I I I I I I II I II I I I I II I
ker GACCATTGGGGGAGGAGATGACTCCTTCAACACCTTCTTCAGTGAGACGG 250
2-2b GCGCTGGCAAGCACGTGCCCCGGGCTGTGTTTGGTAGACTTGGTACCCAC 300
I I I I I I I I I I I II I I I I I I II I I I I II I I I I I II II I I I II I I I I II I
ker GCGCTGGCAAGCACGTGCCCCGGGCTGTGTTT-GTAGACTTGGAACCCAC 300
2-2b AATCATTGATGAAGTTCGCACTTGGCAACTACCGCCAGCTCTTCCACCCT 350
I II II I II I I I I I I I I II I I I II II II I II I I I I I II I I II II I I I I
ker AGTCATTGATGAAGTTCGCAC-TGGCACCTACCGCCAGCTCTTCCACCCT 350
2 -2 b GAGCAGCTCATCACAGGCAAGGAAGATGCTGCCAATAACTATGCCCGAGG 4 00
I I I I I II I I II II I I I I I I I I I II II I I I I II I I I I I I I I I I II I I I II I
ker GAGCAGCTCATCACAGGCAAGGAAGATGCTGCCAATAACTATGCCCGAGG 400
2-2b GCACTACACCATTGGCAAGGAGATC 425
I I I I I I I II I I I I I I I I I I I I I I I I
ker GCACTACACCATTGGCAAGGAGATC 425
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Figure 4.3 Sequence match between the CSC clone 1-6h and the foetal
brain alpha tubulin gene ('fbrn').
l-6h TAAATACATGGCTTGCTGCCTGTTGTACCGTGGTGACGTGGTTCCCAAAG 50
I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I II I I I I I I I
fbrn TAAATACATGGCTTGCTGCCTGTTGTACCGTGGTGACGTGGTTCCCAAAG 3491
l-6h ATGTCAATGCTGCCATTGCCACCATCAAGACCAAGCGTACCATCCAGTTT 100
I I II I I I I II I I I I I II I I II I I I I II I II I II I I I I II II II I I I I I I I
fbrn ATGTCAATGCTGCCATTGCCACCATCAAGACCAAGCGTACCATCCAGTTT 3541
1-6h GTGGATTGGTGCCCCACTGGCTTCAAGGTTGGCATCAACTACCAGCCTCC 15 0
II I I I I I I I II I II I I II II I I I I I II I I I I II I I I I I I I I I I I I I I I II
fbrn GTGGATTGGTGCCCCACTGGCTTCAAGGTTGGCATCAACTACCAGCCTCC 3591
l-6h CACTGTGGTGCCTTGATGGAAGACCTGGCCAAGGTACAAGAGAgCTGTGT 200
II I I I I I I I I I I II III II II I I I I I I I I I I I I I I II I I I I I II I I
fbrn CACTGTGGTGCC-TGGTGG-AGACCTGGCCAAGGTAC-AGAGAGCTGTGT 3641
l-6h GCATNCTGAgCAAACACCACAACCATTGCTGAGGCCTGGGCTCGCCTGGA 250
I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I II I I I II I I I I II
fbrn GCATGCTGAGC-AACACCACAGCCATTGCTGAGGCCTGGGCTCGCCTGGA 3691
l-6h CCACAAGTTTGACCTGATGTATGCCAAACGTGCCTTTGTTCACTGGTACG 300
II I I I I I I I I I I I I I I II I I II I I II I I I I I I II I I I I I II II I I II I II
fbrn CCACAAGTTTGACCTGATGTATGCCAAACGTGCCTTTGTTCACTGGTACG 3741
l-6h TTGGGGAGGGGATGGAGGAAGGTGAGTTTTCAGAGGCCCGTGAGGACATG 350
I I I I I I I I I II II I I I I I I I I I I I II I i I II I I I I I I I I I I I I I I I I I I I
fbrn TTGGGGAGGGGATGGAGGAAGGTGAGTTTTCAGAGGCCCGTGAGGACATG 3791
1-6h GCTGCCCTTGAGAAGGATTATGAGGAGGTTGGTGTGGATTCTGTTGAAGG 400
I I I I I I I I I II I I I I I I II I I I I I I II I I I I II I II I II II II I I I I II
fbrn GCTGCCCTTGAGAAGGATTATGAGGAGGTTGGTGTGCATTCTGTTGAAGG 3841
l-6h AGAGGGTGAGGAAGAAGGAGAGGAATACTAAAGTTAAAACGTCACAAAGG 450
I I II I I I I II II I I I I I I I I I I I I II I I II II I II I II I I II I I I I I I I I
fbrn AGAGGGTGAGGAAGAAGGAGAGGAATACTAAAGTTAAAACGTCACAAAGG 3891
l-6h TGCTGCTTTTACAGGGAAGCTTATTCTGTTTTAAACATTGAAAA-GTTGT 500
I I I I I II I II I II I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I I II
fbrn TGCTGCTTTTACAGGGAAGCTTATTCTGTTTTAAACATTGAAAATGTTGT 3941
l-6h GGTCTGATC 509
I I II I I I I I
fbrn GGTCTGATC 3950
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In addition to the five clones positive for the PCR band, and the two Alu
repeat-containing clones, a further 68 products from the gridded library were
sequenced. Of these, 50 were identified as parts of an a-tubulin gene. Three
clones gave significant database matches with other known genes, the non-
erythroid spectrin gene, the neurodevelopmental gene neuronatin, and a
ribosomal protein gene. One was a short interspersed repeat element
(SINE). Three gave sequence matches with 2-1 Ob (see above) and a further
11 clones had no matches in the database.
4.3.5 A complete analysis of a portion of the library
A virtually complete analysis of 40% of the gridded library was undertaken.
The insert of 188 of the 192 clones was amplified by PCR and the products
run out on 1.5% agarose gels. It was found that of these, 95 of the clones
(50%) possessed either no insert or one too small for useful analysis (less
than ~100bp). Clones consisting of purely vector sequence could have
resulted from incomplete digestion of the vector, or incomplete phosphatase
treatment (which stops the vector from recircularising during the ligation
step). Small insert fragments will be cloned preferentially to larger ones, so
this could explain the high proportion of small clone inserts. Larger clone
insert sizes could have been obtained by using a gel purification step to size
select the PCR amplified material to be cloned.
Of the remaining 93 clones, the average insert size was approximately
500bp. One colony gave two bands upon PCR with the vector primers
flanking the insert. This could reflect a colony composed of two different
clones, a co-cloning of two different plasmids into the same bacterial cell or a
complex chimaeric plasmid formed between two vector and insert
sequences. For twelve clones, the miniprep or sequencing reaction failed
upon the first attempt, and was not repeated. Sixty-nine clones (36%) were
identified as being parts of an a-tubulin gene, 35 of these by sequence
analysis and 34 by hybridisation with other a-tubulin clone probes only. Two
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(1%) were positive with the human Cot1 DNA probe and therefore contained
high copy repeats. Two products gave database matches to known genes
other than a-tubulin and five products had no sequence matches in the
database (4% non-tubulin gene products). Of the latter seven, three were
later found to be artefactual products, resulting from amplification and
cloning of non-coincident cDNA. This implies that less than 3% of the cloned
CSC products were artefactual (3 of the 93 clones with a reasonably sized
insert).
Table 4.1 summarises the main features of the HF-CSC library (as estimated
by analysis of the first 40% of the 480 colonies in the gridded library)
Table 4.1
Clone type Frequency (%)
No insert / insert < 10Obp 50
high copy repeat containing 1
ribosomal DNA 0.4
a-tubulin gene fragments 36
other known genes 1
no database matches 3
unidentified (sequencing failure) 9
4.4 Clones Containing Fragments of an Alpha Tubulin Gene
4.4.1 Tubulin Genes
There are currently three classes of known tubulin genes, alpha, beta and
gamma. Gamma tubulin is associated with the centrosome (Zheng et al,
1991). Alpha and beta tubulin together comprise the major soluble protein
component of microtubules, and are members of small multigene families in
higher eukaryotes. Southern blot analysis reveals that there are
approximately fifteen copies of both the alpha and beta tubulin sequence in
the human genome, though not all of these copies are necessarily
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expressed. Extensive analysis on the beta tubulin gene family has revealed
that most of these bands correspond to non-functional pseudogenes
(Cleveland and Sullivan, 1985), and the same is likely to be true for alpha
tubulin.
For alpha tubulin, three expressed sub-types have been identified. The first,
foetal brain alpha tubulin, demonstrates a pattern of expression restricted to
differentiated cells of neurological origin (Cowan et al, 1983). The second
has a more ubiquitous expression pattern, and is termed keratinocyte alpha
tubulin, reflecting the cell type from which it was isolated (Cowan et al, 1983).
The third, testis specific alpha tubulin, is only expressed in the testis of
monkeys and humans, and has been mapped to chromosome 2q (Gerhard
et al, 1985).
The structure of both foetal brain and keratinocyte a-tubulin comprises 4
exons and 3 introns, the first exon consisting of just the initiator methionine
codon. All three contain a poly(GT) repeat in the first intron (Todd and
Naylor, 1991, Hall and Cowan, 1985). There is 97% sequence homology
between these two alpha tubulin genes, but the 5' and 3' untranslated
regions (UTRs) are different (Cowan et al, 1983). There is however
considerable inter-species homology (65-80%) in the non-coding regions,
which suggests selective conservation throughout evolution, possibly due to
an as yet unknown functional requirement.
The high sequence similarity between the coding regions of the foetal brain
and keratinocyte a-tubulin genes means that hybridisation with these
portions of the gene cannot distinguish between the two. Probes must be
designed from the UTR sequences. Hybridisation of a UTR-derived probe
from both subtypes to total human DNA detects two bands, which are
specific to the subtype. This suggests that only four out of the fifteen a-
tubulin gene copies contain sequence similarity with two of the three known
subtypes.
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The chromosomal loci for the foetal brain or keratinocyte a-tubulin genes are
unknown. Loci for a-tubulin genes or pseudogenes have only been detected
on chromosomes 2q (testis specific gene, TUBA1, Gerhard et al, 1985),
13q 11 (tubulin alpha-like 2, Bonaldo, 1992) and 12 (tubulin alpha-like 1, Gatti
et al, 1987). In addition some bands produced by digestion of the
chromosome 12 family member were identified as present on chromosome
11 (Gatti et at, 1987).
4.4.2 Identification by sequencing and hybridisation
A total of 128 clones containing a-tubulin gene fragment inserts were
identified from the whole gridded library of 480 clones (26%). The complete
analysis of 40% of the library suggested that 36% of the clones were a-
tubulin, which implies that more a-tubulin clones would have been identified
had a complete analysis of the whole gridded library been undertaken.
Of these 128 clones, 54 were proven to be fragments of the a-tubulin gene
by sequence analysis. The other 74 were positive by hybridisation only.
These 74 clones gave strong positive signals with clone 2-2b, clone 1-6h or
tubulin clone lrandom4' from the EL-CSC experiment and/or the PCR band
probe and/or a composite a-tubulin probe made up of cDNA fragments
spanning as much as possible of the whole gene (comprising the inserts of
clones 2-2b, 1-6h, random4 and 1-f5). All these probes, except the PCR
band, had been proven by sequencing to contain a-tubulin fragments alone,
hence it is reasonable to assume that clones unambiguously hybridising to
them do indeed contain tubulin sequences. Only seven clones were positive
by hybridisation to the PCR band only. There must be some doubt as to
whether these clones definitely contain a-tubulin sequence, however none
were positive for any other probes.
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4.4.3 Comparison of CSC a-tubulin clones with the known a-tubulin
gene sequences
Figure 4.4 shows the position of the a-tubulin clones isolated from the CSC
experiment in relation to the known expressed a-tubulin genes from foetal
brain and keratinocyte. It can be seen that a virtually complete coverage of
the coding sequence was achieved. The only portion missing was 130bp
from exon 4. This could be because it was not recovered in the CSC product
DNA, or because it was refractory to cloning. An 110bp fragment from exon
4 was present most abundantly - 29 of the 54 a-tubulin clones sequenced
were derived from this region.
The foetal brain and keratinocyte a-tubulin cDNA sequences are sufficiently
similar throughout most of the translated region that it is impossible to tell
which of the individual cDNA clones were derived from each. Single pass
ABI cycle sequencing is only 98-99% accurate, and so small variations from
the expected sequence may be attributed to sequencing errors. Only in a
small region of exon four is there sufficient divergence between the two
subtypes (a block of nineteen nucleotides in which there are ten mismatched
bases) that assignment to a particular a-tubulin could be accomplished. It
was found that cDNA clones from both types had been isolated. Slightly
more clones in this region were derived from foetal brain cDNA (six clones)
than from keratinocyte cDNA (four clones). This is unsurprising considering
that the cDNA source for the CSC experiment was foetal brain.
Clones in which the sequence extended into the 5' or 3' untranslated (UTR)
regions were easily assigned to be derived from a particular expressed a-
tubulin, since the UTR sequences of the known expressed alpha tubulin
subtypes show no homology among themselves. Of the four clones which
extended into the 3' UTR, three were derived from foetal brain cDNA and two
from a keratinocyte-like cDNA. Four clones extended into the 5' UTR (one of
these from the EL-CSC experiment). Of these, two were derived from a
176
keratinocyte-like cDNA and the other two did not match any known tubulin.
The suffix 'like' is added above since the UTR's of the keratinocyte cDNA
clones did not match perfectly with the published keratinocyte a-tubulin
sequence. The rate of mismatch was slightly higher than could be attributed
to normal sequencing errors - for instance for the clone 2-2b there were 5
mismatches with the keratinocyte a-tubulin within the 70bp of the UTR, but
then only a further 6 mismatches in the remaining 270bp of the clone.
Similarly for the EL clone nonran2b there were 10 mismatched bases in the
70bp of the UTR, and only 9 in the remaining 340bp of the clone. This
implies that there may be other expressed a-tubulin sequence similar to
keratinocyte a-tubulin. The UTR sequences of 2-2b and nonran2b are
however not identical, which implies either the existence of more than one
additional keratinocyte-like expressed a-tubulin gene or a chance excess of
sequencing errors in the UTRs.
Two of the clones with sequence extending into the 5' UTRs (1-1 Od and 3-
4g) were identical to each other, but did not match either the foetal brain or
the keratinocyte a-tubulin genes in the UTR region. This implies that there is
definitely a third type of expressed tubulin gene. No further analysis of this
gene was performed.
4.4.4 An a-tubulin gene on YAC D0485
Three of the CSC a-tubulin clones were used as hybridisation probes back to
the starting genomic resource, that is YAC D0485. The positive hybridisation
signal confirmed that there was genuinely at least one a-tubulin sequence
located on the YAC (see Fig. 5.1). Chapter 5 is concerned with the finer
mapping and further analysis of this sequence.
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4.5 Clones derived from other known genes
Three clones identified from the gridded library matched parts of known
genes other than a-tubulin.
4.5.1 A ribosomal protein
The sequence of one clone (1-7e) was 97% identical to part of the human
ribosomal protein L7a large subunit mRNA. This ribosomal protein gene had
previously been assigned to chromosome 9q34 (Yon et al, 1989). Clone 1-7e
may have been recovered by coincidence, indicating a locus very similar to
that of the ribosomal protein on chromosome 11 q, or alternatively it could
have been recovered as an artefact. Hybridisation of the insert of this clone
onto YAC D0485 (restriction digest fragments resolved on a pulsed field gel)
gave no signal at normal stringency and thus it was interpreted that this
clone represented an artefactual product.
5.5.2 Neuronatin
Clone 4-8c gave significant matches to both rodent genes and human EST's.
The same portion of the clone produced a 73% identity to the Rattus
Norvegicus neuronatin gene, alpha and beta mRNAs (see figure 4.5a). The
gene neuronatin was identified by differential display to define genes
expressed in postnatal brain development (Joseph et al, 1994). A full length
cDNA was isolated, which coded for a novel protein of 81 amino acids, which
was expressed highly in both rat neonatal and human foetal brain. The gene
was expressed during late foetal and early postnatal brain development and
was postulated to be involved in terminal brain differentiation (Joseph et al,
1994).
The same part of the CSC clone also produced a 71% identity to rat brain
calbindin protein 28K. Upon closer inspection of the calbindin sequence in
the database it was discovered that the neuronatin gene sequence is joined
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on after the calbindin sequence itself, and is termed an 'unrelated cDNA
fragment'. The match to calbindin was therefore an artefact of the database.
A search for homology with human EST's produced two extremely close
matches (201 bases identical out of 203 for human EST 135164 and 230
bases identical out of 231 for human EST 13968) (see figure 4.5b). With
near-perfect matches such as this it can be assumed that these two EST's
and the clone 4-8c are derived from the same cDNA species.
The fact that the gene homologous to clone 4-8c, neuronatin, is involved in
brain development made it a very attractive candidate for involvement in
schizophrenia. However, no signal could be seen upon hybridisation of the
insert of this clone onto YAC D0485, even under reduced stringency
conditions (hybridisations and washing at 55°C). It was therefore concluded
that this clone was an artefact in the CSC library.
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Figure 4.5a Sequence match between CSC clone 4-c8 and the rat brain
development gene neuronatin ('neuro').
4-c 8 GGAAATCCAAAACACCGCACCAGCCAGCAGGAATGGACATTCTGACATCG
I I II I I I I I I I I I II I I I I I I I I I I I II I II I I II II
neuro ATGGAGAGCTAACACCCCACCAACCAGCA-GAATGGACATTCTGACATCA
4-c8 CCAGCCGACGCCCTGAATCTTTGGTGCAGCA CCCAACCGCGT
I I I I I I I I I I I I I II I I II I I I I I I I I II I I I I
neuro CCAGCTGAAACCCTGAATC-TCGGTGCAGAAGAGAAAGTGTCAACTGCGT
4-c 8 GCCTGTGTGGCGGGACTGGAGGGCACAGTTGAGGAAGGAGGGTGGTTAAG
II I II II I I II I I I I I III I I I I I I I I I I I I I
neuro GCAGCACTGG-GGGAGTGGAGGGTGTGGGTGGTGGAGGAAGAGGGTTAAG
4-c 8 AAATACAGTGGGGCCCTCTCGCTGTCCCTTGCCCAGGGCACTTGCATTCC






II I I I I I I I I I I I I I I I I I I I II I II III
TGCC TTGCTCCCTCACTCCCCCTCTCC-CCTGCCT TCC
CAAGCCCACCCTACTCCAAAATAATGTGTCACTTGATTTGGAACTATTCA















I I I I I II II
neuro ACCAGTAATTGGATCCCACCT 954
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Figure 4.5b Sequence match between the CSC clone 4-c8 and the human
EST sequence 13968 ('est').
COuI GGAAATCCAAAACACCGCACCAGCCAGCAGGAATGGACATTCTGACATCG




0^ I o 00 CCAGCCGACGCCCTGAATCTTTGGTGCAGCACCCAACCGCGTGCCTGTGT
I I II I I I M M II I I I M I I I I I I I I I II I II I I I I I I II I I II I I II
100
est
I II II I I I I II I II I I I II I I I I II I I I I I I I I I I i I I II I I I I I I I I
CCAGCCGACGCCCTGAATC-TTGGTGCAGCA-CCAACCGCGTGCCTGTGT 100
COuI GGCGGGACTGGAGGGCACAGTTGAGGAAGGAGGGTGGTTAAGAAATACAG
i I i i i I i I i I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I II I
150
est
I I I I I I II I I I I II I I I I I I II I I I I I I I I II I I II I II I I I I I I II I I I
GGCGGGACTGGAGGGCACAGTTGAGGAAGGAGGGTGGTTAAGAAATACAG 150
(4^ I O 00 TGGGGCCCTCTCGCTGTCCCTTGCCCAGGGCACTTGCATTCCAGCCTCGC
I i i M II I M M I M II i I II M I I I I I I I I I I I I I I II M I I I I I I I I I
200
est
I I II I II I II I I I I I I I II I I I I I I I I I I I I I I I I II II I I I II II I II I
TGGGGCCCTCTCGCTGTCCCTTGCCCAGGGCACTTGCATTCCAGCCTCGC 200
0^ I o 00 TGCATTTGCTCTCTCGATTCCCCTTTCCTCCTCACTGCCTCCCAAGCCCA
i i i M i M i M i i i i i i M i i M i i i i M i i M i M M M i i I II i M II
250
est
I I I I II I I I II I I I I H I II II I I II I II II II I I I I II I I II I I I II II
TGCATTTGCTCTCTCGATTCCCCTTTCCTCCTCACTGCCTCCCAAGCCCA 250
0^ I o CO CCCTACTCCAAAATAATGTGTCACTTGATTTGGAACTATTCAAGCAGTAA
M M M M i i i i i II M i i I II i I I I I I II I I I I M I I I I I I I I II I I I I
300
est









Clone 2-12f produced a 96% identity (208 out of 210 bases) with the human
non-erythroid alpha spectrin gene. This gene, also termed alpha fodrin, has
been mapped to 9q33-q34 (Upender et a!, 1994). The very high level of
identity between the clone and the a-fodrin gene implies that they were
derived from the same cDNA (not another transcribed from a locus on 11q).
The existence of an a-fodrin pseudogene within YAC D0485 could have
enabled the selection of the a-fodrin cDNA; however there was no signal
upon hybridisation of clone 2-12f to YAC D0485 under normal high
stringency and so it is likely that this clone represents an artefactual product.
4.5.4 Discussion
Since these three clones did not hybridise back to the starting genomic
resource, they probably represent artefactual products in the library. The
stringency of washes used in the CSC experiment (0.1x SSC at 68°C) was
the same as those used in the hybridisation to D0485, so it is unlikely that
these products could have been recovered by genuine coincidence, but with
imperfect base-pairing such that they did not hybridise to D0485.
It is interesting however, that roles can be foreseen for both alpha-fodrin and
neuronatin in psychiatric illness; the latter because it is involved in brain
development and the former because alpha-fodrin is part of a super family of
structural proteins (Davison et at, 1989), of which itself and other members
may be of significance to the (1; 11) translocation and/or to schizophrenia.
Alpha-fodrin is capable of binding actin, and in myelinated neurons may be
responsible for the distribution of sodium channels at the nodes of Ranvier
(Moon and McMahon, 1990). It is probably also important in the formation
and maintenance of polarised membrane domains (Nelson and Veshnock,
1987). Other proteins in the spectrin superfamily include alpha-actinin and
dystrophin. There are loci for alpha-actinin at 1q42-q43 (ACTN2) and 11 q 13-
q14 (ACTN3) (Beggs et at, 1992), which are cytogenetically close (plus or
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minus 10Mb) to the positions of the breakpoints of the translocation. Also
dystrophin has been previously implicated in schizophrenia (see section
1.10.3). The possibility that structural proteins are involved in the aetiology of
psychiatric illness will be discussed more fully in Chapters 5 and 7. Although
no role for a ribosomal protein as a candidate gene in psychiatric illness can
easily be foreseen, it is located within the same cytogenetic region of the
genome as alpha-fodrin, that is 9q33-34.
4.6 Clones Derived From Novel cDNAs
Fifteen clones from fhe HF-CSC library gave no significant matches with
sequences in the databases, and therefore were derived from novel cDNAs.
These clones were 1-3c, 1-1 Od, 1-11 d, 2-1 Ob, 2-5g, 3-3a, 3-4e, 3-5g, 4-3b,
4-7a, 4-10a, 4-7d, 4-1 f, 4-7g and 5-3c. No further analysis was performed on
1-1 Od and 4-3b since they both had insert sizes of less than 100bp.
Computer assisted comparison of the sequences of the remaining clones
revealed that some could be arranged into families. The clones usually
represented different Sau3AI fragments of the same cDNA species, although
occasionally partial digestion led to overlapping restriction fragments. During
amplification of the CSC product cDNA, the primer often annealed non-
specifically, and in these cases the ends of the clones were not Sau3AI sites.
This was in fact advantageous for analysis of the products, since the clones
were thus often overlapping, and contigs of cDNA clones could be
assembled.
Some of the clones identified from the EL-CSC product library matched the
novel cDNA clones from the HF library. Some were identified by random
sequencing (by Kathy Evans) and others were identified by hybridisation with
HF product probes. The identity of some of those in the latter group was
confirmed by sequencing (by Susan Anderson). In addition, some EL clones
were used as hybridisation probes to identify additional family members in
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the HF library. Incorporating the results from analysis of the EL library, the
clones derived from novel cDNAs could be grouped into five families (Figure
4.6 and Figure 4.7).
Family 1 was composed of sequences derived entirely from the end ligation
experiment. The other families comprised HF and EL clones. Ten other
probable Family 1 clones, eleven probable Family 2 clones and three
probable Family 4 clones were identified from the EL library by hybridisation
but were not sequenced. They have therefore not been included in Figures
4.6 and 4.7. The consensus sequences of the five families were then used to
screen the databases for matches with known genes. No highly significant
database matches were found.
Some of the CSC clones derived from novel cDNAs could not be grouped
into a family. These were clones 2-5g, 4-1 f and 3-3a, all derived from the HF
experiment. Clone 2-5g was found to be an artefact of the library since it did
not hybridise back to YAC D0485 under normal conditions of high stringency.
Clones 4-1 f and 3-3a did however hybridise to the YAC (see Fig. 6.2), these
were termed Products 6 and 7 respectively. A small portion of clone 4-1 f was
90% identical to part of the Alu repeat consensus sequence.
Although the coincident clones derived from novel cDNAs had been grouped
into five families and two other single products, this implied nothing regarding
the number of genes from which they were derived. All the products could be
different fragments of the same gene or there could be several genes. Also
some of the products may be low copy repeat sequences, artefactual though
recovered by genuine coincidence. Further studies to prove the genie nature
of the products and to estimate the number of genes from which they were
derived are described in Chapter 6.
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Figure 4.7 A) to G) Sequences of clones comprising Families 1 to 7
respectively. The consensus sequence ('CON') is also shown where the
Family is comprised of more than one clone (i.e. Families 1 to 5 inclusive).
Spaces inserted into the sequence in order to preserve alignment are shown
by
A) Family 1
'nr' = nonran, '9-2' = pr9-2, '20-3' = pr20-3. Nonran4 is incompletely














2 0-3 T.CCCTGTATGCCCTCCGGGCCAGACACTGGAGGTGTCATTTCCAAAGCA 8 9







nr4 AATTGGAAGCG 2 00




































nr 6 3 GAATAGGCCTGGGGTGGGGCCCAAGAATGAGCAGAAGAACAGGTTTCCTG 100
4-7 g GAATAGGCCTGGGGTGGGGCCCAAGAATGAGCAGAAGAACAGGTTTCCTG 100
3-5g GAATAGGCCTGGGGTGGGGCCCAAGAATGAGCAGAAGAACAGGTTTCCTG 100
CON GAATAGGCCTGGGGTGGGGCCCAAGAATGAGCAGAAGAACAGGTTTCCTG 100
15-3 GATCCCACGTTGAGGACGGAGGGCT 2 5





3 -5g GTGAGGCTGATGCCGCTGGCCCAGGGTTCTCACGTTGAGGGCCGAGAGCT 15 0
CON CTGAGGCTGATGCCGCTGGCCCAGGGTTCTCACGTTGAGGACCGAGAGCT 150
15-3 TTGAAGGTTTTCATGCCTGATAATGGCCAGGAACCCTTCTCAGTAGGCAT 7 5
4-7e TTGA.GKTTATCATGCCTGATGATGCCCAGGAACCCTTCTCAGTAGGCAK 75
1-3 c TTGA.GGTATTCATACCTGATGATGTCCAGGAACCCTTCTCAGTAGGCAC 12 2
2-10b TTGA.GGTTTTCATACCTGATGATGTCCAGGAACCCTTCTCAGTAGGCAC 200
191
















nr 6 3 ACACAGAGNCATCACCGAAATAAAGTGTAAATGAAGGAAGGAANT.GAAC 3 0 0
4-7g ACACAGAGGCATCACCGAATTAAAGTGAAAATGAAGAGAGGAGCT.GAGC 300












1-3 C NCCCAGTCAGGGCACNCTATCATCNCCAACTACTTGTTGAACTACNTTC. 322















4 - 7 a GATCCGTGGGAGCACTGAGATGGTCATCTCCAAATAT.CACATATCTCAC 5 0
5-3c GATCCGTGGGAGCACTGAGATGGTCATCTCCAAATATCCACATATCTCAC 50
3-4e GATCCGTGGGAGCACTGAGATGGTCATCTCCAAATAT.CACATATCTCAC 50
4-10a GATCCGTGGGAGCACTGAGATGGTCATCTCCAAATAT.CACATATCTCAC 5 0
CON GATCCGTGGGAGCACTGAGATGGTCATCTCCAAATAT.CACATATCTCAC 5 0
4-7 a ATCCTCAGAAAGGCTTATATAGCAAGGAATCATTTCCGTGCTCAGAGCAC 100




4 -7 a TATCCACTCTGAAGTNGTTGAGCATGTCTAGGACTCCAGTTATGCACCAT 15 0
5-3c TATCCACTCTGAAGTTGTTGAGCATGTCTAGGACTCCAGTTATGCACCAT 150
3-4e TATCCACTCTGAAGTGGTTGAGCATGTCTAGGACTCCAGTTATGCACCAT 150





































2 -5 c ATCCTGCTATAGATYTAAACCTGTGAGVGAMTCCTACTCAAAACCTGATT 100
CON ATCCTGCTATAGATYTAAACCTGTGAGVGAMTCCTACTCAAAACCTGATT 100


















R Family 6 (clone 4-1 f only)
CGTGAGCCAC CACCCCCGGC CCCAGGACAC ACAGCTTTAA AATTTCTCCT 50
TGGTCTCACC CAGTGCCAAC CACCTAAAAC CTCTCATTTT CCCCCAGACA 100
TTTCTTCTGC CTCCAGGATG GAGGTAGAGA ATCTTGGCCT AGGCCCACGC 150
ACTGGGGACC ATGCTGGGCT GCCGTGGACA GTGACGGACT CAGGTTCTCA 200
CCAGGATC 208
G) Family 7 (clone 3-3a only)
GATCTAGGAG CAGAGGGCAG AGCCTCAGCA GGAAGAGCGT CTCTTTGAGA 50
AGGAGACACA GTGGAGCAGG TGTGTAGGTT CACAGGGCCA GCTATGGGTA 100
GAGTCGGGTG TACATTTTTA GGAGCCACAA TTCCCAAAAA TCTCCTGACT 150
ATAACATCAG TGCACAGAGC CAGTCAAATG GAGGAGGAGT GGGTCCAGGC 200
AATTCAGGAA GAAGGAAAGT AACAAATGAG TGGTTGCAGG AGGACACTTT 250
TTCTTGTCGA GGGTCACTAA ACAAAACATT GTCTCCTCCC CCTCTAACTT 300
CAGAAACAAT GGAGGGTAAG AGTGTCNCCT GGGCCCTGGG GCCAAAGACA 350
GTAGATAACT TCTCTGTCGT GTTCTCCAGA AGGGCCCAAC AANTACAAGG 400
TTCTACGGTT CTAAATTCCA ATCTAGTCTT CCACATCATT TTGAAGGTAT 450




ANALYSIS OF THE D0485 ALPHA TUBULIN SEQUENCE
The large number of alpha tubulin-related clones identified from the two CSC
product libraries was very strongly suggestive of a tubulin-related sequence
located within the YAC D0485. Before any further analysis however, it was
necessary to prove this by hybridisation. Secondly, due to the high degree of
homology between the coding sequences of the known a-tubulin subtypes it
was impossible to deduce whether the D0485 a-tubulin gene had the same
sequence as any of the known subtypes, or whether it represented a novel
subtype. Detailed sequence analysis was required to investigate the latter.
5.1 Map Position of the D0485 Tubulin Gene
The position of the translocation breakpoint on YAC D0485 had recently
been identified by detection of an altered restriction fragment size between
normal and translocation genomic DNA, and by FISH analysis of cosmids
which had been placed on the long range restriction map of the YAC. It was
thus possible to use three CSC a-tubulin clone probes both to prove the
existence of an a-tubulin gene within D0485 and to investigate its location
relative to the translocation breakpoint. The clones chosen were 2-2b,
random 4 and 1-6h. 2-2b is located at the 5' end of the gene, random 4 is
centrally located and 1-6h is at the 5' end of the gene. Both 2-2b and 1-6h
contain sequence from the UTRs (which are not conserved between
subtypes), yet both contain sufficient of the coding sequence to enable
hybridisation to all subtypes.
The three probes were hybridised to Not I, Sal I and Sfi I restriction
fragments of YAC D0485 resolved by PFGE. Figure 5.1 shows the result
obtained with probe 2-2b. It can be seen that the a-tubulin probe hybridised
to a single band in each track, of size 1Mb (Not I), 350kb (Sal I) and 150kb
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(Sfi I). The other probes random 4 and 1-6h also hybridised to these same
bands. This confirmed that there was indeed at least one a-tubulin gene on
YAC D0485, and also enabled placement on the pulsed field map of the YAC
(Figure 5.2). The a-tubulin gene was situated within the same Not I and Sal I
restriction fragment as the translocation breakpoint. Hybridisation onto a set
of the somatic cell hybrids (by Sheila Christie) revealed that the a-tubulin
locus lay centromeric to the chromosome 11 breakpoint.
The same three probes were also used to isolate a-tubulin positive cosmids
from a library made from YAC D0485 by Yoshiro Shibasaki. FISH analysis of
these cosmids on chromosomes from a translocation carrier (by Yoshiro
Shibasaki) confirmed the location of a-tubulin centromeric to the breakpoint
and estimated the distance from a-tubulin to the breakpoint as approximately
250kb ± 40kb. Fingerprint analysis of the cosmids and construction of a
contig from them (by Sheila Christie and Yoshiro Shibasaki) provided no
evidence to suggest that there was more than one copy of the gene. One
end of the contig was fixed by the presence of a Sal I site in several of the
cosmids (see figure 5.2). This enabled the more accurate estimation of







Figure 5.1 Hybridisation of the CSC a-tubuiin clone probe 2-2b to restriction
digested fragments of YAC D0485, resolved by PFGE. Track 1 contains a
Not I digest, track 2 a Sal I digest and track 3 an Sfi I digest. The probe
hybridises to a single band in each track, of size 1Mb (Not I), 350kb (Sal I)
and 150kb (Sfi I).
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5.2 Sequence of the D0485 Alpha Tubulin Gene
5.2.1 Sequencing of cosmid subclones
To enable the sequencing of the a-tubulin gene from an a-tubulin positive
cosmid, it was first necessary to subclone the cosmid into a series of clones
of more useful size, and then select those which were positive for a-tubulin.
Two of the a-tubulin positive cosmids, 39 and 453, were subcloned by Tony
Brookes. The cosmid was digested with Sau3AI to varying degrees of
complete digestion (very partial, partial and complete) by the production of
an enzyme dilution series. 8ng of digested cosmid DNA was then ligated to
10ng pBS vector which had been linearised with BamHI and the cut ends
phosphatased. Transformation of this ligation mix resulted in recombinant
clones.
In order to select for fragments of the cosmid which contained parts of the a-
tubulin gene, filters lifted from the subcloned library were hybridised with the
5' a-tubulin clone probe 2-2b and an oligonucleotide probe, 1000 (see table
2.2) derived from the 3' UTR sequence in the clone 1-6h (the latter by Tony
Brookes). Hybridisation with 2-2b resulted in five definite positives (termed
5'1 to 5'5). These colonies were picked, and their inserts amplified by PCR
(see table 5.1). Clones 5'1, 5'2 and 5'5 were derived from the 'partial digest'
library, clones 5'3 and 5'4 were picked from the 'very partial digest' library.
As expected, the clone with the smallest insert size (5'1) was derived from
the less partial of the two libraries and the clone with the largest insert size
(5'4) was derived from the more partial library. Hybridisation of the
oligonucleotide 1000 was performed at 50°C, then the filters were washed at
50°C in 4x SSC, 0.1% SDS. Five positively hybridising colonies were picked
(termed 3'1 to 3'5). Clone 3' 1 was the same as clone 5'4. PCR amplification













The ends of clones 5'2 to 5'5, 3'2 and 3'4 were sequenced by ABI automated
cycle sequencing, using the primers 291 and 292 derived from the ends of
the pBS sequence. This enabled alignment of these six clones relative to the
known a-tubulin sequences (see Figure 5.3).
The 300-400bp of sequence data from each end of the six subclones was
insufficient to cover the entire a-tubulin gene. In addition, sequence data was
required from both DNA strands to resolve ambiguous sequences or correct
inaccuracies obtained from one strand. Hence more primers were designed
from the new sequence as it became available. These primers were 309,
312, 313, 417, 467, 468, 469, 471, 709 and 710 (see table 2.2). Sequence
data was collated by the GCG fragment assembly computer programs.
Multiple sequencing runs using these primers on miniprep DNA derived from
an appropriate subclone enabled a consensus sequence of 2683bp to be
assembled. The sequence data extended considerably further than the a-
tubulin gene sequence itself, 625bp upstream and 479bp downstream of the
published keratinocyte a-tubulin sequence. The entire consensus had been
sequenced at least twice in one direction and once in the other, apart from
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the first 278bp of sequence which was sequenced many times but only in
one direction.
The sequence of the D0485 a-tubulin gene in relation to the previously
known a-tubulin genes will be discussed in section 5.2.4.
5.2.2 Inaccuracy in the consensus sequence
As sequencing by ABI cycle sequencing is only 98-99% accurate, the
derived consensus sequence was probably imperfect, despite multiple
rounds of sequencing. In addition, the DNA which was sequenced had been
subjected to three rounds of cloning steps - from genomic DNA firstly to a
YAC, then to a cosmid and finally to plasmid subclones. Single base pair
changes in sequence may occur during cloning, and since the DNA used in
the above sequencing reactions was derived from clonal sources, a change
of sequence would not be identified.
The consensus sequence also contained some ambiguities which could not
be resolved by further rounds of sequencing. In these instances, one
particular base was always obtained when the sequencing reaction was in
one direction, and another base was always obtained from sequencing in the
other direction. IUB ambiguity codes were therefore inserted into the
consensus sequence.
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5.2.3 Sequencing of the D0485 tubulin gene from a normal individual and
a translocation carrier
Due to the possible inaccuracies in the a-tubulin consensus sequence
obtained by the automated sequencing of clones, it was necessary to use a
more accurate method to derive the genuine D0485 a-tubulin sequence from
a normal individual. It was also important to ascertain whether this sequence
remained the same in individuals carrying the t(1; 11) translocation. Although
the a-tubulin sequence had been mapped to 340kb away from the breakpoint,
the possibility of a long range effect of the translocation could not be ruled
out. The translocation may remove or insert new enhancer elements
necessary for transcription, or it may introduce a different kind of chromatin
environment. Sequencing reactions which employ PCR-amplified material as
a DNA template rather than piasmid DNA are advantageous in cases where
accuracy of sequence is important. Although errors of sequence will occur
during amplification (the error rate of Taq polymerase is 1 error in every
25x10"6 bp; this enzyme was used although polymerases with lower
misincorporation rates are available), an average of the millions of template
molecules available for sequencing will produce an accurate sequence
overall.
Due to the high similarity in the sequence of the known a-tubulin genes, it was
important to ensure that the DNA amplified and sequenced was indeed from
the D0485 a-tubulin gene alone. For this reason, primers 711 and 712 were
designed (see table 2.2). These primers lie outside the a-tubulin sequence at
the extremities of the consensus sequence derived from the ABI sequencing.
These extremities are anonymous regions of chromosome 11 and therefore
their sequence should be unrelated to that adjacent to other a-tubulin genes.
300ng each of primers 711 and 712 were employed to amplify a region
containing the D0485 a-tubulin gene from 100ng of genomic DNA. The PCR
programme used was:
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Hot start at 90°C.
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter.
Annealing: Touch down from 66°C to 56°C then 56°C, for 30 sees.
Extension: 72°C for 1 min (cycles 1 -10), 2 mins (11 -20) and 4 mins (21-30).
Figure 5.4 shown the results obtained from this PCR amplification. A strong
band of the expected size (2.7kb) was obtained from total human genomic
DNA from a normal individual. Weaker bands of the same size were obtained
from the cell line MAFLI (derived from a translocation carrier) and from the
somatic cell hybrid MAR1 (in which the only chromosome 11 component is
that from the der(11) from a translocation carrier). As further proof of the map
location of the D0485 a-tubulin gene, no PCR product was obtained from
MAR12, which contains the der(1) translocation chromosome and no
chromosome 11 sequence from above the breakpoint. No product was
obtained from total hamster or total mouse genomic DNA, proving that the
band in MAR1 was genuinely derived from the human component of the
hybrid.
It was necessary to use MAR1 as the template from which to derive the
sequence of the D0485 a-tubulin gene from a translocation carrier. MAFLi,
although carrying translocation chromosomes, also contains a set of normal
chromosomes. Unfortunately a strong, clean band could not be obtained from
MAR1 by PCR amplification with primers 711 and 712, despite variation in the
amount of template DNA used and the annealing temperatures of the PCR
programme. Hence a secondary PCR was employed. To facilitate the
production of a large amount of template for sequencing, the size of the target
product was decreased by amplifying the tubulin sequence in smaller
sections, initially two, using either 711 and 312 or 712 plus 469 (see table
2.2). There is only 7bp between the end of 312 and the beginning of 469, so it
was still possible to sequence the vast majority of the a-tubulin gene.
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Secondary PCR in two sections was also employed for the DNA from a
normal individual, partly to increase the amount of template DNA available for
the many sequencing reactions required, and partly because superior
sequencing results were obtained from the shorter templates.
For the secondary PCRs, 1 pil of primary (711-712) PCR product was
reamplified with 300ng each of either primers 711 and 312, or 712 and 469.
The PCR programme used was:
Hot start at 90°C
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
Annealing: Touch down from 60°C to 50°C then 50°C, for 30 sees
Extension: 72°C for 1 min (cycles 1-10), 1.5 mins (11 -20) and 2 mins (21-30)
This resulted in the production of a strong band in all cases which was then
prepared for sequencing.
As much as possible of the a-tubulin gene was sequenced using the existing
primers using a radioactive dideoxy terminator method. Where the sequence
agreed with that obtained from the cycle sequencing, it was not repeated.
Regions in which there were differences from the cycle sequencing
consensus were sequenced at least twice. Since this method of sequencing
only resulted in a maximum of 200bp of sequence per reaction, sequence
from the existing primers alone did not cover the entire gene. The
oligonucleotides 150 to 159 were thus designed to fill in the gaps (see table
2.2). These new oligonucleotides were used both as primers for sequencing
reactions and some as primers for secondary amplification of the 711-712
product. The amplification conditions used were exactly the same as those
given for the secondary PCR above. PCR products were obtained from
amplification with the primer pairs 152-312, 153-151, 155-158 and 156-158
(see Figure 5.5). The 153-151 template spanned the short gap between 312
and 469, and hence the entire gene was covered by PCR product template
DNA for sequencing.
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Figure 5.4 Amplification of the D0485 a-tubulin gene from genomic DNA.
The size marker used is 250ng of the 1kb ladder (track 1). Tracks 2 to 8
contain 10jul of the PCR product generated from different template DNAs with
primers 711 and 712, resolved on a 1% agarose gel. Track 2 = total human
genomic DNA, track 3 = MAFLI, track 4 = MAR1, track 5 = MAR12, track 6 =
total hamster DNA, track 7 = total mouse DNA, track 8 = no DNA PCR
negative control. A band of the expected size (~2.7kb) was obtained from total
human genomic DNA, MAFLI and MART This confirms that the PCR was
specific for a human gene and that a-tubulin is located proximal to the
translocation breakpoint.
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Figure 5.5 Amplification of fragments of the D0485 a-tubulin gene by nested
PCR. Allele specificity was provided by the primary PCR. The size marker
used is 250ng of the 1 kb ladder (track 1). Tracks 2 to 5 show 10pil of the PCR
product generated by re-amplification the primary PCR product with different
primer pairs, resolved on a 1% agarose gel. The products generated were
approximately 700bp with primers 152 and 312 (track 2), 500bp with primers
153 and 151 (track 3), 650bp with primers 155 and 158 (track 4) and 550bp
with primers 156 and 158 (track 5).
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Use of appropriate combinations of primers and template enabled conclusive
sequence data to be obtained for the entire coding sequence of the D0485 a-
tubulin gene, plus 450bp upstream and 160bp downstream, for both a normal
individual and a translocation carrier (see Figure 5.6). In all cases, ambiguous
sequence resulting from the cycle sequencing was resolved. There was
however a small proportion of bases whose identity could not be determined
due to signal across all four tracks ('stops') on the sequencing
autoradiograph. These amounted to 1.9% (39 out of 1960 bases) for the
'normal' sequence and 1.8% (36 out of 1950 bases sequenced) for the
'translocation' sequence. In most cases, these stops occurred in the same
places for each, and were present each time the region was sequenced.
There were no positions in which a stop from the radioactive sequencing
coincided with an ambiguous base from the cycle sequencing, so it was
deemed unnecessary to attempt to resolve them. Only at one position did the
cycle sequencing consensus differ from the radioactive sequencing
consensus. This was the insertion of a guanine residue at position 313. This
residue was clearly absent from multiple radioactive sequencing runs and
hence has not been included in the D0485 a-tubulin final consensus
sequence. This insertion may have been either an artefact of cloning, or a
cycle sequencing error.
There were no differences in sequence identified between the normal
individual and the translocation carrier. This implies that the translocation has
not, by chance, fixed a variant or mutant allele of a-tubulin.
5.2.4 Sequence of the D0485 a-tubulin gene in relation to the
keratinocyte a-tubulin gene
The most striking feature of the D0485 a-tubulin gene is that it is extremely
similar to the keratinocyte a-tubulin cDNA sequence in the database, and as
such it possesses no introns in genomic DNA. There are 77 positions where a
difference is seen between the D0485 a-tubulin sequence and the 1598
209
bases of the keratinocyte a-tubulin sequence (see Figure 5.7). These
differences are summarised in Table 5.2.
The majority of single base substitutions were purine to purine (40.4%) or
pyrimidine to pyrimidine (36.8%). Only 10.5% of changes were pyrimidine to
purine, and 12.3% were purine to pyrimidine. Both of the single base
deletions, both of the insertions, two of the multiple deletions (6 bases altered)
and 11 of the single base changes occurred in the UTRs. This corresponds to
27% of the total number of changes, even though the UTRs comprise only
15.3% of the total length of sequence. Since the coding sequence therefore
contains fewer changes than would be expected by length alone, this may
imply an evolutionary selective pressure imposed on it by functional
constraint.
The predicted protein sequence transcribed from the D0485 a-tubulin gene is
shown in Figure 5.8. Twenty four (51%) of the 47 single base substitutions
occurring within the coding sequence are in the third position of the codon,
only one of which would change the encoded amino acid (a conservative
change from glutamic acid to aspartic acid at position 290 in Figure 5.8). In
addition 74% of the first or second position substitutions result in a
conservative change. The 3bp deletion of CTT, although out of frame itself,
results in a deletion of a phenylalanine residue, and no change of reading
frame. The seven base pair deletion in the D0485 a-tubulin sequence results
in a shift of reading frame, which produces a change in the next two out of
three amino acids before a termination codon is introduced, terminating the
putative peptide.
Figure 5.9 shows a comparison of the D0485 a-tubulin predicted peptide
sequence and the keratinocyte a-tubulin peptide sequence. The predicted
protein derived from the D0485 a-tubulin sequence is 374 amino acids long,





with respect to Change Frequency Comments
the keratinocyte
a-tubulin gene
Single base deletion c 1 Both in 5' UTR
G 1
Multiple base deletion CTT 1 Deletion of phenylalanine
GAGCTGT 1 Shifts reading frame
ATT 1 Across kerat. stop codon
TTG 1 In keratinocyte 3' UTR
Insertion A 1 Both in 5' UTR
C 1
Single base T to C 18 2 in the 69 bp of 5' UTR
substitution A to G 13 (2.9%)
G to A 10
G to C 4 47 in the 1353 bp of
C to G 4 coding sequence (3.5%)
C to T 3
A to C 2 9 in the 176 bp of 3' UTR
T to A 1 (5.1%)
AtoT 1
C to A 1
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Figure 5.6 Sequence of the alpha tubulin gene and the adjacent sequences
from YAC D0485. All has been sequenced by automated ABI cycle
sequencing. The sequence of bases 252 to 2213 has been confirmed by
radioactive sequencing of PCR products. Primers used for PCR and/or
sequencing are highlighted. The name and direction of the primer is
underneath the highlighted region.
1 GATCTGTGTT CTTCAGAAGT GTCAAAGTCA TGAAAGACAA GGAAAAACTG
51 AGGAGCTGTC ACAGGTGGGA GGGGATTAAA GAGATATAAC AACTAAATTC
711—►
101 ACTGTGGTAC AGGCATACTT TGAAGATATT GTGGGTTTGG TTCTAGACCA
151 CTGCAATAAA GCAAATTTCA CAATAAAGTG AGTCATATAA TATTTTAGGT
201 TTCCCAGTGC ATGTAAAAGT CATAACCTAT TAAGTGTGCA ATAGCATGAT
309
251 ATTTAAAAAA TCATATATAT CATATTTACA AATACTGTAT TGCTAAAAAT
301 GTTAATGATT AGTTGAGCCT TTACTGATGG AAAGGCTTGC CTCAATGTTG
«- 710
351 ATGGCTACTG ATTGATCAGG GTGGTGATTG CTGAAGGTTG GAGTGGCTGT
709—>
401 GGCAATTTTT AACAAGACAA CAGTGAAGTT TGCCTCATTG ACTGATTCTT
451 CCTTTCATGA AAAATTTCTC TGTTGCATGT AATGCTGTTC GATAGCATTT
«- 467
501 TACCTAAGTA GGCCTTTTTT TTTTTTTTTT CCAAATTGGA GTCAATCCTC
551 TCAAACTCTG CTGCTGCTTT ATCAACTAAG TTTATGGAAC ATTCCCAGTG
601 TGTTACTTAC CTCAACTCTT AGCTTGTTGG GGACGGTAAC CGGGACCCAG
152 -■>
651 TGTCTGCTCC TGTCACCTTC GCCTCCTAAT CCCTAGCCAC TATGCGTGAA
701 TGCGTCTCCA TCCACGTTGG CCAGGCTGGT GTCCAGATTG GCAATGTCTG
468~~* *-"417
751 CTGGGAGCTC TACTGCCTGG AACATGGCAT CCAGCCCGAT GGCCAGATGC
801 CAAGTGACAA GACCATTGGG GGAGGAGATG ACTCCTTCAA CACCTTCAGT
150 —* 496 —►
851 GAGACGGGTG CTGGCAAGCA TGTGCCCCGG GCTGTGTTTG TAGACTTGGA
901 ACCCATGGTC ATTGATGAAG TTTGCACTGG CACCTACCGC CAGCTCTTCG
714
951 ACCCTGAGCA GCTCATCACA GGCAAGGAAG ATGCTGCCAA TAACTATGCC
153_+
1001 CGAGGGCACT ACACCATTGG CAAGGAGATC ATTGACCTTG TGTTGGACCG
1051 AATTCGCAAG CTGGCTAACC AGTGCACTGG TTTTCAGGGC TTCTTGGTTT
154 —►
1101 SICACAGCTT TGGTGGGGGA ACTGGTTCTG GGTTCACCTC CCTGCTCATA
1151 GAACGTCTCT TAGTTGATTA TGGCAAGAAG TCCAAGCTGG AGTTCTCCAA
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1201 ttacccagcg ccccaggttt ccacagctgt agttgagccc tacaactcca
1251 tcctcaccac ccacaccacc ctggagcact ctgattgtgc cttcatggtifc
4- 312
13 01 gacaatc^cjp j^atctgtga catctgttgt agaaacctca atatcgagcg
1351 CCCAACCTAC ACTAACCTTA accaccttat tagccagatt gtgtcctcta
155 -»•
1401 tcactgcttc cctgagattt gatggagccc tgaatgttga cctgacagaa
151
1451 ttccagacca acctggtacc ctactcccac atccacttcc ctctggcgac
156—►
1501 atatgcccct gtcatttctg ctgagaaagc ctaccatgaa cagctttctg
1551 tagcagagat caccaatgct tcctttgagc cagccaacca gatggtgaaa
1601 tgtgaccctc gccatggtaa atacatggct tgctgcctat tgtaccatgg
1651 tgatgtggtt cccaaagatg ccaatgctgc cattgccacc atcaagacca
1701 agcgtagcat ccagtttgta gattggtgcc ccactggctt caaggttggc
715—>
1751 atcaactacc agtctcccac tgtggtgcct ggtggagacc tggccatggt
1801 acagagtgca tgctgag£a£^accacagcc attgctgagg cctgggctcg
1851 cctggaccac aagtttgacc tgatgtatgc £aagcgtgcc tttgttcact
1901 ggtacgtggg tgaggggatg gaggaaggcg agttttcaga ggcccgtgaa
1951 gacatggctg cccttgaga aggattatgag gaggttggt gtggattj^gt
2001 tgaaggagag ggtgaggaag aaagagagga atactaatcc attccttttg
159 —*■
2051 gccctgcagc atgtcgtgct cccagaattt cagcttcagc ttagctgaca
2101 gacattaaag ctttctggtt agattttcat ttggtgatca tgtcttttcc
313 — 4-157
2151 atgtgtacct gtaatgtttt tccatcatgt ctcaaagtac agtcattaac
2201 ataaaaaaaa aagtttatgt tatattttag atcatgtggt ggcatttcaa
2251 caatgttcac agyatcttca ctaagagtcg attgggtctc aagaamccac
2301 ttttttctcc catccagagg aagaagcttc tcatccactc aagtytcatt
2351 atgagattgs agcaattcag tcacatcttc aggctccact tctaattgta
2401 gctcacttgc tatttccaca tctgcagtta cttcctctaa taatgtcttg
2451 aatactcaaa gtcatcaact tcttcaaact cctgttatgg ttgacatttt
2501 gaccttctct cataaatcac taatgctctt aatgacatct tagaatggtt
2551 aattatttcc caaagttttt caacttgttt agtcaagatc catcagaaga
2 601 ttcacaattt atatggaagc tatagcctta tgaaatgtac tgc'tgaacaa
«- 712
2651 atgagacttg aaaattgaaa tttctctttg atc
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Figure 5.7 Comparison of the sequence of the D0485 a-tubulin gene and
adjacent non-coding sequence ('D0485', upper line) with the published cDNA
sequence of the keratinocyte a-tubulin gene ('kerat', lower line). The
keratinocyte sequence begins at D0485 sequence position 625 and ends at
position 2204. Bases identical between the two are shown by " -Deletions
are shown by " * ". The initiator codon ATG is found at position 692. The
codon for termination of transcription of the keratinocyte gene is at position
2033 (TAA). In the D0485 gene however a seven base deletion in the coding

















kerat --C G G *
DO485 AATGCGTCTCCATCCACGTTGGCCAGGCTGGTGTCCAGATTGGCAATGTC 748
kerat -G A C-
D0485 TGCTGGGAGCTCTACTGCCTGGAACATGGCATCCAGCCCGATGGCCAGAT 798
kerat C
D0485 GCCAAGTGACAAGACCATTGGGGGAGGAGATGACTCCTTCAACACCTT* * 846
kerat CT
214
















































































D0485 TCAGCTTAGCTGACAGACATTAAAGCTTTCTGGTTAGA* * *TTTTCATTT 2132
kerat A TG TTG C--
D0485 GGTGATCATGTCTTTTCCATGTGTACCTGTAATGTTTTTCCATCATGTCT 2182
kerat A A













Figure 5.8 Translation of D0485 a-tubulin gene sequence. Amino acids are
abbreviated using the IUB nomenclature codes. The open reading frame






























































Q S A C *
D0485 CCTGGACCACAAGTTTGACCTGATGTATGCCAAGCGTGCCTTTGTTCACT 1900
D 0 4 8 5 GGTACGTGGGTGAGGGGATGGAGGAAGGCGAGTTTTCAGAGGCCCGTGAA 195 0
D0485 GACATGGCTGCCCTTGAGAAGGATTATGAGGAGGTTGGTGTGGATTCTGT 2000
















Figure 5.9 Comparison of the peptide sequences of the D0485 a-tubulin
('D0485', upper line) and the keratinocyte a-tubulin ('kerat', lower line). The
seven base pair deletion in the D0485 a-tubulin, which occurs within the
codon for amino acid 372 results in a premature termination codon a further
three amino acids downstream. The full length keratinocyte peptide is 451
amino acids long. In addition, a three base pair deletion in the D0485 a-
tubulin sequence removes a phenylalanine amino acid at position 52.
Homologous but not identical amino acids are represented by .
Termination codons are represented by
D0485 MRECVSIHVGQAGVQIGNVCWELYCLEHGIQPDGQMPSDKTIGGGDDSFN 50
I I I I : I I I I I I I I I I II I : I I I I I I I I I I I II I I I I I I I I II I I I I I I I I
kerat MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFN 50
D0485 T-FSETGAGKHVPRAVFVDLEPMVIDEVCTGTYRQLFHPEQLITGKEDAA 99
I I I I I I I I II I I I I I II I II I I I I I I I I I I I II I I I I I I I I I I I I I I
kerat TFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAA 100
DO485 NNYARGHYTIGKEIIDLVLDRIRKLANQCTGFQGFLVFHSFGGGTGSGFT 149
I I I I I I I I I I I I I I I I I I I I I I I I I I : I I I : I I I I I I I I I I I I I II I I I
kerat NNYARGHYTIGKEIIDLVLDRIRKLADQCTRLQGFLVFHSFGGGTGSGFT 150
D0485 SLLIERLLVDYGKKSKLEFSNYPAPQVSTAWEPYNSILTTHTTLEHSDC 199
111:111 I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
kerat SLLMERLSVDYGKKSKLEFSIYPAPQVSTAWEPYNSILTTHTTLEHSDC 2 00
D0485 AFMVDNEAICDICCRNLNIERPTYTNLNHLISQIVSSITASLRFDGALNV 249
111111111:111 I I I : I I I I I II I I I : I I I I I I I II I I I I I I I I I I I I
kerat AFMVDNEAIYDICRRNLDIERPTYTNLNRLISQIVSSITASLRFDGALNV 2 50
D0485 DLTEFQTNLVPYSHIHFPLATYAPVISAEKAYHEQLSVAEITNASFEPAN 299
I I I I I I I I I I I I. : : I I I II I I I II II I I I I I I I I I I I I I : I I I I : I I I I I
kerat DLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVADITNACFEPAN 300
D0485 QMVKCDPRHGKYMACCLLYHGDWPKDANAAIAT IKTKRSIQFVDWCPTG 349
I I I I I I I I I I I I I I I I I I : I I I I I I I : I I I I I I I I I I I : II I I I I I I I I
kerat QMVKCDPGHGKYMACCLLYRGDWPKDVNAAIATIKTKRTIQFVDWCPTG 3 50
D048 5 FKVGINYQSPTWPGGDLAMVQSAC* 374







5.3 Expression of the D0485 Alpha Tubulin Gene
The fact that the D0485 a-tubulin gene has no introns and that alterations in
the coding sequence would lead to the production of a truncated peptide
favours the possibility that this sequence is a pseudogene, resulting from the
integration into the genome of a reverse transcribed keratinocyte a-tubulin
mRNA species. On the other hand, examples of intronless expressed genes
have been reported in the literature. The dopamine D1 receptor is intronless
(Sunahara et al, 1990) as are histone genes (Stein, 1984) and type X
collagen (Ninomiya et at, 1986) among others. Furthermore, the depressed
mutation rate within the coding sequence relative to the UTR regions may
suggest some functional evolutionary pressure for selective retention of the
coding sequence.
5.3.1 Development of an allele specific assay for the D0485 a-tubulin
gene
Due to the similarity between the D0485 a-tubulin gene and other a-tubulin
genes, it would be impossible to investigate the expression of this particular
gene by hybridisation of the CSC tubulin clone probes to Northern blots.
Hybridisation of an allele-specific oligonucleotide probe could resolve this
problem, yet determination of extremely specific hybridisation and washing
conditions would be required. Even so, a negative result would be difficult to
interpret and a positive result difficult to verify. Hence an allele-specific RT-
PCR assay was devised.
This assay employed two oligonucleotides, 496 and 497 (see table 2.2),
which were specific to the D0485 a-tubulin gene. The final three 3' bases of
oligonucleotide 496 spanned the deletion of CTT from the keratinocyte a-
tubulin sequence, and the final three 3' bases of 497 spanned the seven
base pair deletion of from the keratinocyte a-tubulin sequence. When
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employed together as primers in a PCR reaction, the target product was
1013bp, derived specifically from the D0485 a-tubulin sequence.
In order to test the assay, the PCR reaction was firstly performed on D0485
YAC DNA and total human genomic DNA. 300ng of each primer was used to
amplify 50ng of YAC DNA and 200ng of total human genomic DNA. The
PCR programme used was:
Hot start at 90°C
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
Annealing: Touch down from 66°C to 56°C then 56°C, for 30 sees
Extension: 72°C for 1 min (cycles 1 -10), 2 mins (11 -20) and 3 mins (21 -30).
A strong band of the expected size was obtained for both YAC DNA and total
human genomic DNA. In order to verify that this product was indeed derived
specifically from the D0485 a-tubulin gene, the two ends of the product were
sequenced by radioactive sequencing of the PCR product. Oligonucleotides
714 and 715 were designed for this purpose (see table 2.2) - both lie within
the amplified sequence, orientated to permit sequencing across the very end
of the PCR product, where the two deletions are situated. Sequencing of
these two ends confirmed that the product was derived from the D0485 a-
tubulin sequence.
5.3.2 Development of positive control RT-PCR assays
Total RNA was extracted from a variety of human tissues. The tissues used
were adult brain (two different samples), colon, liver, prostate and testis, and
foetal brain (gestational ages 10 and 16.5 weeks), spleen, liver, limb, heart
and kidney. The RNA from these samples was tested by a positive control
PCR to amplify exons 3 to 8 of the ubiquitously expressed glutaraldehyde
phosphate dehydrogenase (GAPDH) gene. 300ng of the forward and
reverse GAPDH primers (see table 2.2) were used to amplify 600ng of
DNase-treated RNA from each tissue. This reaction employed the same
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PCR programme as in the allele-specific a-tubulin assay as above, so that a
GAPDH control could be included with every a-tubulin RT-PCR reaction
carried out. A minus reverse transcriptase enzyme control was also included,
to ensure that any resulting product was derived from RNA and not DNA
contamination.
A band of the expected size (442 bp) was produced from all tissues. This
PCR reaction could therefore be used as a positive control, both for the
integrity of the RNA and for the RT-PCR reaction itself.
A second positive control, to assay for expression of other a-tubulin genes,
was also carried out on 600ng of both gestational ages of foetal brain
DNase-treated RNA. 300ng of each primer was used.
The PCR programme was:
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
Annealing: Touch down from 65°C to 55°C then 55°C, for 30 sees
Extension: 72°C for 30 sees (cycles 1-10), 45 sees (11-20) and 1 min (21-30)
Two primer combinations were used, 152/312 and 156/158 (see table 2.2).
Primers 156 and 158 are both situated within the a-tubulin coding sequence,
which is conserved between subtypes, and therefore the target 531 bp
156/158 PCR product was not subtype-specific. Primer 152 however lies at
the 5' end of the gene, slightly upstream of the beginning of the keratinocyte
a-tubulin sequence. If the target 690bp 152/312 PCR product were
generated, then it would be specific to subtypes with a 5' UTR very similar to
that of keratinocyte a-tubulin. For both PCR reactions, a product of the
expected size was produced from foetal brain RNA. The intensity of the band
was approximately equal to that produced by the GAPDH control RT-PCR,
which indicates that the D0485 a-tubulin specific RT-PCR should be
sufficiently sensitive to detect expression if this gene is expressed at a
similar level to the keratinocyte a-tubulin gene.
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5.3.3 Allele-specific RT-PCR of the D0485 a-tubulin gene
RT-PCR from the aforementioned human tissues was then carried out using
the allele-specific a-tubulin primers 496 and 497 to amplify 600ng of DNase-
treated RNA. The PCR programme used was that employed in the allele-
specific a-tubulin assay in section 5.3.1. An additional PCR performed on
total human genomic DNA provided a control for the primers and other
components of the PCR reaction mix. A set of minus reverse transcriptase
PCRs controlled for the presence of DNA in the RNA samples. Finally a PCR
using the GAPDH primers (plus and minus reverse transcriptase) acted as a
control for the quality of the RNA and the efficiency of the first strand cDNA
synthesis.
Figure 5.10 shows the results of this RT-PCR reaction on four of the tissues.
The control PCRs from DNA and for GAPDH produced strong bands, yet
there was no product for D0485 a-tubulin from RNA. The same results were
obtained for the other eight tissues tested. It must be concluded that the
D0485 a-tubulin gene is not expressed in any of the tissues tested, and is
therefore most likely to be a pseudogene.
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Figure 5.10 Allele specific RT-PCR of a fragment of the D0485 a-tubulin
gene. The size marker used is 250ng of px Hae III (track 1). Tracks 2 to 12
contain 10pt I of PCR product resolved on a 1.5% agarose gel. Tracks 2 to 9
resulted from RT-PCR on DNase-treated RNA from foetal brain (tracks 2 and
6), foetal spleen (tracks 3 and 7), foetal heart (tracks 4 and 8) and adult liver
(tracks 5 and 9) with primers 496 and 497. Tracks 6 to 9 are a minus reverse
transcriptase negative control. The band at 1013 bp in track 10 was the
result of amplification of total human genomic DNA with the same primers
496 and 497. The band at 442 bp in track 11 resulted from RT-PCR of a
portion of the GAPDH gene from foetal brain DNase-treated RNA. Track 12
contains a minus reverse transcriptase control for the GAPDH RT-PCR. The
two positive controls in tracks 10 and 11 imply that the absense of a band in
tracks 2 to 5 is genuinely due to non-expression of the D0485 a-tubulin gene
in these tissues. The same result was obtained from the other tissues tested.
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5.4 Discussion
The lack of introns in the D0485 a-tubulin gene and the lack of expression in
a variety of normal foetal and adult tissues does suggest that this sequence
is a processed pseudogene, resulting from the re-insertion into the genome
of an a-tubulin mRNA species. The close similarity between the sequence of
the D0485 gene and the published keratinocyte a-tubulin gene suggests that
the former is derived from the latter, and that the event occurred fairly
recently in evolutionary terms.
Contrary to the idea that the D0485 a-tubulin sequence is a pseudogene is
the finding that there are more mutations relative to the keratinocyte
sequence in the 5' and 3' UTRs than in the coding sequence; regions which
are subject to less functional constraint. If a protein were translated from the
D0485 a-tubulin gene, it would be truncated to 80% of its normal length (374
amino acids rather than 451 in keratinocyte a-tubulin). The 77 deleted amino
acids are at the C-terminus. The extreme C-terminal end of the a-tubulin
protein has been implicated in the correct formation of microtubules (Arevalo
et at, 1990), binding of ATP (Jayaram and Haley, 1994) the binding of
microtubule associated proteins (Paschal et at, 1989) and some post-
translational modifications (Boucher et at, 1994). It must be assumed that
these aspects of tubulin function would be disturbed by the C-terminal
truncation. However, formation of a-(3 tubulin dimers (Arevalo et at, 1990),
other post-translational modifications (Boucher et at, 1994), G-protein and
GTP binding (Jayaram and Haley, 1994) and the binding of the ATPase
translocators kinesin and dynein (Rodionov et at, 1990) would be unaffected.
Although expression of the D0485 a-tubulin gene was not detected in the
wide range of tissues tested, it is possible that this particular gene is
expressed, but in a highly specific manner, perhaps even developmental^
regulated. Tubulin heterogeneity is higher in the brain and neurons than in
other cell types, and thus implies the existence of tubulin isoforms that are
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expressed predominantly or specifically in neurons (Audebert et al, 1994). If
the D0485 a-tubulin gene were involved in the aetiology of schizophrenia, a
brain/neuron specific expression pattern may be expected.
It is possible that the D0485 a-tubulin gene may be aberrantly expressed in
individuals bearing the t(1; 11) translocation. Although it is approximately
300kb from the translocation breakpoint, no gene has been identified from
chromosome 11 which maps closer, and the pattern of rare cutter restriction
enzyme sites, indicative of CpG islands, suggests that one will not be found.
The translocation could bring new control elements into the vicinity of the
tubulin gene, which may exert an effect on its expression via a position
effect. Other cases have been described in which a cytogenetic abnormality
at a distance from a known gene is associated with the phenotype
associated with mutations in that gene. For instance, two pedigrees have
been described in which chromosomal rearrangements co-segregate with
aniridia (Fantes et al, 1995). In both cases the chromosomal breakpoint is at
least 85kb from the Pax 6 gene (which is known to be mutated in other
aniridia patients) while the gene itself is apparently free of mutations. A
dominant negative effect of the truncated form is also possible, if the der(11)
chromosome but not the normal chromosome 11 version is expressed and
active in particular cells at a critical stage of development.
Allele-specific RT-PCR of the D0485 a-tubulin gene on brain tissue derived
from individuals carrying the translocation or somatic cell hybrid cells
containing the der(1) or der(11) chromosomes only could assess whether the
translocation event causes the aberrant expression of this gene.
Complicating factors such as specificity of expression to certain brain regions
or even a certain developmental stage may however preclude this. A more
direct approach would be to transfer the der (11) translocation chromosome
into suitable cells (for instance rat glioma) in culture, and then to assay for
the transcription of the D0485 a-tubulin gene in vitro.
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Although it has not yet been specifically proposed, a role for a tubulin gene in
the aetiology of schizophrenia can be envisaged. Abnormalities in
cytoarchitecture, of particularly the hippocampus, have long been associated
with schizophrenia, and thus it is of interest to note that tubulin plays a major
role in the architecture of the cell, via microtubules. Microtubules themselves
have also been implicated in schizophrenia (Kerwin, 1993); an abnormality in
microtubule associated proteins (MAPs) may cause a disruption in
microtubule assembly and a consequent developmental anomaly in the
temporal lobe. Abnormal expression of MAP2 and MAP5 has been detected
in the hippocampus of some schizophrenics (Arnold et al, 1991). Another
MAP, tau, has been implicated in Alzheimer's disease. Tau, which is thought
to stabilise microtubules in axons, forms the major component of the
neurofibrillary tangles found in the brains of patients with Alzheimer's disease
(Mandelkow and Mandelkow, 1995).
In general, microtubules are involved in numerous aspects of brain
development and function, including the maintenance and growth of axons,
intracellular transport along axons and the determination of cellular
morphology (Cambray-Deakin and Burgoyne, 1987). All of the above,
especially the former, have been described as abnormal in subsets of
schizophrenics. Neuronal tubulin may play a fundamental role in these
processes, perhaps by the selective stabilisation of certain microtubules
(Mandelkow and Mandelkow, 1995).
A link can also be forged between tubulin and the functioning of
neurotransmitter systems. Components of the cytoskeleton are important in
the localisation of membrane components to post-synaptic sites, and GABAa
receptors probably bind to microtubules directly via tubulin (Item and
Sieghart, 1994). Post-translational modification of a- and (3-tubulin in nerve
cells is very widespread, particularly addition of a short polyglutamate chain
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at the carboxy end of the protein (Audebert et al, 1994). Although the
functional significance of this is not known, increasing length of this chain is
a sign of neuronal differentiation and probably regulates the binding of tau
(Boucher et al, 1994). An abnormally low level of glutamate, as has been
proposed to occur in schizophrenia, may prohibit the formation of this
glutamate chain and therefore interfere with normal neuronal development.
It has also been proposed that dimeric tubulin plays a role in signal
transduction, through its association with the GTP-binding (G) proteins Gs
and Gj( (Roychowdhury and Rasenick, 1994). The a-subunits of some G-
proteins form complexes with dimers of synaptic membrane tubulin
molecules, and transfer a nucleotide from the GTP bound to tubulin. This
may create an interdependence between the shape of the synapse and the
response to neurotransmitters (Roychowdhury and Rasenick, 1994). The
phosphorylation of cytoskeletal proteins may also be important in the non-
receptor-dependent regulation of adenyl cyclase activity by calmodulin, since
calmodulin has been reported to stimulate adenyl cyclase exclusively in
neuronal systems (Rasenick et al, 1990). The GTP and G-protein binding
capabilities of tubulin, which would be most important in modulation of
neurotransmitter function, are also those which would be unaffected by a C-
terminal truncation, as occurs in the D0485 a-tubulin gene.
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CHAPTER 6
ANALYSIS OF THE NOVEL cDNA FRAGMENTS
From the analysis of the CSC product libraries, five families and two single
products of novel cDNA fragments had been identified. Since the sequence
of these products gave no significant database matches, nothing could be
further deduced about the total number of genes from which they were
derived or any aspect of their function. It was firstly necessary to prove the
authenticity of the products by hybridisation back to YAC D0485 and locate
their mapping positions within the YAC. Studies could then be undertaken to
assess the copy number of these fragments in the human genome, to group
the fragments into different genes and to begin to assess the expression
pattern of these genes.
6.1 Hybridisation of cDNA Fragments to YAC D0485
One cDNA fragment from each family (that identified first) plus the two single
fragments (in total, nonran4, 2-1 Ob, 5-3c, 4-7d, 1-11 d, 4-1 f and 3-3a) were
used as hybridisation probes onto filters containing restriction fragments from
YAC D0485, resolved by pulsed field gel electrophoresis (made by John
Maule). These filters contained Sal I, Sfi I and Not I digests, plus double
digests thereof. All of the products gave positive signals on the YAC,
confirming that they were indeed cDNA fragments derived from it. Figure 6.1
shows the results obtained with probes 2-10b and 4-1 f. Table 6.1 shows the
sizes of the restriction fragments to which each of the probes hybridised.
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Figure 6.1 Hybridisation of probes 4-1 f (left) and 2-1 Ob (right) to restriction
digested YAC D0485. For 4-1 f tracks 1 to 5 correspond to Sal I, Sfi I, Sal I
& Not I, Sal I & Sfi I and Sfi I & Not I digests respectively. For 2-1 Ob tracks 1
to 6 correspond lo Sal I, Not I, Sfi I, Sal I & Not /, Sal I & Sfi I and Not I & Sfi I
digests respectively. The sizes of the hybridising bands enabled placement
of the novel cDNA fragment probes on the long-range restriction map of the
YAC.
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Table 6.1 ND= not determined
Restriction fragment sizes to which the probes hybridised (kb)






nonran4 325, 100 120 210, 110 20 20 210, 100
2-1 Ob 325, 100 230, 90 210, 110 230, 90 90, 170 100, 210
5-3c 325, 100 230, 100 ND 20, 230 30, 170 100, 210
4-7d 325 230 210 230 170 210
1-11d 325 230 210 230 170 210
4-1 f 325 230 ND 230 170 210
3-3a 325 230 210 230 170 210
The results from hybridisation of these fragments onto PFGE filters enabled
location of their position on the long range restriction map of the YAC. All the
fragments were derived from the centromeric 'right hand' end of the YAC,
proximal to the translocation breakpoint (Fig. 6.2). This is the same region of
the YAC as that which contains the Not I restriction sites, which are indicative
of CpG islands and therefore genes. Finer scale mapping was required
however before any definite association of the cDNA fragments with the Not I
sites could be asserted. Probes nonran4, 2-1 Ob and 5-3c hybridised to two
different restriction fragments in each track. Combining this information with
data generated from the mapping of two fragments of the cosmid D1 (by
John Brown; data not shown) suggested that the YAC D0485 contains an
inverted repeat structure in this region. It is not equivocally proven whether
this structure represents an artefact in the YAC, or whether it is present in
normal genomic DNA. (Evidence to suggest the latter will be presented in
section 6.3)
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Figure6.2SalI(S),fiF)andNotNp ls df elrest ictionmapfthrighth nfYACD0485showingt e positionsfthenovelcDNAfragm ntirelationtha phatubulig ea dttr nsl cationbr kpoint.Th enlargedportionshowst emaximumregioniwh chtindiv d alfragm tsyl ,ex eptcos idD1f rwhicht exactpositionishown.4-7d,1 11d,-fan3 3aliew thint emeSfI&N tr strictionfrag entdv thereforeb ndepictedass nglr.Nonran4n2-1Obmaptwopl cesihYAC,oeithersi f predictedinvertedr p atstructure.5-3cmapstohpl .Numb rsrepresentthdistanceb tw nrestri tion sites,inkb. novelcDNAalp fragmentstub s 100I6325ihatranslo ulinbreak 340
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6.2 Hybridisation of Fragments to cDNA
As a first step towards proving the genie nature of these novel fragments,
one product from each Family (except Family 5) was used as a hybridisation
probe onto filters containing human foetal brain and mouse cDNA. The
results are shown in Figure 6.3. All the probes hybridised to the cDNA except
nonran4 (Family 1). This may imply that this product is genuinely not
represented in these cDNA populations, or it may indicate merely a very low
expression level that resulted in a signal too weak to see under these
conditions. A very low expression level may explain why this Family is
comprised of clones derived from the more stringent EL-CSC only. The
probe 2-1 Ob (Family 2) gave a strong signal on human cDNA but a much
weaker signal on mouse cDNA. The other probes, 5-3c, 4-7d, 4-1 f and 3-3a
(Families 3, 4 and Products 6 and 7 respectively) all produced a similar
result, allowing them to be tentatively ascribed to the same gene. They all
produced strong signals on cDNA, with approximately equal intensity from
human and mouse.
The signal from the total human genomic track included on the filters permits
some speculation regarding the expression level of these products relative to
each other. For instance, for probe 2-1 Ob the cDNA signal is very strong, and
the signal in the genomic DNA is also clear. For probe 5-3c however, the
cDNA signal is strong, but the genomic DNA track is blank. This may imply
that in fact 5-3c is more highly expressed than 2-1 Ob, since a clear cDNA











Figure 6.3 Hybridisation of six of the CSC novel fragment probes to (a)
catch-linkered & amplified human foetal brain cDNA, (b) catch-linkered &
amplified mouse adult brain cDNA, (c) total human genomic DNA digested
with EcoRI. a = nonran4, b = 2-1 Ob, C = 5-3c, d = 4-7d, e = 4-1 f and f = 3-
3a. Probe nonran4 gave no signal on cDNA, possibly due to a prohibitively
low expression level. The other probes resulted in a smear of size -200-
700bp on cDNA. A smear of hybridisation signal rather than a band is a
result of incomplete digestion of the cDNA, chimaeric products and non¬
specific priming in the PCR reaction. The relevance of the total human
genomic track (c) has been discussed in the text.
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6.3 Copy Number of the cDNA Fragments
In order to investigate the nature of the cDNA fragments with respect to their
copy number in genomic DNA, the fragments nonran4, 2-1 Ob, 5-3c, 4-7d, 1-
11d, 4-1 f and 3-3a were used as hybridisation probes onto filters containing
total human genomic DNA digested with EcoRI, run parallel to total yeast
plus YAC D0485, also digested with EcoRI. The amounts of human genomic
DNA and yeast plus YAC DNA (5pg and 200ng respectively) were adjusted
to give signals of comparable strength. Fig. 6.4 shows the results of these
hybridisations.
Probe nonran4 hybridises to three (and perhaps four) bands in total human
genomic DNA all between 9.5kb and 23kb. The slight background smear
indicates that this probe contains a small region of a high copy repeat
sequence. In the YAC track there was a single band, which was probably the
same size as the largest genomic band, even though it appeared slightly
larger due to the lower signal intensity of the genomic bands. The single
YAC band could indicate a single copy of this sequence in the YAC; however
the inverted repeat structure revealed by pulsed field analysis had previously
demonstrated at least two copies. EcoRI fragments are a great deal smaller
(average fragment size 3.2kb; Drmanac et al, 1986) than those which can be
resolved by PFGE. Since the nonran4 sequence occurs within only one
EcoRI fragment, there are likely to be only two copies within the YAC, unless
the sequence occurs as an array of tandem repeats. Outwith the YAC
D0485, nonran4 occurs at two (possibly three) other sites within the genome.
The signal intensity of each genomic band is approximately equal, which
indicates the same number of copies of nonran4 at each location.
Probe 2-1 Ob hybridises to six bands in total human genomic DNA, all of
relatively equal signal strength (suggesting equal number of copies of 2-1 Ob,
probably one at each locus). In YAC D0485, 2-1 Ob hybridises to two bands,
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of the same size as the smallest two genomic bands (approximately 5kb and
6.5kb).
Probe 5-3c hybridises to three bands of equal intensity in total human
genomic DNA, and to three bands of the same sizes (all between 6 and
9.5kb) in the YAC DNA. This indicates that there are at least three copies of
the 5-3c sequence within the YAC, and that the sequence does not occur at
any other sites in the genome.
Probe 4-7d hybridises to two bands in total human genomic DNA, one at
approximately 5kb and the other at approximately 15kb. The larger band is of
a far greater intensity than the smaller, which suggests that this locus
contains multiple copies of the 4-7d sequence. In the YAC however there is
a single band, which corresponds in size to the smaller band in genomic
DNA. This is consistent with a single copy of 4-7d on the YAC.
Probe 1 -11 d hybridises to four bands in total human genomic DNA, the
upper two of which appear single copy and the lower two of which contain
many copies of 1-11 d. In the YAC, 1 -11 d hybridises to a single band, of the
same size as the second largest band in genomic DNA (approximately 6kb).
This suggests a unique copy of the sequence on the YAC, plus another
single copy locus and two multi-copy loci elsewhere in the genome.
Probe 4-1 f contains part of a high copy repeat sequence (this was revealed
during the database searches) and as such produces an intense smear on
human genomic DNA. The smear masks bands which could also be present,
although there appears to be an intense (therefore multi-copy) band at
approximately 7kb and a single copy band at 1.5kb. In the YAC, 4-1 f
hybridises to a single band of approximately 1,5kb.
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Probe 3-3a gives exactly the same hybridisation pattern as probe 4-7d on
total human genomic DNA and YAC D0485, which suggests that these two
fragments lie in close proximity to each other.
The results from hybridisation of the cDNA fragment probes to total genomic
DNA suggest that all the fragments are present in more than one copy in the
genome. 5-3c is the most localised product, with three copies in the YAC,
and no others elsewhere in the genome. For the fragments producing
intense multi-copy bands on genomic DNA, it is impossible to tell without
further analysis how many copies there are and whereabouts in the genome
they are located. The multi-copy nature of the fragments suggests that the
genes from which they are derived are members of gene families or that
there are pseudogenes derived from them. Alternatively, the fragments could
be derived from low copy repeat (MER) elements, which can be sufficiently
sequence specific that they are mistakenly interpreted as a gene family.
Further proof of the genie nature of the fragments (for instance
demonstration of splicing and expression data) would be required to resolve
this matter.
For all the cDNA fragments, there is a hybridising band in genomic DNA of
the same size as every band present in the YAC. This implies that all the
EcoRI fragments of the YAC in which the cDNA fragments are situated are
present in the same form in genomic DNA. This is evidence to suggest that
the inverted repeat structure in YAC D0485 is also present in uncloned
genomic DNA.
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Figure 6.4 Hybridisation of the CSC novel cDNA fragments to EcoRI-
digested total human genomic DNA (H) and EcoRI-digested total yeast plus
YAC D0485 DNA (Y). a = nonran4, b = 2-1 Ob, c = 5-3c, d = 4-7d, e = 1 -11 d, f
= 4-1 f and g = 3-3a (not aligned horizontally relative to each other). The
results have been discussed in detail in the text.
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6.4 Isolation of Cosmids Positive for the cDNA Fragments
The seven probes nonran4, 2-1 Ob, 5-3c, 4-7d, 1 -11 d, 4-1 f and 3-3a were
used as hybridisation probes onto filters containing a gridded cosmid library
of 520 clones (made by Yoshiro Shibasaki and Sheila Christie). Nonran4
gave a strong positive signal on 42 cosmids, 2-1 Ob on 73, and 5-3c on 55. 4-
7d, 1-11 d, 4-1 f and 3-3a hybridised to a set of 23 cosmids, with very few
differences between them. A total of 520 cosmids of approximately 40kb
each derived from a YAC of 1,3Mb should give a 16-times depth of coverage
of the YAC. Thus for the probes nonran4 and 2-1 Ob, which are present twice
within the YAC, there should have been approximately 32 positive cosmids.
The fact that both these probes hybridised to more cosmids than expected,
especially 2-1 Ob, suggests that the probes may contain a repeat sequence
which occurs within, and is possibly specific to, the D0485 region.
Alternatively some of the hybridisation signals may be false positives. A total
of 48 positive cosmids would be expected for probe 5-3c, since it is present
in three copies on the YAC. This is not very different from the actual figure
observed of 55 positives.
The four probes 4-7d, 1-11 d, 4-1 f and 3-3a hybridised largely to the same
set of cosmids. Figure 6.5 shows the results obtained from probes 4-7d and
3-3a. This implies that these four probes lie in close proximity (within ~40kb)
on genomic DNA. One cosmid was positive for 4-7d, 1-11d and 3-3a only
(c402), two for 4-7d, 4-1 f and 3-3a (c564 and 568) and one for 4-1 f alone
(c620). Assuming these variations in hybridisation pattern were not caused
by deletions, chimaerism or other aberrations in the cosmids themselves, the
genomic order of the probes could be partly determined, (Fig. 6.6) although
the orientation was not known.
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Figure 6.5 Hybridisation of the CSC novel cDNA fragment probes 4-7d
(upper) and 3-3a (lower) to a gridded filter containing the D0485-derived
cosmids 1 to 234 (approximately half of the total set). Both probes hybridise
to the same six cosmids, which indicates that they lie in close proximity in
genomic DNA.
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Figure 6.6 Genomic order of probes 4-7d, 1-11 d, 4-1 f and 3-3a as defined by
hybridisation to individual cosmids. The position of the ends of the cosmids is
not known.
4-1 f 4-7d & 3-3a 1-11d
« 1 c564, c568
« 1 c620
c402 i
1 19 cosmids 1
According to the pulsed field mapping data for the cDNA fragments (Fig.
6.2), there is no overlap between any of nonran4, 2-1 Ob and 5-3c and the set
of four fragments 4-7d, 1-11 d, 4-1 f and 3-3a. This observation is consistent
with the results obtained from hybridisation to cosmids - there was no
overlap in the set of cosmids positive for 4-7d, 1-11 d, 4-1 f and 3-3a with
those positive for nonran4, 2-1 Ob and 5-3c. (One cosmid, c157, which
appeared to be positive for 2-1 Ob and the set of four probes, was later shown
by PCR to be a false positive for the group of four fragments, see table 6.3).
There was however overlap seen in the cosmid sets identified as positives
for probes nonran4, 2-1 Ob and 5-3c. Two cosmids were positive for nonran4
and 2-1 Ob, seven were positive for nonran4 and 5-3c, and seventeen were
positive for 2-1 Ob and 5-3c. Twenty-two cosmids were positive for all three of
these probes.
For the three cDNA fragments nonran4, 2-1 Ob and 5-3c there were cosmids
positive for two of them in all three combinations. This is inconsistent with a
linear genomic order for these sequences without implying false hybridisation
data or deletions or other rearrangements in some cosmids. Since there
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were only two cosmids positive for nonran4 and 2-1 Ob alone, it may be most
likely that these are the false positives or aberrant cosmids, and that the
genomic order of the probes is as in Figure 6.7. The fine mapping of these
probes would be complicated by probable low copy repeat elements within
the probes, and the inverted repeat structure in the YAC, and was not
attempted.
Figure 6.7 Most probable genomic order of probes nonran4, 2-1 Ob and 5-3c,
as judged by hybridisation to cosmids alone. A necessary deletion or other
aberration in two of the cosmids is depicted by a dotted line. The orientation






6.5 Fine Mapping of Fragments 4-7d, 1 -11 d, 4-1 f and 3-3a
Since these four cDNA fragments all mapped in close proximity to each
other, and the genomic locus was unfettered by complicating factors such as
the YAC inverted repeat, a fine scale mapping of a cosmid positive for these
four fragments was undertaken. Cosmid 158 was chosen, since it had been
previously demonstrated (by Sheila Christie) that this cosmid contained a Not
I restriction site.
Further restriction digests were performed on c158, to confirm the presence
of the Not I site, and to investigate whether any other rare-cutter enzymes
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(indicative of CpG islands) had sites within the cosmid. In addition, digests
were also performed with the restriction enzymes used for the pulsed field
mapping. Figure 6.8 shows the results of digesting c158 with the enzymes
Not I, Sal I, Sfi I, Sst II, BssH II and Eag I. It can be seen that there are
restriction sites for the enzymes Not I, BssH II and Eag I within this cosmid,
which would be diagnostic for the presence of a CpG island if they occurred
in close proximity to each other.
In order to map c158 more finely, it was necessary to digest the cosmid with
restriction enzymes which cut DNA more frequently than those above, such
that a detailed restriction map could be constructed. The enzymes BamHI,
Sma I, Sac I and EcoRI were chosen for this purpose. Single and double
digests of c158 were performed using these enzymes, plus those rare-cutter
enzymes which had been found to digest the cosmid. Filters were made by
Southern blotting of the restriction digest fragments which had been
optimally resolved on long 0.8% agarose gels.
The four cDNA fragments (4-7d, 1-11 d, 4-1 f and 3-3a) were used as
hybridisation probes onto these filters. All the probes gave positive signals,
indicating that this cosmid was truly positive for these four fragments. Figure
6.9 shows the results generated with probes 4-7d and 3-3a. The sizes of the
restriction fragments to which each probe hybridised was noted (see Table
6.2), which enabled the construction of a restriction map of the region of the
cosmid containing the four probes (Fig. 6.10). Additional mapping data was
generated by strategic excision of restriction fragments from gels, and then
use of them as hybridisation probes. Combining the hybridisation data with
knowledge of the restriction enzyme sites present in the cosmid vector
(supercos; Evans et at, 1989) enabled the rare cutter sites to be physically
linked to the cDNA fragments (Fig 6.10). Co-migrating and unresolvable
fragments presented difficulties in mapping the extremities of the cosmid, but
this was deemed unnecessary and was not pursued.
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Figure 6.8 Products of digestion of cosmid 158 with rare cutter restriction
enzymes, resolved on a 0.8% agarose gel. The size marker used is 250ng of
XHind III. Track 1 = Not I, track 2 = Sal I, track 3 = Sfi I, track 4 = Sst II, track
5 = BssH II and track 6 = Eag I. The cosmid vector (supercos) contains two
Not I sites and four Eag I sites; the human DNA insert therefore contains one
Not I site, one BssH II site and two Eag I sites (in track 6 the third largest
















Figure 6.9 Hybridisation of the CSC novel cDNA fragment probes 4-7d (left)
and 4-1 f (right) to restriction digested cosmid 158. The marker track visible
on the 4-7d autoradiograph is XHind III. Tracks 1 to 10 correspond to BamHI,
EcoRI, Sac I, Sma I, BamHI & Sac I, BamHI & Sma I, EcoRI & BamHI, Sac I
& EcoRI, Sac I & Sma I and Sma I & EcoRI digests respectively. The sizes of
the hybridising bands (except Sma / single and double digests) are shown in
table 6.2. Hybridisation to rare cutter restriction enzyme digests is not shown.
The restriction map constructed partially from this data is shown in Fig. 6.10.
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Table 6.2
Restriction fragment sizes to which the probes hybridised (kb)






4-7d 2.9 6.5 5.1 2.9 2.5 5.1
1-11d 2.9 6.5 6.4 2.9 0.4 0.4
4-1 f 3.8 6.5 1.6 3.6 1.2 1.0
3-3a 2.9 6.5 5.1 2.9 2.5 5.1
It can be seen from Fig. 6.10 that the four cDNA fragments, 4-7d, 1 -11 d, 4-1 f
and 3-3a all map to within a 6.5kb Sac / fragment. The nearest fragment, 1-
11 d, lies only 3.6kb away from a Not I and Eag I site, 7.4kb away from a
BssH II site and 7.7kb away from a second Eag I site. According to the long
range mapping data (Fig. 6.2), this must correspond to the distal-most Not I
site on the YAC D0485, enabling the placement of the four cDNA fragments
on the pulsed field map with far greater accuracy.
The order of the four cDNA fragments derived by hybridisation to the whole
cosmid set was the same as that derived from the detailed mapping of
cosmid 158. Probes 4-7d and 3-3a were both located within a 2.5kb BamHI
& EcoRI fragment and their order could not be deduced by digesting the
cosmid with the enzymes used. This was resolved by PCR (section 6.6.3).
This mapping data is suggestive that the four novel cDNA fragments 4-7d, 1-
11 d, 4-1 f and 3-3a are all derived from a single, CpG island-associated
gene. RT-PCR could be used to investigate whether these fragments are
derived from the same transcript. Analysis of the methylation status of the
rare-cutter restriction enzyme sites in uncloned genomic DNA will determine
whether or not they mark a CpG island.
247









6.6 Linking the cDNA Fragments by Genomic PGR
Amplification
6.6.1 Primer Design
In order to confirm the order and separating distance of the group of four
cDNA fragments, and to potentially link the other three fragments (nonran4,
2-1 Ob and 5-3c), PCR primers were designed from the consensus
sequences of the five families of cDNA products and the two individual
products. Due to the alternatives in orientation available to the products, two
primers in opposite orientations were required. These primers were designed
such that it would be possible to amplify a short intra-fragment product, to
serve as a positive control for the template DNA. Ambiguous bases were
avoided where possible. Figure 6.11 A to G shows the consensus
sequences of the seven cDNA fragment families and products, with the
primers' name and orientation indicated for each one.
Figure 6.11
A) Family 1 - 482/483 PCR product=198bp
482 ►
1 AGGAGAAGCT GGTGGCTGGT GAGTTCTCCT GGCCACCATG AACTTCAGGA
51 AGTGGGTGCT ATAGCAGCTG CCTGAACTAC ACAATCTGGG CTTTGGTGTA
101 TCCCTGTATG CCCTCCGGGC CAGACACTGG AGGTGTCATT TCCAAAGCAA
< AftS
151 ATTGGAAGCG CTTTTTTGGA ATTTCTCTCC AATGCTTTCT ACTCACAAAG
201 ACTGACATCT TAACACGTGG CAAAGAAAAA AATATTTAAA GGGTCCAGAT
251 CTTATTTATG TAAACAATCA AGAGTGAGTT TGKRGKKGRA AACCCAAAGT
301 TGGANAANTG GTGCATAATA AAAGAAATTT GTTCATTTTC TGCTGTTGTA
351 CATTTGGAAT GATTTTTGTA TTTTGATTTT GTGAACATGT CTCCTAATGT
401 AAATAGCCAA TAGATTCTCT TTTCGGACAG TATCTTCTGA TAGCTGGAAT
451 GTCTGGGTTA TAAAATTTGT GATC
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B) Family 2 - 484/485 PCR product =200bp
1 GATCTGGTGG AAACACAGGC TGCCAGGCCC TGCCCCTGGA GTCTTTCTTT
484—+
51 GAATAGGCCT GGGGTGGGGC CCAAGAATGA GCAGAAGAAC AGGTTTCCTG
101 GTGAGGCTGA TGCCGCTGGC CCAGGGTTCT CACGTTGAGG ACCGAGAGCT
151 TTGAGGTTTT CATACCTGAT GATGTCCAGG AACCCTTCTC AGTAGGCACT
201 GAAGACCATC AGCAGAATCA CAGACCCCAG GAGAGATGTC GTCAGACAGA
4 485
251 CACAGAGGCA TCACCGAATT AAAGTGAAAA TGAAGAAAGG AGCTGAGCAT
301 CTGTTTCATG ACTTTCGTGG CTGTTTTACT AAAGAGGCTA TCCTGGCCCA
351 GTCAGGGCAC GCTATCATCA CCAACTACTT GTTGAACTAT GTCCTGGGTC
401 TTGACCTTGA AGGATGGAHG CGTTBGGGTT GCAAGCCGCC ATGCAGGGTC
451 GAACCGATCC
C) Family 3 - 486/487 PCR product =153bp 4g6 >
1 GATCCGTGGG AGCACTGAGA TGGTCATCTC CAAATATCAC ATATCTCACA
51 TCCTCAGAAA GGCTTATATA GCAAGGAATC ATTTCCGTGC TCAGAGCACT
101 ATCCACTCTG AAGTTGTTGA GCATGTCTAG GACTCCAGTT ATGCACCATG
< 487
151 AAGTGAGCTC TGGGTTCACT GGCTGGGGCT TTTGSATCTG TGCCAAATCA
201 GTCCTTGCTG ATACATTTCT CACATCCTTG
D) Family 4 - 488/489 PCR product =255bp
488 ►
1 GATCCAAATG GCATCTCCTA CCCTATCCCT GTATGGCTTA ACCTAGGGAA
51 ACTCTTTCCC AGAGGAGTCA GGTAAGGAGA CGGTGGCTGA GCTTCTTACA
101 GACTTAAAGG AGGCATCCTG GAATTTRGGA SWCCRTCCTK CCWTTCTGTA
151 AYCMCTGGCA GCTSCTGCTG CTKCKCARAG TTTAGCTTTG TCTCTCAWCC
< 489
201 AGCTCAGACT GKTGCTGGTC CTGATGGCCT CTGCWTAGCT GTATTAGATG
251 TCCTTGCRTT GCWAAAAAGA AATACATGAG ARATACCTTT AGKTGGCTGA
301 TGGTWCCATA GGGDATACAG GAAGCRTGGT GGTTDCTGCT TGTGGGGAGG
351 CCTCAGGAAA CTTTTACTCA AGGTACAGGC CCAATGAGKA AAAAGAAAAA
401 AAAAAAAGCT ACCAGCRCCG CAATGTGGAG TCCTGAKC
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E) Family 5 - 490/491 PCR product =239bp
1 GAATTCTATG CCTCAGGTTY TCATTTTTGT TATGTGCAAA ATAAACTCGT
490 —►
51 ATCCTGCTAT AGATYTAAAC CTGTGAGVGA MTCCTACTCA AAACCTGATT
101 CAAACTTGTG TGTAGATCTT TGYCTCTCTG TGGCATAMRK AATMAWTCCT
151 TCTGGTTTMC TTCCCTCAGA ATAATGGACT TAGACTKCCC ACAAGMCTTC
201 CRGAYAGWMM YCACCTGKCT TATCTGSCTG ARTTACCTCA TAGACCCCAT
251 CACTATAGGC TGSGGGGACA GCYTCTGTAG GCCCTGCCTC TGCCTTMGCT
< 491
301 GGGAAGAAGY ACACACTCCT GCCCYGCATG CAGGGAATCG TCACAGCAGG
351 AAGATTTC
F) Product 6 (4-1f) - 492/493 PCR product =107bp
1 CGTGAGCCAC CACCCCCGGC CCCAGGACAC ACAGCTTTAA AATTTCTCCT
492 ►
51 TGGTCTCACC CAGTGCCAAC CACCTAAAAG CTCTCATTTT CCCCCAGACA
101 SilCTTCTGC CTCCAGGATG GAGGTAGAGA ATCTTGGCCT AGGCCCACGC
< 493
151 ACTGGGGACC ATGCTGGGCT GCCGTGGACA GTGACGGACT CAGGTTCTCA
201 CCAGGATC
G) Product 7 (3-3a) - 494/495 PCR product =264bp
1 GATCTAGGAG GAGAGGGCAG AGCCTCAGCA GGAAGAGCGT CTCTTTGAGA
51 AGGAGACACA GTGGAGCAGG TGTGTAGGTT CACAGGGCCA GCTATGGGTA
101 GAGTCGGGTG TACATTTTTA GGAGCCACAA TTCCCAAAAA TCTCCTGACT
151 ATAACATCAG TGCACAGAGC CAGTCAAATG GAGGAGGAGT GGGTCCAGGC
494 —>
201 AATTCAGGAA GAAGGAAAGT AACAAATGAG TGGTTGCAGG AGGACACTTT
251 TTCTTGTCGA GGGTCACTAA ACAAAACATT GTCTCCTCCC CCTCTAACTT
301 CAGAAACAAT GGAGGGTAAG AGTGTCNCCT GGGCCCTGGG GCCAAAGACA
351 GTAGATAACT TCTCTGTCGT GTTCTCCAGA AGGGCCCAAC AANTACAAGG
401 TTCTACGGTT CTAAATTCCA ATCTAGTCTT CCACATCATT TTGAAGGTAT
< 495




Several of the cosmids which had been positive by hybridisation for one or
more of the cDNA fragments were picked as templates for intra-fragment
PCR with the primer pairs derived from the same cDNA fragments. This was
to test whether the cosmids were positive for the expected fragments, before
using them in inter-fragment PCRs.
The cosmid colony was picked from a fresh agar plate, and transferred to a
microfuge tube containing 50pl of dH20. The tube was the heated to 96°C for
5 mins, the contents spun down for 1 min to separate the DNA solution from
the bacterial cell debris, and then placed on ice. 2pl of template DNA plus
300ng of each primer was used in a PCR reaction. For the intra-fragment
PCRs the programme used was:
Hot start at 90°C for 5 mins
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
Annealing: Touch down from 70°C to 60°C then 60°C, for 30 sees
Extension: 72°C for 30 sees (cycles 1-10), 1 min (11 -20), 1.5 mins (21-30)
It was found that not all the cosmids which had been positive for a product by
hybridisation were also positive by PCR. Table 6.3 summarises these
results. There are several alternative explanations for this phenomenon.
Firstly, the hybridisation results could have been false positives. Secondly,
deletions or other aberrations in the cosmids could have removed one or
both of the primer binding sites, yet retained sufficient of the cDNA fragment
sequence that hybridisation could still take place. Thirdly, intact cosmids
could be positive by hybridisation but negative by PCR if the probe cDNA
sequence was located at the extreme terminus of the cosmid insert. The
PCR primers were derived from the consensus sequence of the cDNA
families, and therefore sometimes lay outwith the sequence of the
representative family member which was used as a probe (that is, nonran4,
2-10b, 5-3c, 4-7d, 1-11d, 4-1f and 3-3a).
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Table 6.3 Fam = Family; ND = not determined
Cosmid Expected PCR Positives Observed PCR Positives
3 Fams 1,2 and 3 Not Fam 1, Fams 2 & 3 ND
22 Fam 2 Fam 2
24 Fam 1 no positives
26 Fams 2 & 3 no positives
42 Fams1 & 3 Fams1 & 3
44 Fams1 & 3 Fams1 & 3
53 Fam 3 Fam 3
85 Fams 2 & 3 Fams 2 & 3
129 Fams 4, 5, 6 & 7 Fams 4, 6 & 7
157 Fams 2, 4, 5, 6 & 7 Fam 2
158 Fams 4, 5, 6 & 7 Fams 4, 6 & 7
208 Fams1 & 2 no positives
499 Fams1 & 2 Fam 2
No PCR product could be obtained from Family 5, even though its existence
on at least c158 had been proven by the mapping of the cosmid. The failure
could therefore be ascribed to the PCR reaction. Primer 491 was later found
to function adequately in the inter-fragment PCRs, and thus it is probable
that the problem was caused by primer 490. No optimisation of PCR
conditions was attempted in order to resolve this.
Neither of the cosmids (208 and 499) which had been positive for Families 1
and 2 by hybridisation were found to be also positive for these fragments by
PCR. This may resolve the discrepancy shown in Fig. 6.7.
For Families 1, 2, 4 and 6, the band obtained by intra-fragment PCR was the
same size as that expected, that is 198bp, 200bp, 255bp and 107bp
respectively. For Families 3 and 7 however, the product band was larger
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than expected. The band in Family 3 was approximately 1.3kb rather than
153bp, and the band in Family 7 was approximately 500bp rather than
264bp. This implies either non-specific annealing of one or both of the
primers at a more distant site, or the presence of introns within the genomic
DNA. Sequence analysis was undertaken to investigate these possibilities
(see Section 6.7).
6.6.3 Inter-fragment PCRs
The cosmids which had been proven to be positive for two or more of the
cDNA fragment families could be used as a template for PCR reactions
attempting to link the different families in genomic DNA. Due to the
alternative orientations and orders available to the fragments all four
combinations of the two primer pairs were required, only one of which should
result in a product. The order of the fragments comprising Families 4/7, 5
and 6 had been previously established by the mapping of cosmid 158, which
also established the approximate distance separating them. Results from
hybridisation of probes nonran4, 2-1 Ob and 5-3c onto the cosmid set had
indicated a likely order for these fragments, but nothing was known regarding
the distance separating them.
A long PCR kit was employed ('Expand'™ or 'Takara'™) for many of the
reactions, in order to increase the likelihood that a PCR product could be
generated. 2pl of cosmid template (prepared as in Section 6.6.2) was used in
the majority of the PCR reactions, although in those indicated a product was
also obtained from 1|il (~100ng) of YAC D0485 miniprep DNA. 300ng of
each primer was used; other components of the reaction mix were according
to the manufacturer's instructions. The PCR programmes used differed only
in the extension times, adjusted according to the length of the target product:
Hot start at 90°C for 5 mins
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
254
Annealing: Touch down from 68°C to 58°C then 58°C, for 30 sees
Extension: 68°C, 5x3 mins, then 25 x 6 mins(1) or 15 mins (2)
Where the long PCR kit was not employed (3>, the PCR programme was:
Hot start at 90°C for 5 mins
Denaturation: 94°C for 30 sees in the first cycle and 15 sees thereafter
Annealing: Touch down from 70°C to 60°C then 60°C, for 30 sees
Extension: 72°C for 2 mins (cycles 1 -10), 4 mins (11 -20) and 6 mins (21-30).
Table 6.4 shows the results of the inter-fragment PCR reactions, with the
cosmid template used, the combination of primers used for successful
amplification of the target product, the size of that product, and the PCR
programme used ('Expand'™ or 'Takara'™, (1) , (2) or standard Taq
polymerase (3), see above text). No product was obtained in each case with










Fam 1 - Fam 3 44 482 / 486 12.0 Takara (2)*
Fam 2 - Fam 3 85 485 / 487 6.5 Takara (2)
Fam 4 -Fam 5 129 6* 158 488/491 2.4 (3)
Fam 4 - Fam 6 489 / 493 4.1 Takara (2)
Fam 4 - Fam 7 489 / 495 0.9 Expand (1)
Fam 5 - Fam 6 491 / 493 6.4 Takara (2)
Fam 5 - Fam 7 491 / 495 3.1 Expand (1)
*
= also obtained with Expand (2)
For the PCR reactions Fam 1 to 3, 2 to 3, 4 to 6, 4 to 7 and 5 to 6, a product
was also obtained when YAC D0485 was used as a template. This was not
attempted for the other two products.
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Figure 6.12A shows the PCR products generated from cosmid DNA between
Families 1 and 3, and 2 and 3. No product was obtained between Families 1
and 2. Fig. 6.12B shows the products similarly obtained between Families 4
and 5, 4 and 7, 4 and 6, 5 and 6, and 5 and 7.
The combined results from the inter-fragment PCR reactions enabled
clarification of the order and orientation of all the seven group of cDNA
fragments (Figure 6.13). The fragments fall into two groups, that comprising
Families 1, 2 and 3, and that comprising Families 4, 5, 6 and 7. This confirms
speculation arising from the pulsed field mapping data and from the
hybridisation to the cosmid set.
PCR reactions were attempted to amplify between the two sets of fragments
on genomic DNA. Knowledge of the order and orientation of the fragments
enabled the primers to be chosen so as to minimise the length of the target
product (that is, 483 or 484 paired with 490 or 492; see Fig. 6.13). The
simplest template DNA for these reactions was however YAC D0485, since
no cosmids had been identified which contained fragments from both groups.
No PCR products were generated, even with use of the 'Expand' long PCR
kit. This is unsurprising when mapping position of the two groups on the YAC
D0485 is considered. The location of the first group (Families 1, 2 and 3) is
fixed by the Sfi I site present between Families 2 and 3 (see Fig. 6.2). The
location of the second group (Families 4, 5, 6 and 7) is also fixed, by its close
proximity to a Not I site demonstrated by the mapping of cosmid 158. The
distance between the Sfi I site and Not I referred to is 170kb, which is not
amplifiable by PCR (even using a kit!).
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a) fc>) M 1
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Figure 6.12 Inter-fragment PCR products generated by amplification of
cosmid DNA with primers designed from the novel cDNA family consensus
sequences (see table 6.4). 10pil PCR product is resolved on a 0.8% (a) or
1% (b) agarose gel.
a) The size markers used are 250ng XHind III (track 1) and 250ng of the 1 kb
ladder (track 2). Track 3 = 12 kb fam1 to fam3 product. Track 4 = 6.5 kb
fam2 to fam3 product.
b) The size marker used is 250ng of the 1kb ladder. Track 1 = 2.4 kb fam4 to
fam5 product. Track 2 = 0.9 kb fam4 to fam7 product. Track 3 = 4.1 kb fam4
to fam6 product. Track 4 = 6.4 kb fam5 to fam6 product. Track 5 = 3.1 kb
fam5 to fam7 product.
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Figure 6.13 Order, orientation and genomic separation distance of cDNA
fragments within the two groups, as defined by PCR (not to scale). The first
set probably occurs in both orientations on the YAC, due to the inverted
repeat structure. The second set probably occurs in the order shown, since
1-11d was found to map closest to the Not I site on cosmid 158. CEN =
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6.7 Sequencing of the YAC D0485 Copy of the cDNA
Fragments
All of the seven novel cDNA fragments, except 5-3c, were found by
hybridisation to total genomic DNA to exist at loci in the human genome
other than within YAC D0485. The selection procedure used to isolate the
coincident DNA will enrich for all the cDNA fragments which form a
sufficiently stable duplex with the genomic DNA. As such it was uncertain
whether the cDNA fragments isolated were derived from transcription of a
gene on YAC D0485 itself, or from a very similar gene transcribed from
elsewhere in the genome. The cDNA fragments were certainly sufficiently
similar to the D0485 copy to give strong clear hybridisation signals on the
YAC and associated cosmids, and only genomic sequence analysis could
reveal the single base changes permitting the assignment of the cDNA to
D0485 or to 'elsewhere in the genome'.
Sequencing of the genomic copy of the cDNA fragments was also important
to verify that the intra- and inter- fragment PCR products were genuinely
amplified from the correct fragments. Thirdly, it was important to ascertain
whether the larger than expected intra-fragment PCR products generated
from Families 3 and 7 were as a result of intervening introns.
The ends of selected inter-fragment PCR products were sequenced using
dideoxy terminator radioactive sequencing, from the primers used to amplify
them. No sequence data was generated for either Family 1 or Family 2.
Sequence was generated for Family 3 from primers 486 and 487 (using the
1.3kb intra-fragment PCR product as a template), for Family 4 from primers
488 and 489 (using the inter-fragment PCR products 488/491 and 489/493),
for Family 5 from 491 (using 488/491), for Family 6 from 493 (using 491/493
and 489/493) and for Family 7 from 494 and 495 (using 491/493 and
491/495). Approximately 200bp of sequence data was generated from each
primer.
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The sequences obtained from the D0485 copy of the cDNA fragments were
compared with those derived from the cDNA fragments themselves. Figure
6.14 A to E shows a comparison of the sequence of the genomic and cDNA
copies of each of the Families 3 to 7.
Figure 6.14
A) Genomic sequence generated from primers 486 and 487 compared with




















I I I I II I I I I I I I II I I I I I
3TCTGAAGTTGTTGAGCATG
TCTAGGACTCCAGTTATGCACCATGAAGTG









The genomic sequence diverges from and then re-converges with the cDNA
sequence at position 106 of the Family 3 cDNA consensus sequence, which
suggests the presence of an intron. The presence of an intron would be
consistent with the intra-fragment PCR product from genomic DNA which
was much larger than expected. In proof of this, reversed consensus splice
donor and acceptor sites (Shapiro and Senapathy, 1987) can be found at
these junctions (bases underlined). The acceptor site sequence has 2 bases
additional to the consensus (YYTTYYYYYYNC/AGG) and the donor site has
7 out of 8 bases identical to the consensus (AG/GTRAGT). These
differences could have arisen from sequencing errors, or be the result of
mutations generating cryptic splice sites.
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Throughout the 77 bases of matched exon region between the genomic and
cDNA sequence there are only two mismatches, which may be attributable to
sequencing errors. The cDNAs comprising Family 3 were therefore all
derived from a D0485 YAC copy of this sequence. This is consistent with the
total genomic hybridisation data for 5-3c, which suggested that there were no
genomic copies of this sequence other than within D0485.
B) Genomic sequence generated from primers 488 and 489 compared with
the Family 4 consensus sequence.
488 GGAAACTCTTTCCCAGAGGA
488 ► 1 1 1 1 II 1 1 II 1 II II II 1 1 1
20
f am4 CCTACCCTATCCCTGTATGGCTTAACCTAGGGAAACTCTTTCCCAGAGGA 66
488 GTCAGGTAAAAAGACAGTGGCNGAGCTTCTTACAGATTTAAAGGAGACAT
i ii m i i m i i i i ii i ii • it i ii i I I I ii i I i I M M M II III
70
f am4
1 1 1 1 1 ii ii 1 1 1 1 ii ii 1 : 1 1 1 ii ii ii 1 ii ii ii 1 ii 1 1 ii iii
GTCAGGTAAGGAGACGGTGGCTGAGCTTCTTACAGACTTAAAGGAGGCAT 116
488 CCTGGAATTTAGGACTCCATCCTTCCTT
i i i ii I ii I I . 1 I I - • II • II I I • I I • I
98
fam4
1 1 1 1 1 1 II 1 1 . II 1 • • II • 1 1 II ■ 1 1 • I
CCTGGAATTTRGGASWCCRTCCTKCCWTTCTGTAAYCMCTGGCAGCTSCT 166
489 ATCCC-GTATGGCTTAACCTAGGGAA 25
I I I I I I II II I I I I I I I I I II II I I
fam4 GATCCAAATGGCATCTCCTACCCTATCCCTGTATGGCTTAACCTAGGGAA 50
489 ACTCTTTCCCAGAGGAGTCAGGTAAAAAGACNGTGGCTGAGCTTCTTACA 75
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I : I I I I I I I I I I I I I I I I I I
fam4 ACTCTTTCCCAGAGGAGTCAGGTAAGGAGACGGTGGCTGAGCTTCTTACA 100
489 GATTTAAAGGAGACATCCTGGAATTTAGGACTCCATCCTTCCNTTCTGT- 124
II I I II I I I I I I I I I I I I I I I I I I : I I I : : I I : I I I I : I I : I I I I I I
fam4 GACTTAAAGGAGGCATCCTGGAATTTRGGASWCCRTCCTKCCWTTCTGTA 150
489 -CCCCTGGCAGCTCCTGCTGCTTCTCAAAGTTTAGCTTTGTCTCTCATCC 173
: I : I I I I I I I I I : I I I I I I I I : I : I I : I I I I I I I I I I I I II I I I I I : I I
fam4 AYCMCTGGCAGCTSCTGCTGCTKCKCARAGTTTAGCTTTGTCTCTCAWCC 200
489 AGCTCAGACTGTTGCTGGTCCT 195
I I I I II I I I I I : I II I II I I I I * 489
fam4 AGCTCAGACTGKTGCTGGTCCTGATGGCCTCTGCWTAGCTGTATTAGATG 250
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A total of 197 bases have been sequenced from the genomic region
corresponding to the Family 4 sequence, 90 of these also sequenced in the
opposite direction. Of these 197, there were 8 different bases between the
genomic and cDNA sequences, 5 mismatches (although one was
ambiguous), and three bases deleted from the genomic sequence. The
Family 4 was composed of sequence from two clones, 4-7d and 5-7e, and
where they differed, a degenerate base was inserted into the consensus. At
all the positions of these degenerate bases, the nucleotide in genomic DNA
was compatible with the degenerate cDNA nucleotide. At ten of these
positions, the base in genomic DNA was the same as the sequence from 4-
7d. However at four degenerate positions and at two of the three deleted
bases, the genomic DNA base was the same as that in 5-7e. Some of these
mismatches will undoubtedly be sequencing errors, whereas some may
reflect genuine sequence changes between different copies of this sequence
throughout the genome. It is therefore difficult to ascertain whether either or
both clones 4-7d and 5-7e were derived from the D0485 copy of the gene,
although they are highly similar.
C) Genomic sequence generated from primer 491 compared with the Family
5 consensus sequence
491 CTTTGCATAGATCTTTGTCTC
i ii i i M i M i i i • M I
21
f am5
1 II 1 1 1 1 1 1 1 II 1 : 1 II
GVGAMTCCTACTCAAAACCTGATTCAAACTTGTGTGTAGATCTTTGYCTC 126
491 TCTATGGCATA-AGAATAAATTCTTCTGGGTTTCTTCCCTCAGAAAAATG
ill I I I II I I • • I M • I • I I I M II I II I II I I I I I I I I I I I M
70
fam5
III 1 1 1 II 1 1 - . 1 1 1 - 1 • I 1 1 1 1 1 I I II I I II II 1 I I I II I I I I
TCTGTGGCATAMRKAATMAWTCCTTCTGGTTTMCTTCCCTCAGAATAATG 176
491 GACTTAGAATTCCCACAAGCCTTCCAGAAAGAACTCACCTGCCTNATCTG
I I I I I I I I I • I I II I 1 I I • II II I • I I I I - - - . I I I I I I I I - I I I I I
120
f am5
1 I II II 1 1 1 • I 1 1 1 II 1 1 . 1 1 1 1 1 . 1 1 1 1 . . . : 1 1 II 1 1 1 1 • 1 II 1 1
GACTTAGACTKCCCACAAGMCTTCCRGAYAGWMMYCACCTGKCTTATCTG 226
491 CCTGAATTACCTCATAGACCCNATCACTATAGGCTGCTGGCACAGTTTCT
• i I i I ■ I I II I I I I I ii i I I i - i I i i i i i i ii i i i i • II i i ii -ill
170
fam5










181 bases of the Family 5 sequence have been sequenced from genomic
DNA, 16 of which are different from the Family 5 consensus (15 mismatched
bases and 1 deletion). This 9% difference rate is higher than would be
usually attributable to sequencing errors and may therefore suggest that the
cDNA clones comprising the Family 5 consensus (1-11 d and 2-5c) may not
be derived from the D0485 copy of the sequence. At the corresponding
genomic DNA positions of the 16 degenerate bases in the Family 5
consensus, 7 were the same as 2-5c and 9 the same as 1-11 d.
D) Genomic Sequence generated with primer 493 compared with the
Product 6 (4-1 f) sequence
493 CCTCGGCCTCTCAAGTGCTGGATTACAGGNGTGAGCNACCGCGCCCGACC
M I I i I • II I I II I I II
83
4-lf
I I II I I • I I I I I II I II
CGTGAGCCACCACCCCCGGCC 21
493 CCAGGACACACAGCTTTAAAAGCTCTCCTTGGTCTCACCCAGTGCCNACC
i i i M i M i i M i i i i M i i i M i M i i I I I M I II I I I II I I I • II I
133
4-lf
I I II I I I I I II II II II M II I I I II II II II I II II I I I II II • II I
CCAGGACACACAGCTTTAAAATTTCTCCTTGGTCTCACCCAGTGCCAACC 71
493 AACTAAAACCTCTCATTTTCCCCCAGGCATTTNTTCTGCCTCCAGGATGG
i i i i i M i M i i M i M M i i M I i M I M ■ II I II I I I M I II II II
183
4-lf









The genomic sequence generated from primer 493 extended further than the
4-1 f sequence itself. This extra sequence may extend the known cDNA
sequence, though it may instead continue into an intron. The former is more
likely as there is no evidence for a splice site in this additional sequence. Of
the 144 bases of the genomic DNA corresponding to the cDNA however,
there were 9 definite mismatches and possibly 4 others in positions where
the genomic base could not be determined. This 6% mismatch rate may be
due to an unusually high rate of sequencing errors or may imply that the 4-1 f
cDNA was not derived from D0485 itself, but from a highly related gene
elsewhere in the genome.
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E) Genomic sequence generated from primers 494 and 495 compared with











I I II I II II I
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I I : I I I I I II I I I I I I I I II I I I I I I I I I II I III
AACAAAACATTGTCTCCTCCCCCTCTAACTTCAGAAA CAATGGAGG
GTAAAAGTGTTGCCTGGGCCCTGGGAGCAAAGGCAGTAGATAACTTCTCT
I II I I I I I I I : I I I I I I II II I I I I I I I I I I I I I I I I II I I I I I I I
GTAAGAGTGTCNCCTGGGCCCTGGGGCCAAAGACAGTAGATAACTTCTCT
GTTGTGTCCTCCAGAAGGGCCTA

















I I II I I I I I I I I I I I I I I : : I I I I : I I I I I I I I I I
CGGTTCTAAATTCCAATCTAGTCTTCCACATCATTTTGAAGGTATAATAT 455
As with the Family 3 sequence, the genomic and cDNA Family 7 sequences
do not match along their whole length. Rather, the genomic sequence
diverges away from the cDNA sequence at cDNA position 389 and then
reconverges at the same point. This is suggestive of the presence of an
intron. The intra-fragment PCR product generated from genomic DNA was
slightly larger than expected, which is consistent with the sequence data.
The Family 7 genomic sequence does not however exhibit consensus splice
sites at the intron/exon boundaries. The 'GT' dinucleotide at the beginning of
the mismatch (underlined) does suggest the 5' end of an intron (Shapiro and
Senapathy, 1987), yet the rest of the consensus is absent. At the 3' end of
the intron, a consensus splice acceptor site does occur (14 out of 15 bases
identical), yet it is not at the position expected from the cDNA/genomic
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sequence match. This probably implies that the cDNA was not derived from
the D0485 copy of this gene fragment, but was instead derived from another
copy of this sequence, and that the exact position of the splice sites has
diverged between the two.
Of the 200bp of the matched region sequenced, there were 33 definite
differences between the cDNA and genomic DNA sequences, with a
possible 8 others unassigned due to ambiguous sequence data. Of the 33
there were 25 base changes and 8 deleted / inserted bases, including one
four base insertion into the genomic DNA sequence. This relatively high rate
of changed sequence between the cDNA and genomic DNA suggests that
the cDNA was not derived from the D0485 copy of the sequence.
6.8 Open Reading Frames Encoded by the Novel cDNA
Products
Additional proof that a DNA sequence is derived from a gene can be
acquired by demonstrating that the sequence contains an open reading
frame (ORF) which can code for a peptide. The cDNA Family and Product
consensus sequences were therefore translated in all three frames and in
both directions. ORFs (coding sequences containing no stop or nonsense
codons) were obtained for one permutation for Families 3, 4 and 5 and
Product 6. These ORFs are shown in Figure 6.15.
Figure 6.15 Open Reading Frames Encoded by Family 3 (A), 4 (B), 5 (C) and
Product 6 (D).
A) Family 3 The ORF was produced by translating the reversed consensus
sequence, beginning at position 2.
1 KDVRNVSART DLAQZQKPQP VNPELTSWCI TGVLDMLNNF RVDSALSTEM 50
51 IPCYISLSED VRYVIFGDDH LSAPTD 76
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B) Family 4 Translation of the Family 4 consensus sequence was impossible
due to the presence of degenerate bases. Translation of one of its
constituents (4-7d) did not yield an ORF; the other (5-7e) also contained
degenerate bases. The ORF below resulted from translation of the reversed
genomic sequence primed from 488, beginning at position 1. The fact that
the cDNA clone sequence did not possess an ORF implies either the
existence of sequencing errors in the cDNA clones, or that the cDNA was
derived from a transcribed pseudogene, in which mutations had destroyed
the ORF.
I KEGWSPKFQD VSFKSVRSSA TVFLPDSSGK EF 32
C) Family 5 This ORF was generated by translating the reversed genomic
sequence primed from 491, starting at position 1. As for Family 4, the Family
5 consensus sequence and a constituent clone (2-5c) could not be translated
due to the presence of degenerate bases. The other constituent clone, 1-
II d, did not possess an ORF.
1 LCIDLVSLWH KNKFFWVSSL RKMDLEFPQA FQKELTCLIC LNYLIDPITI 50
51 GCWHSFCRPC 60
D) Product 6 This ORF was derived by translating the 4-1 f cDNA clone
sequence, beginning at position 1.
1 REPPPPAPGH TALKFLLGLT QCQPPKTSHF PPDISSASRM EVENLGLGPR 50
51 TGDHAGLPWT VTDSGSHQD 69
The presence or lack of an ORF within a DNA sequence is critically
dependent upon that sequence, since only a single wrong base will destroy
the continuity. The cDNA consensus sequences and corresponding genomic
sequences were commonly derived from a single sequencing reaction,
hence errors and ambiguities are inevitable. This could explain why no ORF
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was present in the Family 1, 2 or Product 7 sequence. Although the former
two have not been categorically proven to be coding sequence, this is not so
for Product 7, for which an exon/intron structure has been demonstrated.
Unless the Product 7 sequence was derived from a non-processed
pseudogene, the lack of ORF must be attributed to sequencing errors.
The necessity for accurate sequence data before confirmation of genuine
ORFs may imply that the ORFs mentioned above occur merely a result of
chance. None of the ORFs are particularly long, which makes this possibility
more realistic. The ORFs from Family 4 and Product 6 were in the orientation
that would be predicted, assuming that these cDNA fragments are derived
from the same gene as each other and also as Product 7. This is a
reasonable assumption since these products map close to each other (within
6.5kb) in genomic DNA and lie adjacent to a putative CpG island
(characterised by rare-cutter restriction enzyme sites). The direction of
transcription can be surmised by the orientation of the splice sites present in
the Product 7 sequence and by the presumed presence of the CpG island at
the 5' end of the gene. The ORF from Family 5 was however in the opposite
orientation to that expected from the inter-fragment PCRs, and thus the ORF
probably occurs by chance.
The degeneracy of the genetic code means that products similar at the
amino acid level may appear more diverged at the nucleotide level. Flence a
database search between translated DNA fragments and translated
database entries can increase the power to find homologies. Such database
searches were performed with the seven novel cDNA consensus sequences,
translated in all six possible reading frames to minimise the effect of
sequencing errors. No significant database homologies were found.
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CHAPTER 7
DISCUSSION AND FUTURE PROSPECTS
7.1 Discussion of Results and Related Future Studies
This thesis describes physical mapping of a YAC contig in the region of a
translocation breakpoint associated with schizophrenia, a cDNA selection
experiment designed to isolate genes from the region around the breakpoint,
and then characterisation of the derived cDNAs, to a greater or lesser extent.
The physical mapping of the region, including the isolation of end clones,
splinkerette PCR and pulsed field mapping of YACs has been discussed in
Chapter 3 and therefore will not be alluded to further here.
Since the translocation breakpoint had been shown to be strongly associated
with major mental illness in the pedigree (St.Clair et al, 1990), it was
assumed that the two were causally related, that is that the translocation
event was in some way disrupting, altering the expression of or fixing a
mutant allele of a gene located either at the breakpoint or nearby. The
chromosome 11 side of the translocation breakpoint was chosen for initial
investigation, due to previous associations of cytogenetic rearrangements or
candidate genes from this chromosome with psychiatric illness (St.Clair et al,
1994). Physical mapping in the region of the chromosome 11 translocation
breakpoint led to the construction of a 3Mb YAC contig, in which YAC D0485
was proven to span the breakpoint (Evans et al, 1995 and references
therein).
The YAC D0485 was chosen as the best candidate genomic substrate for a
gene-finding experiment. YAC D0485 contains approximately 800kb of DNA
proximal and 500kb distal to the translocation breakpoint, which should be a
sufficiently large range to detect the gene concerned, even if it was located
at some distance from the translocation breakpoint. The cDNA resource
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chosen was derived from foetal brain. This was partly because candidate
genes for involvement in schizophrenia would most likely be expressed in the
developing brain. Also that it is estimated that at least 30% of all genes are
expressed in the brain (Sutcliffe, 1988), thus increasing the probability that
all relevant genes located within D0485 would be detected by this method.
cDNA selection (HF-CSC) was the gene-finding method of choice, in concert
with a complementary EL-CSC experiment and co-association of putative
transcripts with CpG island-associated restriction enzyme sites on the
chromosome. cDNA selection and EL-CSC are based upon the same
principle and the same DNA input resources were employed. The parallel
analysis of the overlapping spectrum of products thus generated was useful
in ensuring a complete survey of brain-expressed genes in the region.
Products unique to both libraries were identified - Family 1 clones were
derived solely from the EL library whereas Products 6 and 7 were derived
from the HF library and gave no positive signals when hybridised onto the EL
library. EL is a more stringent technique than HF, thus more competent in
the recovery of rare cDNA species, but its requirement for intra-exonic
fragments limits the non-recovery of some genuinely coincident fragments.
Since full length cDNAs have not yet been isolated from the products from
either library it is impossible to tell whether both libraries do in fact contain
different fragments of the same genes.
The most significant drawback of the use of cDNA selection methodology
alone was the restriction to isolation of genes expressed in the tissue
chosen, even though the problem was minimised by the use of brain cDNA.
Alternative strategies such as exon trapping, direct screening of cDNA
libraries and extensive sequence analysis are being evaluated for future
gene-finding experiments in the region of the two breakpoints. A survey of
recent literature reveals that cDNA selection techniques are however
frequently the preferred option for finding genes from cloned resources such
269
as YACs. For instance, cDNA selection was recently utilised in the
identification of approximately 50 new genes from chromosome 21 (Tassone
et at, 1995). Also, during the search for genes from the BRCA1 region on
chromosome 17q, cDNA selection was found to be more efficient than direct
library screening or genomic sequencing, by contributing to the isolation of
39 of the 45 candidate gene fragments (Harshman et al, 1995).
Analysis of the HF and EL libraries led to the identification of a new member
of the a-tubulin family, plus several novel cDNA fragments. The exact
number of novel genes represented by these clones is not known, but
mapping data is consistent with at least two and possibly as many as four.
The a-tubulin-related locus maps closest to the translocation breakpoint,
approximately 250-300kb away. It appears not to be associated with a CpG
island, whereas all the other products map to the region of the YAC which
contains three Not I sites. Since 89% of Not I sites occur within a CpG island
(Lindsay and Bird, 1987) this is consistent with the presence of genes in this
region. A set of 4 of the novel cDNA fragments map to within 6.5kb of each
other and within 10kb of a Not I site, a BssH II site and two Eag I sites, which
is highly suggestive that these fragments are derived from the same gene
and that that gene is associated with a CpG island.
Since there were no genes already known to map to the D0485 region, it
was not possible to evaluate the efficiency of the gene finding experiment
with respect to the isolation of known genes as a positive control. The
paucity of identified genes implies that this is a gene-poor region of the
genome. The average density of human genes is five every 100kb, and
hence a total of 65 genes might be expected to map to the 1,3Mb of D0485.
The map position of the novel gene fragments is consistent with the
distribution of Not I sites (all three clustered at the proximal end) and also the
position of the YAC on the boundary between a G band and an R band. The
almost complete coverage of the a-tubulin gene with cDNA fragment clones
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could perhaps be taken as an indicator that the cDNA selection had indeed
been very efficient at recovering genuinely coincident cDNA fragments.
Similarly the ability to connect randomly picked clones into a set of four by
genomic PCR attests to a high efficiency of recovery of cDNA fragments.
The a-tubulin gene was present at a very high frequency in the HF product
library, probably greater than 36%. This would indicate either numerous
copies of the genomic a-tubulin sequence or a highly expressed cDNA
species, or both. Mapping data from D4085 are consistent with only one
copy of the a-tubulin sequence within the YAC, and as such the high
representation of a-tubulin clones in the library is probably due to abundant
a-tubulin cDNA species. All the known a-tubulin genes are sufficiently
conserved in the coding sequence that one genomic copy can hybridise
strongly to cDNAs derived from other family members; this was reflected in
the distribution of foetal brain, keratinocyte and novel a-tubulin cDNAs in the
HF product library. Sequencing of the a-tubulin gene from D0485 itself was
therefore necessary in order to ascertain which, if any, of the CSC clone
sequences was representative of the a-tubulin gene on the YAC. This was
achieved through the sequencing of plasmid subclones of a-tubulin positive
D0485-derived cosmids, and from the sequencing of PCR products from
within the gene. The allele-specificity of the latter was provided by primary
amplification from primers outside the gene sequence itself.
Comparison of the D0485 a-tubulin gene with known a-tubulin gene
sequences in the database revealed that it was most similar to the
keratinocyte a-tubulin gene. Apart from single base changes relative to the
keratinocyte sequence, and short deletions and insertions (including one 7
base pair deletion in the coding sequence), the major feature of the D0485
a-tubulin gene was a lack of introns. This, and the fact that its expression
could not be detected in a variety of human tissues by allele-specific RT-
PCR, suggest that the D0485 a-tubulin gene is, in fact, a processed
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pseudogene. The gene sequence itself is capable of coding for a protein
very similar to that derived from the keratinocyte a-tubulin gene, although it
would be truncated to 80% of its normal length as a result of the change in
reading frame after the seven base pair deletion. It is still formally possible
therefore that this gene is expressed, but in a highly specific manner and not
in the tissues tested.
It is also possible that expression of the D0485 a-tubulin gene is activated or
repressed by the presence of the translocation. Ways in which this could be
tested and reasons to suppose that a-tubulin could be involved in the
aetiology of schizophrenia have already been discussed in Chapter 5.
Three products were probably artefacts of the product library since they did
not hybridise back to D0485. All the other fragments recovered and tested
did map back to D0485, but none gave matches or significant similarities in
the current sequence databases. Sequence analysis allowed them to be
grouped into 5 families, leaving two individual products. Two of the families
and the two individual products were tentatively grouped together, on the
basis of similar hybridisation patterns on mouse and human cDNA and
extremely close genomic locations as revealed by the detailed mapping of a
cosmid. This group of four products is probably associated with a CpG
island. The other three products were linked by long PCR in genomic DNA,
but no cosmid was common to all three.
Sequencing of the genomic and cDNA copies of these fragments
demonstrated an exon/intron structure for two of the products. This is
accepted to be categorical proof that the sequence of interest is derived from
a gene. In most cases the cDNA sequence was significantly different from
the exon genomic sequence (that is, more differences than can be attributed
to sequencing errors). This is consistent with the observation from
hybridisation to total genomic DNA revealed that most of the products were
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present at other loci in the genome, usually in multiple copies relative to the
single D0485 locus.
Preliminary experiments to assess the expression pattern of these cDNA
fragments will now be undertaken, by Northern blot and RT-PCR analysis.
RNA in situ analysis of some of the fragments is also underway, which
should reveal their expression pattern in mouse embryos of various
gestational ages, and possibly provide an indication of their function.
RT-PCR from a permissive tissue using primers derived from the cDNA
fragments could be used to ascertain the total number of genes represented
by the novel cDNA fragments. Sequencing of these products would be a
direct route to obtaining more coding sequence. Alternatively some further
information could be obtained by extending the length of the known cDNA by
5' or 3' rapid amplification of cDNA ends (RACE) (Frohman et al, 1988 and
Loh et al, 1989) and then sequencing the product. Probably the most
efficient way to obtain all the information possible from the coding sequence
of a gene is to screen a full length cDNA library, and then sequence a
positive clone. For this purpose, a full length foetal brain cDNA library has
been obtained from the HGMP resource centre. The sequence could then be
used to investigate the possible involvement of the genes in schizophrenia
and other psychiatric illnesses by screening for mutations in patients.
Assuming that the CSC novel cDNA fragments are proven to correspond to
bona fide genes by extension of their sequence, studies will be undertaken
to determine the function of these genes. This may be partly possible by
assessing homology with known genes at the nucleotide or protein level, and
by analysis of the protein's hydrophobicity profile and domains indicative of
perhaps membrane spanning or DNA binding regions. Use could possibly be
made of the syntenic genomic regions in other species, where similar genes
may be of known function and/or associated with a phenotype.
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Analysis of the encoded proteins themselves may reveal more information
about function. Western blotting can be used to determine the size of the
protein in different tissues, and the size compared with that expected from
analysis of the coding sequence. Immunofluorescence can reveal the
localisation of a protein within a cell, and co-immunoprecipitation the
interaction with other proteins. Protein-protein interactions can also be
detected by the yeast two hybrid system (Fields and Song, 1989).
To gain more knowledge of the function of a gene, an animal model for over
or under expression of the gene may be created. Insertion of or replacement
with mutated version(s) of the gene at one or both chromosomal copies can
reveal phenotypes caused by haploinsufficiency or complete absence of a
functional protein. Alternatively transgenic mice could be made containing
multiple copies of the normal or mutant human gene, perhaps on a YAC. The
presence or absence of an abnormal phenotype in these situations will
reveal whether the gene acts in a dominant, recessive or dominant negative
fashion and the effect of different mutations (point mutations, gross deletions
etcetera) can be tested. Insertion of a reporter gene (for instance (3-
galactosidase) as a fusion construct into the mouse gene or a human or
mouse YAC transgene could be used to follow expression at the single cell
level throughout development. Study of normal and abnormal gene
expression patterns and physiological study of abnormal phenotypes can
lead to an understanding of the function of the gene in the experimental
animal.
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7.2 Concurrent Mapping of the t(1 ;11) Translocation
Breakpoint and Flanking Genomic Regions
During the course of work for this thesis, other members of the Psychiatric
Genetics group have proceeded with the physical mapping and detailed
analysis of the translocation breakpoints on chromosomes 1 and 11. On
chromosome 11, the cosmids subcloned from YAC D0485 were used to
construct a contig across the translocation breakpoint. FISH analysis on
metaphase chromosomes derived from a cell line bearing the der(1) and
der(11) translocation chromosomes ('MAFLI') was used to prove that
individual cosmids spanned the breakpoint on chromosome 11. These were
then subcloned further, and a detailed restriction map of the breakpoint
region constructed from them. In this way, the region containing the
breakpoint was narrowed to a 2.15kb EcoRI & Hind III fragment. This was
proven to contain the breakpoint by FISH analysis on MAFLI and by
hybridisation to the somatic cell hybrid panel. This 2.15kb fragment was then
sequenced. A trinucleotide repeat within this sequence gave a significant
match with an STS mapped to chromosome 1. Although the STS has not
been mapped in more detail, it is possible that homology between the
breakpoint regions of chromosomes 1 and 11 provides the mechanism for
the translocation event. The exact position of the breakpoint was further
narrowed, to within 220bp, by PCR amplification of fragments within the
2.15kb from the somatic cell hybrids containing either the der(1) or the
der(11) chromosomes.
Splinkerette and Vectorette PCR were used as complementary methods to
'walk' across the breakpoint on the der(1) chromosome. For splinkerette
PCR, the somatic cell hybrid containing the der(1) chromosome, digested
with Bgl II and Bel /, was used as the template for splinkerette ligation and
PCR. The sequence specific primer was derived from the sequence of the
2.15kb breakpoint subclone. A 2.7kb product was derived from the Bel I
digested DNA, which is the size expected from restriction enzyme analysis of
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the normal and translocation chromosomes. This will now be sequenced to
locate the exact position of the breakpoint. No attempt has yet been made to
walk across the breakpoint on the der(11) chromosome.
Progress has also been made on the mapping of the chromosome 1
breakpoint, largely by a collaborating group in France (led by Benoit
Arveiler). Several microdissection clones mapped to chromosome 1 were
used to screen YAC libraries, and a YAC contig which spanned the
breakpoint was assembled by marker analysis with microdissection clones,
YAC end clones and published AFM markers. YACs have been proven to
span the translocation breakpoint by FISH. Cosmids across the breakpoint
are now being isolated by the construction of a cosmid library from one of the
breakpoint-spanning YACs and by screening an ICRF chromosome 1-
specific cosmid library (obtained from H. Lehrach) with markers in the
immediate vicinity of the breakpoint. It is hoped that independent physical
mapping and sequencing of the chromosome 1 breakpoint, plus sequence
data gleaned from the breakpoint-spanning splinkerette PCR products will
facilitate an understanding of the effects and possibly the mechanism of the
translocation.
7.3 How near are we to finding a 'schizophrenia gene'?
The detailed physical mapping of both the translocation breakpoints is
almost complete, which will permit exhaustive sequence analysis in the
immediate vicinity of the breakpoint, and identification, or not, of a gene
whose coding sequence is disrupted by the breakpoint. In this, the simplest
case, this gene may be causally associated with mental illness, or the
predisposition to it, in this pedigree.
The DNA sequence already determined from the immediate chromosome 11
breakpoint region, plus the absence of CSC products and CpG islands,
suggests that there is not a disrupted gene on this side of the breakpoint. No
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sequence data is as yet available for the chromosome 1 side of the
breakpoint. A single Not / site has been detected in the 750kb YAC spanning
the chromosome 1 breakpoint, but its exact distance from the breakpoint is
not yet known.
If there is no gene disrupted by the translocation breakpoint on either
chromosome 1 or 11, then a position effect on a more distant gene is
implicated. The cDNA selection search for genes within YAC D0485 has
yielded possible candidates. The nearest gene to the breakpoint, a-tubulin,
has the characteristics of a pseudogene, and despite plausible mechanisms
by which it may still be involved, the studies required to investigate this are
complex and require a great investment of time. Even if the translocation
event was causing aberrant expression of this gene in psychiatric patients,
then the tissue and temporal expression may be so specific as to prohibit
detection. The other genes identified on D0485 are novel and therefore
require a great deal more study before their potential as candidate genes
can be fully assessed, and if necessary discarded.
Further gene finding experiments on chromosome 11 will be carried out, both
cDNA selection on YACs further from the breakpoint, and possibly other
methods applied to D0485, such as sequence analysis extending outwards
from the breakpoint and a computer search for likely coding sequences.
Gene searches will also be carried out on the chromosome 1 side of the
breakpoint, probably beginning with cDNA selection and direct screening of
cDNA libraries with YACs or cosmids close to the breakpoint. Exon trapping
may also be utilised as a non expression-based method.
In addition to positional cloning, a candidate gene approach is also being
employed in the search for genes. The localisation of two a-actinin genes,
ACTN2 and ACTN3, to the same cytogenetic regions as the translocation
breakpoints on chromosome 1 and 11 respectively (Beggs et at, 1992)
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provoked speculation that these genes were affected by the translocation.
Probes for ACTN2 and ACTN3 have been amplified by RT-PCR from human
foetal limb tissue and their exact locations will be mapped relative to the two
translocation breakpoints. For similar reasons as those put forward for a-
tubulin, a-actinin can be viewed as a possible candidate for involvement in
the aetiology of psychiatric illness. The a-actinins are believed to have
diverse cellular functions, probably related to their ability to cross-link actin
filaments (Beggs et al, 1992). Actin filaments are believed to responsible for
the guidance of the growth cone of growing neurons (Sobue, 1993), a
disturbance of which may be responsible for the neuropathology seen in
some schizophrenics. It is interesting to note that dystrophin, which is a
member of the same 'spectrin superfamily' of proteins and is also capable of
binding to actin, has previously been implicated in the aetiology of
schizophrenia.
The recent description of a gene for Alzheimer's disease on chromosome
1q31-42 (Levy-Lahad et al, 1995 a and b, Rogaev et al, 1995) provided a
second candidate gene in the region. Although the neuropathology seen in
Alzheimer's disease is quite distinct from that seen in schizophrenia, the two
disorders quite frequently co-occur in the same families. Although the YAC
containing this gene has been estimated from linkage maps of chromosome
1 to be between 1 and 3 Mb away from the translocation breakpoint, the
possibility of a long range position effect cannot be dismissed. A fragment
from the gene will be amplified by RT-PCR from somatic cell hybrids
containing the der(1) and der(11) chromosomes to investigate whether
expression of the gene is affected by the translocation. Mutation detection
will be undertaken to assess whether mutated forms of the gene are
associated with presence of the t(1 ;11) translocation.
A search for genes by several methods moving progressively outward from
the breakpoint regions of chromosomes 1 and 11, plus evaluation of
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candidate genes as they arise, should lead to the identification of a gene or
genes which are involved in the aetiology of mental illness in the t(1; 11)
pedigree. This however is not an end-point. The relevant gene must be firstly
be screened for mutations in other, unrelated schizophrenics. If no mutations
are found, as is not unexpected for an aetiologically heterogeneous disorder,
then mutation analysis in these other individuals must be performed with
structurally or functionally-related genes. Also, it is unlikely that a single gene
is responsible in all cases for the complex and varying phenotype of
schizophrenia, so an understanding of the influence of modifying or other
unrelated genes and the effect of the environment must be sought.
Within the last few years, interest in the field of psychiatric genetics as a
whole has grown tremendously. New sophisticated methods of linkage
analysis are more adept at detecting genes involved in complex disorders,
and the detailed emerging maps of the human genome make positional
cloning a simpler task. Progress in these areas is invaluable in resolving the
stalemate that had existed in the field ever since the basic principles of the
psychiatric genetics were described from family, twin and adoption studies.
Genetic analysis of the dementias, notably Alzheimer's disease, is at the
forefront of progress in psychiatric genetics, with mutations in several single
genes shown to be causative of the disorder and alleles of the apolipoprotein
E gene increasing (e4) or decreasing (e2) risk (Selkoe, 1995). This success is
partly due to the clear neuropathological features associated with all cases of
Alzheimer's disease, enabling objective scoring of the affected or unaffected
status. In this respect, robust quantitative or qualitative markers of
susceptibility status must be sought for the psychoses, in order that they may
ultimately replace the current diagnosis based on the psychological profile
alone.
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The positional cloning studies around the breakpoints of the balanced
translocation described here may yield the description of a gene causally
associated with schizophrenia and other major mental illness, albeit in only
one family. However a detailed understanding of the multiple and interacting
genetic and environmental effects which contribute to the disorder in different
people is still placed very firmly in the future.
280
REFERENCES
Abrams R. and Taylor M.A. (1983) The genetics of schizophrenia: a
reassessment using modern criteria. Am. J. Psychiatry, 140, 171-175.
Adams M.D., Kelley J.M., Gocayne J.D., Dubnick M., Polymeropoulos M.H.,
Xiao H., Merril C.R., Wu A., Olde B., Moreno R.F., Kerlavage A.R., McCombie
W.R. and Venter J.C. (1991) Complementary DNA sequencing: expressed
sequence tags and human genome project. Science, 252, 1651-1656.
Adler L.B., Pachtman E., Franks M., Pecevich N., Waldo C. and Freedman R.
(1982) Neurophysiological evidence for a defect in neuronal mechanisms
involved in sensory gating in schizophrenia. Biol. Psychiatry, 17, 639-654.
Altschul S.F., Gish W., Miller W., Myers E.M. and Lipman D.J. (1990) Basic local
alignment search tool. J. Mol. Biol. 215, 403-410.
Anand R., Riley J.H., Butler R., Smith J.C. and Markham A.F. (1990) A 3.5
genome equivalent multi access YAC library: construction, characterisation and
storage. Nucl. Acids. Res. 19, 1951-1956.
Andreasen N.C. and Olsen S. (1982) Negative versus positive schizophrenia.
Arch. Gen. Psychiatry, 39, 789-794.
Arevalo M.A., Nieto J.M., Andreu D. and Andreu J.M. (1990) Tubulin assembly
probed with antibodies to synthetic peptides. J. Mol. Biol., 214, 105-129.
Arnold C. and Hodgson I.J. (1991) Vectorette PCR: a novel approach to
genomic walking. PCR Methods and Applications, 1, 39-42.
281
Arnold S.E., Lee V.M., Gur R.E. and Trojanowski J.Q. (1991) Abnormal
expression of two microtubule-associated proteins (MAP2 and MAP5) in specific
subfields of the hippocampal formation in schizophrenia. Proc. Natl. Acad. Sci.
USA, 88, 10850-10854.
Arveiler B. and Porteous D.J. (1991) Amplification of end fragments of YAC
recombinants by inverse-polymerase chain reaction. Technique, 3, 24-28.
Aschauer H.N., Aschauer-Treiber G., Isenberg K.E., Todd R.D., Knesvich M.A.,
Garver D.L., Reich T. and Cloninger C.R. (1990) No evidence for linkage
between chromosome 5 markers and schizophrenia. Hum. Hered. 40, 109-115.
Aschauer H.N., Fischer G., Isenberg K.E., Meszaros K., Willinger U., Todd R.D.,
Beran H., Strobl R., Lang M., Fuchs K., Sieghart W., Reich T. and Cloninger
C.R. (1993) No proof of linkage between schizophrenia-related disorders
including schizophrenia and chromosome 2q21 region. Eur. Arch. Psychiatry
Clin. Neurosci. 243, 193-198.
Asherson P., Mant R., Taylor C., Sargeant M., Collier D., Clements A., Nanko
S., Whatley S., Gill M., McGuffin P. and Owen M.(1993) Failure to find linkage
between schizophrenia and genetic markers on chromosome 21. Am. J. Med.
Genet. 48, 161-165.
Asherson P., Parfitt E., Sargeant M., Tidmarsh S., Buckland P., Taylor C.,
Clements A., Gill M., McGuffin P. and Owen M. (1992) No evidence for a
pseudoautosomal locus for schizophrenia. Linkage analysis of multiply affected
families. Br. J. Psychiatry, 161, 63-68.
282
Asherson P., Walsh C., Williams J., Sargeant M., Taylor C., Clements A., Gill
M., Owen M. and McGuffin P. (1994) Imprinting and anticipation. Are they
relevant to genetic studies of schizophrenia? Br. J. Psychiatry, 164, 619-624.
Aslanidis C. and de Jong P.J. (1991) Coincidence cloning of Alu-PCR products.
Proc. Natl. Acad .Sci. USA, 88, 6765-6769
Audebert S., Koulakoff A., Berwald-Netter Y., Gros F., Denoulet P. and Edde B.
(1994) Developmental regulation of polyglutamated a- and b-tubulin in mouse
brain neurons. J. Cell Science, 107, 2313-2322.
Axelsson R. and Wahlstrom A. (1984) Chromosome aberrations in patients with
paranoid psychosis. Hereditas, 100, 29-31.
Bachneff S.A. (1991) Positron emission tomography and magnetic resonance
imaging: a review and a local circuit neurons hypo(dys)function hypothesis of
schizophrenia. Biol. Psychiatry, 30, 857-886.
Bailey D.M.D., Carter N.P., de Vos D., Leversha M.A., Perryman M.T. and
Ferguson-Smith M.A. (1993) Coincidence painting: a rapid method for cloning
region specific DNA sequences. Nuci Acids Res. 21, 5117-5123.
Baron M. (1976) Albinism and schizophreniform psychosis: a pedigree study.
Am. J. Psychiatry, 133, 1070-1073.
Baron M. (1977) Linkage between an X-chromosome marker (deutan color
blindness) and bipolar affective illness. Occurrence in the family of a lithium
carbonate-responsive schizo-affective proband. Arch. Gen. Psychiatry, 34, 721-
725.
283
Baron M., Endicott J. and Ott J. (1990) Genetic linkage in mental illness.
Limitations and prospects. Br. J. Psychiatry, 157, 645-655.
Baron M. and Gruen R.S. (1991) Schizophrenia and affective disorder: are they
genetically linked? Br. J. Psychiatry, 159, 267-270.
Barr C.L., Kennedy J.L., Lichter J.B., Van Tol H.H., Wetterberg L., Livak K.J.
and Kidd K.K. (1993) Alleles at the dopamine D4 receptor locus do not
contribute to the genetic susceptibility to schizophrenia in a large Swedish
kindred. Am. J. Med. Genet. 48, 218-222.
Barr C.L., Kennedy J.L., Pakstis A.J., Castiglione C.M., Kidd J.R., Wetterberg L.
and Kidd K.K. (1994a) Linkage study of a susceptibility locus for schizophrenia
in the pseudoautosomal region. Schizophr. Bull. 20, 277-286.
Barr C.L., Kennedy J.L., Pakstis A.J., Wetterberg L., Sjogren B., Bierut L.,
Wadelius C., Wahlstrom J., Martinsson T., Giuffra L., Gelernter J., Hallmayer J.,
Moises H.W., Kurth J., Cavalli-Sforza L.L. and Kidd K.K. (1994b) Progress in a
genome scan for linkage in schizophrenia in a large Swedish kindred. Am. J.
Med. Genet. 54, 51-58.
Bassett A.S. (1991) Linkage analysis of schizophrenia: challenges and promise.
Social Biology, 38(3-4), 189-196.
Bassett A.S. and Honer W.G. (1994) Evidence for anticipation in schizophrenia.
Am. J. Hum. Genet. 54, 864-870.
Bassett A.S., McGillivray B.C., Jones B.D. and Pantzar J.T. (1988) Partial
trisomy of chromosome 5 cosegregating with schizophrenia. Lancet, i, 799-801.
284
Bebbington P. and Kuipers L. (1994) The clinical utility of expressed emotion in
schizophrenia. Acta Psychiatr. Scand. Suppl. 382, 46-53.
Beckwith J.P., Stefanis N.C., McLaughlin D.P. and Kerwin R.W. (1995) The
expression of NMDA receptor subunits in schizophrenia post-mortem
hippocampus. Schizophr. Res. 15(1-2), 54
Beggs A.H., Byers T.J., Knoll J.H.M., Boyce F.M., Bruns G.A.P. and Kunkel
L.M. (1992) Cloning and characterisation of two human skeletal muscle alpha-
actinin genes located on chromosomes one and eleven. J. Biol. Chem. 267,
9281-9288.
Beggs A.H., Hoffman E.P., Snyder J.R., Arahata K., Specht L., Shapiro F.,
Angelini C., Sugita H. and Kunkel L.M. (1991) Exploring the molecular basis for
variability among patients with Becker muscular dystrophy: dystrophin gene and
protein studies. Am. J. Hum. Genet. 49, 54-67.
Beratis S., Gabriel J. and Hoidas S. (1994) Age at onset in subtypes of
schizophrenic disorders. Schizophr. Bull. 20, 287-296.
Berry R., Stevens T.J., Walter N.A.R., Wilcox A.S., Rubano T., Hopkins J.A.,
Weber J., Goold R., Soares M.B. and Sikela J.M. (1995) Gene-based
sequence-tagged-sites (STSs) as the basis for a human gene map. Nat. Genet.,
10, 415-423.
Bird A.P. (1987) CpG islands as gene markers in the vertebrate nucleus.
Trends. Genet. 3(12), 342-347.
Bleich A., Brown S., Kahn R. and van Praag H.M. (1988) The role of serotonin
285
in schizophrenia. Schizophr. Bull. 14(2), 297-315.
Blennow G. and McNeil T.F. (1991) Neurological deviations in newborns at
psychiatric high risk. Acta Psychiatr. Scand. 84, 179-184.
Boguski M.S., Lowe T.M. and Tolstoshev C.M. (1993) dbEST-database for
"expressed sequence tags". Nat. Genet. 4, 332-333.
Boguski M.S. and Schuler G.D. (1995) ESTablishing a human transcript map.
Nat. Genet. 10, 369-371.
Bonaldo M.F. (1992) Tubulin alpha-like 2 (TUBA2).SCW 13.
Boucher D., Larcher J-C., Gros F. and Denoulet P. (1994) Polyglutamylation of
tubulin as a progressive regulator of In vitro interactions between the
microtubule-associated protein tau and tubulin. Biochemistry, 33, 12471-12477.
Bracha H.S., Torrey E.F., Bigelow L.B., Lohr J.B. and Linington B.B. (1991)
Subtle signs of prenatal maldevelopment of the hand ectoderm in
schizophrenia: a preliminary monozygotic twin study. Biol. Psychiatry, 30, 719-
725.
Brookes A.J. (1994) Identifying and directly purifying transcribed elements. In
Hochgeschwender U. and Gardiner K. (eds.), Identification of Transcribed
Sequences. Plenum Press, New York, pp. 111-121.
Brookes A.J., Slorach E.M., Morrison K.E., Qureshi S.J., Blake D., Davies K.
and Porteous D.J. (1994) Cloning the shared components of complex DNA
resources. Hum. Mol. Gen. 3, 2011-2017.
286
Brown P. (1995) Rescuing minds from disease and decay. New Scientist, 14th
Nov (suppl. ), 2-8.
Buckler A.J., Chang D.D., Graw S.L., Brook J.D., Haber D.A., Sharp P.A. and
Housman D.E. (1991) Exon amplification: a strategy to isolate mammalian
genes based on RNA splicing. Proc. Natl. Acad. Sci. USA, 88, 4005-4009.
Burke D.T., Carle G.F. and Olson M.V. (1987) Cloning of large segments of
exogenous DNA into yeast by means of artificial chromosome vectors. Science,
236, 806-812.
Butler P.D., Susser E.S., Brown A.S., Kaufman C.A. and Gorman J.M. (1994)
Prenatal nutritional deprivation as a risk factor in schizophrenia: preclinical
evidence. Neuropsychopharmacol. 11(4), 227-235.
Cambray-Deakin M.A. and Burgoyne R.D. (1987) Post-translational
modifications of a-tubulin:acetylated and detyrosinated forms in axons of rat
cerebellum. J. Cell Biology, 104, 1569-1574.
Campion D., d'Amato T., Bastard C., Laurent C., Guedj F., Jay M., Dollfus S.,
Thibaut F., Petit M., Gorwood P., Babron M.C., Waksman G., Martinez M. and
Mallet J. (1994) Genetic study of dopamine D1, D2, and D4 receptors in
schizophrenia. Psychiatry Res. 51, 215-230.
Cannon T.D. (1991) Genetics and perinatal sources and structural brain
abnormalities in schizophrenia. In Mednick S.A., Cannon T.D., Barr C.E. and
Lyon M. (eds.), Fetal neural development and adult schizophrenia. Cambridge
University Press, New York, pp. 174-178.
287
Cannon T.D. and Marco E. (1994) Structural brain abnormalities as indicators of
vulnerability to schizophrenia. Schizophr. Bull. 20, 89-102.
Cantor-Graae E., McNeil T.F., Sjostrom K., Nordstrom L.G. and Rosenlund T.
(1994) Obstetric complications and their relationship to other etiological risk
factors in schizophrenia. A case-control study. J. Nerv. Merit. Dis. 182, 645-650.
Carter M. and Watts C.A.H. (1971) Possible biological advantages among
schizophrenics' relatives. Br. J. Psychiatry, 118, 453-460.
Castle D.J. and Murray R.M. (1991) The neurodevelopmental basis of sex
differences in schizophrenia. Psychol. Med. 21, 565-575.
Chou Q., Russell M., Birch D.E., Raymond J. and Bloch W. (1992) Prevention of
PCR mis-priming and primer dimerization improves low-copy-number
amplifications. Nucl. Acids Res. 20, 1717-1723.
Chumakov I., Rigault P., Guillou S., Ougen P., Billaut A., Guasconi G., Gervy
P., LeGall I., Soularue P., Grinas L., Bougueleret L., Bellane-Chantelot C.,
Lacroix B., Barillot E., Gesnouin P., Pook S., Vaysseix G., Frelat G., Schmitz A.,
Sambucy J-L., Bosch A., Estivil X., Weissenbach J., Vignal A., Riethman H.,
Cox D., Patterson D., Gardiner K., Hattori M., Sakaki Y., Ichikawa H., Ohki M.,
Le Paslier D., Heilig R., Antonarakis S. and Cohen D. (1992) Continuum of
overlapping clones spanning the entire human chromosome 21 q. Nature, 359,
380-387.
Clarke D.J. and Buckley M.E. (1989) Familial association of albinism and
schizophrenia. Br. J. Psychiatry, 155, 551-553.
288
Claverie J. (1994) A streamlined random sequencing strategy for finding coding
exons. Genomics, 23, 575-581.
Cleghorn J.M., Zipursky R.B. and List S.J. (1991) Structural and functional brain
imaging in schizophrenia. J. Psychiatry Neurosci. 16, 53-74.
Cleveland D.W. and Sullivan K.F. (1985) Molecular biology and genetics of
tubulin. Annu. Rev. Biochem. 54, 331-365.
Cloninger C.R. (1994) Turning point in the design of linkage studies of
schizophrenia. Am. J. Med. Genet. 54, 83-92.
Cohen D., Chumakov I. and Weissenbach J. (1993) A first-generation physical
map of the human genome. Nature, 366, 698-701.
Collinge J., DeLisi L.E., Boccio A., Johnstone E.C., Lane A., Larkin C., Leach
M., Lofthouse R., Owen F., Poulter M., Shah T., Walsh C. and Crow T.J. (1991)
Evidence for a pseudo-autosomal locus for schizophrenia using the method of
affected sib pairs. Br. J. Psychiatry, 158, 624-629.
Collins F.S. (1992) Positional cloning: let's not call it reverse anymore [news],
Nat. Genet. 1, 3-6.
Collins J. and Hohn B. (1978) Cosmids: a type of plasmid gene cloning vector
that is packageable in vitro in bacteriophage lambda heads. Proc. Natl. Acad.
Sci. USA, 75, 4242-4246.
Coon H., Hoff M., Holik J., DeLisi L., Crowe T., Freedman R., Shields G., Boccio
A.M., Lerman M., Gershon E.S., Gejman P.V., Leppert M. and Byerly W. (1993)
289
C to T nucleotide substitution on codon 713 of amyloid precursor protein gene
not found in 86 unrelated schizophrenics from multiplex families. Am. J. Med.
Genet. 48, 36-39.
Coon H., Holik J., Hoff M., Reimherr F., Wender P., Myles Worsley M., Waldo
M., Freedman R. and Byerley W. (1994) Analysis of chromosome 22 markers in
nine schizophrenia pedigrees. Am. J. Med. Genet. 54, 72-79.
Coon H., Jensen S., Hoff M., Holik J., Plaetke R., Reimherr F., Wender P.,
Leppert M. and Byerley W. (1993) A genome-wide search for genes
predisposing to manic-depression, assuming autosomal dominant inheritance.
Am. J. Hum. Genet. 52, 1234-1249.
Coon H., Jensen S., Holik J., Hoff M., Myles Worsley M., Reimherr F., Wender
P., Waldo M., Freedman R., Leppert M. and Byerley W. (1994) Genomic scan
for genes predisposing to schizophrenia. Am. J. Med. Genet. 54, 59-71.
Coon H., Sobell J., Heston L., Sommer S., Hoff M., Holik J., Umar F., Robertson
M., Reimherr F., Wender P., Vest K., Myles-Worsley M., Gershon E.S., DeLisi
L.E., Shields G., Dale P.W., Polloi A., Waldo M., Leonard S., Sikela J.,
Freedman R. and Byerley W. (1994) Search for mutations in the beta 1 GABAA
receptor subunit gene in patients with schizophrenia. Am. J. Med. Genet. 54,
12-20.
Cowan N.J., Dobner P.R., Fuchs E.V. and Cleveland D.W. (1983) Expression of
human a-tubulin genes: interspecies conservation of 3' untranslated regions.
Mot. Cell. Biol. 3, 1738-1745.
Crampton J.M., Davies K.E. and Knapp T.F. (1981) The occurrence of families
290
of repetitive sequences in a library of cloned cDNA torn human lymphocytes.
Nucl. Acids Res. 9, 3821-3834.
Crocq M.A., Mant R., Asherson P., Williams J., Hode Y., Mayerova A., Collier
D., Lannfelt L., Sokoloff P., Gill M., Macher J.P., McGuffin P. and Owen M.J.
(1992) Association between schizophrenia and homozygosity at the dopamine
D3 receptor gene. J. Med. Genet. 29, 858-860.
Cross S.H., Charlton J.A., Nan X. and Bird A.P. (1994) Purification of CpG
islands using a methylated DNA binding column. Nat. Genet. 6, 236-244.
Crow T.J. (1980a) Molecular pathology of schizophrenia: more than one disease
process. BMJ, 280, 66-68.
Crow T.J. (1980b) Temporal lobe assymetries as the key to the etiology of
schizophrenia. Schizophr. Bull. 16(3), 433-443.
Crow T.J., Ball J., Bloom S.R., Brown R., Bruton C.J., Colter N., Frith C.D.,
Johnstone E.C., Owens D.G.C. and Roberts G.W. (1989) Schizophrenia as an
anomaly of development of cerebral assymetry. Arch. Gen. Psychiatry, 46,
1145-1150.
Crow T.J., DeLisi L.E., Lofthouse R., Poulter M., Lehner T., Bass N., Shah T.,
Walsh C., Boccio Smith A., Shields G. and Ott J. (1994) An examination of
linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal
region (Xp22.3). Br. J. Psychiatry, 164, 159-164.
Crow T.J. and Done D.J. (1992) Prenatal exposure to influenza does not cause
schizophrenia. Br. J. Psychiatry, 161, 390-393.
291
Crow T.J., Poulter M., Lofthouse R., Chen G., Shah T., Bass N., Morganti C.,
Vita A., Smith C., Boccio Smith A., Shields G. and DeLisi L.E. (1993) Male
siblings with schizophrenia share alleles at the androgen receptor above chance
expectation. Am. J. Med. Genet. 48, 159-160.
Crowe R.R., Black D.W., Wesner R., Andreasen N.C., Cookman A. and Roby J.
(1991) Lack of linkage to chromosome 5q 11 -q 13 markers in six schizophrenia
pedigrees. Arch. Gen. Psychiatry, 48, 357-361.
Cuesta M.J. and Peralta V. (1994) Lack of insight in schizophrenia. Schizophr.
Bull. 20(2), 359-366.
d'Amato T., Campion D., Gorwood P., Jay M., Sabate O., Petit C., Abbar M.,
Malafosse A., Leboyer M., Hillaire D., Clerget-Darpoux F., Feingold J.,
Waksman G. and Mallet J. (1992) Evidence for a pseudoautosomal locus for
schizophrenia. II: Replication of a non-random segregation of alleles at the
DXYS14 locus. Br. J. Psychiatry, 161, 59-62.
D'Arcangelo G., Miao G.G., Chen S.C., Soares H.D., Morgan J.I. and Curran T.
(1995) A protein related to extracellular matrix proteins deleted in the mouse
mutant reeler. Nature, 374, 719-723.
Dausset J., Ougen P., Abderrahim H., Billault A., Sambucy J.L., Cohen D. and
Le Paslier D. (1992) The CEPH YAC library. Behring. Inst. Mitt. 13-20.
Davies T. (1994) Psychosocial factors and relapse of schizophrenia. BMJ. 309,
353-354.
292
Davis K.L. (1991) Dopamine in schizophrenia: a review and reconceptualization.
Am. J. Psychiatry, 148, 1474-1486.
Davison M.D., Baron M.D., Critchley D.R. and Wootton J.C. (1989) Structural
analysis of homologous repeated domains in alpha-actinin and spectrin. Int. J.
Biol. Macromol. 11, 81-90.
Dawson E.B., Moore T.D. and McGanity W.J. (1970) The mathematical
relationship of drinking water lithium and rainfall to mental hospital admission.
Diseases of the Nervous System, 12, 811-820.
deLeon J., Dadvand M., Canuso C., White A.O., Stanilla J.K. and Simpson G.M.
(1995) Schizophrenia and smoking: an epidemiological survey in a state
hospital. Am. J. Psychiatry, 152(3), 453-455.
DeLisi L.E. (1992) The significance of age of onset for schizophrenia.
Schizophr. Bull. 18, 209-215.
DeLisi L.E., Devoto M., Lofthouse R., Poulter M., Smith A., Shields G., Bass N.,
Chen G., Vita A., Morganti C., Ott J. and Crow T.J. (1994) Search for linkage to
schizophrenia on the X and Y chromosomes. Am. J. Med. Genet. 54, 113-121.
Detera-Wadleigh S.D., Berettini W.H., Goldin L.R., Boorman D., Anderson S.
and Gershon E. (1987) Close linkage of the c-Harvey-ras-1 and the insulin gene
to affective disorder is ruled out in three North American pedigrees. Nature, 325,
806-808.
Detera-Wadleigh S.D., Goldin S.R., Sherrington R., Encio I., Miguel C., de
Berrettini W., Gurling H. and Gershon E.S. (1989) Exclusion of linkage to 5q 11-
293
13 in families with schizophrenia and other psychiatric disorders. Nature, 340,
391-393.
Devereux J., Haeberli P. and Smithies O. (1984) A comprehensive set of
sequence analysis programs for the VAX. Nucl. Acids Res. 12, 387-395.
Devon R.S. and Brookes A.J. (1996) Coincidence cloning: taking the
coincidences out of genome analysis. Molecular Biotechnology, in press.
Devon R.S., Porteous D.J. and Brookes A.J. (1995) Splinkerettes - improved
vectorettes for greater efficiency in PCR walking. Nucl. Acids Res. 23, 1644-
1645.
Dominguez O. and Lopez-Larrea C. (1994) Gene walking by unpredictably
primed PCR. Nucl. Acids Res. 22, 3247-3248.
Don R.H., Cox P.T., Wainwright B.J., Baker K. and Mattick J.S. (1991)
"Touchdown" PCR to circumvent spurious priming during gene amplification.
Nucl. Acids Res. 19, 4008
Donaldson J. (1987) The physiopathologic significance of manganese in the
brain: its relation to schizophrenia and neurodegenerative disorders.
Neurotoxicology, 8, 457-462.
Done D.J., Crow T.J., Johnstone E.C. and Sacker A. (1994) Childhood
antecedents of schizophrenia and affective illness: social adjustment at ages 7
and 11. BMJ. 309, 699-703.
Douglass A.B., Shipley J.E., Haines R.F., Scholten R.C., Dudley E. and Tapp A.
294
(1993) Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol. Psychiatry, 34,
773-780.
Drmanac R., Petrovic N., Glisin V. and Crkvenjakov R. (1986) A calculation of
fragments lengths obtainable from human DNA with 78 restriction enzymes: an
aid for cloning and mapping. Nucl. Acids Res. 14, 4691-4692.
Duyk G.M., Kim S., Myers R.M. and Cox D.R. (1990) Exon trapping: a genetic
screen to identify candidate transcribed sequences in cloned mammalian
genomic DNA. Proc. Natl. Acad. Sci. USA, 87, 8995-8999.
Eaton W.W. (1991) Update on the epidemiology of schizophrenia. Epidemiol.
Rev. 13, 320-328.
Egeland J.A., Gerhard D.S., Pauls D.L., Sussex J.N., Kidd K.K., Allen C.R.,
Hostetter A.M. and Housman D.E. (1987) Bipolar affective disorders linked to
DNA markers on chromosome 11. Nature, 325, 783-787.
Elvin P., Slynn G., Black D., Graham A., Butler R., Riley J., Anand R. and
Markham A.F. (1990) Isolation of cDNA clones using yeast artificial
chromosome probes. Nucl. Acids Res. 18, 3913-3917.
Erlenmeyer-Kimling L. and Paradowski W. (1966) Selection and Schizophrenia.
The American Naturalist, 100(916), 651-665.
Erlenmeyer-Kimling L., Rainer J.D. and Kaliman F.J. (1966) Current
reproductive trends in schizophrenia. In Hoch P. and Zubin J. (eds.),
Psychopathology of schizophrenia. Grune and Stratton, New York, pp. 252-276.
295
Evans G.A., Lewis K. and Rothenburg B.E. (1989) High efficiency vectors for
cosmid microcloning and genomic analysis. Gene, 79, 9-20.
Evans K.L., Brown J., Shibasaki Y., Devon R.S., He L., Arveiler B., Christie S.,
Maule J.C., Baillie D., Slorach E.M., Anderson S.M., Gosden J.R., Petit J.,
Weith A., Gosden C.M., Blackwood D.H.R., St.Clair D.M., Muir W.M., Brookes
A.J. and Porteous D.J. (1995) A Contiguous Clone Map over 3Mb on the Long
Arm of Chromosome 11 across a Balanced Translocation Associated with
Schizophrenia. Genomics, 28(3), 420-428.
Fantes J., Redeker B., Breen M., Boyle S., Brown J., Fletcher J., Jones S.,
Bickmore W., Fukushima Y., Mannens M., Danes S., van Heyningen V. and
Hanson I. (1995) Aniridia-associated cytogenetic rearrangements suggest that a
position effect may cause the mutant phenotype. Hum. Mol. Gen. 4(3), 415-422.
Faraone S.V. and Tsuang M.T. (1985) Quantitative models of the genetic
transmission of schizophrenia. Psychological Bulletin, 98(1), 41-66.
Feinberg A.P. and Vogelstein A. (1983) A technique for radiolabelling DNA
restriction fragments to high specific activity. Anal. Biochem. 132, 6-13.
Feinberg A.P. and Vogelstein A. (1984) A technique for radiolabelling DNA
fragments to high specific activity. Anal. Biochem. 137, 266-267.
Fields S. and Song O. (1989) A novel genetic system to detect protein-protein
interactions. Nature, 340, 245-246.
Fischer M. (1971) Psychosis in the offspring of schizophrenia monozygotic twins
and their normal co-twins. Br. J. Psychiatry, 118, 43-52.
296
Fischer M., Harvald B. and Hauge M. (1969) A Danish twin study of
schizophrenia. Br. J. Psychiatry, 115, 981-990.
Fletcher J.M., Evans K.L., Baillie D., Byrd P., Planratty D., Leach S., Julier C.,
Gosden J.R., Muir W., Porteous D.J., St.Clair D. and van Heyningen V. (1993)
Schizophrenia-associated chromosome 11q21 translocation: identification of
flanking markers and development of chromosome 11 q fragment hybrids as
cloning and mapping resources. Am. J. Hum. Genet. 52, 478-490.
Foster H.D. (1988) The geography of schizophrenia: possible links with
selenium and calcium deficiencies, inadequate exposure to sunlight and
industrialisation. J. OrthomolecularMedicine, 3, 135-140.
Frankenburg F.R. (1994) History of the development of antipsychotic
medication. Psych. Clin. North Am. 17(3), 531-540.
Freeman H. (1994) Schizophrenia and city residence. Br. J. Psychiatry Suppi.
39-50.
Frohman M.A., Dush M.K. and Martin G.R. (1988) Rapid production of full-
length cDNAs from rare transcripts: amplification using a single gene-specific
oligonucletide primer. Proc. Natl. Acad. Sci. USA, 85, 8998-9002.
Fukuda R., Hattori M., Sasaki T., Kazamatsuri H., Kuwata S., Shibata Y. and
Nanko S. (1993) No evidence for a point mutation at codon 713 and 717 of
amyloid precursor protein gene in Japanese schizophrenics. Jpn. J. Hum.
Genet. 38, 407-411.
297
Fulker D.W., Cherny S.S. and Cardon L.R. (1995) Multipoint interval mapping of
quantitative trait loci, using sib pairs. Am. J. Hum. Genet. 56, 1224-1233.
Gallant D.M. (1990) Diagnosis of the schizophrenic disorders. Psychiatr. Med. 8,
21-40.
Gattaz W.F., Hubner C.V., Nevalainen T.J., Thuren T. and Kinnunen P.K.
(1990) Increased serum phospholipase A2 activity in schizophrenia: a
replication study. Biol. Psychiatry, 28, 495-501.
Gatti R.A., Shaked R., Wei S., Mohandas T.K. and Salser W. (1987) Biallelic
DNA polymorphism of an alpha-tubulin gene family member on chromosome 12
(TUBA/Mspl/2.2;2.0kb). Nucl. Acids Res. 15, 8119
Genest P., Dumas L. and Genest F.B. (1976) Translocation chromosomique
t(2;18)(q21 ;q23) chez un individu schizophrenie et sa fille. Union Med. Can.
105, 1676-1681.
Gerhard D.S., Dobner P.R. and Bruns G. (1985) Testis specific alpha tubulin is
on chromosome 2q. Cytogenet. Cell. Genet. 40, 639-640.
Gershon E.S. and Rieder R.O. (1992) Major disorders of mind and brain. Sci.
Am. 267, 126-133.
Ghosh S., Palmer S.M., Rodrigues N.R., Cordell H.J., Hearne C.M., Cornall
R.J., Prins J.B., McShane P., Lathrop G.M., Peterson L.B., Wicker L.S. and
Todd J.A. (1993) Polygenic control of autoimmune diabetes in nonobese
diabetic mice. Nat. Genet. 4, 404-409.
298
Gill M., McGuffin P., Parfitt E., Mant R., Asherson P., Collier D., Vallada H.,
Powell J., Shaikh S., Taylor C., Sargeant M., Clements A., Nanko S., Takazawa
N., Llewellyn D., Pilowsky L., Brush Y., Williams J., Whatley S., Murray R. and
Owen M. (1993) A linkage study of schizophrenia with DNA markers from the
long arm of chromosome 11. Psychol. Med. 23, 27-44.
Goate A., Chartier Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L.,
Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K.,
Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rosor M.,
Owen M. and Hardy J. (1991) Segregation of a missense mutation in the
amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349,
704-706.
Goodman A.B. (1994) A family history study of schizophrenia spectrum
disorders suggests new candidate genes in schizophrenia and autism.
Psychiatr. Q. 65, 287-297.
Goodman A.B. (1995) Chromosomal locations and modes of action of genes of
the retinoid (vitamin A) system support their involvement in the etiology of
schizophrenia. Am. J. Med. Gen. 60, 335-348.
Gorwood P., Leboyer M., d'Amato T., Jay M., Campion D., Hillaire D., Mallet J.
and Feingold J. (1992) Evidence for a pseudoautosomal locus for
schizophrenia. I: A replication study using phenotype analysis. Br. J. Psychiatry,
161, 55-58.
Goss S.J. and Harris H. (1975) New method for mapping genes in human
chromosomes. Nature, 225, 680-684.
299
Gottesman I.I. and Shields J. (1982) Schizophrenia: The Epigenetic Puzzle.
Cambridge University Press, New York.
Grandy D.K., Narchionni M.A., Makam H., Stotko R.E., Alfano M., Frothingham
L., Fischer J.B., Burke-Howie K.J., Bunzow J.R., Serrer A.C. and Civelli O.
(1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc.
Natl. Acad. Sci. USA, 86, 9762-9766.
Gyapay G., Morissette J., Vignal A., Dib C., Fizames C., Millasseau P., Marc S.,
Bernardi G., Lathrop M. and Weissenbach J. (1994) The 1993-94 Genethon
human genetic linkage map. Nat. Genet. 7, 246-339.
Hale T. (1993) Will the new antipsychotics improve the treatment of
schizophrenia? BMJ. 307, 749-750.
Hall J.L. and Cowan N.J. (1985) Structural features and restricted expression of
a human a-tubulin gene. Nucl. Acids Res. 13, 207-223.
Hallmayer J., Kennedy J.L., Wetterberg L., Sjogren B., Kidd K.K. and Cavalli
Sforza L.L. (1992) Exclusion of linkage between the serotonin2 receptor and
schizophrenia in a large Swedish kindred. Arch. Gen. Psychiatry, 49, 216-219.
Hanson I.M., Poutska A. and Trowsdale J. (1991) New genes in the class II
region of the human major histocompatibility complex. Genomics, 10, 412-424.
Harrison G. and Mason P. (1993) Schizophrenia-falling incidence and better
outcome? Br. J. Psychiatry, 163, 535-541.
300
Harshman K., Bell R., Rosenthal J., Katcher H., Miki Y., Swenson J., Gholami
Z., Frye C., Ding W., Dayananth P., Eddington K., Norris F.H., Bristow P.K.,
Phelps R., Hattier T., Stone S., Shaffer D., Bayer S., Flussey C., Tran T.,
Richardson K., Dehoff B., Lai M., Rosteck P.R., Skolnick M.H., Shattuck-Eidens
D. and Kamb A. (1995) Comparison of the positional cloning methods used to
isolate the BRCA1 gene. Hum. Mol. Gen. 4, 1259-1266.
Hearne C.M., Ghosh S. and Todd J.A. (1992) Microsatellites for linkage analysis
of genetic traits. Trends. Genet. 8, 288-294.
Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C. and Oepen G. (1994)
One hundred years of schizophrenia: a meta-analysis of the outcome literature.
Am. J. Psychiatry, 151, 1409-1416.
Hemmings G. (1990) Causes of schizophrenia. Nutr. Health, 7, 11-19.
Heston L.L. (1966) Psychiatric disorders in foster home reared children of
schizophrenic mothers. Br. J. Psychiatry, 112, 819-825.
Hodge S.E. (1994) What association analysis can and cannot tell us about the
genetics of complex disease. Am. J. Med. Genet. 54, 318-323.
Hodgkinson S., Sherrington R., Gurling H., Marchbanks R., Reeders S., Mallet
J., Mclnnis M., Petursson H. and Brynjolffson J. (1987) Molecular genetic
evidence for heterogeneity in manic depression. Nature, 325, 783-787.
Holden R.J., Mooney P.A. and Newman J.C. (1994) Schizophrenia: an
extended etiological explanation. Med. Hypotheses. 42, 115-123.
301
Holland G. and Gosden C. (1990) A balanced chromosomal translocation
partially segregating with psychotic illness in a family. Psych. Res. 32, 1-8.
Holzman P.S. (1992) Behavioral markers of schizophrenia useful for genetic
studies. J. Psychiatr. Res. 26, 427-445.
Holzman P.S., Proctor L.R., Levy D.L., Yasillo N.J., Meltzer H.Y. and Hurt S.W.
(1974) Eye tracking dysfunction in schizophrenic patients and their relatives.
Arch. Gen. Psychiatry, 31, 143-151.
Horrobin D.F., Glen A.I. and Vaddadi K. (1994) The membrane hypothesis of
schizophrenia. Schizophr. Res. 13, 195-207.
Horrobin D.F. and Huang Y. (1983) Schizophrenia: the role of abnormal
essential fatty acid and prostaglandin metabolism. Medical Hypotheses, 10,
329-336.
Hozier J., Graham R., Westfall T., Siebert P. and Davis L. (1994) Preparative in
situ hybridisation: selection of chromosome region-specific libraries on mitotic
chromosomes. Genomics, 19, 441-447.
Humphries C.R., Virgo L., Mortimer A., Barnes T., Hirsch S. and de Belleroche
J. (1995) The expression of the N-methyl-D-aspartate receptor subunit NR-1 is
decreased in schizophrenia. Schizophr. Res. 15(1-2), 60
Huntington's Disease Collaborative Research Group (1993) A novel gene
containing a trinucleotide repeat that is expanded and unstable on Huntington's
disease chromosomes. Cell, 72, 971-983.
302
Huxley J., Mayr E., Osmond H. and Hotter A. (1964) Schizophrenia as a genetic
morphism. Nature, 204, 220-221.
Hyde T.M., Nawroz S., Goldberg T.E., Bigelow L.B., Strong D., Ostrem J.L.,
Weinberger D.R. and Kleinman J.E. (1994) Is there cognitive decline in
schizophrenia? A cross-sectional study. Br. J. Psychiatry, 164, 494-500.
loannou P.A., Amemiya C.T., Games J., Kroisel P.M., Shizuya H., Chen C.,
Batzer M.A. and de Jong P.J. (1994) A new bacteriophage P1 -derived vector for
the propagation of large human DNA fragments. Nat. Genet. 6, 84-89.
Ishida T., Yoneda H., Sakai T., Nonomura Y., Inayama Y., Kono Y. and
Kobayashi S. (1993) Pseudoautosomal region in schizophrenia: sex
concordance of the affected sibpairs and the association study with DNA
markers. Am. J. Med. Genet. 48, 151-155.
Item C. and Sieghart W. (1994) Binding of y-aminobutyric acidA receptors to
tubulin. J. Neurochem., 63(3), 1119-1125.
Itokawa M., Arinami T., Futamura N., Hamaguchi H. and Toru M. (1993) A
structural polymorphism of human dopamine D2 receptor, D2(Ser311->Cys).
Biochem. Biophys. Res. Commun. 196, 1369-1375.
James M.R., Richard III C.W., Schott J., Yousry C., Clark K., Bell J., Terwilliger
J.D., Hazan J., Dubay C., Vignal A., Agrapart M., Imai T., Nakamura Y.,
Polymeropoulos M., Weissenbach J., Cox D.R. and Lathrop G.M. (1994) A
radiation hybrid map of 506 STS markers spanning human chromosome 11.
Nat. Genet., 8, 70-76.
303
Jayaram B. and Haley B.E. (1994) Identification of peptides within the base
binding domains of the GTP- and ATP-specific binding sites of tubulin. J. Biol.
Chem., 269(5), 3233-3242.
Johnstone E.C. (1993) Schizophrenia: problems in clinical practice. Lancet, 341,
536-538.
Johnstone E.C., Crow T.J., Frith D.C., Husband J. and Krel L. (1976) Cerebral
ventricular size and cognitive impairment in schizophrenia. Lancet, ii, 924.
Jones C.P., Janson M. and Nordenskjold M. (1989) Separation of yeast
chromosomes in the megabase range suitable as size markers for pulsed field
gel electrophoresis. Technique, 1, 90-95.
Jones C.T., Morris S., Yates C.M., Moffoot A., Sharpe C., Brock D.J.H. and
St.Clair D. (1992) Mutation in codon 713 of the B amyloid precursor protein
gene presenting with schizophrenia. Nat. Genet. 1, 306-309.
Jones D.S.C. and Schofield J.P. (1990) A rapid method for isolating high quality
plasmid DNA suitable for DNA sequencing. Nucl. Acids Res. 18, 7463-7464.
Jones K.W., Shapero M.H., Chevrette M. and Fournier R.E. (1991) Subtractive
hybridization cloning of a tissue-specific extinguisher: TSE1 encodes a
regulatory subunit of protein kinase. Cell, 66, 861-872.
Jones P., Rodgers B., Murray R. and Marmot M. (1994) Child development risk
factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 344,
1398-1402.
304
Jordan E. (1992) The Human Genome Project: where did it come from, where is
it going? Am. J. Hum. Genet. 51, 1-6.
Joseph R., Dou D. and Tsang W. (1994) Molecular cloning of a novel mRNA
(neuronatin) that is highly expressed in neonatal mammalian brain. Biochem.
Biophys,Res. Commun. 201, 1227-1234.
Julier C., Hyer R.N., Davies J., Merlin F., Soularue P., Briant L., Cathelineau G.,
Deschamps I., Rotter J.I., Froguel P., Boitard C., Bell J.I. and Lathrop G.M.
(1991) lnsulin-IGF2 region on chromosome 11 p encodes a gene implicated in
HLA-DR4-dependent diabetes susceptibility. Nature, 354, 155-159.
Kalman M., Kalman E.T. and Cashel M. (1990) Polymerase chain reaction
(PCR) with a single primer. Biochem. Biophys. Res. Commun. 167, 504-506.
Kalsi G., Brynjolfsson J., Butler R., Sherrington R., Curtis D., Sigmundsson T.,
Read T., Murphy P., Sharma T., Petursson H. and Gurling H.M.D. (1995)
Linkage analysis of chromosome 22q12-13 in a United Kingdom/Icelandic
sample of 23 multiplex schizophrenia families. Am. J. Med. Gen. 60, 298-301.
Keefe R.S., Silverman J.M., Siever L.J. and Cornblatt B.A. (1991) Refining
phenotype characterization in genetic linkage studies of schizophrenia. Soc.
Biol. 38, 197-218.
Kelsoe J.R., Ginns E.I., Egeland J.A., Gerhard D.S., Goldstein A.M., Bale S.J.,
Pauls D.L., Long R.T., Kidd K.K., Conte G., Housman D.E. and Paul S.M.
(1989) Re-evaluation of the linkage relationship between chromosome 11 p loci
and the gene for bipolar affective disorder in the Old Order Amish. Nature, 342,
238-243.
305
Kendell R.E. and Kemp I.W. (1989) Maternal influenza in the etiology of
schizophrenia. Arch. Gen. Psychiatry, 46, 878-882.
Kendler K.S., Gruenberg A.M. and Tsuang M.T. (1985) Psychiatric illness in first
degree relatives of schizophrenic and surgical control patients. Arch. Gen.
Psychiatry, 42, 770-779.
Kennedy J.L., Giuffra L.A., Moises H.W., Cavalli-Sforza L.L., Pakstis A.J., Kidd
J.R., Casriglione C.M., Sjogren B., Wetterburg L. and Kidd K.K. (1988) Evidence
against linkage of schizophrenia to markers on chromosome 5 in a Northern
Swedish pedigree. Nature, 336, 167-170.
Kerwin R.W. (1993) Glutamate receptors, microtubule associated proteins and
developmental anomaly in schizophrenia: an hypothesis. Psychol. Med. 23,
547-551.
Kerwin R.W. and Harrison P.J. (1995) Loss of non NMDA receptors in medial
temporal lobe - a robust neurochemical finding: autoradiographical, gene
expression and immunocytochemical findings. Schizophr. Res. 15(1-2), 62.
Kety S.S., Rosenthal D., Wender P.H., Schulsinger F. and Jacobson B. (1975)
Mental illness in the biological and adoptive families of adopted individuals who
have become schizophrenic: a preliminary report based on psychiatric
interviews. Proc. Am. Psychopathol. Soc. 63, 147-165.
Kety S.S., Rosenthal D., Wender P.H., Schulsinger F. and Jacobson B. (1978)
The biologic and adoptive families of individuals who become schizophrenic:
prevalance of mental illness and other characteristics. In Wynne L.C., Cromwell
306
R.L. and Matthysse S. (eds.), The Nature of Schizophrenia. John Wiley and
Sons Inc. New York, pp. 25-37.
King M., Coker E., Leavey G., Hoare A. and Johnson Sabine E. (1994)
Incidence of psychotic illness in London: comparison of ethnic groups. BMJ.
309, 1115-1119.
Knight J.G., Knight A. and Pert C.B. (1987) In Helmchen H. and Henn F.A.
(eds.), Biological perspectives of schizophrenia. Wiley, New York.
Kohn M.L. (1976) The interaction of social class and other factors in the etiology
of schizophrenia. Am. J. Psychiatry, 133(2), 177-180.
Korn B., Sedlacek S., Manca A., Kioschis P., Konecki P., Lehrach H. and
Poutska A. (1992) A strategy for the selection of transcribed sequences in the
Xq28 region. Hum. Mol. Gen. 1, 235-242.
Kruglyak L. and Lander E.S. (1995) High-resolution mapping of complex traits.
Am. J. Hum. Genet., 56, 1212-1223.
Kunugi H., Nanko S. and Takei N. (1992) Influenza and schizophrenia in Japan.
Br. J. Psychiatry, 161, 274-275.
Kunugi H., Nanko S., Takei N., Saito K., Murray R.M. and Kazamatsuri H.
(1995) Small head circumference at birth and schizophrenia. Schizophr. Pes.
15(1-2), 192
Kunugi H., Takei N., Nanko S., Saito K. and Kazamatsuri H. (1994) Head
circumference at birth and schizophrenia. Br. J. Psychiatry, 165, 551-559.
307
Lannfelt L., Sokoloff P., Martres M.P., Pilon C., Giros B., Jonsson E., Sedvall G.
and Schwartz J.G. (1992) a a substitution in the dopamine D3 receptor as a
useful polymorphism for investigating psychiatric disorders. Psych. Gen. 2, 249-
256.
Lapensee M.A. (1992) A review of schizoaffective disorder: I. Current concepts.
Can. J. Psychiatry, 37, 335-346.
Larin Z., Monaco A.P. and Lehrach H. (1991) Yeast artificial chromosome
libraries containing large inserts from mouse and human DNA. Proc. Natl. Acad.
Sci. USA, 88, 4123-4127.
Larsen F., Gunderson G., Lopez R. and Prydz H. (1992) CpG islands as gene
markers in the human genome. Genomics, 13, 1095-1107.
Leboyer M., Malafosse A., Boularand S., Campion D., Gheysen F., Samolyk D.,
Henriksson B., Denise E., des Lauriers A., Lepine J.P., Zarifan J-P., Clerget-
Darpoux F. and Mallet J. (1990) Tyrosine hydroxylase polymorphisms
associated with manic-depressive illness. Lancet, 335, 1219.
Leff J. (1992) Over the edge: stress and schizophrenia. New Scientist, 4th Jan,
30-33.
Leonard S., Adler L.E., Bickford P.C., Hall M., Rollins Y., Breese C., Logel J.,
Drebing C., Adams C., Barnhart M., Byerley W., Coon H. and Freedman R.
(1995) Association of neuronal nicotinic acetylcholine receptors with
schizophrenia. Schizophr. Res. 15(1-2), 64
Levinson D.F. and Mowry B.J. (1991) Defining the schizophrenia spectrum:
308
issues for genetic linkage studies. Schizophr. Bull. 17(3), 491-514.
Levy D.L., Holzman P.S., Matthysse S. and Mendell N.R. (1994) Eye tracking
and schizophrenia: a selective review. Schizophr. Bull. 20, 47-62.
Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell
W.H., Yu C., Jondro P.D., Schmidt S.D., Wang K., Crowley A.C., Fu Y.,
Guenette S.Y., Galas D., Nemens E., Wijsman E.M., Bird T.D., Schellenburg
G.D. and Tanzi R.E. (1995a) Candidate gene for the chromosome 1 familial
Alzheimer's disease locus. Science, 269, 973-977.
Levy-Lahad E., Wijsman E.M., Nemens E., Anderson L., Goddard K.A.B.,
Weber J.L., Bird T.D. and Schellenburg G.D. (1995b) A familial Alzheimer's
disease locus on chromosome 1. Science, 269, 970-973.
Lim L.C., Gurling H., Curtis D., Brynjolfsson J., Petursson H. and Gill M. (1993)
Linkage between tyrosine hydroxylase gene and affective disorder cannot be
excluded in two of six pedigrees. Am. J. Med. Genet. 48, 223-228.
Lim L.C., Nothen M.M., Korner J., Rietschel M., Castle D., Hunt N., Propping P.,
Murray R. and Gill M. (1994) No evidence of association between dopamine D4
receptor variants and bipolar affective disorder. Am. J. Med. Genet. 54, 259-
263.
Lindor N.M., Sobell J.L., Heston L.L., Thibodeau S.N. and Sommer S.S. (1994)
Screening the dystrophin gene suggests a high rate of polymorphism in general
but no exonic deletions in schizophrenics. Am. J. Med. Genet. 54, 1-4.
Lindsay S. and Bird A.P. (1987) Use of restriction enzymes to detect potential
309
gene sequences in mammalian DNA. Nature, 327, 336-338.
Link A.J. and Olson M.V. (1991) Physical map of the Saccharomyces cerevisiae
genome at 110kb resolution. Genetics, 127, 681-698.
Litt M., Kramer P., Hauge X.Y., Weber J.L., Wang Z., Wilkie P.J., Holt M.S.,
Mishra S., Donis Keller H., Warnich L., Retief A.E., Jones C. and Weissenbach
J. (1993) A microsatellite-based index map of human chromosome 11. Hum.
Mol. Genet. 2, 909-913.
Litt M. and Luty J.A. (1989) A hypervariable microsatellite revealed by in vitro
amplification of a dinucleotide repeat within the cardiac muscle actin gene. Am.
J. Hum. Genet. 44, 397-401.
Liu P., Legerski R. and Sicilliano M.J. (1989) Isolation of human transcribed
sequences from human-rodent somatic cell hybrids. Science, 246, 813-815.
Liu W.G. and Whittier R.F. (1995) Thermal Asymmetric Interlaced PCR:
Automatable amplification and sequencing of insert end fragments from P1 and
YAC clones for chromosome walking. Genomics, 25, 674-681.
Livingston M.G. (1994) Risperidone. Lancet, 343, 457-460.
Loh E.Y., Elliott J.F., Cwirla S., Lanier L.L. and Davis M.M. (1989) Polymerase
chain reaction with single sided specificity: analysis of T cell receptor d chain.
Science, 243, 217-220.
Lohr J.B. and Bracha H.S. (1989) Can schizophrenia be related to prenatal
exposure to alcohol? Some speculations. Schizophr. Bull. 15(4), 595-603.
310
Lohr J.B. and Bracha H.S. (1992) A monozygotic mirror-image twin pair with
discordant psychiatric illnesses: a neuropsychiatric and neurodevelopmental
evaluation. Am. J. Psychiatry, 149, 1091-1095.
Lohr J.B. and Flynn K. (1992) Smoking and schizophrenia. Schizophr. Res. 8,
93-102.
Lohr J.B. and Flynn K. (1993) Minor physical anomalies in schizophrenia and
mood disorders. Schizophr. Bull. 19, 551-556.
Lovett M. (1994) Fishing for complements: finding genes by direct selection.
Trends Genet. 10, 352-357.
Lovett M., Kere J. and Hinton L.M. (1991) Direct selection: a method for the
isolation of cDNAs encoded by large genomic regions. Proc. Natl. Acad. Sci.
USA, 88, 9628-9632.
Macciardi F., Kennedy J.L., Ruocco L., Giuffra L., Carrera P., Marino C., Rinaldi
V., Smeraldi E. and Ferrari M. (1992) A genetic linkage study of schizophrenia
to chromosome 5 markers in a Northern Italian population. Biol. Psychiatry, 31,
720-728.
Macciardi F., Verga M., Kennedy J.L., Petronis A., Bersani G., Pancheri P. and
Smeraldi E. (1994) An association study between schizophrenia and the
dopamine receptor genes DRD3 and DRD4 using haplotype relative risk. Hum.
Hered. 44, 328-336.
Mallet J., Meloni R. and Laurent C. (1994) Catecholamine metabolism and
psychiatric or behavioral disorders. Curr. Opin. Genet. Dev. 4, 419-426.
311
Mandelkow E. and Mandelkow E. (1995) Microtubules and microtubule-
associated proteins. Current Opinion in Cell Biology, 7, 72-81.
Mant R., Williams J., Asherson P., Parfitt E., McGuffin P. and Owen M.J. (1994)
Relationship between homozygosity at the dopamine D3 receptor gene and
schizophrenia. Am. J. Med. Genet. 54, 21-26.
Marneros A., Deister A. and Rohde A. (1992) Comparison of long-term outcome
of schizophrenic, affective and schizoaffective disorders. Br. J. Psychiatry
Suppi. 44-51.
Matthysse S., Holzman P.S. and Lange K. (1986) The genetic transmission of
schizophrenia: application of Mendelian latent strucutre analysis to eye tracking
dysfunctions in schizophrenia and affective disorders. J. Psychiatric Res. 20,
57-76.
Maule J.C. (1994) Electrophoretic karyotype analysis: pulsed field gel
electrophoresis. In Gosden J.R. (ed.), Chromosome Analysis Protocols.
Humana, Totowa, N.J. pp. 221-252.
McBride O.W. and Ozer H.L. (1973) Transfer of genetic information by purified
metaphase chromosomes. Proc. Natl. Acad. Sci. USA, 70(4), 1258-1262.
McGrath J.J., Pemberton M.R., Welham J.L. and Murray R.M. (1994)
Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: a southern
hemisphere study. Schizophr. Res. 14, 1-8.
McGuffin P., Farmer A. and Gottesman I.I. (1987) Is there really a split in
schizophrenia? The genetic evidence. Br. J. Psychiatry, 150, 581-592.
312
McGuffin P., Reveley A. and Holland A. (1982) Identical triplets: non-identical
psychosis? Br. J. Psychiatry, 140, 1-6.
McGuffin P., Sargeant M., Hetti G., Tidmarsh S., Whatley S. and Marchbanks
R.M. (1990) Exclusion of schizophrenia susceptibility gene from the
chromosome 5q 11-13 region: new data and a reanalysis of previous reports.
Am. J. Hum. Genet. 47, 524-535.
McGuffin P. and Stuart E. (1986) Genetic markers and schizophrenia. Hum.
Hered. 36, 65-88.
McNeil T.F., Cantor-Graae E. and Cardenal S. (1993) Prenatal cerebral
development in individuals at genetic risk for psychosis: head size at birth in
offspring of women with schizophrenia. Schizophr. Res. 10, 1-5.
Mednick S.A., Machon R.A., Huttunen M.O. and Bonett D. (1988) Adult
schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen.
Psychiatry, 45, 189-192.
Melmer G. and Buchwald M. (1992) Identification of genes using
oligonucleotides corresponding to splice site consensus sequences. Hum. Mol.
Genet. 1, 433-438.
Mendlewicz J., Sevy S., Brocas H., Simon P., Charon F., Legros S. and Vassart
G. (1987) Polymorphic DNA marker on X chromosome and manic depression.
Lancet, i, 1230-1232.
Michels R. and Marzuk P.M. (1993) Progress in psychiatry (1). N. Engl. J. Med.
329, 552-560.
313
Moon R.T. and McMahon A.P. (1990) Generation of diversity in nonerythroid
spectrins. J. Biol. Chem. 265(8), 4427-4433.
Monaco A.P., Neve R.L., Colletti-Feener C., Bertelson C.J., Kurnit D.M. and
Kunkel L.M. (1986) Isolation of candidate cDNAs for portions of the Duchenne
muscular dystrophy gene. Nature, 323, 646-650.
Morgan J.G., Dolganov G.M., Robbins S.E., Hinton L.M. and Lovett M. (1992)
The selective isolation of novel cDNAs encoded by the regions surrounding the
human interleukin 4 and 5 genes. Nucl. Acids Res. 20, 5173-5179.
Morris A.G., Gaitonde E., McKenna P.J., Mollon J.D. and Hunt D.M. (1995)
Hum. Mol. Genet., 4(10), 1957-1961.
Morton N.E. and McLean C.J. (1974) Analysis of family resemblance III.
Complex segregation analysis of quantitative traits. Am. J. Hum. Genet. 26,
489-503.
Mott F.W. (1911) Heredity and Insanity. Lancet, 3, 1251-1259.
Mueller P.R. and Wold B. (1989) In vivo footprinting of a muscle specific
enhancer by ligation mediated PCR. Science, 246, 780-786.
Muir W.J., Gosden C.M., Brookes A.J., Fantes J., Evans K.L., Maguire S.M.,
Stevenson B., Boyle S., Blackwood D.H., St.Clair D.M., Porteous D.J. and Weith
A. (1995) Direct microdissection and microcloning of a translocation breakpoint
region, t(1 ;11 )(q42.2;q21), associated with schizophrenia. Cytogenet. Cell
Genet. 70, 35-40.
314
Mullis K.B. and Faloona F.A. (1995) Specific synthesis of DNA in vitro via a
polymerase catalysed chain reaction. Methods Enzymol. 155, 335-350.
Murray R.M., Lewis S. and Reveley A.M. (1985) Towards an etiological
classification of schizophrenia. Lancet, i, 1023-1026.
Nanko S., Fukuda R., Hattori M., Sasaki T., Dai X.Y., Gill M., Kuwata S.,
Shibata Y. and Kazamatsuri H. (1994a) No evidence of linkage or allelic
association of schizophrenia with DNA markers at pericentric region of
chromosome 9. Biol. Psychiatry, 36, 589-594.
Nanko S., Fukuda R., Hattori M., Sasaki T., Dai X.Y., Yamaguchi K. and
Kazamatsuri H. (1994b) Further evidence of no linkage between schizophrenia
and the dopamine D3 receptor gene locus. Am. J. Med. Genet. 54, 264-267.
Nanko S., Gill S., Owen M., Takazawa N., Moridaiwa J. and Kazamatsuri H.
(1992) Linkage study of schizophrenia with markers on chromosome 11 in two
Japanese pedigrees. Jap. J. Psychiatr. Neurol. 46(1), 155-159.
Nanko S., Hattori M., Dai X.Y., Fukuda R. and Kazamatsuri H. (1994c) DRD2
Ser311/Cys311 polymorphism in schizophrenia. Lancet, 343, 1044
Nanko S., Kunugi H., Sasaki T., Fukuda R., Kawate T. and Kazamatsuri H.
(1993a) Pericentric region of chromosome 9 is a possible candidate region for
linkage study of schizophrenia. Biol. Psychiatry, 33, 655-658.
Nanko S., Sasaki T., Fukuda R., Hattori M., Dai X.Y., Kazamatsuri H., Kuwata
S., Juji T. and Gill M. (1993b) A study of the association between schizophrenia
and the dopamine D3 receptor gene. Hum. Genet. 92, 336-338.
315
Nelson D.L., Ledbetter S.A., Corbo L., Vicotia M.F., Ramirez-Solis R., Webster
T.D., Ledbetter D.H. and Caskey C.T. (1989) Alu polymerase chain reaction: a
method for rapid amplification of human specific sequences from complex DNA
sources. Proc. Natl. Acad. Sci. USA, 86, 1-5.
Nelson W.J. and Veshnock P.J. (1987) Modulation of fodrin (membrane
skeleton) stability by cell-cell contact in Madin-Darby canine kidney epithelial
cells. J.Cell. Biol., 104, 1527-1537.
Neylan T.C. and van Kammen D.P. (1990) Biological mechanisms of
schizophrenia: an update. Psychlatr. Med. 8, 41-52.
NIH/CEPH Collaborative Mapping Group (1992) A comprehensive linkage map
of the human genome. Science, 258, 67-87.
Nimgaonkar V.L., Scott J.A., Brar J.S., Ganguli R. and Chakravarti A. (1993a)
Co-occurrence of schizophrenia and Treacher Collins syndrome. Am. J. Med.
Genet. 48, 156-158.
Nimgaonkar V.L., Zhang X.R., Caldwell J.G., Ganguli R. and Chakravarti A.
(1993b) Association study of schizophrenia with dopamine D3 receptor gene
polymorphisms: probable effects of family history of schizophrenia? Am. J. Med.
Genet. 48, 214-217.
Ninomiya Y., Gordon M., van der Rest M., Schmid T., Linsenmayer T. and
Olsen B.R. (1995) The developmental^ regulated type X collagen gene
contains a long open reading frame without introns. J. Biol. Chem. 261, 5041-
5050.
316
Nothen M.M., Cichon S., Hemmer S., Hebebrand J., Remschmidt H., Lehmkuhl
G., Poustka F., Schmidt M., Catalano M., Fimmers R., Korner J., Rietschel M.
and Propping P. (1994) Human dopamine D4 receptor gene: frequent
occurrence of a null allele and observation of homozygosity. Hum. Mol. Genet.
3, 2207-2212.
Nothen M.M., Cichon S., Propping P., Fimmers R., Schwab S.G. and
Wildenauer D.B. (1993) Excess of homozygosity at the dopamine D3 receptor
gene in schizophrenia not confirmed. J. Med. Genet. 30, 708-709.
O'Callaghan E., Sham P., Takei N., Glover G. and Murray R.M. (1991)
Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet,
337, 1248-1249.
O'Callaghan E., Sham P.C., Takei N., Murray G., Glover G., Hare E.H. and
Murray R.M. (1994) The relationship of schizophrenic births to 16 infectious
diseases. Br. J. Psychiatry, 165, 353-356.
O'Donovan M.C., Guy C., Craddock N., Murphy K.C., Cardno A.G., Jones L.A.,
Owen M.J. and McGuffin P. (1995) Expanded CAG repeats in schizophrenia
and bipolar disorder. Nat. Genet., 10, 380-381.
O'Neil J., Brynjolfsson J., Curtis D., Rifkin L., Maloney E., Murphy P., Petursson
H. and Gurling H. (1993) Testing the hypothesis for genomic imprinting and
anticipation in bipolar and related unipolar affective disorder. Psych. Genet. 3,
151
O'Reilly R.L. and Davis B.A. (1994) Phenylethylamine and schizophrenia. Prog.
Neuropsychopharmacol. & Biol. Psychiat. 18, 63-75.
317
Ochman H., Gerber A.S. and Hartl D.L. (1988) Genetic applications for an
inverse polymerase chain reaction. Genetics, 120, 621-623.
Olson M., Hood L., Cantor C. and Botstein D. (1989) A common language for
the physical mapping of the human genome. Science, 245, 1434-1435.
Orbach M.J., Vollrath D., Davis R.W. and Yanofsky C. (1988) An electrophoretic
karyoptype of Neurospora crassa. Mol. Cell. Biol. 8(4), 1469-1473.
Owen F. and Simpson M. (1994) The neurochemistry of schizophrenia. In Owen
F. and Itzhaki R. (eds.), Molecular and Cell Biology of Neuropsychiatric
Diseases. Chapman & Hall, London, pp. 133-159.
Owen M.J., Mant R., Parfitt E., Williams J., Asherson P., O'Mahoney G., Van Os
J., Llewellyn D., Collier D., Gill M. and McGuffin P. (1992) No association
between RFLPs at the porphobilinogen deaminase gene and schizophrenia.
Hum. Genet. 90, 131-132.
Parfitt E., Asherson P., Sargeant M., Whatley S., McGuffin P. and Owen M.
(1991) A linkage study of the pseudoautosomal region in schizophrenia.
Psychiatr. Genet. 2, 92-93.
Parimoo S., Patanjali S.R., Shukla H., Chaplin D.D. and Weissman S.M. (1991)
cDNA selection: efficient PCR approach for the selection of cDNAs encoded in
large chromosomal DNA fragments. Proc. Natl. Acad. Sci. USA, 88, 9623-9627.
Parker J.D., Rabinovitch P.S. and Burmer G.C. (1991) Targeted gene walking
polymerase chain reaction. Nucl. Acids Res. 19, 3055-3060.
318
Parks C.L., Chang L. and Shenk T. (1991) Polymerase chain reaction mediated
by a single primer: cloning of genomic sequences adjacent to a serotonin
receptor protein coding region. Nucl. Acids Res. 19, 7155-7160.
Paschal B.M., Obar R.A. and Vallee R.B. (1989) Interaction of brain cytoplasmic
dynein and MAP2 with a common sequence at the C terminus of tubulin.
Nature, 342, 569-572.
Patel K., Sheer D. and Hampton G.M. (1993) "Junction Trapping". A simple
PCR-based method for the isolation of YAC-insert termini. GATA, 10, 42-48.
Pearson W.R. and Lipman D.J. (1988) Improved tools for biological sequence
comparison. Proc. Natl. Acad. Sci. USA, 85, 2444-2448.
Persico A.M., Wang Z.W., Black D.W., Andreasen N.C., Uhl G.R. and Crowe
R.R. (1995) Exclusion of close linkage of the dopamine transporter gene with
schizophrenia spectrum disorders. Am. J. Psychiatry, 152, 134-136.
Petronis A. and Kennedy J.L. (1995) Unstable genes - unstable mind? Am. J.
Psychiatry, 164-172.
Pickar D., Owen R.R., Jr., Litman R.E., Hsiao J.K. and Su T.P. (1994)
Predictors of clozapine response in schizophrenia. J. Clin. Psychiatry, 55 Suppl
B, 129-132.
Polymeropoulos M.H., Coon H., Byerley W., Gershon E.S., Goldin L., Crow T.J.,
Rubenstein J., Hoff M., Holik J., Smith A.M., Shields G., Bass N.J., Poulter M.,
Lofthouse R., Vita A., Morganti C., Merril C.R. and DeLisi L.E. (1994) Search for
319
a schizophrenia susceptibility locus on human chromosome 22. Am. J. Med.
Genet. 54, 93-99.
Polymeropoulos M.H., Xiao H., Glodek A., Gorski M., Adams M.D., Moreno
R.F., Fitzgerald M.G., Venter J.C. and Merril C.R. (1992) Chromosomal
assignment of 46 brain cDNAs. Genomics, 12, 492-496.
Polymeropoulos M.H., Xiao H., Sikela J.M., Adams M., Venter J.C. and Merrill
C.R. (1993) Chromosomal distribution of 320 genes from a brain cDNA library.
Nat. Genet. 4, 381-386.
Pope H.G., Jonas J.M., Cohen B.M. and Lipinski J.F. (1982) Failure to find
evidence of schizophrenia in first degreee relatives of schizophrenic probands.
Am. J. Psychiatry, 139, 826-827.
Potts N.L.S., Davidson J.R.T. and Krishnan K.R.R. (1993) The role of nuclear
magnetic resonance imaging in psychiatric research. J. Clin. Psychiatry, 54:12
(suppl), 13-18.
Prescott C.A. and Gottesman I.I. (1993) Genetically mediated vulnerability to
schizophrenia. Psychiatr. Clin. North Am. 16, 245-267.
Pulver A.E., Karayiorgou M., Lasseter V.K., Wolyniec P., Kasch L., Antonarakis
S., Housman D., Kazazian H.H., Meyers D., Nestadt G., Ott J., Liang K-Y.,
Lamacz M., Thomas M. and Childs B. (1994b) Follow-up of a report of a
potential linkage for schizophrenia on chromosome 22q 12-q 13.1: Part 2. Am. J.
Med. Genet. 54, 44-50.
Pulver A.E., Karayiorgou M., Wolyniec P.S., Lasseter V.K., Kasch L., Nestadt
320
G., Antonarakis S., Housman D., Kazazian H.H., Meyers D., Ott J., Lamacz M.,
Liang K-Y., Hanfelt J., Ullrich G., Dimarchi N., Ramu E., McHugh P.M., Adler L.,
Thomas M., Carpenter W.T., Mansschreck T., Gordon C.T., Kimberland M.,
Babb R., Puck J. and Childs B. (1994a) Sequential strategy to identify a
susceptibility gene for schizophrenia: report of potential linkage on chromosome
22q12-q13.1: Part 1. Am. J. Med. Genet. 54, 36-43.
Pulver A.E., Liang K.Y., Brown C.H., Wolyniec P., McGrath J., Adler L., Tarn D.,
Carpenter W.T. and Childs B. (1992) Risk factors in schizophrenia. Season of
birth, gender, and familial risk. Br. J. Psychiatry, 160, 65-71.
Rao M.L. and Moller H.J. (1994) Biochemical findings of negative symptoms in
schizophrenia and their putative relevance to pharmacologic treatment. A
review. NeuropsychobioL, 30, 160-172.
Rasenick M.M., Wang N. and Yan K. (1990) Specific association between
tubulin and G proteins: participation of cytoskeletal elements in cellular signal
transduction. Adv. Second Mess. & Phos. Res., 24, 381-386.
Reveley A.M., Reveley M.A., Clifford C.A. and Murray R.M. (1982) Cerebral
ventricular size in twins disocrdant for schizophrenia. Lancet, i, 540-541.
Ridley R.M. and Baker H.F. (1990) Implications of age of onset for the genetics
of schizophrenia. Biol. Psychiatry, 28, 455-458.
Riecher Rossler A., Hafner H., Dutsch Strobel A., Oster M., Stumbaum M., van
Gulick Bailer M. and Loffler W. (1994) Further evidence for a specific role of
estradiol in schizophrenia? Biol. Psychiatry, 36, 492-494.
321
Rieder R.O. and Gershon E.S. (1978) Genetic strategies in biological
psychiatry. Arch. Gen. Psychiatry, 35, 866-873.
Rifkin L., Lewis S., Jones P., Toone B. and Murray R. (1994) Low birth weight
and schizophrenia. Br. J. Psychiatry, 165, 357-362.
Riley J., Butler R., Ogilvie D., Finniear R., Jenner D., Powell S., Anand R., Smith
J.C. and Markham A.F. (1990) A novel, rapid method for the isolation of terminal
sequences from yeast artificial chromosome (YAC) clones. Nuci. Acids Res. 18,
2887-2890.
Risch N. (1992) Genetic linkage: interpreting lod scores. Science, 255, 803-804.
Roberts G.W. and Bruton C.J. (1990) Notes from the graveyard: neuropathology
and schizophrenia. Neuropathol. Appl. Neurobiol. 16, 3-16.
Rodionov V.I., Gyoeva F.K., Kashina A.S., Kuznetsov S.A. and Gelfand V.I.
(1990) Microtubule-associated proteins and microtubule-based translocators
have different binding sites on tubulin molecule. J. Biol. Chem. 265(10), 5702-
5707.
Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y.,
Chi H., Lin C., Holman K., Tsuda T., Mar L., Sorbi S., Nacmias B., Piacentini S.,
Amaducci L., Chumakov I., Cohen D., Lannfelt L., Fraser P.E., Rommens J.M.
and St.George-Hyslop P.H. (1995) Familial Alzheimer's disease in kindreds with
missense mutations in a gene on chromosome 1 related to the Alzheimer's
disease type 3 gene. Nature, 376, 775-778.
Rosenthal A. and Jones D.S.C. (1990) Genomic walking and sequencing by
322
oligo-cassette mediated polymerase chain reaction. Nucl. Acids Res. 18, 3095-
3096.
Rosenthal D., Wender P.H., Kety S.S., Welner J. and Schulsinger F. (1971) The
adopted-away offspring of schizophrenics. Am. J. Psychiatry, 128, 307-311.
Roth B.L. (1994) Multiple serotonin receptors: clinical and experimental aspects.
Ann. din. Psychiatry, 6, 67-78.
Roux K.H. and Dhanarajan P. (1990) A strategy for single site PCR amplification
of dsDNA: priming digested cloned or genomic DNA from an anchor-modified
restriction site and a short internal sequence. Biotechniques, 8, 48-57.
Roychowdhury S. and Rasenick M.M. (1994) Tubulin-G protein association
stabilises GTP-binding and activates GTPase: cytoskeletal participation in
neuronal signal transduction. Biochemistry, 33, 9800-9805.
Rubinsztein D.C., Leggo J., Goodburn S., Crow T.J., Lofthouse R., DeLisi L.E.,
Barton D.E. and Ferguson Smith M.A. (1994) Study of the Huntington's disease
(HD) gene CAG repeats in schizophrenic patients shows overlap of the normal
and HD affected ranges but absence of correlation with schizophrenia. J. Med.
Genet. 31, 690-693.
Rybakowski J.K. and Lehmann W. (1994) Decreased activity of erythrocyte
membrane ATPases in depression and schizophrenia. Neuropsychobiology, 30,
11-14.
Saiki R.K., Gelfand D.H., Stoffel S., Schart S.J., Higuchi R., Horn G.T., Mullis
323
K.B. and Erlich H.A. (1988) Primer-directed enzymatic amplification of DNA with
a thermostable DNA polymerase. Science, 239, 487-491.
Sambrook J., Fritsch E.F. and Maniatis T. (1989) Molecular Cloning. A
laboratory manual. CSH Laboratory Press, Cold Spring Harbor.
Sanders A.R., Hamilton J.D., Fann W.E. and Patel P.I. (1991) Association of
genetic variation in the porphobilinogen deaminase gene with schizophrenia.
Am. J. Hum. Genet. 49, A2011
Sarkar G., Kapelner S., Grandy D.K., Marchionni M., Civelli O., Sobell J.,
Heston L. and Sommer S.S. (1991) Direct sequencing of the dopamine D2
receptor (DRD2) in schizophrenics reveals three polymorphisms but no
structural change in the receptor. Genomics, 11, 8-14.
Sasaoka T. and Tonegawa S. (1995) A molecular genetic approach to the
pathogenesis of schizophrenia using genetically engineered mice. Schizophr.
Res. 15(1-2), 70.
Schwartz D.C. and Cantor C.R. (1984) Separation of yeast chromosome-sized
DNAs by pulsed field gel electrophoresis. Cell, 37, 67-75.
Seeman P., Guan H.C. and Van Tol H.H.M. (1994a) Dopamine D4 receptors
elevated in schizophrenia. Nature, 365, 441-445.
Seeman P., Ulpian C., Chouinard G., Van Tol H.H., Dwosh H., Lieberman J.A.,
Siminovitch K., Liu I.S., Waye J., Voruganti P., Hudson C., Serjeant G.R.,
Masibay A.S. and Seeman M.V. (1994b) Dopamine D4 receptor variant,
324
D4GLYCINE194, in Africans, but not in Caucasians: no association with
schizophrenia. Am. J. Med. Genet. 54, 384-390.
Selkoe, D.J. (1995) Missense on the membrane. Nature, 375, 734-735.
Selten J.P. and Slaets J.P. (1994) Evidence against maternal influenza as a risk
factor for schizophrenia. Br. J. Psychiatry, 164, 674-676.
Senger G., Ludecke H.J., Horsthemke B. and Claussen U. (1990)
Microdissection of banded human chromosomes. Hum. Genet. 84, 507-511.
Serra A., Brahe C., Millington Ward A., Neri G., Tedeschi B., Tassone F. and
Bova R. (1990) Pericentric inversion of chromosome 9: prevalence in 300 Down
syndrome families and molecular studies of nondisjunction. Am. J. Med. Genet.
Suppi. 7, 162-168.
Shaikh S., Ball D., Craddock N., Castle D., Hunt N., Mant R., Owen M., Collier
D. and Gill M. (1993) The dopamine D3 receptor gene: no association with
bipolar affective disorder. J. Med. Genet. 30, 308-309.
Shaikh S., Gill M., Owen M., Asherson P., McGuffin P., Nanko S., Murray R.M.
and Collier D.A. (1994) Failure to find linkage between a functional
polymorphism in the dopamine D4 receptor gene and schizophrenia. Am. J.
Med. Genet. 54, 8-11.
Shapiro M.B. and Senapathy P. (1987) RNA splice junctions of different classes
of eukaryotes: sequence statistics and functional implications in gene
expression. Nucl. Acids Res. 15(17), 7155-7174.
325
Sharp C.W., Muir W.J., Blackwood D.H.R., Gosden C. and St.Clair D.M. (1994)
Schizophrenia and mental retardation associated in a pedigree with retinitis
pigmentosa and sensorineural deafness. Am. J. Med. Gen. 54, 354-360.
Shen M.R., Batzer M.A. and Deininger P.L. (1991) Evolution of the master Alu
gene(s). J. Mol. Evol. 33, 311-320.
Shen W.W. (1994) Pharmacotherapy of schizophrenia: the American current
status. Keio. J. Med. 43, 192-200.
Sherrington R., Brynjolfsson J., Petursson H., Potter M., Dudleston K.,
Barraciough B., Wasmuth J., Dobbs M. and Gurling H. (1988) Localization of a
susceptibility locus for schizophrenia on chromosome 5. Nature, 336, 164-167.
Shibasaki Y., Maule J.C., Devon R.S., Slorach E.M., Gosden J.R., Porteous
D.J. and Brookes A.J. (1995) Catch-linker + PCR labeling: a simple method to
generate fluorescence in situ hybridisation probes from yeast artificial
chromosomes. PCR Methods and Applications, 4, 209-211.
Shields J. and Slater E. (1967) Genetic aspects of schizophrenia. Hospital
Medicine, 579-584.
Shizuya H., Birren B., Kim U., Mancino V., Slepak T., Tachiri Y. and Simon M.
(1992) Cloning and stable maintenance of 300-kilobase-pair fragments of
human DNA in Escherichia Coli using an F-factor based vector. Proc. Natl.
Acad. Sci. USA, 89, 8794-8797.
Siebert P.D., Chenchik A., Kellogg D.E., Lukyanov K.A. and Lukyanov S.A.
326
(1995) An improved PCR method for walking in uncloned genomic DNA. Nucl.
Acids Res. 23, 1087-1088.
Smith M., Wasmuth W., McPherson J.D., Wagner C., Grandy D., Civelli O.,
Potkin S. and Litt M. (1989) Cosegregation of an 1q22-9p22 translocation with
affective disorder: proximity of the dopamine D2 receptor gene relative to the
translocation breakpoint. Am. J. Hum. Genet. 45, A220
Smith M.W., Holmsen L.N., Wei Y.H., Peterson M. and Evans G.A. (1994)
Genomic sequence sampling: a strategy for high resolution sequence-based
physical mapping of complex genomes. Nat. Genet. 7, 40-47.
Sobell J.L., Heston L.L. and Sommer S.S. (1993) Novel association approach
for determining the genetic predisposition to schizophrenia: case-control
resource and testing of a candidate gene. Am. J. Med. Genet. 48, 28-35.
Sobue K. (1993) Actin-based cytoskeleton in growth cone activity. Neurosci.
Res. 18, 91-102.
Sokoloff P., Giros B., Martres M.P., Bouthenet M.L. and Schwartz J.C. (1990)
Molecular cloning and characterization of a novel dopamine receptor (D3) as a
target for neuroleptics. Nature, 347, 146-151.
Sommer R. and Tautz D. (1989) Minimal homology requirements for PCR
primers. Nucl. Acids Res. 17, 6749.
Sommer S.S., Lind T.J., Heston L.L. and Sobell J.L. (1993) Dopamine D4
receptor variants in unrelated schizophrenic cases and controls. Am. J. Med.
Genet. 48, 90-93.
327
Southern E.M. (1975) Detection of specific sequences among DNA fragments
separated by gel electrophoresis. J. Mol. Biol. 98, 503-517.
Squires R.F. and Saederup E. (1991) A review of evidence for GABergic
predominance/glutamatergic deficit as a common etiological factor in both
schizophrenia and affective psychoses: more support for a continuum
hypothesis of "functional" psychosis. Neurochem. Res. 16, 1099-1111.
St.Clair D., Blackwood D., Muir W., Carothers A., Walker M., Spowart G.,
Gosden C. and Evans H.J. (1990) Association within a family of a balanced
autosomal translocation with major mental illness. Lancet, 336, 13-16.
St.Clair D. (1994) Expanded CAG trinucleotide repeat of Huntington's disease
gene in a patient with schizophrenia and normal striatal histology. J. Med.
Genet. 31, 658-659.
St.Clair D., Blackwood D., Muir W., Baillie D., Hubbard A., Wright A. and Evans
H.J. (1989) No linkage of chromosome 5q 11 -q 13 markers ot schizophrenia in
Scottish families. Nature, 339, 305-309.
St.Clair D., Muir W. and Blackwood D. (1994) Molecular Biology of
Schizophrenia. In Owen F. and Itzhaki R. (eds.), Molecular and Cell Biology of
Neuropsychiatric Diseases. Chapman and Hall, London, pp. 160-172.
Stein G.S., Stein J.L. and Marzluff W.F. (1995) Histone genes: structure,
organization and regulation. John Wiley and Sons, Inc. New York.
Sulston J., Du Z., Thomas K., Wilson R., Hillier L., Staden R., Halloran N.,
Green P., Thierry Mieg J., Qiu L., Dear S., Coulson A., Craxton M., Durbin R.,
328
Berks M., Metzstein M., Hawkins T., Ainscough R. and Waterston R. (1992) The
C. elegans genome sequencing project: a beginning. Nature, 356, 37-41.
Sunahara R.K., Niznik H.B., Weiner D.M., Stormann T.M., Brann M.R., Kennedy
J.L., Gelernter J.E., Rozmahel R., Yang Y.L., Israel Y., Seeman P. and O'Dowd
B.F. (1990) Human dopamine D1 receptor encoded by an intronless gene on
chromosome 5. Nature, 347, 80-83.
Susser E., Neugebauer R., Hoek H., Brown A., Lin S., Labowitz D. and Gorman
J. (1995) An epidemiologic study of schizophrenia after prenatal exposure to
famine. Schizophr. Res. 15(1-2), 197.
Sutcliffe J.G. (1988) mRNA in the mammalian central nervous system. Ann.
Rev. Neurosci. 11, 157.
Szpirer C., Molne M., Antonacci R., Jenkins N.A., Finelli P., Szpirer J., Riviere
M., Rocchi M., Gilbert D.J., Copeland N.G. and Gallo V. (1994) The genes
encoding the glutamate receptor subunits KA1 and KA2 (GRIK4 and GRIK5)
are located on separate chromosomes in human, mouse, and rat. Proc. Natl.
Acad. Sci. USA, 91,11849-11853.
Tadokoro K., Oki N., Fujii H., Oshima A., Inoue T. and Yamada M. (1995)
Genomic organisation of the human WT1 gene. Jpn. J. Cancer Res. 83, 1198-
1203.
Tassone F., Xu H., Burkin H., Weissman S. and Gardiner K. (1995) cDNA
selection from 10Mb of chromosome 21 DNA: efficiency in transcriptional
mapping and reflections of genome organisation. Hum. Mol. Gen. 4(9), 1509-
1518.
329
Taylor G.R. (1991) Polymerase chain reaction: basic principles and automation.
In McPherson M.J., Quirke P. and Taylor G.R. (eds.), PCR. A Practical
Approach. Oxford University Press, Oxford, Vol.1, pp. 1-14.
Terwilliger J.D. and Ott J. (1994) Handbook of Human Genetic Linkage. The
Johns Hopkins University Press, Baltimore and London.
Tienari P., Wynne L.C., Moring J., Lahti I., Naarala M., Sorri A., Wahlberg K.E.,
Saarento O., Seitamaa M., Kaleva M. and Laksy K. (1994) The Finnish adoptive
family study of schizophrenia. Implications for family research. Br. J. Psychiatry
Suppl. 20-26.
Todd S. and Naylor S.L. (1991) Dinucleotide repeat polymorphism in the human
alpha tubulin 1 (testis specific) gene (TUBA1). NucL Acids Res. 19, 3755.
Torrey E.F., Bowler A.E. and Rawlings R. (1991) An influenza epidemic and the
seasonality of schizophrenic births. In Kurstak E. (ed.), Second World Congress
on Viruses and Mental Health. Plenum Press, New York, pp. 109-116.
Torrey W.C. and Drake R.E. (1994) Current concepts in the treatment of
schizophrenia. Psychiatry, 57, 278-285.
Trofatter J.A., MacCollin M.M., Rutter J.L., Murrell J.R., Duyao M.P., Parry D.M.,
Eldridge R., Kley N., Menon A.G., Pulaski K., Haase V.H., Ambrose C.M.,
Munroe D., Bove C., Haines J.L., Martuza R.L., MacDonald M.E., Seizinger
B.R., Short M.P., Buckler A.J. and Gusella J.F. (1993) A novel moesin-, ezrin-,
radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.
Cell, 75, 826.
330
Upcroft P. and Healey A. (1991) PCR priming from the restriction endonuclease
site 3' extension. Nucl. Acids Res. 21, 4854.
Upender M., Gallagher P.G., Moon R.T. and Forget B.T. (1994) Localisation of
the human alpha-fodrin gene (SPTAN1) to 9q33-q34 by fluorescence in situ
hybridisation. Cytogenet. Cell. Genet. 66, 39-41.
Valdes J.M., Tagle D.A. and Collins F.S. (1994) Island rescue PCR: a rapid and
efficient method for isolating transcribed sequences from yeast artificial
chromosomes and cosmids. Proc. Natl. Acad. Sci. U. S. A. 91, 5377-5381.
Van Tol H.H.M., Bunzow J.R., Guna H.C., Sunahara R.K., Seeman P., Niznik
H.B. and Jovanovic V. (1991) Cloning the gene for a human dopamine D4
receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.
Van Tol H.H.M., Wu C.M., Guan H.C., Ohara K., Bunzow J.R., Civelli O.,
Kennedy J., Seeman P., Niznik H.B. and Jovanovic V. (1992) Multiple dopamine
D4 receptor variants in the human population. Nature, 358, 149-152.
Waddington J.L. (1993) Schizophrenia: developmental neuroscience and
pathobiology. Lancet, 341, 531-536.
Waddington J.L., O'Callaghan E., Larkin C. and Kinsella A. (1993) Cognitive
dysfunction in schizophrenia: organic vulnerability factor or state marker for
tardive dyskinesia? Brain Cogn. 23, 56-70.
Wallace M. (1987) The forgotten illness, 'The Times' newspaper, May.
331
Wang S., Sun C., Walczak C.A., Ziegle J.S., Kipps B.R., Goldin L.R. and Diehl
S.R. (1995) Evidence for a susceptibility locus for schizophrenia on
chromosome 6pter-p22. Nat. Genet. 10, 41-46.
Weber J.L. and May P.E. (1989) Abundant class of human DNA polmorphisms
which can be typed using the polymerase chain reaction. Am. J. Hum. Genet.
44, 388-396.
Weil D., Blanchard S., Kaplan J., Guilford P., Gibson F., Walsh J., Mburu P.,
Varela A., Levilliers J., Weston M.D., Kelley P.M., Kimberling W.J., Wagenaar
M., Levi-Acobas F., Larget-Piet D., Munnich A., Steel K.P., Brown S.D.M., and
Petit C. (1995) Defective myosin VIIA gene responsible for Usher syndrome
type 1B. Nature, 374, 60-61.
Weiner H. (1995) Schizophrenia: etiology. In Kaplan H. and Sadock I. (eds.),
Comprehensive Textbook of Psychiatry. Balti, Williams and Wilkins, Vol.4th. pp.
650-679.
Weiss M. and Green H. (1967) Human-mouse hybrid cell lines containing partial
complements of human chromosomes and functioning human genes. Proc.
Natl. Acad. Sci. USA, 58, 1104-1111.
Weissenbach J., Gyapay G., Dib C., Vignal A., Morissette J., Millasseau P.,
Vaysseix G. and Lathrop M. (1992) A second-generation linkage map of the
human genome. Nature, 359, 794-801.
Weith A. (1994) The analysis of disease-specific chromosomal rearrangements
with microcloned DNA markers. In Adolph K. (ed.), Methods in Molecular
Genetics, Vol 5, Part C. Academic Press, London, pp169-194.
332
Welham J.L., McLachlan G.J. and McGrath J.J. (1995a) Time-series as an
alternative analysis of seasonality in schizophrenia birth-rates. Schizophr. Res.
15(1-2), 202.
Welham J.L., Vacca J. and McGrath J.J. (1995b) Seasonality in schizophrenia
births: a review of Southern hemisphere studies. Schizophr. Res. 15(1-2), 202.
Wilson R., Ainscough R., Anderson K., Baynes C., Berks M., Bonfield J., Burton
J., Connell M., Copsey T., Cooper J., Coulson A., Craxton M., Dear S., Du Z.,
Durbin R., Favello A., Fraser A., Fulton L., Gardner A., Green P., Flawkins T.,
Hillier L., Jier M., Johnston L., Jones M., Kershaw J., Kirsten J., Laisster N.,
Latreille P., Lightning J., Lloyd C., Mortimore B., O'Callaghan M., Parsons J.,
Percy C., Rifken L., Roopra A., Saunders D., Shownkeen R., Sims M., Smaldon
N., Smith A., Smith M., Sonnhammer E., Staden R., Sulston J., Thierry-Mieg J.,
Thomas K., Vaudin M., Vaughan K., Waterston R., Watson A., Weinstock L.,
Wilkinson-Sproat J. and Wohldman P. (1994) 2.2 Mb of contiguous nucleotide
sequence from chromosome III of C. elegans. Nature, 368, 32-38.
Winship P.R. (1989) An improved method for directly sequencing PCR amplified
material using dimethyl sulphoxide. Nucl. Acids Res. 19, 1266-1226.
Wright P., Gill M. and Murray R.M. (1993) Schizophrenia: genetics and the
maternal immune response to viral infection. Am. J. Med. Genet. 48, 40-46.
Wyatt R.J., Alexander R.C., Egan M.F. and Kirch D.G. (1988) Schizophrenia,
just the facts. What do we know, how well do we know it? Schizophr. Res. 1, 3-
18.
Yang L., Li T., Wiese C., Lannfelt L., Sokoloff P., Xu C.T., Zeng Z., Schwartz
333
J.C., Liu X. and Moises H.W. (1993) No association between schizophrenia and
homozygosity at the D3 dopamine receptor gene. Am. J. Med. Genet. 48, 83-
86.
Yanisch-Perron C., Vieira J. and Messing J. (1985) Improved M13 phage
cloning vectors and host strains: nucleotide sequence of the M13mp18 and
pUC19 vectors. Gene, 33, 103-119.
Yon S., Palmer R.W., Sheer D. and Fried M. (1989) Localisation of the surfeit
gene cluster containing the ribosomal protein L7a to chromosome bands 9q33-
34. Ann. Hum. Genet. 53, 149-155.
Zamani M.G., De Hert M., Spaepen M., Hermans M., Marynen P., Cassiman
J.J. and Peuskens J. (1994) Study of the possible association of HLA class II,
CD4, and CD3 polymorphisms with schizophrenia. Am. J. Med. Genet. 54, 372-
377.
Zatz M., Vallada H., Melo M.S., Passos Bueno M.R., Vieira A.H., Vainzof M.,
Gill M. and Gentil V. (1993) Cosegregation of schizophrenia with Becker
muscular dystrophy: susceptibility locus for schizophrenia at Xp21 or an effect of
the dystrophin gene in the brain? J. Med. Genet. 30, 131-134.
Zheng Y., Jung M.K. and Oakley B.R. (1991) Gamma-tubulin is present in
Drosophila melanogaster and Homo sapiens and is associated with the
centrosome. Cell, 65, 817-823.
334
PAPERS PRESENTED DURING
THE COURSE OF THIS THESIS
335
1644-1645 Nucleic Acids Research, 1995, Vol. 23, No. 9 © 1995 Oxford University Press
Splinkerettes—improved vectorettes for greater
efficiency in PCR walking
Rebecca S. Devon*, David J. Porteous and Anthony J. Brookes
MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Received October 3, 1994; Revised and Accepted November 25, 1994
Vectorettes enable PCR amplification of DNA sequences which
lie between a single known primer and a nearby restriction site.
They have been applied in the isolation of end fragments from
YAC recombinants (1) and also in PCR walking (2). Vectorettes
consist of a double-stranded linker sequence with a central region
ofmismatch and a cohesive end suitable for ligation to restriction
enzyme-digested DNA (Fig. 1). The vectorette primer employed
in the PCR is exactly the same sequence as the mismatched
portion of the upper strand, and therefore cannot anneal to and
initiate priming from the vectorette until its complementary
sequence has been synthesised by polymerase extension from the
specific target DNA primer.
The specificity of the vectorette PCR reaction is, however, not
absolute. Illegitimate products result from non-specific annealing
ofeither primer and from a reaction we term 'end-repair' priming.
End-repair priming involves the free cohesive ends of unligated
vectorettes and inserts which are based on restriction sites that
produce 5' overhangs. These ends are filled in during the first
cycle of the PCR reaction. After the subsequent denaturing step,
these ends are able to anneal to each other with sufficient stability
to initiate priming (3). Extension across a vectorette sequence at
either end of the insert molecule will result in the production of
a sequence complementary to the vectorette primer, allowing
exponential PCR amplification without involvement of the
specific target DNA primer. Vectorette dimers will also be
produced by end-repair priming, but will not be amplified in the
PCR because the two halves will form a stable hairpin structure
which will be refractory to amplification.
The splinkerette we describe here is designed to decrease
end-repair priming. Rather than a central DNA mismatch, the
splinkerette incorporates a hairpin structure on the bottom strand
(Fig. 1). The primer is of the same sequence as the top strand and
therefore, as with the vectorette, is unable to act as a primer until
the complement of this strand has been synthesised. In a PCR
reaction the free 3' end of the bottom strand will flip back on itself
to form a hairpin and begin elongation further along the bottom
strand. The resulting double-stranded structure is stable and is
functionally removed from further reaction. It is therefore not
able to cause end-repair priming. Furthermore, in the splinkerette
system, only the top strand is available to act as a non-specific
primer whereas in the vectorette system both the top strand
(which after end-repair is four bases longer than that of the
splinkerette) and the bottom strand could causemispriming in this





- mismatched region j
primer
Figure 1. Schematic diagram of the vectorette and splinkerette.
covalent bond between the splinkerette bottom strand and the
DNA to be amplified. This avoids elongation from the hairpin
along the whole length of the insert molecule.
Here we demonstrate the practical advantages of splinkerettes
over vectorettes by comparing the efficiency ofboth in producing
unique products from the complex resource of total human
genomic DNA. To enable direct comparison, splinkerettes and
vectorettes were designed to be compatible with a single primer.
For small target PCR products (< 500 bp) it was found that the
efficiency of both the splinkerette and vectorette was adequate to
produce the expected products after one or two rounds of PCR
(data not shown). However, Figure 2 shows the advantages of
splinkerettes over vectorettes in the amplification of larger
fragments where formation of the target product may be hindered
by increased competition from end-repair primed artefacts. A 2.3
kb fragment from the WT1 gene (4) was successfully amplified
only with the splinkerette. We ascribe the reproducible failure of
vectorette PCR to amplify this fragment, and the smear of
non-specific products instead resulting, to end-repair priming.
The usefulness of splinkerette PCR has been further demon¬
strated by the routine isolation of long end fragments (up to 3.6
kb) from YAC recombinants (5).
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Figure 2. Comparison of splinkerettes and vectorettes in PCR walking. The
target PCR product was a 2.3 kb fragment derived from the WTI gene (3).
Vectorettes were obtained from ICI. Splinkerettes were made by duplexing the
top strand (5'-CGA ATC GTA ACC GTT CGT ACG AGA ATT CGT ACG
AGA ATC GCT GTC CTC TCC AAC GAG CCA AGG-3') and the bottom
strand (5 '-GATCCC TTGGCTCGTTTT TTT TTG CAA AAA-3') by mixing
the oligonucleotides (150 pg/ml each) at 90°C in 10 mM Tris-HCl (pH 7.4),
5 mM MgCl2 and leaving to cool to room temperature. Total human genomic
DNA was digested with BamHl and ligated with a 15 x molar excess of
splinkerettes or vectorettes in 20 pi for 4Vi h at room temperature. PCR
combined Hot Start (6) and Touchdown (7) protocols and conditions were as
follows: denaturation, 95 °C for 30 s in the first cycle and 15 s thereafter;
annealing, for 1 min at 71 °C initially, decreasing by 2°C to 61 °C per cycle and
61 °C thereafter; extension, 72°C for 2 min (cycles 1-10), then 4 min (cycles
11-20) and finally 6 min (cycles 21-30). In the primary PCR reaction 1 pi of
ligation product was amplified in 50 pi using 400 ng WTI primer (5'-CCA
AGG GCC GTG AGG ATA GCG GAA G-3') and 250 ng splinkerette/vecto-
rette primer (5 '-CGA ATC GTA ACC GTT CGT ACG AGA A-3'). Secondary
PCR was performed using 1 pi primary PCR product, 400 ng internal WTI
primer (5'-GCA CGC AGG CAC TGG CCC CCG ACA T-3') and 250 ng
internal splinkerette/vectorette primer (5'-TCG TAC GAG AAT CGC TGT
CCT CTC C-3'). Tracks 1 and 2 show 10 pi vectorette and splinkerette
secondary PCR product respectively resolved on a 1% agarose gel. The marker
is the 1 kb ladder (Gibco-BRL). No product was visible after primary PCR for
either the vectorette or the splinkerette. Tracks 3 and 4 show results of Southern
blot analysis of tracks 1 and 2, respectively, with a 1.1 kb probe derived from
within the target PCR product.
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Forty-nine clones derived by microdissection of a
schizophrenia-associated t(l;ll)(q42.1;ql4.3) break¬
point region have been assigned by somatic cell hybrid
mapping to seven discrete intervals on the long arm
of human chromosome 11. Eleven of the clones were
shown to map to a small region immediately distal to
the translocation breakpoint on llq. A 3-Mb contigu¬
ous clone map of this region was established by isola¬
tion of corresponding YAC recombinants. The contig
was oriented and shown to traverse the translocation
breakpoint by FISH and microsatellite marker analy¬
sis. This contig will facilitate the isolation of candidate
sequences whose expression may be affected by the
translocation. © 1995 Academic Press, Inc.
INTRODUCTION
Progress toward a comprehensive map of the human
genome has been greatly accelerated by the advent of
YAC cloning for physical mapping and the utilization
of microsatellite repeats for genetic mapping. Indeed,
framework physical and genetic maps of the entire ge¬
nome are now in place (NIH/CEPH Collaborative Map¬
ping Group, 1992; Weissenbach et ol., 1992; Cohen et
al., 1994). Nevertheless, the limited resolving power of
conventional linkage mapping and the effect of YAC
chimerism on contig assembly mean that considerable
effort is still required to map accurately subchromoso-
mal regions ofparticular clinical interest. Human chro-
1 To whom correspondence should be addressed. Telephone: (44)
31-332 2471, x2121. Fax: (44) 31-343 2620. Email: davep@hgu.mrc.
ac.uk.
mosome 11 is one of the better mapped chromosomes
(Evans, 1993; James et al., 1994), but as is also true
for all other chromosomes, there is a relative dearth of
markers in certain subregions. This reflects, at least in
part, the manner in which markers are selected and
the inherent biases in certain cloning procedures for
or against subclasses of nonrandomly distributed
DNA sequences. One such poorly mapped region is
llql4—q21, between tyrosinase (TYR) and the marker
D11S388 on the long arm of human chromosome 11, a
distance estimated to be ~ 8 cM (NIH/CEPH Collabora¬
tive Mapping Group, 1992). We have previously shown
that a balanced translocation, t(l;ll)(q42.1;ql4.3),
which cosegregates with schizophrenia and other se¬
vere mental illness in a large Scottish pedigree (St.
Clair et al., 1990), breaks in this region (Fletcher et al.,
1993).
To characterize the molecular nature of this translo¬
cation breakpoint, it was first necessary to obtain new
markers for this region. To this end, we undertook to
microdissect and microclone the region directly from
the der(l) translocation chromosome (Muir et al.,
1995). In situ hybridization "painting" of the microdis¬
section library back onto metaphase chromosomes from
the translocation patient had shown that approxi¬
mately 50% of the cloned material derived from chro¬
mosome 1, immediately proximal to the breakpoint,
and approximately 50% from chromosome 11, immedi¬
ately distal to the breakpoint. The cloned inserts aver¬
aged 1.5 kb in length and thus were potentially suitable
for direct hybridization screening of genomic libraries
and Southern blots. We have also described previously
a panel of somatic cell hybrids bearing reduced human
chromosomes 11, which permit high-resolution local-
0888-7543/95 $12.00
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ization of such markers on the long arm (Fletcher et
al., 1993; Evans et al., 1993, 1995; Slorach et al., 1995).
The objectives of this study were (a) to localize re¬
gionally microdissection-derived clones (MDs) on the
long arm ofchromosome 11 by somatic cell hybrid map¬
ping, (b) to use those mapping closest to the transloca¬
tion breakpoint as probes to isolate YAC recombinants,
and (c) to construct a contiguous clone map across the
region of chromosome 11 disrupted by the schizophre¬
nia-associated translocation. This would provide a
starting point for studies aimed at determining the mo¬
lecular nature of that breakpoint and the effect it may
have on the expression of neighboring genes. This
study demonstrates the utility of the microdissection
clones as hybridization probes. Using just five of the
microdissection clones that map to the interval on llq
closest to the breakpoint, we were able to establish a
contig map of ~3 Mb with only a single gap. Isolation
of critical end clones and one further round of YAC
library screening allowed that gap to be filled and vali¬
dated the contig. Fluorescence in situ hybridization and
microsatellite marker analysis were used to establish
orientation and to confirm that this contiguous clone
map on chromosome 11 did extend over the transloca¬
tion breakpoint.
MATERIALS AND METHODS
Somatic cell hybrid lines. A subset of hybrid cell lines from our
previously described chromosome llq mapping panel (Fletcher et al.,
1993; Evans et al., 1993, 1995; Slorach et al., 1995) was used to
localize the microdissection clones regionally. The hybrids MIS 7.4,
PG48, CF52, WJX 5.4,WJX 11.2, and E67.4 constitute the minimum
set that defines all discernible intervals distal to the t(l; 11)
(q42.1;ql4.3) translocation breakpoint and are described briefly be¬
low. MIS 39.8 was used to define the region on human chromosome
11 centromeric to the t(l;ll)(q42.1;ql4.3) translocation breakpoint.
(a) MIS 7.4 and MIS 39.8 are mouse hybrids formed by fusion of
a human lymphoblastoid cell line carrying the t(l;ll)(q42.1;ql4.3)
and retain several human chromosomes but carry only the der(l)
and der(ll) translocation chromosomes, respectively, in the absence
of any normal chromosome 1 or 11 material.
(b) PG48 is a hamster hybrid that retains several human chromo¬
somes but whose only human chromosome 11 material is a translo¬
cated chromosome 11, which lacks llq22-qter.
(c) CF52 is a mouse hybrid that retains several human chromo¬
somes but has as its only human chromosome 11 component a
t(ll;16)(ql3;pll) translocation chromosome.
(d) The X irradiation hybrids, WJX 5.4 and WJX 7.4, are hamster
hybrids that contain multiple subfragments of human chromosome
11 (derived from the human chromosome 11-only hamster hybrid
J1), obtained by positive selection for expression of human-specific
cell surface markers encoded by genes on llq.
(e) The HRASl-selected chromosome-mediated gene trans-
formant, E67.4, is a mouse hybrid that carries a single human trans-
genome comprising only human chromosome 11 material, derived
from both the short and the long arms with multiple interstitial
deletions.
Cell culture methods and DNA isolation. Standard conditions
were used, as described previously (Fletcher et al., 1993).
Mapping of microdissection clones to somatic cell hybrids. The
microdissection, microcloning, and preparation of inserts is described
m detail elsewhere (Muir et al., 1995). Briefly, inserts of individual
microdissection clones were amplified by PCR using primers flanking
the EcoRI cloning site. Vector sequences were removed by EcoRI
digestion and electrophoresis through 1% LMP agarose. The inserts
were labeled by random priming and then hybridized directly to
Southern blots of EcoRI restriction digested hybrid DNA (~5 pg/
track). Southern blots were hybridized at 68°C and washed to O.lX
SSC at 68°C. Hybridization signal was detected by a Molecular Dy¬
namics Phosphorlmager after exposure for 24 h.
Mapping of D11S931 and D11S873 to somatic cell hybrids and
YAC recombinants. Previously published primers and PCR condi¬
tions for amplification of D11S931 (Weissenbach et al., 1992) and
D11S873 (Litt et al., 1993) were used.
YAC libraries. The ICI YAC library (Anand et al., 1990) was grid-
ded by one of us (B.A.) at the UK HGMP Resource Centre, London.
The library consists of approximately 35,000 YAC recombinants grid-
ded on 23 filters of 8 X 12 cm using a 96-pin device. The average
insert size is approximately 350 kb, and the theoretical complexity
of the library is therefore >3.5 genome equivalents. Duplicate filters
of three of the large-insert high-density gridded ICRF YAC libraries
(Lehrach et al., 1990; Larin etal., 1991) comprising—21,000 clones in
total and representing —3 genome equivalents were made available
(courtesy of Hans Lehrach) through the ICRF Reference Library Da¬
tabase.
YAC library screening. Microdissection clones from the interval
immediately distal to the translocation breakpoint on chromosome
11 were prepared as described above and used to screen the ICI
and ICRF YAC libraries by filter hybridization. The microdissection
clones chosen, MD 283 (ICI library screening only), MD 122, MD
176, MD 220, and MD 471, were those that failed to hybridize to
human Cot I DNA and that showed no evidence of repetitive content,
as judged by hybridization to Southern blots of human genomic DNA
digests.
Isolation of YAC DNA. DNA was prepared from YAC recombi¬
nants by standard procedures described elsewhere (Arveiler, 1994).
Isolation of YAC end clones. The vectorette method used was as
originally described (Riley et al., 1990) using Sau3Al compatible
ends. Total yeast DNA was digested with BamHI, Bgl II or BcZI
before ligation. The PCR employed a "hot-start" (Chou et al., 1992).
Conditions were 95°C for 40 s, 72°C for 4 min (cycles 1 to 10), 5 min
(cycles 11 to 20), 7 min (cycles 21 to 30), and finally 10 min (cy¬
cle 31).
The splinkerette method was essentially as described elsewhere
(Devon et al., 1995). Total yeast DNA was digested with BamHI plus
BglII and ligated to duplexed oligonucleotides with Saa3AJ compati¬
ble ends. The PCR employed hot-start (Chou et al., 1992) and "touch
down" (Don et al., 1991) conditions. Secondary amplification with a
primer internal to the left arm YAC primer was sometimes used.
The YAC arm primers were derived from those described previously
for inverse PCR (Arveiler and Porteous, 1991). Splinkerette PCR:
left arm YAC primer, 5' CCC GTC CTG TGG ATC AAT TC 3'; left
arm internal, 5' GCC AAG TTG GTT TAA GGC GC 3'; right arm
YAC primers, 5' GCT CCT TCC TTC GTT CTT CC 3' or 5' CCA
CCA TAC CCA CGC CGAAAC AA 3'. Splinkerette oligonucleotides:
upper, 5' CGA ATC GTA ACC GTT CGT ACG AGA GTT CGT ACG
AGA ATC GCT GTC CTC TCC AAC GAG CCA AGG 3'; lower, 5'
GAT CCC TTG GCT CGT TTT TTT TTG CAA AAA 3'. Splinkerette
primer, 5' CGA ATC GTA ACC GTT CGT ACG AGA A3'; PCR
conditions, denaturation, 94°C, 30 s (cycle 1) and then 15 s to end;
annealing, 70 -» 60°C (by 2°C per cycle) and then 60°C to end for 1
min; extension, initially 3 min (cycles 1 to 10), then 5 min (cycles 11
to 20), and finally 8 min (cycles 21 to 30) at 72°C.
Catch tinkering of YAC recombinants. The method has been de¬
scribed in detail elsewhere (Shibasaki et al., 1995). Briefly, YAC
recombinants were separated from the yeast chromosomes by analyt¬
ical PFGE (—5 p.g of total yeast DNA), digested with Sau3Al, ligated
to a compatible oligonucleotide duplex (upper strand, 5' CCG AAT
TCT AGA GTC GACC 3'; lower strand, 5' GAT CGG TCG ACT CTA
GAA TTC G 3'), and PCR primed and amplified using the upper-
strand oligonucleotide as follows: 35 cycles of 93°C for 15 s; 54°C for
30 s; 72°C for 1 min (cycles 1-10), then 2 min (cycles 11-20), and
finally 4 min (cycles 21-35).
TABLE 1
Regional Mapping of Microdissection Clones
MD
clone GDB No. MIS 7.4 CF52 PG48 WJX7.4 WJX5.4 E67.4
MD 543 D11S2107 + + + + _ +
MD 104 D11S2108 + + + + - +
MD 282 D11S2109 + + + + - +
MD 437 D11S2110 + + + + - +
MD 220 D11S2111 + + + + - +
MD 286 D11S2112 + + + + - +
MD 283 D11S2113 + + + + - +
MD 176 D11S2114 + + + + - +
MD 122 D11S2115 + + + + - +
MD 412 D11S2116 + + + + - +
MD 471 D11S2117 + + + + - +
D11S873 + + + + - +
MD 174 D11S2129 + + + — — -
MD 139 D11S2130 + + + - - -
D11S388 + + + - - -
MD 128 D11S2118 + + + — - +
MD 118 D11S2119 + + + - - +
MD 310 D11S2120 + + + - - +
MD 130 D11S2122 + + + - - +
MD 040 D11S2123 + + + - - +
MD 159 D11S2124 + + + - - +
MD 129 D11S2125 + + + - - +
MD 377 D11S2126 + + + - - +
MD 421 D11S2127 + + + - - +
MD 281 D11S2128 + + + - - +
MD 074 D11S2121 + + + - - +
MD 558 D11S2131 + + + — + +
MD 330 D11S2132 + + + - + +
MD 173 D11S2138 + + + - + +
MD 038 D11S2139 + + + - + +
MD 021 D11S2140 + + + - + +
MD 063 D11S2141 + + — _ + +
MD 136 D11S2142 + + - - + +
MD 027 D11S2143 + + - - + +
MD 151 D11S2144 + + - - + +
MD 509 D11S2145 + + - - + +
MD 211 D11S2146 + + - - + +
MD 116 D11S2147 + + - - + +
MD 388 D11S2148 + + - - + +
MD 596 D11S2149 + + - - + +
MD 075 D11S2150 + + - - + +
MD 399 D11S2151 + + - - + +
CLG + + - - + +
STMY1 + + - - + +
D11S385 + + - - + +
MD 110 D11S2152 + + _ _ _ +
MD 453 D11S2153 + + - - - +
MD 214 D11S2154 + + - - - +
NOAM + + - + - +
DRD2 + + - + - -
MD 096 D11S2155 + + _ _ + _
MD 054 D11S2156 + + - - + —
MD 162 D11S2157 + + - — + -
MD 044 D11S2158 + + - - + -
MD 215 D11S2159 + + - - + —
MD 277 D11S2160 + + - - + -
D11S351 + + ND - + -
THY1 + + ND - + -
Note. The table summarizes the hybridization results of 49 microdissection clones assigned to chromosome 11 and regionally mapped
using the chromosome llq mapping panel. Established markers mapped previously to the panel are included for reference. In many cases,
microdissection clones were placed in a previously defined interval, but in several cases (e.g., MD 021; see Fig. lb) the segregation pattern
identified a new interval. In this situation markers were arranged in the order that assumed the least number of independent blocks of
human DNA in the various hybrids. +, present; —, absent; ND, not determined.
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Note. The table summarizes the results ofhybridization of each of the 11 microdissection clones in the interval closest to the translocation
breakpoint to restriction-digested DNA from all 23 of the YACs obtained by screening with MDs 220, 283, 176, 122, and 471.
The whole catch linker product was directly labeled for use as a
FISH probe by PCR amplification using the upper-strand primer
biotinylated at the 5' end (Shibasaki et al., 1995). Catch linkered
products were also cloned by Sau3Al digestion and ligation into the
BamHI cloning site ofpBluescribe (Stratagene). Inserts from individ¬
ual colonies were recovered by reamplification using universal prim¬
ers flanking the cloning site (Gussow and Clackson, 1989).
Fluorescence in situ hybridization. Interphase and prometaphase
chromosomes were prepared essentially as described previously (Shi¬
basaki, 1994) from fresh peripheral blood lymphocytes or lympho-
blastoid cell lines from individuals either with a normal karyotype
or bearing the t(l;ll)(q42.1;ql4.3) chromosomes. Cosmids corre¬
sponding to selected MD clones were obtained by hybridization to
gridded filters of the ICRF Reference Library No. 107(L4/FS11) con¬
structed by D. Nizetic (Lehrach et al., 1990). YAC in situ hybridiza¬
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FIG. 1. Regional mapping ofmicrodissection clones to the hybrid
Panel. The figure shows representative results with two microdissec¬
tion clones, (a) MD 021 and (b) MD 283. Both clones hybridize to
MIS 7.4, the hybrid representing the microdissected chromosome.
The pattern ofhybridization observed in the other hybrids was used
assign each clone to an interval distal to the t(l;ll)(q42.1;ql4.3)
translocation breakpoint (see Table 1). The marker is the 1-kb ladder
(Gibco BRL). The size of the hybridizing fragment corresponds to
that of the particular insert, as EcoRI was used both to produce the
Microdissection clone insert and to digest the target genomic DNA.
in detail elsewhere (Shibasaki et al., 1995). Chromosomal in situ
suppression hybridization was used throughout (Lichter et al., 1988;
Shibasaki, 1994). Cosmid DNA and AZu-PCR products of YACs were
labeled by nick-translation using either bio-16-dUTP or DIG-11-
dUTP. Catch-linkered YAC inserts were labeled directly by PCR
using biotinylated primer (Shibasaki et al., 1995). The signal detec¬
tion for the biotin-avidin system was performed according to Pinkel
et al. (1986) using FITC-avidin DCS (Vector Labs) and biotinylated
anti-avidin antibody (Vector Labs). For multicolor FISH, DIG-labeled
probes were visualized together with biotin-labeled probes by using
mouse monoclonal anti-DIG antibody (Boehringer Mannheim), rab¬
bit anti-mouse antibody conjugated to Texas red (Jackson Immuno-
Research Lab.), and mouse anti-rabbit antibody conjugated to Texas
red (Jackson ImmunoResearch Lab.). To generate yellow color, equal
amounts of biotin- and DIG-labeled probes were cohybridized and
detected by FITC and Texas red. FISH slides were examined under
a Zeiss AxioPhoto microscope equipped with a Photometries CCD
FIG. 2. Isolation ofYAC end clones and "catch linker" products,
(a) The molecular weight marker is Haelll-digested 0X174. Lanes
1 to 4 show end clones isolated by splinkerette PCR from the left
arm of ICI yacs 19EE2, 21BG4, 2AH11, and 33EB11, respectively.
Note that the products from 19EE2 and 21BG4 are indistinguishable
in size, part of the evidence for these YACs being an identical set,
together with ICI yac 11BA9. (b) The molecular weight marker is
.f/aelll-digested 0X174. CL is the primary catch linker PCR product.
Lanes 1 to 8 show amplified inserts after cloning into pBluescribe,
as described under Materials and Methods.
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TABLE 3
Localization and Characterization ofMD-Derived Cosmid and YAC Clones by PFGE and FISH
Clone designation Size Location Note End clones mapped to
cos Tyr 7H3 (TYR) <40 kb Uql4.3
«•
ICI yac 12GE1 (TYR) 350 kb Uql4.3 CL
ICRF cl07 A0551 (MD104) <50 kb Uql4.3-q21
ICRF cl07 F790 (MD220) <50 kb Ilql4.3-q21
ICRF cl07 A0543 (MD283) <50 kb Ilql4.3-q21
ICRF y901 D0485 1.3 Mb Uql4.3-q21 CL, cosmid subclones (cYS4) L: 36IF5, 6DB11, 14LA11
ICI yac 36IF5 600 kb Ilql4.3-q21, 5pl4 AZu-PCR, CL, chimeric, L: D0485
cosmid subclones (cYS2) R: chimeric end
ICI yac 141All 350 kb Uql4.3-q21 CL
ICRF y900 A0846 600 kb Uql4.3-q21 CL L: 36IF5, 6DB11, 14IA11
R: D11155, 11EA9, 15IE11, 16GB9
ICRF y900 D11155 700 kb Uql4.3-q21 CL L: A04135, 8AB2, D0165
R: A0846
ICI yac 11EA9 270 kb Uql4.3-q21 CL L: D11155, 15IE11, 16GB9, 11BA9, C04151
R: A0846, 37GE11, 35IA2, D11155
ICI yac 15IE11 240 kb Ilql4.3-q21 CL
ICI yac 16GB9 330 kb Uql4.3-q21 CL, cosmid subclones (cYS3) L: 11BA9, 2AH11
R: 11EA9, 15IE11
ICI yac 11BA9 300 kb Ilql4.3-q21 Alu-PCR L: 11EA9, 15IE11, 16GB9
ICI yac 2AH11 200 kb Uql4.3-q21 A/u-PCR L: 15IE11, 16GB9, 11BA9,
ICI yac 33EB11 350 kb Uql4.3-q21, Alu-PCR, CL, chimeric L: chimeric end
18q23 R: 16GB9, 11BA9, 2AH11
ICRF y900 A04135 700 kb Uql4.3-q21 CL L: D11155, 11BA9, 2AH11, C04151
R: H0921
ICI yac 8AB2 260 kb Uql4.3-q21 Alu-PCR R: A04135, 5FD7, D0165, H0921, 34GE5
ICI yac 38CE7 280 kb Ilql4.3-q21, 19? A/u-PCR, chimeric? R: 8AB2, 34GE5
ICI yac 5FD7 250 kb Uql4.3-q21 CL L: 8AB2, 34GE5, 38CE7
cosCJ52.4 (D11S388) <50 kb llq21
Note. The table summarizes the cosmid and YAC clones used in FISH analysis, the insert sizes of the YACs as estimated by pulsed-field
gel electrophoresis, their localization on the long arm of chromosome 11, and how they were labeled and identifies those shown or suspected
to be chimeric. YAC clones from which end clones and subfragments were isolated are also identified. CL, catch linker plus PCR labeling;
L, left arm YAC end clone; R, right arm YAC end clone.
camera and an IPLab image analyzing system on an Apple Macintosh
computer or a Leiz microscope equipped with a Bio-Rad MRC-600
confocal laser scanning system.
RESULTS
We have described elsewhere a somatic cell hybrid
mapping panel that allows precise localization ofmark¬
ers on the long arm ofhuman chromosome 11 (Fletcher
et al., 1993; Evans et al., 1993, 1995; Slorach et al.,
1995). By combining somatic cell hybrids bearing
translocation chromosomes with stable, positively se¬
lected radiation-reduced or chromosome-mediated
gene transformant hybrids, it was possible to assemble
a panel that facilitated high-resolution mapping in the
region immediately distal to the t(l; 11) breakpoint
from a minimum of genomic DNAs. This has obvious
advantages over the use of large sets of transient radia¬
tion hybrids (James et al., 1994), not least the fact that
these hybrids represent a stable replenishable map¬
ping resource and allow direct hybridization to be used
in addition to PCR-based mapping procedures. Eighty-
six microdissection-derived clones (MDs) were mapped
onto a subpanel of just six somatic cell hybrids that
FIG. 3. An 3-Mb contig on chromosome Ilql4-q21. The figure shows the contig in diagrammatic form and approximately to scale. All
YACs have been tested with all MDs, and their presence is indicated by a solid vertical bar. Isolated YAC end clones are indicated, and
their presence in other YACs is marked by a bar. Not all of the YACs have been tested with all of the end clones, and this is indicated by
a "?". Chimeric YACs are asterisked, and the region of chimerism is indicated where known. Only minimum addresses are shown for each
YAC (see text and Tables 2 and 3 for full details).
FIG. 4. Orientation of the contig and breakpoint analysis by multicolor FISH, (a) Triple-color FISH analysis reveals the order of MD
104 (ICRF cl07 A0551, red) and MD 220 (ICRF cl07 F790, yellow) relative to TYR (ICI yac 12GE1, green), establishing the orientation of
the contig. Note that the distance between TYR (green) and MD 104 (red) is much greater than that between MD 104 (red) and MD 220
(yellow), (b) The result of triple-color FISH using MD 283 (ICRF cl07 A0543, green), ICRF y900 A0846 (red), and MD 176/122 (cYS3-pool,
yellow), placing the YAC into the gap of the first-generation contig. This result also confirms the orientation of the contig with respect to
the translocation breakpoint, (c) A partial metaphase plate of a patient carrying the reciprocal t(l; 11) chromosomes hybridized with catch-
linkered ICRF y901 D0485. Confined signals are seen on the der(ll) as well as the der(l) and normal chromosome 11, demonstrating that
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included the hybrid, MIS 7.4, bearing the schizophre¬
nia-associated der(l) translocation chromosome. Rep¬
resentative hybridization results are shown in Fig. 1.
Of these 86 MDs, 49 were localized to intervals on llq,
while the remaining 37 (43%) hybridized only to MIS
7.4 and were therefore provisionally assigned to chro¬
mosome 1.
All 49 of the chromosome 11 assigned microdissec¬
tion clones mapped to or above the interval defined
by THYI (see Table 1), in general agreement with the
expectation from our previous FISH "painting" analy¬
sis of the library (Muir et al., 1995). Microdissection
clones were mapped to all intervening intervals defined
by the hybrid panel, with the exception of those marked
by NCAM and by DRD2. Other studies have shown
that these genes map within ~500 kb of each other
(McConville et al., 1990). The microdissection clones
also define two new intervals on chromosome 11. Most
importantly, 11 map to a region immediately distal
to the breakpoint, as defined by the microsatellite
D11S873, a recently defined marker that lies centro-
meric to D11S388 (Litt et al., 1993; Evans et al., 1995).
These results are therefore in keeping with our previ¬
ous estimate that the microdissected region on chromo¬
some 11 corresponds to ~15 Mb (Muir et al., 1995) and
the expectation that the markers approximate
to a normal distribution around the translocation
breakpoint itself. The distance separating TYR and
D11S388 has been estimated to be ~8 cM and that
between D11S873 and D11S388 to be ~2.4 cM (NIH/
CEPH Collaborative Mapping Group, 1992; Weissen¬
bach et al., 1992). It was therefore considered likely
that the 11 MDs mapped to the "breakpoint-DHS873"
interval would be sufficient to isolate a complete YAC
contig of the region.
Isolation of YAC Recombinants
To construct a contiguous clone map toward the
translocation breakpoint, five repeat-free microclones
(MD 220, MD 283, MD 176, MD 122, and MD 471)
were selected from this set of 11 and used as direct
hybridization probes to gridded filters of YAC recombi¬
nants. Two libraries were screened, the ICI YAC li¬
brary (Anand et al., 1990) (courtesy of the UK HGMP
Resource Centre) (with all five MDs) and the ICRF
Reference Library (Larin et al., 1991) (courtesy of Dr.
Hans Lehrach) (MD 283 not used). A total of 23 inde¬
pendent YAC recombinants were obtained. These were
reprobed with the remaining six microdissection clones
to assemble a first-generation contig map as shown in
Table 2. By this simple screening procedure, a contig
map was assembled with just a single gap (between
MD 283 and MD 176), but it contained no information
regarding orientation (relative or absolute), net size, or
extent of overlap between YACs.
Isolation of YAC Endclones and Gap Closure
To confirm the first-generation contig map and
achieve closure of the single gap, end clones were iso¬
lated from selected YAC recombinants by either the
vectorette (Riley et al., 1990) or the splinkerette (Devon
et al., 1995) methods (Fig. 2a) and probed onto the
primary set of 23 YACs. In addition, selected YAC re¬
combinants were purified and ligated to catch linkers
for PCR amplification (Fig. 2b). Single-copy subclones
isolated from plasmid libraries, derived from catch
linkered material, were also used to confirm overlaps
between YAC recombinants and as additional markers
for genomic hybridization. YAC recombinants were
sized by pulsed-field gel electrophoresis as summarized
in Table 3 and analyzed with end clones. Secondary
screening of the ICI YAC library was carried out with
the right arm end clone of ICI yac 11EA9, which identi¬
fied ICI yacs 37GE11 and 35IA2. Isolation of a left arm
end clone from ICI yac 37GE11 confirmed the link from
ICRF y900 A0846 through the ICI yacs 14IA11 and
36IF5 and therefore to ICRF y900 D0485 (see Table 3
and Fig. 3). This analysis allowed us to establish the
consensus map shown in Fig. 3. Note that the marker
positions are relative, not absolute. The estimated end-
to-end length of the contig map is ~3.5 Mb. When the
most telomeric and only partially characterized YAC
ICRF y905 H0921 is excluded, the validated contig,
which extends across the translocation breakpoint, is
itself greater than 2.8 Mb. This follows from the insert
sizes of ICRF y901 D0485, ICRF y900 A0846, ICI yac
2AH11, and ICRF y900 A04135, which alone sum to
~2.8 Mb, but this does not take into account the two
internal regions represented by (a) MD 286 and MD
283 (three positive overlapping YACs) or (b) the left
end clone of ICI yac 11EA9 (five positive overlapping
YACs). The core contig, that is, excluding the terminal
regions represented only by D0485 and H0921, respec¬
tively, sums to —2.2 Mb. This agrees well with the size
estimate based on (i) our previous mapping results, (ii)
the known genetic distance between flanking markers,
and (iii) the estimated physical distance based on our
previous FISH analysis (Muir et al., 1995).
Establishing Orientation and Crossing the
Translocation Breakpoint
To establish the orientation of the cloned contig,
FISH analysis on prometaphase and interphase chro¬
mosomes was undertaken, with reference to estab¬
lished, previously mapped markers (Fig. 4). Figure 4a
shows a representative result, using the TYR locus (in
the form of ICI yac 12GE1) as a reference marker in
green and cosmids isolated using two microdissection
clones MD 104 and MD 220 in red and yellow, respec¬
tively. The demonstration that MD 104 maps between
TYR and MD 220 establishes orientation of the contig
with respect to the chromosome 11 centromere and
therefore the translocation breakpoint. This result was
confirmed by independent analysis of (a) additional cos-
mid clones (either derived by screening with microdis¬
section clones or subcloned from YAC recombinants)
and (b) catch linkered total YAC probes (Table 3). Fig-
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ure 4b shows a similar analysis with cosmid clones
corresponding to MD 283 (green) and MD 176/122 (yel¬
low) plus catch linkered ICRF y900 A0846 (red).
The orientation of the contig as determined by FISH
predicts that the YAC recombinant ICRF y901 D0485
maps closest to the translocation breakpoint. To test
this, the YAC insert was purified by catch linker ampli¬
fication and hybridized to lymphocyte metaphase
spreads from a schizophrenic patient carrying the
translocation (Fig. 4c). Signal was seen on both the
der(l) and the der(ll) chromosomes, establishing that
this YAC recombinant does cross the translocation
breakpoint. In addition, the signal was confined to the
normal chromosome 11 and to the derived chromo¬
somes 1 and 11, confirming that this YAC recombinant
is nonchimeric. Independent confirmation of this result
was obtained by PCR analysis of somatic cell hybrid
DNAs and the YAC recombinant ICRF y901 D0485
using primers specific for the microsatellite repeat
marker D11S931 (Weissenbach et al., 1992). Two frag¬
ments of 261 and 265 bp were amplified from total
genomic DNA from a t(l; 11) subject. No band was am¬
plified from MIS 7.4, the patient-derived hybrid that
contains the der(l) chromosome as its sole chromosome
11 material. Only one band, of 265 bp, was amplified
from MIS 39.8, the patient-derived hybrid that carries
the der(ll) chromosome as its sole chromosome 11 ma¬
terial. PCR analysis of the YAC recombinants showed
that only ICRF y901 D0485 was positive for D11S931.
These results demonstrate that the t(l; 11) breakpoint
lies within the region flanked by D11S931 (centro-
meric) and MD 104 (telomeric) and represented by
ICRF y901 D0485.
DISCUSSION
This study demonstrates the value ofmicrodissection
for establishing a very high density of region-specific
markers. Forty-nine newmarkers have been regionally
localized on the long arm of human chromosome 11,
of which more than a fifth map to a small interval
immediately telomeric to the t(l; 11) breakpoint and
previously identified by only a single marker. We have
shown the utility of these markers for direct hybridiza¬
tion mapping to somatic cell hybrids and for screening
of gridded YAC libraries. The value of panels of stable
somatic cell and chromosome-reduced hybrids for accu¬
rate subregional mapping should also be emphasized.
The six somatic cell hybrids together define aminimum
of nine discrete intervals in the region Ilql4.3-q23
and provide new and useful markers for seven of these.
We have been able to establish an extensive contiguous
clone array of YAC recombinants with a minimum
number of screening steps. The method compares fa¬
vorably with PCR-based methods of screening YAC su-
perpools and pools for individual recombinants, a pro¬
cedure prone to PCR amplification biases that may
mean that valuable recombinants are not recovered.
In this regard, it is of interest to note that three
examples of duplicate YAC recombinants were identi¬
fied upon screening the ICI YAC library. Insert size,
Cot I hybridization, fingerprint analysis, and hybrid¬
ization with end clones and internal probes were used
to establish identity (data not shown). Two sets are
probably artifacts of the original gridding procedure
(ICI yacs 37GE11 and 37GE12 are identical, as are ICI
yacs 34GE5 and 34GF5). The third set comprising ICI
yacs 11BA9, 19EE2, and 21BG4 is presumably genuine
replica clones. These findings attest to the efficiency of
the filter screening procedure.
FISH analysis with reference to known flanking
markers and to the translocation breakpoint was ini¬
tially used to establish the orientation of the cloned
array (Fig. 4). This was subsequently confirmed by in¬
dependent marker analysis on somatic cell hybrids. Al¬
though the microdissection clones themselves are too
small to be used reliably for in situ hybridization, it
is relatively trivial to obtain corresponding cosmids,
again by direct filter hybridization. Furthermore, high-
resolution FISH analysis is possible using minute
quantities of YAC recombinants purified by analytical
pulsed-field gel electrophoresis and subsequently am¬
plified by catch linker-based PCR (Shibasaki et al.,
1995). As a by-product of this analysis, we were able
to assess the degree of chimerism among the YAC re¬
combinants. Three were shown to be definitely chimeric
by FISH analysis and/or hybridization analysis with
relevant end clones, microdissection clones, and/or
catch linker-derived markers. A further three are likely
to be chimeric based on provisional evidence from one
or the other of the above analyses. We conclude that
the level of chimerism is ~12.5% in both YAC libraries,
but without any apparent bias toward those YACs with
larger inserts.
This study was undertaken as part of our concerted
effort to investigate the molecular basis of psychiatric
disorders. While it remains to be seen whether the
translocation described here is causally related to
schizophrenia, the presence of a discrete breakpoint on
a chromosome provides a precise target for positional
cloning and an unique opportunity to investigate the
molecular architecture of the translocation and its pos¬
sible relationship to the manifestation of the disorder.
The contiguous clone map described here establishes
the key reagents necessary to achieve this aim. By
applying these same methodological procedures, it
should be equally possible to assemble contiguous clone
maps rapidly for other intervals on chromosome 11
(and indeed chromosome 1) defined by regionally as¬
signed microdissection clones.
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Catch-linker+PCR Labeling: A Simple
Method to Generate Fluorescence In Situ
Hybridization Probes from Yeast
Artificial Chromosomes
Yoshiro Shibasaki, John C. Maule, Rebecca S. Devon, Euan M. Slorach, John R. Gosden,
David J. Porteous, and Anthony J. Brookes
Medical Research Council (MRC) Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
A simple and efficient method to
generate hapten-labeled DNA frag¬
ments from a trace amount of YAC
DNA isolated by PFCE is described. Af¬
ter agarase digestion of the gel slice
containing the resolved YAC recom¬
binant, the purified DNA is digested
with 5au3AI and a compatible CL oli¬
gonucleotide duplex ligated on. A
probe is generated by PCR amplifica¬
tion using a primer complementary
to the CL with a single biotin moiety
incorporated at the 5' end. When
used as a FISH probe, this material
yields mapping results superior to
A/u-PCR orwhole YAC labeling meth¬
ods and allows sensitive detection of
chimerism.
rhe large insert size of yeast artificial
chromosomes (YACs) has made them
the method of choice for cloning and
mapping large genomic regions. With
the increasing dependence on YACs,
however, a number of problems associ¬
ated with their use have come to light
and must be addressed. Principal among
these is the high level of chimerism
present in several widely used YAC li¬
braries.(1_3) Fluorescence in situ hybrid¬
ization (FISH) is a convenient and pow¬
erful complementary technique to YAC
cloning and has the potential to detect
chimerism. A number of methods have
been described for direct or indirect la¬
beling of YAC recombinants for use in
FISH analysis, but current methods are
tedious, insensitive, and/or selective
with respect to the fraction of the insert
labeled.
Labeling total yeast DNA is simple but
requires large amounts of DNA and is in¬
sensitive. Diverse PCR-based approaches,
such as Alu-PCR(4) and degenerate olig-
onucleotide-primed PCR (DOP-PCR),(S>
have been developed to facilitate the iso¬
lation of discrete internal YAC fragments
to generate probes, but all involve te¬
dious efforts to eliminate uneven ampli¬
fication of the YAC insert and none is
comprehensive. Difficulties in obtaining
probes representing the entire insert
of the YAC also limit the identification
of potentially important information
within the large clone and restrict the
ability to detect chimerism.
Here, we present a simple and effi¬
cient method to generate hapten-labeled
DNA probes that represent essentially
the entire YAC insert using a trace
amount of YAC DNA isolated by pulsed
field gel electrophoresis (PFGE). This
technique generates DNA probes that
can be directly used for FISH with high
sensitivity and very low background.
MATERIALS AND METHODS
YAC DNA Preparation
YAC DNA was isolated in a gel slice by
preparative PFGE in 1% low melting
temperature agarose using minimal
ethidium bromide and UV light expo¬
sure.<6) An equal volume of 0.1 m NaCl
was added, and the sample was melted
by heating to 70°C for 15 min, then al¬
lowed to cool at room temperature for
30 sec. During this 70°C incubation, the
sample was mixed vigorously and centri-
fuged briefly three or four times. One
unit of (3-agarase I (New England Bio-
labs) per 50 p.1 sample volume was added
and the reaction incubated at 37°C for 3
hr. YAC DNA was precipitated by the ad¬
dition of one-tenth volume of 2 m so¬
dium acetate (pH 5.5) and two volumes
of ethanol. After chilling at - 20°C for 1
hr, the DNA was recovered by 15 min of
centrifugation. The DNA pellet was re-
suspended in 5 p.1 of Sau3A\ buffer and
digested with 1 unit of SauiAl enzyme at
37°C for 1 hr. The enzyme was inacti¬
vated by heating at 70°C for 15 min.
Catch-linker preparation
Oligonucleotides employed were A (5'-
CCGAATTCTAGAGTCGACC-3') and B
(5'-GATCGGTCGACTCTAGAATTCGG-
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3')- Four micrograms of oligonucleotide
B was 5'-phosphorylated by treatment
with 25 units of T4 polynucleotide ki¬
nase (BRL) in 50 pi at 37°C for 30 min.
The oligonucleotide B was recovered by
CHCl3/isoamyl alcohol extraction, ether
extraction, and ethanol precipitation.
Based on an estimated recovery effi¬
ciency of 25%, 1 pg of oligonucleotide A
was mixed with 1 pg of the kinase-
treated oligonucleotide B in 10 pi of 10
mM Tris-HCl, 5 mM MgCl2 (pH 7.4). The
mixture was placed in a 200-ml water
bath at 70°C and allowed to cool to room
temperature over ~1 hr. This produced
200 ng/pl of AB duplexed catch-linker
(CL) that can be frozen and stored indef¬
initely.
CL to YAC Ligation
On ice, —20 ng of the processed YAC
DNA (as judged by the initial pulsed field
gel) was mixed with 100 ng of duplexed
CL in a 10-pl ligation reaction employ¬
ing 2 units of T4 DNA ligase (Boehringer
Mannheim). After incubation at 16°C
overnight, the ligase was heat inacti¬
vated at 70°C for 15 min.
PCR amplification and labeling
Oligonucleotide bio-A was synthesized
with a single biotin moiety incorporated
at the 5' end of oligonucleotide A during
synthesis. Using 600 ng of oligonucle¬
otide A-bio as a primer, 1-pl aliquots of
the ligation reaction were amplified in
PCR reactions of 50 pi volume using 1
unit of Taq polymerase (Boehringer
Mannheim) and an OmniGene thermal
cycler (Hybaid). PCR conditions were as
follows: For 35 cycles using tube temper¬
ature control , the denaturation steps
were 93°C for 15 sec; the annealing steps
were 54°C for 30 sec; and the extension
steps were 72°C for 1 min (cycles 1-10), 2
min (cycles 11-20), and 4 min (cycles
21-35). Ten microliters of the PCR prod¬
uct was examined by electrophoresis on
a 1.5% agarose gel. The remainder of the
PCR reaction was ethanol precipitated
and resuspended at a concentration of
20 ng/pl in TE.
Alternative preparation of FISH
probes
Yeast DNA containing a human YAC re¬
combinant was isolated by a standard
method.(7> A/u-PCR was performed ac¬
cording to Breen et al.(4) Both total yeast
DNA and A/w-PCR products were biotin-
labeled by nick translation.
FISH
Chromosomal in situ suppression hy¬
bridization was performed as described
previously.'8' Briefly, the chromosomal
DNA was denatured by incubation of the
slides in 0.1 m glycine buffer (pH 12.5), at
room temperature for 3 min followed by
dehydration in 70% ethanol and 99.5%
ethanol at -20°C and then air-dried.
The hybridization mixture containing
biotin-labeled DNA probes (6 ng/pl for
CL + PCR or Alu-PCR products, and 100
pg/pl for total yeast DNA), 500 ng/pl of
Cot-1 DNA (BRL), 1.5x SSC, 10% dextran
sulfate, and 50% formamide were dena¬
tured by heating at 78°C for 5 min,
chilled on ice, and placed at 37°C for 15
min to allow annealing of repeated DNA
sequences and thus suppress their hy¬
bridization to chromosomal homologs.
Thirty microliters of the hybridization
mixture was added to each prewarmed
(37°C) slide under a 22x22-mm cover-
slip, which was sealed with rubber ce¬
ment. The hybridization was carried out
at 37°C overnight in a humid chamber.
Following hybridization, the slides
were washed three times in 50% forma-
mide/2x SSC, once in 2x SSC, and once
in PN buffer [100 mM sodium phosphate
buffer at pH 8.5, with 0.1% NP-40 (Phar¬
macia)] at 45°C for 5 min each, and then
incubated in 5% nonfat dry milk in PN
buffer (PNM) at 37°C for 10 min. Signal
detection was performed by incubation
in FITC-avidin DCS (Vector Laborato¬
ries) diluted to 1:100 in PNM at room
temperature for 20 min. The signal was
amplified with 5 pg/ml of biotinylated
anti-avidin antibody D (Vector Laborato¬
ries) followed by a second layer of 1:100
FITC-avidin DCS (Vector Laboratories)
at room temperature for 20 min each.
The successions of antibody incubations
were separated by washing twice with PN
buffer at room temperature for 2 min
each. After the final wash, the slides were
mounted by a fluorescent anti-fade solu¬
tion, VectaShield (Vector Laboratories),
containing 0.5 pg/ml of propidium io¬
dide. Chromosome preparations were
examined under a Leitz microscope
equipped with a Bio-Rad MRC-600 con-
focal laser scanning system.
Results and Discussion
ICI yac 36IF5, a human YAC recombi¬
nant with an insert size of —600 kb, was
identified by hybridization of gridded
filters with a microdissection clone,
MD220, which we had mapped previ¬
ously to the long arm of chromosome
ll.(9) Figure 1 shows the comparisons of
FISH results using probes for ICI yac








FIGURE 1 Partial metaphases hybridized with
ICI yac 36IF5. Probe DNAs are prepared by
three different methods: (A) (CL) + PCR label¬
ing of ICI yac 36IF5; (B) total yeast DNA of ICI
yac 36IF5 labeled by nick translation; and (C)
pooled Alu-PCR products for ICI yac 36IF5
followed by nick translation. Arrows indicate
FITC signals of ICI yac 36IF5 on chromosome
band Ilql4.3-q21. This YAC is chimeric and
gives minor signals on chromosome band
5pl4 (arrowheads). Cross-hybridization of
yeast rRNA genes onto acrocentric chromo¬
somes was also seen by the total yeast method
(double arrowheads).
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ods: (A) CL plus PCR (CL+ PCR); (B) total
yeast DNA containing a YAC labeled by
nick translation; and (C) Alu-PCR fol¬
lowed by nick translation.
Arrows indicate FITC signals of ICI
yac 36IF5 on chromosome band
Ilql4.3-q21. This YAC is chimeric as
demonstrated by the minor signal on
chromosome band 5pl4 (arrowheads).
The FISH results from both CL + PCR,
and the total yeast methods showed
clean signals without background noise
(Fig. 1A,B). However, YAC DNA consists
of only about one-tenth to one-fiftieth
of total yeast DNA; therefore, the total
yeast method requires a large amount of
yeast DNA to compensate for the
amount of YAC DNA necessary for FISH.
In addition, the vast majority of labeled
DNA is the yeast genomic DNA, and this
causes cross-hybridization of conserved
sequences such as rRNA onto human
chromosomes (Fig. IB: double arrow¬
heads).
All three labeling methods correctly
localize ICI yac 36IF5 to Ilql4.3-q21.
The study, however, illustrated several
points that limit the usefulness of total
yeast or A/u-PCR and favor the CL+PCR
method.
1. Alu-PCR labeling is accompanied
by a high background noise that
may obscure or falsely indicate
chimerism (Fig. 1C).
2. Although both CL+PCR and total
yeast labeling give low background
noise, the amount of material re¬
quired for total yeast labeling is
large and the sensitivity is low. As
little as 2 ng of YAC will generate
by CL + PCR sufficient probe for 10
FISH analyses.
3. Labeling of total yeast DNA but not
CL + PCR results in labeling of hu¬
man homologs of yeast sequence,
most notably rRNA genes (Fig. IB,
double arrowheads).
4. The success of Alu-PCR (or related
methods) but not CL + PCR is lim¬
ited to human recombinants and is
heavily dependent on the local dis¬
tribution of repeated DNA se¬
quence motifs that serve to prime
PCR.
5. Because all ends of restriction frag¬
ments are converted to priming
sites for PCR in CL + PCR, but not
other methods, essentially the
complete YAC DNA is directly
available without sequence bias for
FISH, comprehensive cloning, and
further molecular analysis by
other techniques.
Because the DNA fragment size range af¬
ter CL+PCR technique (200-700 bp;
data not shown) is optimal for FISH
without further digestion with DNase I,
hapten labeling of DNA fragments dur¬
ing the PCR reaction is preferred. The
conventional way of labeling DNA dur¬
ing PCR is to substitute 1 of the 4 nucle¬
otides in the reaction mixture with a
labeled one such as bio-n-dUTP or DIG-
11-dUTP. This requires a high concentra¬
tion of labeled nucleotide, and is there¬
fore costly. On the other hand, the
labeling efficiency by CL+PCR using a
biotinylated primer without additional
labeled nucleotide in the PCR reaction is
adequate both for the standard signal de¬
tection procedure for FISH (Fig. 1A) and
for filter hybridization (data not shown).
Our experiences with CL + PCR have
shown the method to be extremely reli¬
able and sensitive (12 YACs tested and all
successful). Estimated from the results of
contig construction, the size of chimeric
fragment of ICI yac 36IF5 mapped on
chromosome 5 is <50 kb. Furthermore,
once the YAC clone is confirmed to be
valuable for further analysis, the ampli¬
fied DNA fragments by CL + PCR can be
subcloned into suitable vector, using the
internal EcoRI site on the linker adapter
or the Sau3Al of the original ligation site.
We conclude that the CL + PCR label¬
ing technique offers valuable advantages
over current methods for high-resolu¬
tion YAC mapping and the detection of
chimerism by FISH analysis.
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Coincidence Cloning: taking the
coincidences out of genome analysis
Rebecca S. Devon and Anthony J. Brookes
Abstract
The term Coincidence Cloning encompasses a wide range of methodologies,
the aim of which is to isolate DNA sequences which occur in both of two
input DNA sources. The nature of these input DNAs may be genomic or
cDNA, cloned or uncloned, and as such the far reaching applicability of the
techniques can be imagined. If the input DNAs are genomic then the product
will be enriched for useful markers co-occurring between the two. If the input
DNAs comprise one genomic resource and one cDNA resource the product
will contain genes mapping to that particular genomic region. In this review a
comparative description of the range of Coincidence Cloning methods is
given, together with a discussion of their applications. Finally, consideration
is given to the general limitations of these techniques.
Key Words
cloning, coincident, methods, PCR, enrichment
Despite the many and various molecular genetic technologies currently
available, a detailed analysis of all but the smallest genomes remains a
colossal and extremely arduous task. The primary reason for this is the sheer
size and complexity of the genomes currently being scrutinised. To help
counter this problem, efforts have been made to develop strategies for DNA
investigation that are ever more sophisticated and increasingly powerful.
Several such procedures share, as a common purpose, the selective cloning
of DNA sequences that are distinguished by their presence in both of a pair
of DNA resources. By and large, these methods are dependent upon the
polymerase chain reaction (PCR) (1). A generic name that may be applied to
these technologies is 'Coincidence Cloning' (the cloning of sequences
coinciding.between two resources).
Systems for Coincidence Cloning have been developed for use with many
types of DNA resource. These include i) genomic DNA mixtures such as
individual or pooled recombinants (cosmids, phage, yeast artificial
chromosomes etc.) and even whole somatic cell hybrid or single species
total genomic DNAs, ii) the transcribed portions of a genome available in the
form of cDNA resources, and iii) pre-constructed libraries of whole genomes,
sub-genomes or tissue specific cDNAs. The application of Coincidence
Cloning to a pair of genomic DNAs will provide access to a highly focused
set of genomic markers. Alternatively, if one employs a genomic resource
plus a cDNA resource then the procedure will identify groups of transcribed
sequences encoded within that genomic region. These fundamental goals of
marker or gene isolation represent the current applications of Coincidence
Cloning and hence are the focus of this review. However, other possibilities
for exploitation of the Coincidence Cloning concept can be imagined, and are
considered briefly.
For convenience we shall refer to the DNA mixtures used in coincidence
cloning studies as Source I and Source II DNAs, use 'integration' to describe
their joint processing and the 'product' to describe the resultant set of
coincident DNAs. In most circumstances, Coincidence Cloning procedures
do not actually purify target sequences to homogeneity, instead coincident
DNAs are preferentially recovered. The degree of enrichment achieved is
expressed in terms of an 'enrichment factor'. The enrichment factor is given
by the ratio of the relative mass representation of a target sequence in the
product DNA mixture, over its relative mass representation in one of the
(usually the most complex) input DNA resources.
Coincidence Cloning procedures are all based upon the same underlying
principle, namely the formation and subsequent selective isolation of duplex
DNA molecules (Inter-Resource Duplexes; IRDs) comprised of
complementary DNA strands from each of the input DNA resources. This
general scheme is represented in figure 1. The logic of this scheme is clear,
since IRDs can exist only for coincident DNA sequences. Thus, Coincidence
Cloning can be viewed simply as a form of DNA hybridisation that uses a
highly complex probe to both detect and simultaneously recover the
hybridising sequences of interest. The fundamental challenge to coincidence
cloning lies not in the hybridisation step (the kinetics of duplex DNA
formation is well understood) but in the selective recovery of the desired
sequences (the IRDs).
For the purposes of this review, the primary modes that have been used for
the IRD selection have been divided into four groups. These are i) cloning
selection, ii) physical selection, iii) physical plus PCR selection, and iv)
physical plus PCR plus ligation selection. A summary of these selection
methods is shown in Table 1. The basis for Cloning Selection is the selective
cloning of the inter-resource duplexes but not the intra-resource duplexes.
This is usually achieved by the presence of different restriction enzyme sites
on each end of the IRD molecule. Although the use of cloning as a selection
method removes the need for subsequent cloning of the product prior to
analysis, non-specific products are usually recovered at an unacceptably
high level. Physical Selection would be the method of choice for Coincidence
Cloning studies employing whole chromosomes. The Source II DNA is used
as a fluorescent in-situ hybridisation (FISH) probe, which enables
visualisation of the region of coincidence before physically removing the
bound probe from the slide. This is useful for large scale studies, although
the requirement for whole chromosomes on a slide reduces its versatility.
Physical plus PCR Selection makes use of different primer sites incorporated
into the Source I and II DNAs, along with physical retention of one of the
input DNAs. This allows molecules not forming a stable duplex to be washed
away, and then the IRD may be selectively amplified by PCR. PCR selection
can achieve greater enrichment than either cloning or physical selection
alone. However, the product may contain non-coincident products which had
not been removed by the washing steps, and PCR itself is subject to a
number of limitations (as discussed later). An improvement on
straightforward PCR selection, Physical plus Ligation plus PCR Selection,
involves ligation of primer sites onto the Source II product molecules while
they are present in a duplex with Source I DNA. Stringent conditions in the
ligation step ensure that only truly coincident molecules will acquire the
primer sites essential for amplification and selection. The enrichment factors
achieved by the incorporation of this extra step are higher than with standard
PCR selection.
Two major factors conspire to compromise the effectiveness of coincidence
cloning. The first of these is input DNA complexity. A typical mammalian
genome is so large (~106 kb) that to integrate anything but relatively small
portions of it would require unacceptably long incubation times to achieve
effective DNA hybridisation. To overcome this, most procedures simplify the
Source I and/or Source II DNAs, usually via a PCR step, to create
'representations' of the originals. The second problem is that all repetitive
elements present in both source DNAs will be genuinely coincident and
therefore recovered in the product DNA. For example the human Alu repeat
family is highly reiterated and members comprise approximately 5% of the
total genome and are present in 3-5% of cDNAs (2). This high frequency
means that there will be Alu repeats coincident between the two resources
which therefore will be enriched in the product library. However, pre-
hybridisation of the denatured input DNAs with an excess of Alu repeat DNA
before duplex formation can result in the near complete functional removal of
the Alu repeat sequences from the input DNAs (3). Similarly, this 'pre-
blocking' can also be used to alleviate other problems of non-specific
recovery, such as for ribosomal RNA sequences (3).
The methodologies which fall under the general heading of Coincidence
Cloning can be distinguished by the different ways in which the IRD is
selected. In order to differentiate the inter-resource duplex from the intra-
resource duplex, it is necessary to distinguish between the Source I and the
Source II DNAs in some manner. This may involve modification of the ends
of the molecules by addition of different linkers to each resource, such that
they contain different restriction enzyme sites or PCR primer sites, or
alternatively differentiation may simply involve physical separation of one
from the other by binding to a filter or fixing on a slide. Once the two Source
DNAs can be discriminated in this manner, then one of the selection
methods can be employed.
Methods for selecting the IRD
Cloning selection
For the IRDs to be selected by cloning, use can be made of different
restriction enzyme sites in the linkers used to amplify the starting DNA (4,5).
This is depicted in figure 2. The Source I is amplified by PCR using a primer
that incorporates a restriction enzyme site. The Source II is similarly
amplified, but a different enzyme site is incorporated into the otherwise
similar primer. The two resulting PCR products are then digested with the
appropriate restriction enzyme, before denaturing and mixing them together.
As reannealing takes place, the Source I and Source II sequences may of
course reanneal to themselves, yet IRDs will also be formed and are
distinguishable by the presence of different restriction enzyme half-sites at
each end of the duplex. These may then be directly selected by cloning all
the duplexed material into an appropriately doubly digested vector. Only the
IRD formed between source I and source II DNAs would be able to be
correctly ligated into the vector and cloned.
Cloning selection was utilised in an early coincidence cloning experiment, in
which markers were isolated from two somatic cell hybrids which contained a
small amount of human DNA in common (4). Alu-PCR (6) was used to
amplify the somatic cell hybrids, employing Alu consensus primers for each
hybrid incorporating a different restriction enzyme site. This study achieved
an enrichment factor of 10-20 fold. The use of repeat directed PCR with
cloning selection has also been extended to other species. For instance
primers directed towards a pig specific SINE have been used to amplify the
porcine component of a somatic cell hybrid (the Source I DNA) and a flow
sorted pig chromosome 6 (the Source II DNA), with subsequent cloning
selection employed to enrich for the coincident sequences between them (7).
Cloning selection is limited by the recovery of significant levels of
background products due to i) the cloning of Source l-only or Source ll-only
duplexes into an incompletely digested vector, ii) the cloning of chimaeric
products and iii) the recovery of false IRDs that have poor inter-strand
homology. For these reasons other methods for selection of the IRDs have
since been developed.
Physical selection
The techniques of FISH have been applied to coincidence cloning, allowing
visualisation of the region of coincidence before physical isolation of the IRD.
This approach is useful when the experiment is on a large scale, for instance
when one or more of the input DNAs comprises whole chromosomes. Figure
3 depicts a general scheme for physical selection. The Source I DNA is used
as a FISH probe onto the Source II DNA which has been fixed on a slide.
Excess probe and that which is non-specifically bound can be washed off,
enabling the genuinely coincident sequences to be visualised and then
eluted off, PCR amplified and cloned.
The two methods of 'Coincidence painting' (8) and 'Prep-ISH' (9) employ
FISH and physical selection methods. Coincidence Painting was used to
obtain marker sequences from the region of coincidence between two
chromosomes which share a small portion of their sequence - the two DNA
sources being a derivative chromosome from a translocation cell line plus
flow sorted normal chromosomes. It was calculated that this method yielded
approximately one unique clone for every 53kb of the coincident sequence.
This is a substantially higher density of markers than that produced by the
Alu-PCR based method, which produced on average one clone every 250kb
(4).
In contrast, Prep-ISH (9) is a method published primarily to isolate genes
mapping to a specific chromosomal region although it could equally be
applied to isolating coincident genomic markers. A linker-amplified cDNA
library or genomic region of interest is used as a probe for FISH onto an
array of chromosomes fixed on a slide. After appropriate washing, the region
of coincidence is recovered by microdissection and reamplification.
Mammalian genomes can be resolved into 300 to 1000 or more recognisable
chromosome bands, thus a cDNA library containing 10,000 different
transcripts could be reduced in complexity by Prep-ISH to a more
manageable 10 to 30 transcripts mapped to a specific region of the genome.
This is potentially extremely useful for producing a small set of candidate
genes from a specific genomic region without the need for further physical
mapping and selection of cDNAs.
Physical plus PCR selection
In solely physical selection methods, the elution of the bound probe from the
slide provides separation of the IRD from the background, and yet for there
to be sufficient product for analysis it is necessary to first PCR amplify the
eluted material. An expedient alternative therefore would be a PCR based
selection approach, which could select the IRD and concomitantly result in
sufficient material for analysis.
In methods employing PCR selection (see figure 4), oligonucleotide linkers of
different sequence are used to amplify the Source II and usually the Source I
material. In addition, the denatured Source I DNA is attached to a physical
support, which may be either by binding to a filter or by attachment to
streptavidin coated magnetic beads. After integration of the two resources,
the IRD is physically retained by attachment to the filter or beads, while the
excess Source II DNA is removed by washing. The product Source II can
then be eluted off the physical support and amplified using specific primers.
This strategy is therefore closely related to the FISH based methods
described above, but is more versatile.
PCR selection has been largely used for gene isolation studies, whereby the
product is enriched in cDNAs mapping to a particular genomic region (i.e.
coincident between a cDNA resource and a specific genomic resource). This
technique is sometimes referred to as 'cDNA fishing', with the analogy that
the genomic region acts like a fishing rod, to dip into the pool of cDNA 'fish'
and physically reel in coincident sequences.
Filter hybridisation The first experiments using PCR selection were related
schemes for cDNA fishing, called 'direct cDNA selection'. These involved the
hybridisation of a whole cDNA library (the Source II) onto YACs or cosmids
(the Source I) which had been immobilised on a filter. In one study (10) an
amplifiable foetal kidney cDNA library was pre-blocked for high copy repeats
and integrated with a 550kb YAC, which was denatured and immobilised on
a filter. After washing off the non-specifically bound cDNAs the product was
eluted off, amplified and cloned. In the second study (11) the only
fundamental difference was that the immobilised genomic DNA, not the
cDNA, was pre-blocked for repeats. The optimisation of hybridisation and
washing conditions is obviously critical in this type of experiment, to
determine the level of specificity achieved. The enrichment factor achieved in
both studies was -1000 fold. This is impressive yet is still insufficient to
reliably recover rare transcripts.
Solution Hybridisation In later studies the focus of Coincidence Cloning
experiments has changed to solution rather than filter hybridisation
(12,13,14), for which the kinetics are more easily controlled. As an alternative
to immobilisation of the genomic DNA on a filter, the genomic DNA is usually
attached to streptavidin-coated magnetic beads by way of biotin moieties.
The biotin residue may be added during the initial amplification of the
genomic DNA resource, either by the use of a biotinylated primer or one
biotinylated nucleotide in the reaction mix. The pre-blocked amplified cDNA
(Source II) is added before (14) or after (12) the genomic DNA fragments
(Source I) have been immobilised. cDNAs forming stable duplexes with the
genomic DNA will be retained by the beads upon washing, while the excess
cDNA is removed. The product cDNA may then be eluted, amplified and
cloned as before. Further rounds of cDNA selection can be applied to
increase the enrichment, although at the possible expense of some
genuinely coincident cDNA species, since further rounds of PCR
amplification can induce biases in sequence recovery.
Physical plus Ligation plus PCR selection
In PCR selection methods, it is straightforward to separate Source II product
DNA from Source I DNA, since the primers used to amplify each resource
are not compatible with each other. However, the primers used to amplify the
product Source II DNA are equally able to amplify Source II DNA from
imperfectly matched IRDs and also Source II intra-resource duplexes which
have not been removed during the washing steps. This can lead to the
recovery of artefacts in the product material.
A method termed 'end ligation coincident sequence cloning' (EL-CSC)(15,16)
has been developed which, by incorporating an extra step into the protocol
significantly reduces the contamination of the product library with non-
coincident Source II DNA. This is shown in figure 5. The extra step is a high
stringency ligation reaction which joins synthetic 'capture' oligonucleotides
onto the Source II DNA molecules while they are present in a duplex with
Source I molecules. The capture oligonucleotides are designed to be
complementary to linkers present at the ends of the Source I molecules and
hence the ligation can only take place if the Source I and Source II IRD is
perfectly matched both in length and terminal sequence. After washing and
elution, the product Source II molecules are amplified using primers directed
against the unique regions of the added oligonucleotides. Hence only those
coincident products which fulfil the criteria of perfect length match and end
sequence identity will be amplified and subsequently cloned. The technique
has been validated in studies designed either to isolate region specific
markers (single copy markers coincident between somatic cell hybrids and a
pool of microdissection clones) (15) or transcribed sequences from a
particular genomic region (six genes were isolated as coincident between
260kb of pooled cosmids and human foetal brain cDNA) (15).
The higher specificity of EL-CSC relative to cDNA fishing techniques means
that enrichment factors of greater than 106 fold can be achieved, at least 10
fold greater than those possible with most cDNA fishing. It has been found
however that a slightly different spectrum of products is generated by
performing EL-CSC versus cDNA fishing with the same input DNAs. The
most efficient way of detecting coincident sequences would thus appear to
be the use of a combination of EL-CSC and cDNA fishing, with the two
methods being viewed as complements rather than alternatives. With this
objective in mind, a procedure has now been developed which can
accomplish these two objectives in a single tube reaction (17).
General problems and limitations
Artefactual products
Inevitably, some of the DNA present in the final product will be artefactual
sequences. Low copy genomic repeat elements such as MER sequences
can confound the search for real genes, since they are sometimes present in
expressed elements, making them genuinely coincident between the two
resources (3). Their copy number is insufficiently high to permit effective
blocking in the preannealing step even by Cot10 DNA. Also, the design of
cDNA fishing means that in addition to the genuine gene, other members of
a gene family or expressed pseudogenes may well have sufficient cross-
homology to be fished out.
These problems have been overcome to a certain extent by EL-CSC since
the requirements for perfect length match and end-sequence identity will less
frequently be met in pseudogenes and related sequences. In this respect,
EL-CSC may be seen to a greater extent as a method for isolating genes
rather than just enriching them. A constraint of EL-CSC is that it is only able
to isolate intra-exonic fragments due to the requirement for length match
between the genomic and cDNA versions of the gene. However, inspection
of a random set of gene sequences for which the genomic structure is known
reveals that the majority will contain multiple recoverable fragments using
one or more of a set of common restriction enzymes (15).
PCR
PCR amplification is an essential component of most coincidence cloning
techniques, both those involved in marker isolation and in gene isolation.
PCR amplification is generally used in the preparation of the input DNAs (for
instance Alu-PCR (6), DOP-PCR (18) and catch linker PCR (19) and is also
necessary for the amplification of the coincident product sequences, so that
there is sufficient material for cloning and further manipulation. It is therefore
unfortunate that PCR amplification does not result in an unadulterated
expansion of the starting material. Firstly, PCR amplification is biased
towards shorter fragments, so it is important to ensure that the starting
material is digested to a suitable length. Standardising the length of material
to be amplified also helps to ensure that it is all amplified - longer fragments
would be in direct competition with the shorter ones and invariably lose.
Secondly, PCR biases are also prevalent against certain sequences with
high G+C content, resulting in uneven amplification of the starting material.
Some length and sequence biases may be overcome by modification of the
PCR programme, for instance by employing longer extension times and
sufficiently high temperatures such that GC-rich sequences are properly
denatured. A third drawback associated with PCR is that sequence errors
are introduced by the polymerase, which may corrupt open reading frames
and give other artefactual results. High fidelity polymerases with a proof¬
reading activity have been recently introduced, which should reduce this
problem. Minimising the number of PCR cycles is important in reducing all
three problems.
Quality of input DNA resources
The effectiveness of Coincidence Cloning at enriching a product library for
sequences of interest is critically dependent upon the methodology used.
Equally important however is the type and quality of the input DNAs. The
ability of coincidence cloning to handle complex genomic and cDNA
resources obviously results in a limitation in efficiency. In this respect, fewer
artefactual products are usually recovered when using cosmid DNA rather
than YAC DNA (3), cosmids being approximately one tenth of the size of
YACs and more readily produced in a pure form. A balance must be
achieved between the level of specificity required for a particular experiment
against the length of the genomic region to be studied.
a) YACS A significant drawback when YACs are used as the genomic
Source I resource is that they are difficult to isolate in a pure form - excised
preparative pulse field gel slices will inevitably be contaminated with yeast
sequences to some degree (3). Parts of the yeast genome show sufficient
conservation with human cDNA that they may be genuinely recovered by
coincidence cloning. Ribosomal RNA sequences are particularly noteworthy
in this respect due to their high abundance in the yeast genome. Pre-
blocking the cDNA with an excess of denatured ribosomal RNA however can
significantly alleviate the problem. In the same way, mitochondrial DNA and
2(i plasmid sequences in the cDNA can be problematic when using cDNA
libraries that may contain these elements (3).
Due to the difficulty in isolating the pure YAC DNA, some experimenters
have used total yeast DNA plus YAC as the genomic resource. Parimoo et al
(1993) isolated HLA-A cDNA clones in this way (20), although the practical
advantage did result in a drop in sensitivity. Enrichment of only 100 fold was
achieved after two rounds of selection. Forster and Rabbitts (1993) also
used the total yeast plus YAC method to isolate fusion cDNAs from tumour
tissue (21), and achieved a 104 fold enrichment after two rounds of selection.
Amplification of a total yeast plus YAC resource by Alu-PCR would
selectively amplify the human YAC sequences rather than yeast sequences,
although as discussed earlier, PCR biases and non-random distribution of
Alu sequences would result in a genomic resource not truly representative of
the starting material.
b) cDNA The quality of the cDNA resource in gene isolation experiments is
also of crucial importance. It is generally found that oligo-dT primed cDNA
gives the best results, since cDNA libraries are often plagued with artefacts,
and problems can arise due to homology between the cDNA and genomic
resource vectors resulting in vector sequences forming a large proportion of
the product material. A potential problem with oligo-dT primed cDNA can be
foreseen if the region of coincidence lies solely at the 5' end of a long cDNA,
since amplification of this 5' end will be at a disadvantage in a PCR reaction.
However the observed greater exonic length at the 3' end is advantageous,
especially for EL-CSC. Alternatively, the cDNA may have a long internal
hairpin structure, which disables it from forming a duplex with coincident
genomic DNA. The tissue from which the cDNA is made must be carefully
selected, since genes not expressed in this tissue cannot be recovered by
Coincidence Cloning no matter how high the enrichment factors. To partially
overcome this doubt, it may be preferable to use a cDNA resource which has
been made from a mixture of tissues, each with its overlapping but slightly
different complement of expressed genes. This insurance policy may
however result in the non-recovery of genes rarely expressed in only one
tissue, since the recovery rate of genes will be dependent on their
expression level. If developmental genes are involved, non-recovery may be
simply due to the fact that the genes are only expressed (and hence only
present in the cDNA resource) at particular developmental stages. This can
be somewhat problematic to overcome for human genes, however if there is
sufficient cross species conservation use could potentially be made of
mouse developmental stage-specific cDNA.
Future Directions
But what of the future of Coincidence Cloning? The need for isolation of
marker sequences from the human genome is not so pressing as it was
several years ago, and the pace of gene isolation is stepping up with the
development of improved technologies in fields such as exon trapping
(22,23) and the increasingly realistic concept of direct sequencing of large
genomic regions coupled with effective gene finding algorithms (24,25). For
these reasons, the flexibility of coincidence cloning and its ability to use large
uncloned genomic regions as input DNA resources are to its distinct
advantage. The ability of coincidence cloning to scan long stretches of DNA
for genes means that candidate gene analysis may begin earlier in the
process of positional cloning, before fine scale mapping and linkage analysis
have maximally narrowed down the region of interest.
One potential avenue for expansion and development of the technology is in
the identification of conserved sequences between species. Just as a
conventional 'zoo blot' can reveal the genie nature of a small probe by
assessing its cross-species conservation, Coincidence Cloning can do the
same, but on a much larger scale. Preliminary experiments in this field have
been reported (26) in which conserved regions from the human genome
were isolated by performing coincidence cloning between human cosmids
and mouse or pig genomic clones, by using a low stringency magnetic bead
based protocol.
The ultimate extension to finding regions of coincidence between two
subgenomic regions or cDNAs is that whereby whole human genomes
become the input DNA sources. The concept of 'Identity by Descent' (IBD)
may then be exploited, whereby among consanguineous individuals affected
with a genetic defect, the only region of complete genomic sequence identity
will be that involved in causing the disease, (the location of a disease
gene)(27). On a small scale, IBD has been demonstrated by genotyping
microsatellite markers in individuals affected by Hirschprung disease (28). It
is not difficult to extrapolate this idea and to visualise an application for high
stringency coincidence cloning in a larger scale search where the location of
the disease gene has not been pinpointed.
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Table 1) Methods for the selection of inter resource duplex (IRD) DNA
Selection Method Principle Advantage Disadvantage
1} Clonina Directed cloning Removes need for
cloning step after
selection
High level of background
products
2) Physical FISH hybridisation and
physical isolation
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Fig. 1) General schema
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Fig. 2) Cloning selection
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